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Abstract 
 
This introduction covers the aspects of thrombosis, the haemostatic system and the development of 
the thrombin generations test. In addition, applications of the thrombin generation test as well as the 
availability of various fluorogenic peptide substrates are discussed.  
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Chapter 1 
 14
1.1 Thrombosis  
 
 
The word "thrombosis" was thought to be first coined by the Greek physician Claudius Galen (AD 
129–201), however, it did not come into popular usage until about 1856 when Rudolf Ludwig Karl 
Virchow, postulated his ideas on the phenomena "embolism" and "thrombosis".1 The word thrombosis 
consists of the prefix thrombo- originating from the Greek word thrombos, meaning a lump or clump, 
or a curd or clot, and the noun suffix -sis meaning “condition of”. Therefore, thrombosis can be 
described as the formation or presence of a blood clot (or thrombus) in a blood vessel.  
The great philosophers and physicians Hippocrates, Plato, Aristotle and Galen were the first to 
describe the clotting of blood. They, however, discarded the physiological and pathological 
significance as to them it was no more than jellification upon cooling.2 It was not until the eighteenth 
century before the English surgeon Hewson,3 thoroughly explored the clotting process. In 1856 Rudolf 
Virchow suggested three main factors that are thought to conduce to venous thrombosis: 1) alterations 
in normal blood flow (stasis); 2) injuries to the vascular endothelium; 3) alterations in the constitution of 
blood (hypercoagulability). These three factors attributing to the arising of thrombosis are now known 
as the Virchow triad. Nowadays two types of thrombosis are known; arterial thrombosis, occurring in 
arteries, which can result in myocardial arrest (heart attack) or cerebral infarction (stroke) and venous 
thrombosis, most commonly in the form of deep vein thrombosis (DVT) occurring in the veins of the 
legs which can result in pulmonary embolism. Although both types of thrombosis arise as a result of 
clot formation, they have partially different causes. Deep vein thrombosis can be caused by low blood 
circulation, in combination with hypercoagulability of blood itself, e.g. due to the excessive presence of 
clotting factors or lack of natural clotting factor inhibitors. Arterial thrombosis originates mainly on basis 
of atherosclerosis, notably on a ruptured plaque in the arterial wall. The underlying causes of 
atherosclerosis are smoking, high cholesterol, high blood pressure and diabetes.  
The three factors of Virchow are of different importance in venous and arterial thrombosis. In venous 
thrombosis absence of flow seems to be more important than the status of the vessel wall, in arterial 
thrombosis the inverse is true. The coagulability of the blood definitely plays a role in venous 
thrombosis, as can be seen from the increased incidence of this disease when the natural blood 
clotting inhibitors fail, but they certainly also play a role in arterial disease, as can be seen from the 
fact that inhibition of thrombin generation with vitamin K antagonists or with heparin decreases the 
frequency of coronary infarction.4,5,6 It has long been thought that venous thrombosis is a problem of 
blood clotting and arterial thrombosis one of platelet adhesion and aggregation. Treatment of patients 
suffering from coronary- or cerebral infarction was therefore mainly focussed on inhibition of platelets 
by medication such as Aspirin, Clopidogrel and Tirofiban. Later research showed that these “platelet 
inhibitors” also inhibit thrombin generation in platelet rich plasma.7 
 
 
 
Figure 1.1 Drugs for the treatment of thrombotic diseases.8   
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Treatment of deep vein thrombosis is mainly focussed on prevention of clot growth, clot arrest and 
avoidance of reoccurrence of clots via inhibition of clotting factors. DVT is generally treated with 
anticoagulant medication, i.e. immediate acting heparin (either unfractionated heparin (UH), low 
molecular weight heparin (LMWH) or the synthetic heparin Fondaparinux) and the slow onset oral 
anticoagulants (vitamin K antagonists) like Warfarin, see Figure 1.1. With the crucial role of thrombin 
in blood coagulation came numerous reports describing its shape and function.9 Hence, elucidation of 
the thrombin active site by X-ray crystallography10 greatly facilitated researchers to develop direct 
thrombin inhibitors such as Argatroban, Melagatran and Ximelagatran (Figure 1.1)11 which are, 
however, not yet in common use. 
 
Since thrombosis is on the basis of diseases such as cerebral- and coronary infarction and pulmonary 
embolism it can be considered the major cause of morbidity and mortality in the western world. 
Monitoring the coagulation behavior of blood is therefore of the utmost importance, in the first place to 
detect the propensity of a patient to develop such disorders and secondly, if necessary, in a later 
stage to monitor the effectiveness of medication during treatment. 
 
 
1.2 Haemostatic system 
 
 
Damage to a blood vessel triggers a complex series of events designed to prevent blood loss and, 
eventually, to repair the damaged vessel. If, however, arrest of blood flow occurs in intact vessels 
normal circulation is disordered endangering normal functioning. Tissues and organs are damaged 
and can die as a result of prolonged arrest of blood supply. Nature provided an admiringly, highly 
complex process known as the haemostatic system, to assure adequate plugging of any vessel in a 
wound while maintaining the fluidity of the blood in intact vessels. 
 
Haemostasis is brought about by the interplay between blood cells, the blood platelets, and a set of 
proteins of the blood plasma, the coagulation system.12 On a damaged part of the vessel wall, 
platelets stick to the collagen (intercellular tissue matrix) in the wound and create a setting in which 
blood can clot without the clot being washed away by the flowing blood. The interactions between the 
wound and blood platelets lead to the formation of thrombin which is responsible for a whole set of 
reactions, with the actual clotting, i.e. solidification of the blood, being only one. Thrombin activates the 
platelets and acts on the cell of the vessel wall. Activated platelets, in turn, promote thrombin 
formation.13 Thrombin plays a part in a whole set of positive and negative feedback reactions that first 
increase the thrombin production enormously, but inhibit it in a later stage. Consequently, the increase 
and subsequent decline of the amount of thrombin formed upon triggering of blood coagulation is the 
best indicator of the function of the haemostatic system.14 
 
 
1.2.1 Coagulation mechanism 
 
Blood coagulation results from a series of enzymatic reactions involving circulating protein clotting 
factors. These clotting factors are often present in the blood as inactive precursors (zymogens). In the 
coagulation process, protein clotting factors undergo enzymatic or proteolytic reactions that convert 
the inactive clotting factor to an active protease or enzyme. The active protease or activated clotting 
factor then activates the next clotting factor, eventually leading to the formation of a fibrin clot. This 
series of proenzyme-enzyme transformations is traditionally called a “cascade”. In addition to this 
“clotting cascade” a complicated set of checks and balances has been built in, assuring the limitation 
of thrombin formation in time and place via positive and negative feedback control. It therefore is more 
appropriate to consider the clotting system as a series of entangled loops rather than a cascade.  
 
A fast variety of enzymes is involved in the coagulation process. An enzyme is a protein capable of 
enhancing a specific chemical reaction. Enzymes are mostly highly specific both in the reaction 
catalyzed and in their choice of reactants, called substrates. An enzyme usually catalyzes only a 
single chemical reaction or a set of related chemical reactions. They can furthermore act as molecular 
switches in regulating catalytic activity and transforming energy as a result of their capacity to couple 
actions of separate binding sites.15 The concept of proenzyme-into-enzyme conversion is essential for 
the understanding of the events taking place during coagulation. Proteolytic enzymes (or proteases) 
are those enzymes that can break up other proteins into smaller fragments.16 Due to their high 
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reactivity, the proteolytic enzymes are usually formed and transported in the body as proenzymes. 
Proenzymes are usually larger than enzymes and cannot do any harm. Upon hydrolysis at a specific 
cleavage site, their enzyme character emerges. Various clotting factors involved in coagulation, 
indicated by F and a Roman numeral (see Table 1.1), are inactive proenzymes. When a proenzyme is 
activated into an enzyme, an "a" is added to the Roman number (e.g. FII (prothrombin) upon activation 
becomes FIIa (thrombin)).  
 
Table 1.1 Proteins involved in coagulation 
Factor* Common name Pathway Function 
I Fibrinogen Common Formation of fibrin clot.17 
II Prothrombin Common Zymogen of serine protease. Activated by prothrombinase complex on the platelet surface.18 
III Tissue factor Extrinsic Cofactor to FVII.19 
IV Calcium++ Common Activation of multiple factors20 
V Proaccelerin Common Activated by thrombin. Cofactor to FX-induced FII activation.21 
VII Proconvertin Extrinsic Zymogen of serine protease. Precursor for VIIa.
22 
Activated by the FVIIa/TF complex.23 
VIII  Antihemophilic factor A Intrinsic Cofactor to FIXa in the activation of FX.
24 
Activated by vWF and thrombin. 
IX 
Christmas factor 
Antihemophilia factor B 
Intrinsic Zymogen of serine protease. Activated by FXIa in the presence of Ca ions.25 
X Stuart-Prower factor Common FXa and cofactor FVa form prothrombinase complex, which catalyzes FII to FIIa conversion.26 
XI Thromboplastin precursor Intrinsic Zymogen of serine protease.
27 
XII Hageman factor Intrinsic 
Zymogen of serine protease. Activated by FXIIa 
binds to exposed collagen at wound site.28 
Activated by HMW kininogen and kallikrein.  
XIII Pro-transglutaminase or fibrin stabilizing factor Common 
Transglutaminase stabilizes fibrin clot by covalent 
cross-linking. Activated by thrombin in the 
presence of Ca ions.29 
Prekallikrein Fletcher factor Intrinsic Proenzyme in 1:1 complex with HMW kininogen. 
Converted to kallikrein by FXIIa and with FXIIa 
converts HMW kininogen into bradykinin - an 
important mediator of fibrinolysis.30 HMW 
kininogen Fitzgerald factor Intrinsic 
vWF Von Willebrand factor 
Intrinsic 
platelet 
adhesion 
Carrier molecule for FVIII.31 In platelet adhesion it 
serves as a bridging protein between the 
GPIb/IX/V receptor on platelets and collagen.32 
Protein S   Regulation Cofactor of activated protein C (APC). Inactivation of FVIIIa and FVa.33 
Protein C   Regulation Activated to APC by thrombin bound to thrombomodulin. Degrades FVIIIa and FVa.34 
TM Thrombomodulin Regulation Binds thrombin, which then activates protein C.35 
ATIII Antithrombin III Regulation Downregulates activity of FIIa, FIXa, XIa, and XII.36 
* Factors marked bold are proenzymes, undergoing transformation into enzymes. 
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The clotting mechanism is based on an ordered series of proenzyme - enzyme conversions. The first 
proenzyme of the series is transformed into the active enzyme that in sequence activates the next 
proenzyme and so on. In this way a few molecules in the beginning of the series create an explosion 
of the final active enzyme i.e. thrombin.37 Apart from proenzyme-enzyme conversion, two additional 
principles govern thrombin generation: surface bound enzyme complexes and feedback activation- 
and inhibition. Furthermore blood platelets play an important role in the clotting mechanism in 
providing the surfaces for adsorption. Nevertheless the cascade of proenzyme-enzyme conversions 
does remain the skeleton of the mechanism. Thrombin formation is dependent upon the formation of 
the prothrombin activator complex (prothrombinase). The prothrombin activator is formed via two basic 
pathways. The extrinsic pathway is initiated by trauma caused to the vascular wall and surrounding 
tissues and the intrinsic pathway starts by contact of the blood with a foreign surface such as sub-
endothelial connective tissues or with negatively charged surface that are exposed as a result of 
tissue damage. From the prothrombin activator complex onwards the two pathways follow a common 
pathway resulting in the formation of fibrin polymer strands. The whole coagulation mechanism is 
depicted in Figure 1.2.  
The extrinsic pathway is initiated by traumatized tissue exposing tissue factor (TF), a membrane 
protein of the perivascular cells that do not come into contact with blood unless in a wound. After 
binding of factor VII to TF, factor VIIa can be generated by Ca2+ mediated autoactivation.38 TF does 
not only localize the reaction in the wound but also triggers structural changes in factor VII so that the 
proteolytic attack of its substrates, factors X and IX, can take place. These and subsequent reactions 
require binding of the reactants to a phospholipid (PL) containing membrane in the presence of Ca2+ 
ions. The surface bound complex of factor VIIa and TF activates factors X and IX. Activated factor X 
(Xa) splits prothrombin (FII) to generate thrombin (FIIa).37,39 Figure 1.2 shows the activation of factor X 
by the TF/VIIa complex and the subsequent activation of FII by Xa into thrombin (FIIa). 
 
 
 
 
 
 
Figure 1.2 Combined intrinsic-, extrinsic-, and common pathway in the coagulation mechanism. 
Dashed arrows indicate activation of a clotting factor by another activated clotting factor or complex.  
 
Factor Xa however, is not a very efficient enzyme and requires the presence of activated factor V (a 
cofactor) to form the prothrombin activator complex (VaXa, prothrombinase). This complex speeds up 
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prothrombin activation by a factor three thousand.40 Prothrombinase and prothrombin bind to a 
phospholipid surface facilitating the conversion of prothrombin to thrombin. 
 
The second mechanism for initiating the formation of prothrombin activator complex starts upon 
contact of the blood with a negatively charged surface (contact activation) and is known as the intrinsic 
pathway (see also Figure 1.2). Contact activation makes that factor XII takes on a new configuration, 
thereby becoming a proteolytic enzyme (XIIa). Activated factor XII acts on factor XI; this reaction 
requires the presence of high molecular weight kininogen (HMW kininogen), which is converted to 
bradykinin.30 This reaction is accelerated by prekallikrein (PK), which is converted to kallikrein (KK). 
The activated factor XI then enzymatically works on factor IX generating activated factor IX (IXa). 
Factor IXa in combination with factor VIII, Ca2+, and phospholipids present on the surface of platelets, 
activates factor X, analogous to the FVIIa-TF complex.41,42  
 
The following conversions are common for both the intrinsic and the extrinsic pathway (i.e. the 
common pathway): factor Xa combined with factor Va and phospholipids form the prothrombin 
activator complex, this in turn initiates the cleavage of prothrombin to thrombin (FIIa). In the presence 
of thrombin, fibrinogen (Figure 1.3) is converted into fibrin monomers by cleavage of respectively two 
negatively charged fibrinopeptides A (16 amino acid residues) and B (14 amino acid residues) from 
the N-terminal ends of the Aα- and Bβ-chains.43  
 
 
 
 
Figure 1.3 Structure of fibrinogen consisting of 2 sets of triple protein helices [(Aα)-(Bβ)-γ]2 joined by 
disulfide bonds. 
 
Removal of the fibrinopeptides A and B allow the fibrin monomers to self-assemble to form long 
polymers as shown in Figure 1.4. At this stage, the fibrin monomers are bound to each other by non-
covalent interactions. However, covalent cross-linking of fibrin is required for adequate clot strength 
and normal wound healing. Therefore, pro-transglutaminase (factor XIII) is converted to FXIIIa by the 
action of thrombin (see Figure 1.2 and 1.5). FXIIIa then induces covalent cross-linking of specific 
lysine and glutamate residues at the C-terminus of the -strands of fibrin.44 Several other sites become 
cross-linked more slowly and give the clot additional strength. 
 
2
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Figure 1.4 Formation of fibrin polymers by self-assembly of fibrin monomers. 
 
An overall representation of the two pathways initiating the formation of prothrombin activator complex 
(XaVa:PL) which is responsible for the formation of thrombin and thereby the blood coagulation, is 
shown in Figure 1.2. There are several interactions between the two coagulation pathways. Firstly, 
FVIIa-TF (extrinsic pathway) activates factor IX (intrinsic pathway) resulting in factor X activation either 
by factor XIa or by FVIIa-TF. Secondly, there is the proteolytic effect of thrombin on factor VIII and 
factor XI. Therefore, initiation by the extrinsic pathway will eventually also result in activation of factors 
of the intrinsic pathway.  
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1.2.2 Feedback activation and inhibition 
 
A series of activation and inhibition reactions control the formation of thrombin. Though, the key 
enzyme in the control of this rate of formation is thrombin itself. Small amounts of thrombin are able to 
activate cofactor V. The formed prothrombinase complex gives rise to an explosion of prothrombin 
conversion. The excess thrombin, however, also down-regulates its own production by binding to 
thrombomodulin (TM), a membrane protein of the endothelial surface. The resulting complex activates 
protein C (C  APC), the enzyme responsible for the degradation of factor Va and VIIIa. Hence, 
further thrombin generation is halted. Because the activation of factor V by thrombin is direct, while the 
inactivation is mediated via TM and proteins C, a ‘window in time’ is created in which thrombin 
generation is particularly efficient. 45 The thrombin production and inhibition is depicted in Figure 1.5. 
Comparable to the role of factor V in prothrombinase is that of factor VIII which facilitates activation of 
factor X by factor IXa. However, as mentioned before, factor VIIIa is also inactivated by APC, resulting 
in down regulation of thrombin production.  
 
 
 
Figure 1.5 Chart of all positive and negative feedback reactions in the coagulation network.  
 
An additional negative feedback mechanism arises when factor Xa binds to tissue factor pathway 
inhibitor (TFPI). The resulting complex binds to the VIIa-TF complex and blocks its activity. With only 
minute quantities of TF available, insufficient activated factor X may survive to ensure adequate 
thrombin generation. At that moment it is useful that factor IX is present to create an independent 
source of factor X activator. As depicted in Figure 1.5, there is a reinforcement loop, the so-called 
Josso loop.46 VIIa-TF at very low concentrations activates factor IX and factor IXa activates factor X. 
This mechanism becomes important if little TF is available, so that few Xa is formed directly. At still 
lower concentrations of TF the fact that factor XI can be activated by thrombin begins to count, 
initiating the pathway XI → IX → X → II.41 The activation of platelets by thrombin and fibrin are other 
examples of feedback activation (vide infra). Overall at least five positive and three negative regulatory 
feedback mechanisms can be recognized to control blood coagulation. 
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1.2.3 Role of platelets and surface bound enzymes 
 
Both Hemker47 and Rosing40 observed an increase of catalytic activity of reversible enzyme 
complexes in the presence of phospholipids (PL). The phospholipids that are able to attribute in the 
coagulation reactions need to contain a certain amount of the negatively charged aminophospholipids, 
phosphatidyl serine (PS) and phosphatidyl ethanolamine (PE) in order to bind coagulation factors. 
These phospholipids are not found on the outside of the cell membrane double layer, but present on 
the inside. As a result of cell damage the inner layer is exposed, initiating the coagulation process. 
There are four types of phospholipids bound clotting factor complexes. The most common three 
complexes are Xa-Va-PL that activates prothrombin, IXa-VIIIa-PL activating factor X and the complex 
PL-APC-protein S which inactivates factors Va and VIIIa. Finally, the tissue factor-VIIa complex, 
generated upon contact of blood with perivascular tissue, is formed. The kinetic constants of these 
complexes are dependent upon the phospholipid composition of the surface.48 This composition 
changes in time with the degree of activation of the platelets. This makes that the rate of thrombin 
formation is subjected to changes dependent upon the activation state of the platelets.49 
 
Not only regulation in time is important, also containment in space is necessary. Platelets (or 
thrombocytes) play a key role in coagulation since they bind to the site of a damaged vessel. Upon 
rupture of a vessel, collagen is exposed and the platelets adhere to it. This adhesion can take place 
directly via membrane bound glycoproteins (GP) e.g. GPIa/IIa, GPIIIb and GPIV or indirectly via linker 
proteins such as the von Willebrand Factor (vWF), see Figure 1.6.  
 
 
 
Figure 1.6 Binding patterns at a damaged vessel wall. Initial binding of GPIa to collagen followed by 
adhesion of platelets or adhesion to vWF. Activation of the platelets by thrombin generates GPIIb/IIIa 
binding sites. Adhesion of fibrinogen results in the aggregation of multiple platelets.  
 
The adhesion of platelets to GPIa/IIa or vWF causes a structural modification of the heterodimer 
composed of glycoproteins IIb and IIIa (GPIIb/IIIa) on the surface of the platelets. The phospholipids 
(PE & PS) turn from the inside of their membrane to the outside thereby supporting thrombin 
generation. Thrombin then stimulates the platelets in the formation of more GPIIb/IIIa receptors. 
Platelets adhere to each other via these GPIIb/IIIa proteins and fibrinogen. Although fibrin is presumed 
as the inert end product of blood coagulation, it in fact is an active component since, via platelet 
activation, it promotes thrombus growth. The platelet plug acts as a sponge of which the formed 
thrombin is not washed away by the flowing blood. That is why the primary haemostatic plug and the 
arterial thrombus consist mainly of platelets. 
 
 
1.2.4 Fibrinolysis 
 
Once haemostasis is restored and the tissue is repaired, the clot or thrombus must be removed from 
the injured tissue. This is achieved by the fibrinolytic pathway. Fibrinolysis is controlled by activation 
and inhibition processes resulting in the formation of the enzyme plasmin (Figure 1.7, left). This potent 
proteolytic enzyme with a broad spectrum of activity is formed by activation of the proenzyme 
plasminogen by either plasma or tissue activators. Tissue plasminogen activators are found in most 
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tissues. The two best characterized activators are vascular activator (commonly known as tissue 
plasminogen activator or tPA) and urokinase plasminogen activator (uPA).50 tPA requires fibrin for 
effective conversion of plasminogen into plasmin, thus tPA is inactive in the absence of a fibrin clot. 
The native form of plasminogen in plasma has glutamic acid at the N-terminal and is termed Glu-
plasminogen. Other plasminogen forms generated through cleavage by plasmin contain mostly lysine 
at the N-terminal position and are subsequently termed Lys-plasminogen.12 Triggering of the 
fibrinolysis pathway occurs when the plasminogen activator, plasminogen, and fibrin are in close 
proximity. Both plasminogen and its activator bind to fibrin as the clot forms. The close association 
stimulates the production of Lys-plasminogen which allows proteolysis of fibrin to proceed. 
 
 
 
Figure 1.7 Left: chart of fibrinolytic activation and inhibition; right: mode of action of plasminogen 
activator on fibrin-bound and circulating plasminogen.  
 
The fibrin specificity of plasminogen activators reflects their ability to distinguish between fibrin-bound 
and circulating plasminogen. Activation of fibrin-bound plasminogen results in plasmin generation on 
the fibrin surface and subsequent fibrin degradation. In contrast, activation of circulating plasminogen 
results in systemic plasminemia and degradation of fibrinogen and other clotting factors (Figure 1.7, 
right).50 In addition, the close proximity effect prevents inhibition of plasmin by inhibitors. Plasmin 
inhibitors (antiplasmins), which control plasmin activity include; α1-antitrypsin, α2-antiplasmin, C1 
inhibitor, antithrombin and α2-macroglobulin.51 Plasmin can attack fibrin at a number of different sites, 
at least 50, reducing its size such that it no longer holds together. Multiple fragments are formed 
during this process and some retain the capacity to polymerize. As a result, some of the early stage 
degradation products can compete with fibrinogen for activation by thrombin thus acting as inhibitors 
of clot formation. This may prevent the clot being removed before the tissue is repaired. By continuous 
cleavage of fibrin and generation of new C-terminal lysine residues, plasmin stimulates its own 
formation in a positive feedback loop. This positive feedback loop is halted by the activity of activated 
TAFI, i.e. thrombin activatable fibrinolysis inhibitor.52 Because this inhibitor originates by the action of 
thrombin it forms a direct link between the fibrinolytic system and thrombin generation, explaining why 
defective thrombin generation can lead to increased fibrinolysis. Finally, more and more leukocytes 
appear at the haemostatic clot site, indicating that the clearance of the clot is in progress.53 
 
 
1.3 Measuring thrombin 
 
 
Since thrombin plays a pivotal role in the coagulation cascade (vide supra), assessment of thrombin 
generation (i.e. appearance and disappearance) provides clinicians with a tool for the diagnosis of the 
blood coagulation capacity and associated haemostatic disorders.    
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1.3.1 Classical thrombin generation test 
 
Ever since Virchow enhanced the understanding of blood coagulation scientists have strived to 
develop methods for the determination of the blood clotting behavior. A variety of methods describing 
the use of clotting times of whole blood were reported throughout the 19th and beginning of the 20th 
century.54 Pioneers in this field such as Richardson, Vierordt and Lee and White, monitored the 
formation of a clot from fibrin in glass tubes, initiating the coagulation by contact activation on the 
glass surface.2 
In addition to the whole blood clotting time tests, a method for plasma clotting times measurement was 
developed by Gram in 1921.55 He used citrate as an anticoagulant to prevent preliminary coagulation 
and measured clotting at 37 °C. The results of plasma clotting times remained freely interpretable, as 
a result of contact activation and admixture of white cells and platelets. Quick was the first to add 
“thromboplastin”, i.e. a more or less standardized excess amount of tissue factor. He and his 
associates noted that clotting times in plasma could still vary and such variations they attributed to 
variations in prothrombin. He therefore called his method the prothrombin time test.56 In 1953, Biggs 
and Macfarlane57a and Pitney and Dacie57b simultaneous presented a method for the measurement of 
thrombin generation, the predecessor of the current thrombin generation test. In the same issue of J. 
of Clinical Pathology, Biggs and Douglas58 presented the thromboplastin generation test, which found 
widespread applications in the determination of Haemophilia A and B. 
 
Measurement of the changing of thrombin concentration of blood (Macfarlane and Biggs) or recalcified 
plasma (Pitney and Dacie) during coagulation gave useful information. A curve describing the amount 
of thrombin formed in time could be constructed (see Figure 1.8). Abnormalities to the curve were 
found as a result on hemophilia and other conditions with deficient thromboplastin formation. The 
thrombin generation test gave easily interpretable information and was found to be sensitive to small 
changes. The thrombin generation test (TGT) exploited by Biggs and Macfarlane59 was one of the 
most sensitive tests for the determination of blood coagulation, though it was complex and subjected 
to error if not performed routinely. The labor intensive classical method by Biggs and MacFarlane for 
the determination of thrombin generation can be described as follows:59 
The time-monitoring is started when citrated blood is recalcified. Every 30 seconds, 0.1 mL of blood is 
taken from a test-tube filled with clotting blood and is added to another tube filled with a fibrinogen 
solution. With a different set of stopwatches the clotting times of the fibrinogen solutions are measured 
and from these the thrombin concentration is inferred. A short clotting time corresponds to a large 
amount of thrombin present in the sample. This correlation between the amount of thrombin and 
clotting time has been determined on forehand. Because the clotting process can take up to 15 till 30 
minutes, 30 to 60 samples have to be taken and also have to be monitored in time. To obtain 
representative results this experiment has to be conducted in duplicate or in triplicate.  
 
 
This method is known as the subsampling 
method. One result obtained by Biggs and 
MacFarlane applying this method is 
illustrated in Figure 1.8. There is a clear 
delay-phase of approximately three 
minutes in which no thrombin can be 
detected that shortens to one minute at 
the addition of a small amount of thrombin 
at zero time, thus illustrating the positive 
feedback action of thrombin. Biggs and 
Macfarlane also observed that rapid 
thrombin generation not precedes but 
follows the on-set of fibrin formation. In 
haemophilic and thrombotic subjects, 
marked changes in thrombin generation 
were observed. Overall the thrombin 
generation test was a good indicator for 
H&T diseases but in the form as applied 
by Biggs and Macfarlane cannot be 
applied with the facility and throughput 
required by a modern laboratory. 
Figure 1.8 Thrombogram obtained with the classical 
subsampling method. The thrombin generation test 
was carried out in glass tubes in the presence and 
absence of one unit of thrombin added at t = 0.  
From R. Biggs & R.G. Macfarlane, Human blood 
coagulation and its disorders, ref 59.  
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1.3.2 Optical density based thrombin generation test 
 
The classical thrombin generation test suffers from some important drawbacks; the sample from the 
mixture in which thrombin was generated had to be tested immediately with a fibrinogen containing 
reagent, and estimation of low concentrations of thrombin tended to be imprecise and time-
consuming. In an attempt to streamline the classical method, Hemker and Béguin60 applied 
subsampling from activated plasma into a solution containing chromogenic substrate S2238 
(Figure 1.9) and read the thrombin concentration spectrophotometrically from the development of 
colored product (p-nitroaniline). The determination of the time course of amidolytic activity (i.e. the 
sum of the activities of free thrombin and of the α2-macroglobulin-thrombin complex formed) was 
performed using a push-button pipette triggering automatic time recording during subsampling. In this 
way it was possible to obtain a thrombin generation curve (TGC) with sampling intervals that were as 
small as 5 seconds (see Figure 1.9, left). The generated curves could be used to calculate the time 
course of the process that generated thrombin independently of the processes that inactivate 
thrombin.60 In an attempt to continuously measure thrombin generation directly, the chromogenic 
substrate S2238 was added to the clotting plasma. However, the high rate of hydrolysis resulted in 
complete conversion of the substrate long before TG was over. Additionally the affinity of the substrate 
for thrombin was too high causing interference with natural thrombin inactivation and other 
physiological reactions of thrombin. To prevent the substrate being exhausted a slowly reacting 
substrate was required (i.e. low turnover number (kcat)). To minimize the interference with physiological 
thrombin substrates, a high Michaelis constant (KM) of the artificial substrate was required as well. 
These requirements were met with chromogenic substrate MeO-mal-Aib-Arg-pNA (SQ68). 
Consequently, substrate SQ68 allowed continuous registration of thrombin activity in plasma, see 
Figure 1.9, right.61  
 
  
 
Figure 1.9 Left: TG curve obtained by subsampling in a solution containing chromogenic substrate 
S2238; right: picture of an on-line thrombogram (or TGC) using SQ68. The enzyme concentration from 
the reaction velocity of SQ68 conversion is calculated via Et = vt ·(KM+S0/kcat·S0). 
 
The general form of the spectroscopically obtained thrombogram is shown in Figure 1.9. Since the 
thrombin-substrate was present at a virtually constant concentration during the whole thrombin 
generation, the velocity of conversion was proportional to the concentration of thrombin. From the 
substrate conversion velocities (= slope) the level of thrombin was calculated via the formula dS/dt = 
kcat · E · S/ (KM + S).61,62 During the lag time the traces of thrombin that are formed, through feedback 
activation, cause the explosive thrombin formation. The peak-height was found to be a good indication 
of maximal prothrombin conversion velocity.  
An interesting feature of the obtained thrombin generation curve or thrombogram was the area under 
the curve, initially called thrombin potential61 and later the endogenous thrombin potential or ETP.63 It 
represents the capacity of the enzyme thrombin to convert substrates or the number of “man-hours” of 
thrombin that develops, and hence the amount of “enzymatic work” that thrombin is capable of during 
its lifetime in clotting blood.62 The actual value depends on the area under the TGC and the kinetic 
properties and concentration of the substrate. It is an area in a graph of thrombin-concentration versus 
time and therefore has the dimension concentration  time, i.e. nM·min. The amount of artificial 
substrate converted under experimental conditions will be a direct indicator of the amount of natural 
substrate that thrombin can convert when it is generated in a volume of clotting blood in vivo. The 
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endogenous thrombin potential (ETP) was proposed as a parameter for plasma-based hyper-
coagulability and to monitor anticoagulant treatment64 or the effect of oral contraceptives.65 Increased 
concentrations of heparin caused an identical decrease of the ETP in the intrinsically- and the 
extrinsically triggered clotting system though resulted in variable lag-times.66 Since there is no fixed 
relation between the lag-phase ( clotting time) and the area under the curve (ETP) the thrombogram 
demonstrated the limited significance of clotting times in assessing thrombin generation. 
 
A technical problem arose from the fact that part of the thrombin in plasma reacts with 2-
macroglobulin (2M) to form a complex that, though biologically inactive, still was capable to convert 
small substrates. Thus, during thrombin generation in vitro, amidolytic activity that is not due to 
thrombin itself appeared which is not related to known biological activity. Two methods were 
developed to eliminate this irrelevant activity and obtain the activity curve of free thrombin only. The 
first method applied mathematical processing of the thrombin generation curve by correcting for the 
undesired 2-macroglobulin-thrombin activity.67 The second method applied deactivation of 2-
macroglobulin activity by addition of a metalloprotease or a synthetic substrate in combination with 
hydroxylamine.68 Both methods allowed ETP determination as an endpoint measurement of the optical 
density. A far greater problem was the fact that the presence of SQ68 influences the amount of free 
thrombin that appears in plasma since it competitively inhibits the deactivation of thrombin by ATIII 
and α2-macroglobulin.61  
 
 
Figure 1.10 Structures of synthetic chromogenic substrates for monitoring thrombin generation.  
 
Svendsen et al.69 developed various para-nitroaniline containing thrombin specific substrates such as 
Bz-Phe-Val-Arg-pNA (see Figure 1.10). Based on the findings of Svendsen, Rijkers et al. developed 
new slow reacting substrates so that during the whole course of thrombin generation the velocity of 
color production remained proportional to the amount of enzyme.70 Since the process of thrombin 
generation took place in a plasma sample, the synthetic substrate needed to be free of any inhibitory 
activity on other coagulation factors influencing thrombin generation. Moreover, the ideal substrate 
would be a highly thrombin specific compound, having no interaction with factor Xa. The kinetic 
parameters of hydrolysis served as a first basis for selection of improved thrombin substrates. Based 
on the aforementioned criteria substrates with the general formula H-Val-Arg-pNA·2HCl, Msc-Val-Arg-
pNA·HCl and H-Glu-Gly-Gly-Val-Arg-pNA·2HCl and the compounds H-D-Phe-Pip-Orn-pNA·2HCl, H-D-
Phe-Pip-Glu-pNA·2HCl and DEMZ-Gly-Arg-pNA·HCl (DEMZ: diethyl malonic acid monomethyl ester) 
(Figure 1.10) were found to be most suitable for the continuous thrombin assay.71,72 Initial experiments 
demonstrated that all the clotting factors deficiencies, except for factor XIII, could now be measured in 
platelet poor plasma using these substrates.73,85 
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Because the method depended upon the measurement of optical density, it could not be carried out in 
a mixture that would become turbid due to clot formation. All thrombin generation experiments were 
therefore carried out in defibrinated and consequently platelet poor plasma. Going from platelet poor 
plasma (PPP) to platelet rich plasma (PRP) to whole blood, the physiological system becomes more 
representative of what happens in the body though concomitantly, technically more difficult to assess. 
Application of fluorogenic substrates made measurement in non defibrinated and platelet rich plasma 
possible and thus brought the assay system one step nearer to the physiological system.  
 
 
1.3.3 Fluorescence based thrombin generation test 
 
The use of the thrombogram as a global function test has been limited by the technical difficulties in 
obtaining the curve. The classical subsampling method takes 1–2 hours of two trained people for a 
series of six curves. The thrombogram could be measured continuously by the use of chromogenic 
substrates. In a suitably automated laboratory, 24 thrombograms could be recorded simultaneously in 
this way. The drawback was the necessity to defibrinate the plasma in order to prevent turbidity which 
disturbed optical density registration upon coagulation. This automatically prevented measurements in 
platelet rich plasma (PRP) which is preferred since platelets play an important role in coagulation. This 
problem could be circumvented by using a fluorogenic substrate.  
 
Not long after the development of the continuous thrombin generation using chromogenic substrates, 
Hemker and coworkers developed a method for monitoring the thrombin generation automatically in 
PRP through the continuous measurement of the fluorescent split-product of the substrate Z-Gly-Gly-
Arg-AMC (see Figure 1.11).74 Since the signal is not impaired by turbidity, proper measurement was 
not disturbed by the occurrence of a clot or the presence of platelets resulting in the possibility to 
measure directly in platelet rich plasma. 
 
 
Figure 1.11 Left: structure of Z-Gly-Gly-Arg-AMC, Z = benzyloxycarbonyl; right: absorption and 
emission spectra of 7-amino-4-methylcoumarin (AMC).75  
 
Upon hydrolysis by thrombin, the fluorogenic substrate Z-Gly-Gly-Arg-AMC releases the fluorophore 
7-amino-4-methylcoumarin (AMC), which can be measured by a 390 nm excitation and a 460 nm 
emission filter set (Figure 1.11, right). Substrate Z-Gly-Gly-Arg-AMC was found useful for this system 
due to a good signal-to-noise ratio. By using platelet rich plasma and the fluorogenic substrate it was 
now possible to examine the role of platelets in thrombin generation.76,77  
Unfortunately, the fluorogenic based thrombin generation method also suffers from some drawbacks. 
Firstly substrate-depletion was no longer negligible as a result of the poor kinetic parameters. 
Secondly, the poor solubility of the substrate in aqueous media required vast quantities of DMSO to be 
added which can affect protein activity and damage platelets. And finally, increasing quantities of AMC 
resulted in partial quenching of the fluorescent signal as a result of the inner-filter effect.78 The velocity 
of fluorescence increase per unit enzyme therefore decreases during the experiment as a function of 
the amount of substrate converted into enzyme, i.e. in a unique way as a function of the fluorescence 
observed.  
Since the fluorescence increase thus was not linear to thrombin concentration a method was required 
to correct for this effect. To this end each TG experiment was accompanied by an experiment in which 
a fixed amount of thrombin activity (in the form of 2-macroglobulin-thrombin complex) was active, so 
that at every level of substrate and product concentration the appropriate calibration factor could be 
read. Each experiment therefore requires two sets of readings, one from a well in which thrombin 
generation takes place (TG well) and a second one from a well to which the calibrator has been added 
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(CL well). Plasma quenches fluorescence and different plasmas quench to a different extent, 
therefore, each plasma needed to be compared to its own calibrator measurement. The thrombin 
activity can then be calculated as a function of time by comparing the fluorescent signal from the 
thrombin-generating sample to that from a known stable concentration of thrombin activity measured 
simultaneously in a parallel sample (Figure 1.12, black and gray line, respectively). This method is 
currently known as calibrated automated thrombography (CAT)79 and reflects to a great extent the 
overall function of clotting blood.80  
The calibrator used in CAT is the complex of anti-thrombin 2-macroglobulin and thrombin (2-M-T). In 
the encapsulated form thrombin is unable to act on its natural substrates and is not subject to further 
inactivation, however, amidolytic activity of thrombin within the 2-M-T complex remains,81 resulting in 
continuous hydrolysis of small substrates such as Z-Gly-Gly-Arg-AMC (or chromogenic substrates 
vide ante). Consequently, it can serve as a known stable concentration of thrombin activity.74 
 
 
 
Figure 1.12 Online registration of thrombin generation (black line) calculated by the first derivative of 
the fluorescent signal as a result of hydrolysis of the Z-Gly-Gly-Arg-AMC by thrombin. The light gray 
lines represent the hydrolysis of Z-Gly-Gly-Arg-AMC by a calibrator (i.e. 2-M-T complex).  
 
A typical CAT experiment generates thrombograms shown in Figure 1.12. The upper two frames in 
Figure 1.12 display thrombin generation measurements in platelet rich plasma (PRP) with different 
quantities TF added resulting in a shift in lag-time and peak height but not in ETP value. The lower two 
frames again show measurements with varying TF concentration though additional heparin is added. 
As a result, thrombin generation is completely inhibited (low TF conc.) or strongly suppressed (high TF 
conc.). On-line signal averaging and calculation of the first derivative in a dedicated instrument allows 
obtaining the thrombogram directly. The correction for the thrombin like activity that is due to 
2-macroglobulin bound thrombin appears to be much smaller in fibrinogen containing media than in 
defibrinated plasma, so that the first derivative of the fluorescence curve already gives a first 
impression of the thrombin generation during the course of the experiment. The substrate 
concentration used in this assay has a significant effect on the area under the curve, but there was a 
minor effect of the time to reach maximal rate (tmax). It was demonstrated that addition of 0.5-2.0 nM 
tissue factor has a marked effect on the rate and amount of thrombin generation.82  
 
Since the current assay system employs microtiter plates, this provides a high throughput platform for 
profiling anticoagulation drugs, platelet related deficiencies, clinical diagnostics and monitoring the 
effects of other drugs on the coagulation system.  
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1.4 Application of the thrombin generation test 
 
 
The use of the thrombogram as a function test of the haemostatic and thrombotic system for the 
laboratory diagnosis of bleeding and thrombotic diseases as well as anticoagulant research and drug 
monitoring has been extensively reviewed.83,14,84  
 
 
1.4.1 Diagnosis 
 
For every patient dying of a bleeding disorder, over a hundred die of untoward formation of a clot or 
thrombus, measuring hyperactivity (i.e. thrombosis risk) is at least as important as measuring 
hypoactivity (i.e. bleeding risk). Bleeding risk, to a certain extent goes hand in hand with prolonged 
clotting times, hypercoagulability on the other hand is not accompanied by shortened clotting times. 
Thrombin generation with peak height and the endogenous thrombin potential (ETP) provides 
parameters that increase with hypercoagulability and decrease with hypocoagulability independent of 
the condition that is responsible for its origin (congenital, acquired or drug induced).77  
Reduced thrombin generation has been reported to be associated with a number of rare clotting factor 
deficiencies (II, V, VII, X and XII)85 and with haemophilia deficiency factors VIII, IX or IX.86 In 
congenital deficiencies such as the clotting factors II, V, VII, VIII, IX, X and XI the lag-time is 
considerably prolonged and the peak and ETP are lowered. Increased risk of bleeding is observed 
when the ETP drops to below 20% of a normal value.85,86b  
Measuring thrombin generation in haemophilic patients is also useful for testing the effect of 
substitution therapy with factors VIII or IX. It is the only way to assess in vitro the effect of FVIII bypass 
therapy, i.e. the therapy that is needed if a patient has developed antibodies against the missing 
factor.87 Turecek and coworkers demonstrated the applicability of the TGT by monitoring FVIII-
bypassing therapy in order to achieve the desired balance between hypo- and hypercoagulability.88 In 
addition, they showed that using FEIBA® (a FVIII by-passing agent) on FVIII-deficient plasma restored 
thrombin generation to normal levels in terms of thrombin potential (Figure 1.13).89, 88b  
 
 
Figure 1.13 Changes in TG in FVIII inhibitor plasma reconstituted in vitro with either FEIBA® or rFVIIa.  
A) concentrations FEIBA in plasma from top to bottom: 2, 1, 0.8, 0.4, 0.2, 0.1, 0.5 and 0 U/mL. B) 
concentrations FVIIa in plasma from top to bottom: 125, 62.5, 25, 12.5, 6.25, 2.5, 1.25, 0.32, 0.08, 
0.02 and 0 μg/mL (Figure taken from ref. 88b).  
 
The use of a fluorogenic substrate in thrombin generation testing in addition enables the use of PRP.74 
Since thrombin is a potent platelet activator, the interactions between platelets and the clotting 
systems, including fibrin, can be revealed measuring TG in PRP. Platelet inhibition will therefore result 
in a decrease of thrombin formation. Studies by Heemskerk et al.90 have demonstrated that the 
exposure of phosphatidylserine (PS) on the surface of activated platelets initiated and regulated the 
thrombin generation since addition of annexin A5 completely stopped thrombin formation. The results 
thus underline the fact that plasma and platelets are not two separate systems, but operate jointly in 
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the body and open a field of clinical and physiological investigation that thus far has remained 
unexploited. For example, the mechanism by which fibrin, vWF and GPIb play a role in platelet 
activation was shown in a coupled PRP and PPP experiment.91 In von Willebrand disease thrombin 
generation is considerably lower in PRP compared to PPP which rules out the association with FVIII 
deficiency. A diminished TG was also observed in PRP (but not in PPP) of patients with 
hypofibrinogenaemia and Bernard-Soulier syndrome (congenital lack of GPIa) indicative for a fibrin-
vWF-GPIb coupled mechanism. Marchetti et al.92 demonstrated that, in addition to platelets, the role of 
fibrinogen and the effect of fibrin polymerization on prothrombotic tendency should be considered 
since this has a significant effect on thrombin generation.  
 
Thrombin generation has also been shown to be a useful tool in detection and quantification of 
thrombotic tendencies. Disturbances of the APC system, such as deficiency of protein S, protein C 
either congenital or acquired (oral contraceptives or pregnancy) and factor VLeiden can readily be 
traced, giving rise to an increased ETP of approximately 10%.93 This increase becomes much more 
evident when the APC system is activated by addition of APC or thrombomodulin.94,80,79 An APC 
sensitivity ratio is thus obtained which is much more precise than that measured by other 
techniques.95 It allows distinguishing between the extents of obtained APC-resistance induced by 
different types of oral contraceptives.96 
 
Furthermore, age-dependence in thrombin generation was demonstrated among neonates, juveniles 
and adolescents without known risk factors, in the absence97 and in the presence98 of an anticoagulant 
(Melagatran). Assuming that thrombin potential is an indicator for the risk of thrombosis, these findings 
are in accordance with the observation of increased occurrences of thrombembolic diseases at higher 
age.99 Finally, assessing the risk of recurrence of venous thromboembolism (VTE) demonstrated that 
patients without recurrent VTE had lower thrombin generation than patients with recurrence100 and the 
endogenous thrombin potential (ETP) in the recurrent VTE group was significantly higher than for the 
controls.101  
 
 
1.4.2 Treatment 
 
Drugs used in haemostatic and thrombotic disorders can basically be divided into two main groups; (a) 
coagulation reducing agents, and (b) coagulation facilitating agents. Within theses clusters a 
separation can be made based on the mode action of a particular drug (Figure 1.14). 
 
 
 
Figure 1.14 Organogram of drugs used in coagulation disorders.102 
 
Anticoagulant strategies to inhibit thrombogenesis focus on inhibiting thrombin or its generation, either 
by targeting coagulation factors higher in the cascade or by directly blocking thrombin. Anticoagulants 
commonly used to prevent venous thrombosis are Warfarin and low molecular weight heparins 
(LMWH).103 Coumarin derivatives, like Warfarin, effect coagulation by interfering with the cyclic 
conversion of vitamin K, thereby affecting the γ-carboxylation of coagulation factors II, VII, IX and X.104 
Unfractionated heparin (UFH) was the first antithrombin (AT) activating drug, but it has been largely 
replaced by low-molecular-weight heparin (Enoxaparin) because of the more favorable 
pharmacokinetics (less injections per day) and the lower risk of heparin-induced thrombocytophia.105 
The synthetic analogue of LMWH, the pentasaccharide Fondaparinux, demonstrated selective factor 
Xa inhibition. Al Dieri et al. studied the inhibition of thrombin generation induced by LMWHs (e.g. 
Certoparin and Enoxaparin), MMWH (medium molecular weight heparin) and UFH by profiling the 
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effects on the function tests aPTT and ETP.106 This study demonstrated that LMWHs have invariably 
an inhibitory effect on thrombin generation. This was confirmed by Gerotziafas et al.107 who profiled 
LMWH’s (Bemiparin, Nadroparin, Dalteparin and Tinzaparin) and compared them to UFH, 
Fondaparinux and Enoxaparin (FXa inhibitors).108 Direct thrombin inhibitors are another class of 
anticoagulant drugs. The advantage of this class of anticoagulant is that, contrary to heparins, they 
inhibit both clot-bound and free thrombin. Examples of direct thrombin inhibitors are Desirudin, 
Bivalirudin, Argatroban and Ximelagatran (orally active precursor of Melagatran). The thrombogram 
demonstrated its applicability in drug research by demonstrating the effect of anticoagulants 
Argatroban109 and Melagatran110 on thrombin generation. A detailed study was performed by Samama 
and co-workers, monitoring the effect of six different anticoagulants (i.e. r-Hirudin, Melagatran, 
Dabigatran, Argatroban, Fondaparinux and Danaparoid) on thrombin generation. The patterns of TG 
inhibition by Fondaparinux and Danaparoid were different compared to the other four anticoagulants 
as a result of different modes of action (FIIa or FXa inhibition).111 This confirmed that all the 
anticoagulants demonstrated a profound effect on the parameters obtained from the thrombogram (i.e. 
lag-time, time-to-peak and ETP). 
 
Aspirin, Ticlopidine, Clodipogrel, Abciximab and Tirofiban are examples of drugs that interfere with the 
activity of platelets. Previously they were thought to act as inhibitors of platelet aggregation. Now it is 
recognized that they also affect thrombin generation. The effect of aspirin on platelets and thrombin 
generation was in fact known since long.66,112 More recently it was shown that addition of the platelet 
inhibitor Tirofiban to heparinized blood prolonged the activated clotting time and significantly delayed 
the platelet activated thrombin generation.113 The same holds for the platelet inhibitors such as 
Abciximab.7  
In summary, a diminished ETP value was observed for all the anticoagulant drugs that have been 
tested. Opposite to the classical tests, the ETP could also quantify the effect of mixed oral 
anticoagulant and heparin treatment.114 As a rule, the therapeutic dosage of a drug caused a reduction 
of the ETP to 50–30% of its normal level.77 Until now no exception to the rule that a drug that 
diminishes thrombin generation in platelet rich plasma has an antithrombotic effect has been found. 
Presumably any systematic inhibition of thrombin generation will cause an antithrombotic effect, 
proportional to the decrease of ETP. This is probably independent of the mode of action of the drug. 
Probably the pharmacokinetic aspects (how constant is the effect of the used drug) are more 
important than the pharmacodynamic ones (how the effect is brought about).80 One can surmise that 
the thrombogram can not only be used as a tool in the control of antithrombotic treatment but also will 
be a powerful tool in the search for new and improved antithrombotics. 
Generally, the results obtained with the thrombogram suggest that this method reflects most of the 
overall function of the haemostatic and thrombotic system.14 However, further research is required 
towards standardization of the thrombin generation test since large inter- and intra-individual as well 
as inter- and intra-assay coefficients of variation have been found for thrombin generation 
parameters.82 The search for better substrates is one of the more important ways to ameliorate the 
performance of this potentially very useful test. 
 
 
1.5 Substrate development 
 
 
The majority of the coagulation factors are proenzymes for serine proteases.115 When activated they 
act by cleaving other proteins (other clotting factors) at specific sites. An extensive study on the mode 
of action of serine proteases was presented by Warshel et al.116 leading to the understanding of the 
serine proteases and giving rise to the mechanism that is generally accepted nowadays (Scheme 1.1). 
The pivotal amino acids found in the active site of all the serine proteases are histidine (His), aspartic 
acid (Asp) and serine (Ser). Since the side chains of these amino acids are in close proximity of each 
other, proton transfer from the serine hydroxyl to the carboxylate anion of aspartic acid, via the 
imidazole ring of histidine, is in constant equilibrium. This charge relay system of the catalytic triad 
His57-Asp102-Ser195 in thrombin generates a highly reactive hydroxyl moiety of Ser195. In the 
presence of a substrate, this hydroxyl anion acts as nucleophile attacking an amide bond of the 
substrate. The formed tetrahedral intermediate then abstracts a proton from the His57 residue to form 
the enzyme-acyl intermediate.117 Exchange of the amine functionalized substrate residue for water 
generates an intermediate capable of giving nucleophilic attack on the enzyme-acyl complex. Again a 
tetrahedral intermediate is formed, which rapidly eliminates the carboxylic acid functionalized 
substrate fragment, to regenerate the serine active site for the next cycle.  
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Scheme 1.1 Catalytic cycle of substrate hydrolysis by serine protease. 
 
 
1.5.1 Fluorogenic peptide substrates 
 
The understanding of the mode of action of serine proteases and discovery of active site specificity of 
proteases led to the development of chromogenic and fluorogenic peptide based substrates for 
assaying particular proteases.69,118,119 Upon hydrolysis of a functionalized peptide by a serine 
protease, the released probe could be measured by means of optical density or fluorescence (Scheme 
1.2). Via mathematical processing, the desired kinetic parameters could be obtained.  
 
 
Scheme 1.2 Applied concept for monitoring enzymatic activity. Upon hydrolysis of the labeled peptide, 
the probe is released giving a distinct signal. 
 
The concept of monitoring enzyme activity applying 7-amino-4-methylcoumarin in fluorescently labeled 
peptides was first introduced by Zimmerman in 1976.120 Using H-Glu-Phe-AMC as a substrate he was 
able to selectively determine the activity of chymotrypsin. Two years later, he introduced the substrate 
Z-Gly-Gly-Arg-AMC, currently in use for monitoring thrombin generation, for the determination of the 
kinetic parameters and the inhibitor profile of urokinase and plasminogen activators.121 Around the 
same time, Morita et al.122 tested 20 peptidyl-aminomethylcoumarins as possible substrates for 
thrombin, factor Xa, kallikreins, urokinase, and plasmin. These fluorogenic peptides contained 
arginine-AMC as the carboxyl-terminus and the following were found to be specific substrates for 
individual enzymes: Boc-Val-Pro-Arg-AMC for thrombin, Boc-Ile-Glu-Gly-Arg-AMC and Boc-Ser-Gly-
Arg-AMC for factor Xa, Z-Phe-Arg-AMC for plasma kallikrein, and glutaryl-Gly-Arg-AMC for urokinase 
(see Table 1.2). Moreover, all of these peptide-AMC substrates were resistant to plasmin. Throughout 
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the next decades various fluorogenic substrates were developed for selective targeting of coagulation 
proteases and for monitoring their activity (summarized in Table 1.2). 
 
Table 1.2 Substrates for coagulation proteases 
Factor Substrates Reference 
IIa (thrombin) Ac-Nle-Thr-Pro-Arg-AMC  
Ac-Nle-Leu-Pro-Arg-AMC 
Boc-Asp(OBzl)-Pro-Arg-AMC 
Boc-Val-Pro-Arg-AMC 
Boc-Val-Arg-AMC 
Tos-Gly-Pro-Arg-AMC 
123 
124 
125 
122, 125 
126 
127 
VIIa Ac-Trp-Tyr-Thr-Arg-ACC1 
Ac-Gln-Val-Arg-ACC2 
128 
129 
IXa Boc-Glu(OBzl)-Gly-Arg-AMC  130 
Xa Ac-Ile-Phe-Phe-Arg-AMC 
Ac-Nle-Arg-Gly-Arg-AMC 
Z-Glu-Gly-Arg-AMC 
Boc-Ser-Gly-Arg-AMC 
124 
131 
125 
122 
XIa Boc-Glu(OBzl)-Ala-Arg-AMC 
Boc-Phe-Ser-Arg-AMC 
125 
132 
XIIa Boc-Gln-Gly-Arg-AMC 125 
Plasmin H-D-Val-Leu-Lys-AMC  
Suc-Ala-Phe-Lys-AMC  
133 
134 
1 Recombinate FVIIa was used for profiling, 2 FVIIa in combination with TF, ACC = 7-amino-4-carbamoylmethylcoumarin 
 
The specificity of the enzymes for a particular substrate depends on the interactions of the amino 
acids in the substrate and the amino acids forming the specificity pockets (S1-n) of the active site. For 
the coagulation proteases depicted in Table 1.2, the primary specificity pocket (S1) contains one or 
more negatively charged amino acid side-chains (e.g. Asp or Glu), resulting in the favorable binding of 
positively charged side chains (e.g. Lys or Arg) at position one (P1) of the substrate. Since all of these 
proteases favor a positively charged amino acid at P1, the specificity of a particular substrate is 
determined by the interaction of the amino acids at P2, P3 and P4 with the secondary, tertiary and 
quaternary specificity pocket (S2, S3 and S4). A tool frequently employed for profiling protease activity 
and specificity by active site profiling is the construction of position scanning combinatorial substrate 
libraries (PS-CSL).123,135 Based on the principle of solid-phase peptide synthesis, a library of 
substrates is generated by varying the amino acids sequence, though keeping one amino acid residue 
constant at a specific position.136 The substrate cleavage profile of thrombin is restricted as a result of 
the specificity determined by the S2-S4 substrate binding sites. The sequence space for thrombin’s P2, 
P3, and P4 substrate preference has been completely sampled by Backes et al.123 Profiling of thrombin 
with the position scanning libraries revealed that the preferred P2-P4 substrate specificity was for large 
aliphatic amino acids at P4, such as norleucine, leucine, and isoleucine, negligible discrimination at P3, 
and high specificity for proline at P2. These preferences were validated through single-substrate kinetic 
analysis using arginine in the P1 position. The requirement for aliphatic amino acids at P4 has a less 
pronounced effect than the requirement for proline at P2, as reflected by the activities. 
 
Profiling of the enzyme activity and specificity requires the fluorophore (AMC) to be coupled to the C-
terminus of the substrate, for thrombin specific peptides this being an arginine residue. The 
troublesome coupling of amino acids, and in particular arginine, with AMC has led to a wide range of 
methods for the synthesis of amino acid-AMC derivatives (Scheme 1.3). 
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Scheme 1.3 Methods for the coupling of 7-amino-4-methylcoumarin to amino acids; DCC,120,122 
EDC,137  HATU,138 HBTU,139 PCl3,140 POCl3,141 para-nitrophenol (pNP),142 acid chloride,143 Boc2O,144,145 
iBu-chloroformate,146,147 and diethyl phosphonate.148  
 
The most frequently applied methods for the coupling of AMC to an amino acid are based on peptide 
coupling reagents (e.g. DCC, EDC, HATU or HBTU). Depending on the amino acid and the coupling 
reagent used, the product is obtained in moderate to reasonable yield. Other methods utilize reagents 
forming mixed-anhydride intermediates which upon addition of AMC react to produce the desired 
product.   
 
An elegant synthesis of AMC containing peptides using a solid-phase strategy was reported by 
Camarero and coworkers.149 They applied an arylhydrazine functionalized resin for the synthesis of a 
peptide fragment, followed by mild oxidation with NBS forming an acyldiazene resin which readily 
reacted with the amino function of AMC, thereby in-situ cleaving the peptide from the resin 
(Scheme 1.4).  
 
 
 
Scheme 1.4 Solid phase methodology for the synthesis of AMC containing peptides. 
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The basic guanidine moiety of the arginine side chain (pKa = 12.48) complicates both synthesis and 
purification of arginine containing peptides. As a result, various research groups focussed on the 
synthesis of Arg-AMC containing peptides using solid-phase technology. The most commonly applied 
method is side chain anchoring of an amino acid to a resin145,150,151 (see Chapter 4). However, in all 
these cases the aminomethylcoumarin was coupled to an amino acid or amino acid precursor prior to 
coupling to the resin. A different anchoring strategy, using a modified coumarin species, was 
introduced by Ellman and co-workers (Scheme 1.5).152 They developed a modified aminocoumarin 
leaving group, 7-amino-4-carbamoylmethylcoumarin (ACC), which could directly be attached to a solid 
support, enabling solid-phase synthesis of peptide-ACC substrates. 
 
 
 
Scheme 1.5 Substrate synthesis via solid phase anchoring of Fmoc-ACC.  
 
The wide variety of applicable methods for fast and efficient substrate synthesis creates a window of 
opportunities for scientists to explore the boundaries of thrombin activity and specificity. 
 
 
1.5.2 Biohybrid fluorogenic peptide substrates 
 
Polymer-peptides or polymer-proteins conjugates (i.e. biohybrid materials) have been widely used for 
applications in the areas of medicine, biotechnology, and materials science.153 Polymer-peptide 
conjugates are increasingly applied in research areas such as smart polymers or stimuli responsive 
soft materials,154 enzyme catalyzed formation of hydrogels155 and bioactive polymer materials.156 The 
groups of Chen and Mitra recently demonstrated the applicability of bioactive polymers by introducing 
RGD-containing peptides to biocompatible polymers (i.e. PEG, PMMA or HMPA) thereby generating 
therapeutic biohybrid polymers.157 Peptidase activity measurement is another application of bioactive 
polymer materials. By monitoring the fluorescence increase upon hydrolysis of Gly-AMC-3-carboxyl-
(PEG)-dextran conjugates, Bronk et al. were able to assess the activity of aminopeptidase.158  
The concept of applying polymer-peptides in enzyme activity assays is actually not a recent one. A 
report by Kalal et al. on the use of water-soluble poly[N-(2-hydroxypropyl) methacrylamide] bearing in 
the side chains the chromogenic substrate L-phenylalanine-4-nitroanilide for the determination of 
chymotrypsin activity, dates back to 1976.159 More recently, an excellent paper by Hortin and 
co-workers160 underlines the relevance of these water-soluble biohybrid structures by elegantly 
demonstrating the use of PEG-based macromolecular chromogenic substrates for the assessment of 
protease activity (Figure 1.15).  
 
 
 
Figure 1.15 Polymer-peptide biohybrid structures. 
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Although polymer-peptide biohybrid research is a promising field of science, an extensive literature 
search on thrombin specific fluorogenic polymer-peptide based biohybrid structures gave little to no 
results. A patent by Brynes and Andrade-Gordon161 demonstrates the use of immobilized fluorogenic 
substrates bearing an enzyme-specific oligopeptide functionalized with a fluorophore, a spacer group 
to couple the peptide and polymer fragments and finally a biologically inert polymer. Applying the 
same principle as Brynes, Ito and co-workers demonstrated the interaction of thrombin with a synthetic 
fluorescent substrate immobilized on a polymer membrane (Figure 1.15). Thrombin specific 
fluorogenic peptides (VPR-AMC, PFR-AMC and IEGR-AMC) were immobilized on a polyether-
urethaneurea (PEUU) membrane with carboxylic end-groups. Subsequently, the hydrolysis by 
thrombin was monitored by time-resolved fluorescence. Although the hydrolysis was reduced by 
immobilization the highly reactive substrate, the rate of hydrolysis was still significant due to rapid 
thrombin adsorption onto the membrane surface.162  
 
In order to prepare biohybrid block copolymers with a sequence-defined peptide segment, several 
routes have been developed.163,164 In effect, these routes follow two general approaches: (i) the 
coupling of a preformed polymer to a peptide (i.e. grafting-to), and (ii) the propagation (growing) of a 
polymer from a peptide initiator (i.e. grafting-from). Building up a polymer from a peptide initiator is an 
elegant way to prepare peptide-polymer conjugates. However, in most cases it is often more desirable 
to follow the grafting-to approach, since this allows the contrasting blocks to be prepared separately 
under optimal conditions. A prerequisite of the grafting-to approach, obviously, is an efficient coupling 
strategy to link together bulky building blocks. Among the various reactions that can be considered for 
this purpose,165 the bioorthogonal Cu(I)-catalyzed azide-alkyne 1,3-dipolar cycloaddition reaction 
(CuAAC, see Scheme 1.6) has recently proven to be of particular value.166,167,168 The fundamental 
basis of bioorthogonal methodologies relies on the principle of specific reaction between two 
participating functional groups that are tuned such that interference with coexisting functionalities is 
circumvented. Other tools employed in this field are the Diels–Alder ligation,169 the Staudinger 
ligation,170 and the strain-promoted [3+2] cycloaddition reaction devised by Bertozzi and co-workers 
(see Scheme 1.6).171 
 
 
 
Scheme 1.6 Frequently used bioconjugation methods. 
 
A comparative study of the ligation methods depicted in Scheme 1.6, has demonstrated that the 
efficiency of the individual methods is depended on the application pursed.172 With respect to polymer-
peptide conjugation, the CuAAC reaction has demonstrated to be a suitable methodology (vide supra).  
Both the Staudinger ligation and the [3+2] strain-promoted cycloaddition reaction, however, have not 
yet been explored as suitable conjugation techniques in this area.  
 
 
1.6 Outline of thesis  
 
 
Although the thrombin generation test was developed more than 50 years ago by Biggs and 
Macfarlane, the full potential of this test has only recently been recognized. With the modification 
made by Hemker and coworkers, resulting in a calibrated and automated thrombin generation test, the 
Introduction 
    35
potential of TGT was rediscovered. Deficiencies in the haemostatic system could now be assessed 
with great precision in only a fraction of the time required to construct a traditional thrombogram. The 
introduction of slow reacting fluorogenic substrates enabled scientists to perform measurements in 
platelet rich plasma, a preferred medium for studying the interaction of platelets in the coagulation 
process. Currently, the calibrated automated thrombin generation assay is used by a multitude of 
research groups throughout the world for a fast variety for scientific purposes (this Chapter).        
The thrombin generation assay requires the substrates to have a high KM (µM range) and to be added 
to the blood plasma in the same concentration range. The preparation of µM aqueous solutions of the 
currently employed substrate (Z-Gly-Gly-Arg-AMC) necessitates the addition of a significant amount of 
DMSO due to the poor solubility of this substrate in aqueous media, which especially at higher 
concentrations influences the function of the blood platelets. Moreover, Z-Gly-Gly-Arg-AMC is also a 
substrate for the α2-macroglobulin-thrombin complex. Determination of thrombin concentrations from 
substrate conversion rates therefore requires the denaturation of α2-macroglobulin with the risk of 
affecting other elements of the physiological system. Alternatively, an additional mathematical 
operation is necessary to compensate for the activity of the 2-macroglobulin-thrombin complex, so as 
to obtain accurate thrombin concentrations. To circumvent these drawbacks is the main target of the 
project proposed here. 
In the forthcoming chapter (Chapter 2) the synthesis of a variety of AMC-containing fluorogenic 
peptide substrates is described. Improvement of water solubility and the kinetic parameters are the 
primary focus points since these are the major limiting factors of the fluorogenic substrate (Z-Gly-Gly-
Arg-AMC) currently in use in the thrombin generation test. Amongst the synthesized substrates there 
are compounds resembling the structure of human fibrinogen and thrombin substrate SQ68.   
The determination of the kinetic parameters KM and kcat of the synthesized substrates on thrombin is 
described in Chapter 3. Applying a new tool, the so-called ‘diagnostic plot’, enabled rapid 
determination of the applicability of the synthesized substrates in the calibrated automated thrombin 
generation test. From the obtained diagnostic plots a selection of substrates was made suitable for 
thrombin generation determination. These substrates were subsequently applied in the thrombin 
generation assay using normal pooled platelet poor plasma. The outcome (i.e. thrombin generation 
curve or Thrombogram) provided valuable information in terms of clotting times, thrombin 
concentrations and endogenous thrombin potential (ETP). 
With the basic guanidine moiety of the arginine side chain being a disturbing feature, purification via 
traditional silica-based column chromatography is difficult. A solution to this problem is counter current 
chromatography, a liquid-liquid extraction process. This purification method is, however, extremely 
time consuming and requires large quantities of solvent. On-resin substrate synthesis would 
circumvent the troublesome purification since a purified substrate can be obtained by merely rinsing 
and subsequent cleavage off the resin. However, 7-amino-4-methylcoumarin lacks a handle for resin-
linkage. The development of an innovative solid-phase methodology for the synthesis of Arg-AMC 
containing peptide libraries is described in Chapter 4.  
The topics of Chapter 5 are the synthesis and evaluation of a cyclic peptide. Not only have cyclic 
peptides shown to be great thrombin inhibitors (e.g. cyclotheonamides A and B), they also propose a 
great challenge for the scientific community to construct them. In particular cyclization of tetrapeptides 
can be extremely troublesome. Our goal (or challenge) was to confine the rapidly hydrolyzed thrombin 
substrate, H-Gly-Pro-Arg-AMC, in a cyclic conformation, thereby decreasing its affinity for the thrombin 
active-site. The powerful copper catalyzed 1,3-dipolar cycloaddition reaction was employed for the 
construction of the coumarin containing macrocyclic thrombin substrate.   
Since one of the objectives of this research was to circumvent the hydrolysis of thrombin specific 
substrates by the 2-macroglobulin-thrombin complex, the synthesis of bulky biohybrid amphiphiles 
was pursued. Chapter 6 discusses the synthesis of PEG-peptides, poly(PEGMA)-peptides as well as 
PS-peptides amphiphiles, in combination with the biological evaluation of these biohybrid complexes.  
Chapter 7 elaborates on the pursuit of an improved conjugation method for the formation of polymer-
peptide amphiphiles. Inspired by the work of Sharpless, Bertozzi and Ju we set out to explore the field 
of 1,3-dipolar cycloaddition reactions, which resulted in an elegant metal-free bioconjugation 
methodology employing oxanorbornadienes and azides.  
The final chapter (Chapter 8) demonstrates the applicability of the metal-free tandem 1,3-dipolar 
cycloaddition retro-Diels–Alder reaction in the field of PEGylation, protein modification and cancer 
research (i.e. tumor imaging).  
An epilogue, summaries, list of publications and a Curriculum Vitae conclude this thesis. 
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Fluorogenic Thrombin Substrates 
 
 
 
 
 
 
 
 
Abstract 
 
This chapter focuses on the synthesis of water soluble peptide based thrombin substrates. A series of 
23 peptides containing C-terminal arginine 7-amino-4-methyl-coumarin (AMC) was synthesized. The 
coupling of the fluorophore AMC to the arginine residue was achieved using phosphoryl chloride as 
the condensing agent. The lead structure in this research was commercially available Z-Gly-Gly-Arg-
AMC currently in use in the thrombin generation test. The water solubility of this compound (crucial for 
the use in the thrombin generation test) was greatly improved by removal of the Z-protecting group 
generating a free N-terminus. A straightforward four-step synthesis of H-Gly-Gly-Arg-AMC·2HCl is 
described. This substrate appeared to have greatly improved kinetic properties and therefore was 
taken as a starting point for further optimization. A series of N-terminally substituted H-Gly-Gly-Arg-
AMC derivatives was designed and synthesized. Small structural changes were implemented via 
introduction of the amino acid alanine at either the P2 or the P3 position of the peptide to further 
improve the kinetic properties. In addition, the synthesis of two substrates resembling the structure of 
human fibrinogen Aα as well as a peptide having structural similarities to SQ68 and a peptide of which 
an amide bond is replaced by a 1,2,3-triazole isostere were investigated.  
 
2 
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2.1 Introduction 
 
 
In various pathological disturbances of the haemostatic system, such as bleeding and thrombosis, 
thrombin plays a pivotal role. Inhibition of this enzyme may lead to useful treatment of thrombotic 
disorders which constitute a large number of mortality and morbidity in patients worldwide.1 The 
central function of thrombin in clot formation makes it a prime target for the design of antithrombotic 
drugs.2 Structure activity relationship (SAR) and parallel synthesis have led to the development of an 
array of novel thrombin inhibitors acting either on a mechanism-based approach3 or as reversible 
inhibitors binding exclusively by noncovalent interactions.4 The antithrombotic agents currently in 
clinical use possess a number of limitations such as the need for constant monitoring to assure 
effective drug-plasma levels and avoidance of bleeding complications and secondly potential drug–
drug interactions. There are, however, only a limited number of methods for estimating the 
appearance and disappearance of thrombin in plasma or whole blood. Current tests based on the 
measurement of clotting times give only a superficial impression of the functioning of the coagulation 
pathway in the presence of anticoagulants. The overall function of the blood clotting system is 
reflected more accurately by measuring the course of thrombin concentration in time (i.e. constructing 
a thrombin generation curve (TGC) or thrombogram, Figure 2.1).5 In contrast to clotting times, the 
thrombogram measures both low and high reactivity of the clotting system and is sensitive to the 
action of all types of antithrombotic drugs.6 Hence, this method can be used as a universal monitor of 
clotting function and thus is of the highest medical importance. 
 
A thrombogram can be measured by 
treatment of a clotting sample with a 
thrombin specific substrate labeled 
with either a chromophore or a 
fluorophore. Upon hydrolysis by 
thrombin, the released probe can be 
measured spectroscopically, and thus 
the amount of thrombin formed can be 
calculated.  Initially the chromogenic 
thrombin-specific substrates S2238 
and SQ68 (Figure 2.2) were employed 
to derive the thrombin concentration 
from the rate of substrate conversion in 
plasma.7 However, these substrates 
have a major restriction, namely that 
the optical density measurements can 
only be performed on an optically clear 
medium. This requires the complete 
removal of fibrinogen and blood cells, 
which significantly disturbs the effect of fibrin and/or platelets on thrombin generation. Consequently, 
further research in this field eventually led to the complete replacement of the chromogenic substrates 
by a second-generation fluorogenic substrate, Z-Gly-Gly-Arg-AMC (Figure 2.2, viz. 1), the substrate 
currently in use for TGC determination.8 The main advantage of a fluorophore-based substrate is that 
the inevitable optical turbidity increase during measurement, due to fibrin formation, does not disturb 
the fluorescent signal. Therefore, thrombin generation in platelet-poor and platelet-rich plasma9 as well 
as whole blood10 can be measured directly without defibrination. Nevertheless, this commercially 
available fluorogenic substrate leaves considerable room for improvement due to its poor water 
solubility, obviously the solvent of choice for mimicking physiological conditions, and its moderate 
kinetic parameters.  
 
The thrombin generation method requires a substrate which is slowly hydrolyzed by thrombin to 
prevent substrate exhaustion before thrombin generation is over, even at high substrate 
concentrations. Additionally, the binding constant (KM) should be high for two reasons. Firstly, the 
occupancy of the enzyme by substrate must be low to minimize any inhibition effects. Since the KM 
value represents the substrate concentration at which half of the enzyme is saturated, the substrate 
concentration must be below KM. Secondly the total amount of converted substrate must be minimal to 
exclude lower conversion rates due to declining substrate concentrations. These two requirements are 
Figure 2.1 Real time display of a Thrombogram 
Design, Synthesis, Fluorogenic Substrates 
 43
met in a high KM value. With respect to our before mentioned requirements the ideal substrate would 
be highly specific for thrombin, has a high KM and a low kcat, and is vastly soluble and stable in plasma. 
 
 
 
Figure 2.2 Structures of the chromogenic substrate S2238 and SQ68 and the fluorogenic substrates 
Z-Gly-Gly-Arg-AMC (1) and derivative H-Gly-Gly-Arg-AMC·2HCl (2) 
 
The use of fluorogenic peptide substrates was first reported by Zimmerman and co-workers who 
employed peptides containing 7-amino-4-methylcoumarin (AMC) for the assessment of the activity of 
various proteases and peptidases.11 This concept led to the widespread application of AMC-containing 
peptides for monitoring the activity of aminopeptidase,12 dipeptidase13 and carboxypeptidases.14 
Sakakibara et al. was one of the first to report on specific and sensitive peptide-AMC substrates for 
coagulation related proteins such as thrombin,15,16 factor Xa,15,16 factor XIIa,17 APC,18 and plasmin.19  
More recently fluorogenic substrate libraries for the determination of protease specificity have been 
produced by the groups of Edwards and Ellman. Ellman and coworkers applied a strategy for the 
synthesis of positional-scanning synthetic combinatorial libraries (PS-SCL) based on a safety catch 
linker system producing P1 Lys-AMC combinatorial libraries.20 Edwards et al. devised a route which 
employed solid phase peptide synthesis (SPPS), linking the side-chain of arginine to an Argo-pore® 
resin via a CMtr linker resulting in a P1 Arg-AMC peptide library.21  The above mentioned research 
efforts mainly focused on the discovery of highly specific, rapidly hydrolyzable protease substrates. 
The number of publications describing the synthesis of slow-reacting thrombin specific fluorogenic 
peptide substrates is, however, limited. 
   
Our research focused on the development of thrombin specific substrates with increased water 
solubility and improved kinetic parameters (i.e. high KM and a low kcat, vide supra) for their use in the 
thrombin generation test (TGT). To this end, various structural changes were incorporated in the 
peptide chain (R1 and R2 in Figure 2.2) by varying the amino acids. In addition, different end groups 
(R3) were introduced starting from the synthon H-Gly-Gly-Arg-AMC (2). This chapter focuses on the 
synthesis of these novel peptide-based fluorogenic thrombin substrates, while the kinetic properties of 
these substrates will be discussed in Chapter 3. 
 
 
2.2  Design and synthesis of peptide-based fluorogenic substrates 
 
 
With the poor water solubility of commercially available Z-Gly-Gly-Arg-AMC22 (1) being its worst 
feature, initial studies were directed towards a seemingly straightforward carbobenzyloxy (Cbz) 
deprotection to obtain H-Gly-Gly-Arg-AMC (2). This was accomplished by the use of Pd/C (5 mol%) 
under an H2 atmosphere in deuterated methanol. Unfortunately, N-deprotection to the desired product 
was accompanied by the formation of a byproduct resulting from partial hydrogenation of the double 
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bond of the AMC fragment. Using HBr (33 wt% in AcOH) also resulted in fast product formation. 
However, hydrolysis of the Arg-AMC bond appeared to be a severe side reaction. Due to these side 
reactions, a Boc-protected peptide synthesis strategy was designed allowing deprotection of the Boc-
group under acidic conditions in the last step. A straightforward four-step synthesis, depicted in 
Scheme 2.1, provided compound 2 in satisfactory 40% overall yield.  
 
 
 
Scheme 2.1 Synthesis of H-Gly-Gly-Arg-AMC·2HCl (2). Reagents and conditions; i) AMC, POCl3, 
pyridine (dry), -15 °C to r.t. (68%); ii) 2.6 M HCl in EtOAc, r.t. (94%); iii) Boc-Gly-Gly-OH (1.02 equiv), 
DMF, EDC·HCl (1.1 equiv), DMAP (2 equiv), 0 ºC to r.t. (86%); iv) 2.6 M HCl in EtOAc, Et2O, r.t. 
(98%). 
 
The critical step in the synthesis of compound 2 is the coupling of Boc-protected arginine and the 
fluorescent label AMC. Various literature procedures describe methods involving a protection-
deprotection strategy for the guanidine moiety of the arginine side-chain.23 A more straightforward 
approach, however, would entail the coupling of AMC to side-chain unprotected Boc-arginine, which 
was pursued by applying a modified procedure described by Rijkers et al.24 To this end, a mixture of 
Boc-arginine and AMC in pyridine at -15 °C was treated dropwise with 1.5 equiv of phosphoryl 
chloride. Much to our satisfaction, after stirring overnight at room temperature, Boc-Arg-AMC (3) was 
obtained in 68% yield after purification. This efficient protocol obviates the laborious protection-
deprotection steps of the guanidine moiety. Deprotection of the Boc-moiety resulted in the formation of 
product 4 as the di-HCl salt in 94% yield. The coupling of commercially available Boc-Gly-Gly-OH with 
H-Arg-AMC·2HCl (4) (Scheme 2.1) turned out to be somewhat more challenging. The standard 
peptide coupling method (DCC and Et3N)25 did not lead to the desired product 5. Gratifyingly, altering 
the solvent, coupling reagent and the base resulted in the formation of compound 5 in a good yield 
(83%). The final step in the synthesis of compound 2 was Boc-deprotection of Boc-Gly-Gly-Arg-AMC 
(5). Since the di-HCl salt seemed most attractive to us, a suspension of 5 in diethyl ether was treated 
with a solution of 2.6 M HCl in ethyl acetate affording, after lyophilization, the desired tripeptide 2 in 
pure form and 96% yield. 
 
 
 
Scheme 2.2 Library synthesis of Arg-AMC containing dipeptides. Reagents and conditions: i) H-Arg-
AMC (4), DMF, EDC·HCl (1.1 equiv), DMAP (2 equiv), HOBt (1.0 equiv), 0 ºC to r.t.; ii) 2.6 M HCl in 
EtOAc, Et2O, r.t.; iii) Msc-OSu, DiPEA, DMF, 0 ºC to r.t.; iv) Btsc-OSu, DiPEA, DMF, 0 °C to r.t. 
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Having synthesized the key intermediate 4 allowed us to rapidly prepare small peptide libraries. 
Initially dipeptides containing valine, D-phenylalanine and proline at P2 were synthesized (Scheme 
2.2). 1-Hydroxybenzotriazole (HOBt), used in the synthesis of the dipeptides 6, 8 and 10 to prevent 
undesired racemization of the P2 amino acid, appeared to have a strong affinity for the unprotected 
arginine residue (P1). The crude products were initially purified by counter current chromatography 
using an n-BuOH/H2O (1:1 v/v) system. Since this solvent system did not give the pure products, a 
more hydrophobic system (n-BuOH/EtOAc/H2O 1:1:2 v/v/v) was used to separate HOBt from the 
products. Unfortunately, HOBt was still present in equimolar quantities in all of the products. This 
phenomenon can be explained by the hydrogen bond formation between the hydroxytriazole moiety of 
HOBt and the guanidine moiety of the arginine residue (Figure 2.3 A) resembling DNA A-T base pair 
hydrogen bonding (Figure 2.3 B).   
 
 
 
Figure 2.3 Hydrogen bonding between A) HOBt and guanidine, and B) adenine and thymine; C) HCl-
“protected” guanidine moiety of arginine.  
 
In the second step (step ii, Scheme 2.2) deprotection of the Boc-group was performed, resulting in the 
free N-terminus. Fortunately, the basic guanidine moiety (pKa = 12.48)26 was protonated under the 
conditions employed, subsequently replacing the undesired HOBt by HCl (Figure 2.3 C). The yields for 
products 7, 9 and 11 were therefore calculated over two steps and were good to excellent. Compound 
11 was further functionalized with either an Msc- or a Btsc-group. The Msc-group was introduced 
since Msc-Val-Arg-pNA reported by Rijkers et al.27 displayed good kinetic parameters. The aromatic 
Btsc-group was considered to fit in the aryl-binding pocket (S3) of thrombin28 and so enhance the 
binding of this substrate. Both substrates 12 and 13 were obtained in reasonable yields after reacting 
H-Val-Arg-AMC (11) with the appropriate succinimide esters Msc-OSu and Btsc-OSu. 
 
Both human kallikrein29 and serine protease tryptase21 have been demonstrated to possess amidolytic 
activity towards the substrate H-Gly-Pro-Arg-AMC. Since thrombin is a member of the serine protease 
family we set out to synthesize this substrate (see Scheme 2.3) in order to explore its kinetic 
parameters. The synthetic route toward compound 17 enclosed the coupling of N-protected glycine to 
proline methyl ester using DCC as coupling reagent and NMM as base which yielded the dipeptide 14. 
After saponification, the carboxylic acid 15 was coupled to H-Arg-AMC (4) using EDC, HOBt and 
DMAP, resulting in the tripeptide Boc-Gly-Pro-Arg-AMC (16) in a good yield (70%). The desired 
tripeptide 17 was obtained after Boc-deprotection using 2.6 M HCl in EtOAc in virtually quantitative 
yield. 
 
 
Scheme 2.3 Preparation of tripeptide H-Gly-Pro-Arg-AMC·2HCl. Reagents and conditions: i) H-Pro-
OMe, DCC (1.05 equiv), NMM (1.1 equiv), EtOAc, 0 ºC to r.t., 18 h; ii) NaOH (2M), THF, r.t., 16 h; iii) 
H-Arg-AMC (4), DMF, EDC·HCl (1.1 equiv), DMAP (2 equiv), HOBt (1.0 equiv), 0 ºC to r.t., 18 h; iv) 
2.6 M HCl in EtOAc, Et2O, r.t., 16 h.  
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In order to further investigate the influence of the amino acid at the P2 and P3 positions, we set out to 
synthesize a series of peptides containing small structural changes at the P2 and P3 positions 
(Scheme 2.4). In this study the amino acid at P1 was an arginine residue to ensure optimal interaction 
with the S1 pocket. The residue at P2 was systematically varied, incorporating glycine, valine, proline 
or alanine. The amino acid residue at the P3 position was always alanine except for compound 19. The 
peptide coupling conditions and the deprotection procedure as described for compounds 7, 9, 11 and 
17 were subsequently employed in the synthesis of the Ala-containing peptide library (Scheme 2.4). 
The dipeptide H-Ala-Arg-AMC (19) was obtained in two steps, involving coupling of H-Arg-AMC (4) 
with Boc-Ala-OH and subsequent Boc-deprotection of the dipetide 18. The tripeptides 23, 27 and 31 
were synthesized via a four-step reaction protocol. To obtain H-Ala-Pro-Arg-AMC first Boc-Ala-OH 
was coupled to H-Pro-OMe followed by saponification affording dipeptide 21 in a 60% yield over two 
steps. Subsequent coupling of the dipeptide fragment to H-Arg-AMC (4) and Boc-deprotection using 
TFA in CH2Cl2 resulted in compound 23 in a 48% overall yield. The yield of compound 22 was not 
determined as result of HOBt coordination to the arginine residue (vide supra) and thus was calculated 
over two steps (i and ii, 80%). The same sequence was applied to obtain H-Ala-Gly-Arg-AMC in a 43% 
overall yield over 4 steps.   
 
 
 
Scheme 2.4 Synthesis of Ala-containing peptide library. Reagents and conditions: i) H-Arg-AMC (4), 
DMF, EDC·HCl (1.1 equiv), DMAP (2 equiv), HOBt (1.0 equiv), 0 ºC to r.t.; ii) TFA, CH2Cl2, 0 ºC to r.t.; 
iii) H-AA-OMe, CH2Cl2, EDC·HCl (1.1 equiv), DiPEA (1.1 equiv), HOBt (1.0 equiv), 0 ºC to r.t.; iv) 1 M 
NaOH, THF, 0 ºC to r.t.; v) H-Gly-OMe, EtOAc, DCC (1.05 equiv), NMM (1.1 equiv), HOBt (1.0 equiv), 
0 ºC to r.t.; vi) 2.6 M HCl in EtOAc, Et2O, r.t. a 2 M NaOH instead of 1 M. b No HOBt added. 
 
 
Tripeptide 31 was synthesized starting from Boc-Ala-OH and H-Gly-OMe, which were coupled using 
DCC and NMM to produce Boc-Ala-Gly-OMe (28) in a good yield (83%). Subsequent saponification 
and coupling to H-Arg-AMC afforded tripeptide 30 in reasonable yield. In the last step Boc-
deprotection was performed, resulting in the desired tripeptide H-Ala-Gly-Arg-AMC in good yield 
(86%). The overall yields of the Ala-containing peptides 19, 23, 27 and 31 ranged from 28 to 80%.    
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2.3 Synthesis of fibrinogen-like fluorogenic substrates 
 
 
Fibrinogen, the natural substrate of thrombin, is a covalently linked dimer consisting of three 
polypeptide chains, A, B and  with the general structure (AB)2.30 The first step toward fibrinogen 
polymerization is the formation of fibrin monomers. This is accomplished by the cleavage of 
fibrinopeptides A and B from the amino-terminal segments of the Aα and Bβ chains by thrombin 
(hydrolysis at Arg16 and Arg14, respectively).31 Removal of the fibrinopeptides leads to spontaneous 
polymerization of the monomers into fibrin. The specific binding of fragment 1-23 of the A-chain (see 
Figure 2.4) is responsible for to the selective hydrolysis by thrombin.32  
 
 
 
Figure 2.4 Sequence of human fibrinogen A (1-23). 
 
Several studies have been conducted to reveal the contribution of the individual amino acids in this 
specific region. The decapeptide (7-16) was found to be the minimal sequence for high affinity binding 
to thrombin. Furthermore, it was demonstrated that the side chains of Leu9 and Val15 were bound into 
the apolar binding pocket (S2) of thrombin.33 Other investigations revealed salt-bridge formation 
between Glu11 of the polypeptide and Arg173 in thrombin, thus stabilizing the peptide within the 
active-site cleft of the enzyme. 
 
The synthesis of fluorophore-containing fibrinogen mimics was based on the approach reported by 
Rijkers et al.,27 who demonstrated the use of various Val-Arg-pNA derivatives as slow reacting 
thrombin substrates. The valine residue implemented at the P2 position is well accommodated in the 
S2 pocket of thrombin. Modification of the linker length and its flexibility influenced the KM since 
variation of the length of the glycyl-spacer, affected the ability to form the salt-bridge between Glu11 
and Arg173 which is directly reflected in the value for KM. To this end we synthesized two Val-Arg-
AMC derivatives with varying lengths (Scheme 2.5) 
  
 
 
Scheme 2.5 Synthesis of fibrinogen-like peptides. Reagents and conditions: i) HOSu, EtOAc, DCC 
(1.05 equiv), NMM (1.1 equiv), 0 °C to r.t.; ii) H-(Gly)n-OH, H2O/MeCN, NaHCO3, r.t.; iii) H-Val-Arg-
AMC (11), DMF, EDC·HCl (1.1 equiv), DMAP (2 equiv), HOBt (1.0 equiv), 0 ºC to r.t.; iv) TFA, CH2Cl2, 
0 ºC to r.t. or 2.6 M HCl in EtOAc, Et2O, r.t. 
 
Three synthons were required for the construction of compounds 35 and 36 being the previously 
synthesized dipeptide H-Val-Arg-AMC (11) (vide supra) and glutamic acid containing di- and tripeptide 
33a and 33b, respectively. Coupling of N-hydroxysuccinimide to Boc-Glu(OtBu)-OH provided the 
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activated OSu-ester which was directly used in the next reactions. Unprotected glycine was reacted 
with Boc-Glu(OtBu)-OSu (32) under basic conditions resulting in the dipeptide 33a in good yield (83%). 
Identical to the procedure described for compound 33a, tripeptide 33b was obtained in an excellent 
yield (96%). All three synthons were now available and solution phase peptide coupling of compounds 
33a and 33b with H-Val-Arg-AMC (11) gave the desired tetra- and pentapeptide (34a and 34b, 
respectively). Since a combination of EDC and HOBt was used for the coupling of 11 and 33b, traces 
of HOBt were still present after purification with counter current chromatography of compound 34b. 
Consequently, the yield of compound 36 was determined after Boc and tert-butyl ester deprotection 
over two steps (60%). Deprotection of Boc-Glu(OtBu)-Gly-Val-Arg-AMC (34a) gave compound 35 in 
near quantitative yield. 
 
 
2.4 Synthesis non-peptidyl fluorogenic substrates  
 
 
To study the influence of N-terminal substituents, a series of N-terminus-substituted derivatives 
(37-44) based on the tripeptide H-Gly-Gly-Arg-AMC (2) were synthesized (Scheme 2.6). 
 
 
 
Scheme 2.6 Library of N-terminus-substituted H-Gly-Gly-Arg-AMC (2) derivatives. 
 
 Table 2.1 Reaction conditions applied for the preparation of compounds 37-44  
Entry Reagent Reaction conditions Product Yield(%)a 
1 AcCl Dioxane, Et3N, r.t., 72 h 37 47 
2 EtSO2Cl MeCN, Et3N, 45 C, 4 h 38 68 
3 EtOCOCl CH2Cl2, Et3N, r.t., 72 h 39 50 
4 (CF3CO)2O Dioxane, Et3N, r.t., 18 h 40 59 
5 Phthalic anhydride MeCN, Et3N, r.t., 16 h 41 0 
6 2-Furanoic acid DMF, EDC, DMAP, r.t., 16 h 42 35 
7 Nicotinic acid DMF, EDC, DMAP, r.t., 16 h 43 69 
8 Bicyclo[2.2.1]hepta-2,5-diene-
2-carboxylic acid 34 
DMF, EDC, DMAP, r.t., 18 h 44 15 
 
a  Isolated yields after purification. 
 
Different techniques were applied for the introduction of the substituents at the N-terminus of 
compound 2. The acetyl, ethylsulfonyl and ethoxycarbonyl substituents were introduced at the N-
terminus using the corresponding chloride and Et3N in an appropriate solvent (Table 2.1, entries 1-3). 
In all cases the use of one equivalent of the acid or sulfonyl chloride was insufficient for complete 
conversion. Therefore, an additional equivalent was added and the reaction times prolonged. This led 
to full conversion, although, some di- and trisubtituted products were obtained in the synthesis of 
compounds 38 and 39. As a result of the aqueous work-up, the acid chlorides were converted into the 
corresponding acids. These acids (i.e. acetic acid and ethylsulfonic acid) were observed after 
purification in both 1H- and 13C-NMR spectroscopy which may suggest that they act as counter-ions of 
the guanidine. Introduction of a trifluoroacetyl group at the N-terminus was achieved using 
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trifluoroacetic acid anhydride in dioxane in the presence of triethylamine. As a result, compound 40 
was obtained in reasonable yield (59%). The end-groups of compounds 41-44 were selected because 
of their aromatic character (capable of binding in the aromatic pocket of thrombin) and/or hydrophilic 
disposition. The attempt to introduce a benzoic acid moiety via ring opening of phthalic anhydride was 
successful according to TLC analysis, however, purification of the product failed. Separation of the 
product (41) and base (DMAP) was hindered due to the zwitterion character of compound 41 caused 
by the benzoic acid and the basic guanidine moiety. Substrates 42-44 were obtained using standard 
peptide chemistry.25 The coupling of 2-furanoic acid to H-Gly-Gly-Arg-AMC gave compound 42 in a 
moderate yield (35%). Coupling of nicotinic acid and subsequent lyophilization from dilute aqueous 
HCl gave compound 43 in good yield (69%). This compound proved to have excellent solubility in 
water. With the N-terminal incorporation of the bicyclo[2.2.1]hepta-2,5-diene-2-carboxylic acid, the 
hydrophilicity of the substrate will decrease, however, enhanced space filling of the norbornadiene 
system might increase the binding affinity in the aromatic pocket of thrombin, creating preferred kinetic 
behavior. Bicyclo[2.2.1]hepta-2,5-diene-2-carboxylic acid, prepared according to a literature 
procedure, was coupled to H-Gly-Gly-Arg-AMC to afford the desired compound 44, albeit in a poor 
yield (15%). The seven obtained N-terminus functionalized H-Gly-Gly-Arg-AMC derivatives showed 
good water solubility, with the exception of compound 42 (moderate) and 44 (expected).    
 
Further exploration of potential substrates for continuous thrombin generation led to the replacement 
of a peptide bond in the substrate H-Gly-Gly-Arg-AMC (2) by a 1,2,3-triazole functionality. Literature 
studies suggested that these 1,2,3-triazole moieties might be perfect isosteres for peptide bonds35 and 
that triazole mimics of biological active substrates often retain their biological activity.36 For that reason 
a 1,2,3-triazole was placed between the two glycine residues of H-Gly-Gly-Arg-AMC replacing the 
amide bond in order to investigate the kinetic effects of this substitution.   
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Scheme 2.7 Synthesis of 1,2,3-triazole containing H-Gly[triazole]Gly-Arg-AMC. Reagents and 
conditions: i) NaN3, DMF, r.t., N2 atmosphere (95%); ii) Boc2O, CH2Cl2, 0 ºC to r.t. (68%); iii) 
CuSO4·5H2O (5 mol%), Na-ascorbate (10 mol%), tBuOH/H2O, r.t. (86%); iv) 2 M NaOH, dioxane/H2O, 
0 ºC to r.t. (72%); v) H-Arg-AMC (4), DMF, EDC·HCl (1.1 equiv), DMAP (2 equiv), 0 ºC to r.t. (68%); vi) 
2.6 M HCl in EtOAc, Et2O, r.t. (87%). 
 
Scheme 2.7 shows the synthetic pathway toward triazole-containing H-Gly[triazole]Gly-Arg-AMC. The 
synthetic procedure applied for the preparation of methyl 2-azidoacetate (45) involved reaction of 
commercially available methyl bromoacetate with sodium azide. The mixture was stirred for a few 
hours, after which the slightly volatile azide 45 was obtained in excellent yield (95%). To obtain the 
triazole functionality, a copper-catalyzed 1,3-dipolar cycloaddition reaction,37 the so-called “click 
reaction”,38 was envisioned. Although “click chemistry” is a robust method and tolerant towards many 
functional groups,39 unprotected propargylamine appeared unsuited for the copper-mediated 
cycloaddition reaction. Multiple products were formed, but, the desired product 47 was not isolated so 
that protection of propargylamine was required. To this end, propargylamine was stirred in presence of 
di-tert-butyldicarbonate to afford Boc-protected propargylamine 46 in a reasonable yield (68%). 
Applying the click reaction to the two glycine derivatives 45 and 46, using sodium ascorbate and 
copper sulfate dissolved in a mixture of water and tert-butanol, now resulted in the formation of Boc-
Gly[triazole]Gly-OMe (47) in good yield (86%). Subsequent methyl ester saponification furnished Boc-
Gly[triazole]Gly-OH (48). Tripeptide Boc-Gly[triazole]Gly-Arg-AMC (49) was synthesized via the 
coupling of H-Arg-AMC (4) and triazole dipeptide Boc-Gly[triazole]Gly-OH (48) using common peptide 
coupling conditions. Compound 49 was obtained in a reasonable yield (67%) after purification with 
counter-current chromatography. The final step in the synthesis of H-Gly[triazole]Gly-Arg-AMC (50) 
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involved Boc-deprotection of 49 through treatment with hydrochloric acid in ethyl acetate, which gave 
H-Gly[triazole]Gly-Arg-AMC (50) in an excellent yield (87%, Scheme 2.7). 
 
Previous studies have shown that the substrate SQ68 (Figure 2.1) possesses interesting kinetic 
properties suitable for the thrombin generation test.40 We set out to synthesize a compound with 
structural similarities though bearing a fluorescent probe (AMC) instead of the para-nitroaniline 
chromophore (Scheme 2.8).  
 
 
Scheme 2.8 Synthesis of Et-Malonyl-Gly-Arg-AMC (53). Reagents and conditions: i) H-Gly-OtBu, 
CH2Cl2, EDC·HCl (1.1 equiv), DMAP (2 equiv), 0 ºC to r.t. (58%); ii) TFA, CH2Cl2, 0 °C to r.t. (84%); iii) 
H-Arg-AMC (4), DMF, EDC·HCl (1.1 equiv), DMAP (2 equiv), 0 ºC to r.t. (66%). 
 
First step in the synthesis toward 53 was the coupling of mono-ethyl malonate to tert-butyl protected 
glycine. Using the tert-butyl glycine ester allowed selective, acid catalyzed deprotection of the tert-
butyl ester thereby retaining the ethyl ester. Performing the reaction in CH2Cl2 in the presence of TFA 
generated compound 52 in good yield (84%). Subsequent coupling of H-Arg-AMC gave 53 in 
reasonable yield (66%) after counter-current chromatography. 
 
 
 
Figure 2.5 13C-NMR overlay of Et-Malonyl-Gly-Arg-AMC (53); A) in CD3OH malonate carbon peak at 
42.86 ppm visible; B) in CD3OD no malonate carbon atom visible. 
 
Although mass spectroscopy indicated that the desired compound was obtained, both 1H-NMR and 
13C-NMR could not confirm the structure of compound 53 since the malonic CH2 peak only weakly 
appeared in the proton spectrum and did not appear at all in the carbon spectrum (Figure 2.5 B), 
confirming the presence of compound 53. This phenomenon could be attributed to the acidity of the 
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malonate protons (pKa ≈ 11), which were rapidly exchanged with the protic deuterium of deuterated 
methanol-d4 (CD3OD). Measuring the NMR spectra in deuterated methanol-d3 (CD3OH) resulted in the 
visualization of the CH2 peak in both proton and carbon NMR (Figure 2.5 A). 
 
 
2.5  Conclusions 
 
 
A series of 23 arginine-AMC-containing peptides were successfully synthesized starting from key 
intermediate H-Arg-AMC. The water soluble variant of Z-Gly-Gly-Arg-AMC (i.e. H-Gly-Gly-Arg-
AMC·2HCl) was produced in a straightforward four-step protocol and served as the basis for further 
optimization by N-terminal substitution. A small library of peptides was constructed starting from 
H-Gly-Gly-Arg-AMC using either strong electrophiles (-SO2Cl, -COCl or -OCOCl) or carboxylates in 
combination with peptide coupling methods. The different synthetic strategies led to a series of N-
terminus modified compounds in reasonable to good yields. To explore the effect on the kinetic 
parameters resulting from minute structural changes in lead compound H-Gly-Gly-Arg-AMC, the amino 
acid alanine was incorporated at P3 replacing one of the glycine residues. Furthermore, the amino acid 
at P2 was varied, replacing the glycine residue by either a proline or a valine residue. In addition, two 
substrates having the structural motive H-Glu-(Gly)n-Val-Arg resembling the motive found in human A 
fibrinogen were successfully synthesized in good overall yields (58% for n = 1 and 51% for n = 2). A 
three step protocol was applied in the synthesis of SQ68 mimic, Et-malonyl-Gly-Arg-AMC. This 
desired compound was obtained after a coupling-deprotection-coupling sequence in an overall yield of 
32%. The introduction of a triazole moiety, replacing an amide bond, proceeded efficiently applying the 
copper-catalyzed 1,3-dipolar cycloaddition reaction on Boc-protected propargylamine and methyl 
2-azidoacetate. The desired triazole-containing dipeptide was subsequently hydrolyzed and subjected 
to routine peptide coupling. Boc-deprotection resulted in the triazole containing tripeptide H-Gly-
[triazole]-Gly-Arg-AMC. Although coupling of H-Arg-AMC to various peptide fragments proceeded 
nearly quantitatively according to TLC analysis, isolated yields after counter current chromatography 
were generally only up to 60-70%. Possibly, yields may be improved making use of guanidine-
protected arginine, which would in addition prevent HOBt coordination, though, an additional 
deprotection- and purification step will be required. Solid phase peptide synthesis might be an 
alternative strategy to improve the yields without troublesome purification (see Chapter 4). 
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2.7 Experimental section 
 
 
General experimental: 
 
Methods and materials 
 
Unless otherwise stated, all chemicals were obtained from commercial sources and used without 
further purification. Analytical thin layer chromatography (TLC) was performed on Merck precoated 
silica gel 60 F-254 plates (layer thickness 0.25 mm) with visualization by ultraviolet (UV) irradiation at 
 = 254 nm and/or  = 366 nm and/or staining with KMnO4. Preparative thin layer chromatography 
(Prep-TLC) was performed on Merck precoated silica gel 60 F-254 plates (layer thickness 1.00 mm) 
with concentration zone and visualization by UV irradiation at  = 254 nm and/or  = 366 nm. 
Purification by silica gel chromatography was performed using Acros (0.035 – 0.070 mm, pore 
diameter ca. 6 nm) silica gel. Counter current distribution was carried out using n-butanol and water, 
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where the stationary phase was H2O saturated with n-BuOH and the mobile phase used was n-BuOH 
saturated with H2O. Unless otherwise stated, all experiments were performed under ambient 
atmosphere and temperature. THF was distilled under nitrogen from sodium/benzophenone. CH2Cl2, 
Et2O and EtOAc were distilled under nitrogen from CaH2.  
 
Instrumentations 
 
NMR spectra were recorded on Bruker DPX200 (200 MHz and 50 MHz for 1H and 13C, respectively), 
Bruker DMX300 (300 MHz and 75 MHz for 1H and 13C, respectively) and Varian Inova 400 
spectrometers. 1H-NMR chemical shifts () are reported in parts per million (ppm) relative to a residual 
proton peak of the solvent,  = 3.31 for CD3OD,  = 7.26 for CDCl3,  = 2.50 of DMSO-d6 and  = 4.79 
for D2O. Multiplicities are reported as: s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of 
doublets), dt (doublet of triplets), dq (double quartet), ddd (double, double doublet), ddt (double, 
double triplet) or m (multiplet). Broad peaks are indicated by br. Coupling constants are reported as a 
J value in Hertz (Hz). The number of protons (n) for a given resonance is indicated as nH, and is 
based on spectral integration values. 13C-NMR chemical shifts () are reported in ppm relative to 
CD3OD ( = 49.0), DMSO-d6 ( = 39.5) or CDCl3 ( = 77.0). Electrospray LC-MS analysis was 
performed using a Shimadzu LC/MS 2010A system. Matrix assisted laser desorption/ionisation time-
of-flight (MALDI-ToF) spectra were measured on a Bruker Biflex III spectrometer and samples were 
prepared from MeOH solutions using indoleacrylic acid (IAA) (20 mg/mL) as a matrix. ESI-MS analysis 
was performed using Thermo scientific Advantage LCQ Lineair-Iontrap Electrospray (LRMS). 
Electrospray ionization time-of-flight (ESI-ToF) spectra were measured with a JEOL AccuToF. 
Elemental analyses were carried out using a Carlo Erba Instruments CHNS-O EA 1108 element 
analyzer. FT-IR spectra were recorded on an ATI Matson Genesis Series FT-IR spectrometer fitted 
with an ATR cell. The vibrations () are given in cm-1. FCPC purification was performed on a Kromaton 
Prep-FCPC A200 complete system equipped with 200 mL rotor, an Arman gradient high pressure 
pump 100 mL/min, an Alltech ELSD2000 detector with flow split and an Advantec MFS CHF122SB 
fraction collector. The flow rate of the mobile phase used during purifications was 5.0 mL/min. 
 
Synthesis 
 
Boc-Arg-AMC·HCl (3) 
 
To a cold solution (-15 ºC) of Boc-Arg-OH·HCl (4.64 g, 5.0 mmol) and 7-amino-4-methyl-coumarin 
(875 mg, 5.0 mmol) in pyridine (15 mL), phosphoryl chloride (0.51 ml, 5.5 mmol) was added drop wise. 
A color change going from yellow to orange was observed. The mixture was stirred for 2 hours at 
-15 °C, then allowed to warm to room temperature and stirred for an additional hour. The reaction 
mixture was quenched with water (15 mL). The solvents were evaporated under reduced pressure. 
The crude reaction mixture was purified by FCPC chromatography. The product was obtained as a 
light yellow powder (1.59 g, 68%). RF = 0.65 (n-BuOH/H2O/AcOH 4:1:1 v/v). 1H-NMR (300 MHz, 
CD3OD) : 7.70 (d, J = 2.13, 1H), 7.60 (d, J =  11.6 Hz, 1H), 7.38 (d, J = 12 Hz, 1H), 6.13 (d, J = 
1.6 Hz, 1H), 4.16-4.10 (m, 1H), 3.12 (t, J = 8.8 Hz, 2H), 2.36 (s, 3H), 1.59 -1.85 (m, 4H), 1.45 (s, 9H). 
13C-NMR (50 MHz, CD3OD) : 173.6, 163.2, 158.6, 158.0, 155.2, 143.3, 126.7, 117.2, 113.6, 108.0, 
80.9, 56.4, 42.1, 30.6, 28.8, 26.5, 18.6. HRMS (ESI+) m/z calcd for C21H29N5O5 [M+H]+ 432.2247, 
found: 432.2247. 
 
H-Arg-AMC·2HCl (4) 
 
To a suspension of Boc-Arg-AMC·HCl (3) (1.18 g, 2.53 mmol) in Et2O (50 ml), a solution of 
hydrochloric acid in EtOAc (2.6 M, 10 mL) was added. The suspension was stirred overnight at room 
temperature after which the solvents were removed in vacuo. The product was re-suspended in Et2O 
(20 mL), stirred for 2 hours and collected by filtration to yield a white powder (993 mg, 97%). RF = 0.17 
(n-BuOH/H2O/AcOH 4:1:1 v/v).1H-NMR (400 MHz, CD3OD) : 7.91 (s, 1H), 7.76 (d, J = 8.8 Hz, 1H), 
7.55 (d, J = 8.4 Hz, 1H), 6.27 (s, 1H), 4.18-4.11 (m, 1H), 3.27 (t, J =  6.8 Hz, 2H), 2.47 (s, 3H), 1.95-
2.15 (m, 2H), 1.68-1.82 (m, 2H). 13C-NMR (50 MHz, CD3OD) : 169.0, 155.4, 155.2, 142.6, 127.0, 
117.7, 117.3, 113.9, 108.3, 54.8, 41.8, 29.8, 25.5, 18.7. Anal. C16H21N5O2 · 3.0 HCl calculated 
C 45.15% H 5.69% N 16.45%, measured C 45.12% H 5.43% N 16.57%.  
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Boc-Gly-Gly-Arg-AMC·HCl (5) 
 
H-Arg-AMC·2HCl (4) (993 mg, 2.46 mmol), Boc-Gly-Gly-OH (696 mg, 3.0 mmol) and 
4 (dimethylamino)pyridine (DMAP, 611 mg, 5.0 mmol) were dissolved in DMF (20 mL). The mixture 
was cooled to 0 °C and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC·HCl, 
531 mg, 2.8 mmol) was added in small portions. The mixture was stirred for 15 min at 0 oC and 
16 hours at room temperature. The solvent was removed under reduced pressure and the crude 
reaction mixture was purified by FCPC. The product was obtained as an off-white solid (1.13 g, 86%). 
RF = 0.48 (n-BuOH/H2O/AcOH 4:1:1 v/v). 1H-NMR (300 MHz, CD3OD) : 7.82 (d, J = 1.9 Hz, 1H), 7.71 
(d, J = 8.7 Hz, 1H), 7.48 (dd, J = 2.1, 8.6 Hz, 1H), 6.24 (s, 1H), 4.57 (t, J = 8.9 Hz, 1H), 3.92 (s, 2H), 
3.75 (s, 2H), 3.22 (t, J = 7.0 Hz, 2H), 2.45 (s, 3H), 2.05-1.91 (m, 1H), 1.85-1.60 (m, 3H), 1.42 (s, 9H). 
13C-NMR (75 MHz, CD3OD) δ: 173.8, 172.5, 172.1, 163.2, 158.7, 155.33, 155.27, 143.3, 126.7, 117.4 
(2C), 113.7, 108.2, 81.0, 55.1, 45.0, 43.9, 42.0, 30.0, 28.8, 26.4, 18.6. HRMS (ESI+) m/z calcd for 
C25H36N7O7 [M+H]+ 546.2676, found: 546.2641 
 
H-Gly-Gly-Arg-AMC·2HCl (2) 
 
To a suspension of Boc-Gly-Gly-Arg-AMC·HCl (5) (1.00 g, 1.72 mmol) in Et2O (30 mL) was added HCl 
in EtOAc (2.5 mL, 2.6 M). The reaction mixture was stirred 4 hours at room temperature. The resulting 
gum was dried in vacuo and re-suspended in Et2O (20 mL). The resulting solid was filtered off, 
washed with Et2O (2  10 mL) and dried in vacuo. Product 2 was obtained as an off-white solid 
(870 mg, 98%). RF = 0.20 (n-BuOH/H2O/AcOH 4:1:1 v/v). 1H-NMR (400 MHz, CD3OD) : 7.86 (d, J = 
2.0 Hz, 1H), 7.72 (d, J = 8.7 Hz, 1H), 7.55 (dd, J = 8.7, 2.1 Hz, 1H), 6.25 (d, J = 1.2 Hz, 1H), 4.56 
(m, 1H), 4.03 (s, 2H), 3.84 (s, 2H), 3.25 (t, J = 7.0 Hz, 2H), 2.46 (d, J = 1.2 Hz, 3H) 2.08-1.95 (m, 1H), 
1.86-1.58 (m, 3H). 13C-NMR (50 MHz, CD3OD) : 172.5, 171.4, 168.1, 163.0, 158.4, 155.1, 154.9, 
142.9, 126.4, 117.1, 117.0, 113.4, 107.8, 55.2, 43.3, 41.8, 41.5, 29.9, 26.2, 18.4. Anal. calcd. for 
C20H27N7O5 · 3.5 HCl; C 41.79% H 5.36% N 17.06%, measured C 41.72% H 5.71% N 17.17%. HRMS 
(ESI+) m/z calcd for C20H28N7O5 [M+H]+ 446.2152, found: 446.2176. 
 
General procedure for the coupling of Boc-(AA)n-OH to H-Arg-AMC (4): 
 
To a cooled solution (0 °C) of Boc-(AA)n-OH (1 equiv), H-Arg-AMC (4) (1 equiv), HOBt (1 equiv) and 
DMAP (2 equiv) in a solvent (5-10 mL) EDC·HCl (1.1 equiv) was added slowly. The reaction mixture 
was stirred at 0 °C for 30 min and an additional 16-18 hours at room temperature. The solvent was 
evaporated in vacuo and the crude reaction mixture was purified by counter current chromatography 
using n-BuOH/H2O. 
 
General procedure for the Boc-deprotection of Boc-(AA)n-Arg-AMC: 
 
Method A: 
 
To a suspension of Boc-(AA)n-Arg-AMC in Et2O (5-10 mL) was added 2.6 M HCl in EtOAc (1-3 mL). 
The reaction mixture was stirred at room temperature for 16-18 hours. The solvents were removed 
under reduced pressure and the obtained oil was either lyophilized from H2O (10 mL), or purified by 
counter current chromatography using n-BuOH/H2O and subsequently lyophilized in the presence 2 M 
HCl (0.5 mL) from H2O/dioxane (10 mL 1:1 v/v), to give the product as a solid. 
 
Method B:  
 
To a cooled suspension of Boc-(AA)n-Arg-AMC in CH2Cl2 (5-10 mL) was added trifluoroacetic acid 
(TFA, typically 10 equiv). The reaction was allowed to warm to room temperature and stirred 
overnight. The solvent and excess TFA were removed under reduced pressure and the obtained oil 
was either lyophilized from H2O (10 mL), or purified by counter current chromatography using 
n-BuOH/H2O and subsequently lyophilized in the presence 2 M HCl (0.5 mL) from H2O/dioxane 
(10 mL 1:1 v/v), to give the product as a solid.  
 
Boc-(D)-Phe-Arg-AMC·HCl (6) 
 
General procedure for H-Arg-AMC coupling; quantities used: Boc-D-Phe-OH (146 mg, 0.55 mmol), 
H-Arg-AMC·2HCl (4, 202 mg, 0.5 mmol), DMAP (122 mg, 1.0 mmol), HOBt (74 mg, 0.55 mmol), DMF 
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(9 mL) and EDC·HCl (105 mg, 0.55 mmol) The DMF was removed in vacuo and purification of the 
product with counter-current chromatography (EtOAc/BuOH/H2O, 25:25:50 v/v) afforded an off-white 
powder (+100%, still some HOBt present, used as such in the next experiment) RF = 0.62 
(BuOH/H2O/AcOH 4:1:1). 1H-NMR (400 MHz, CD3OD) : 7.86 (t, J = 1.1, Hz, 1H), 7.69 (s, 1H), 7.32-
7.19 (m, 5H), 6.23 (d, J = 1.2 Hz, 1H), 4.39 (dd, J = 9.5, 3.9 Hz, 1H), 4.27 (t, J = 7.8 Hz, 1H), 3.04 
(t, J = 6.9, 2H), 2.98 (d, J = 7.8 Hz, 2H), 2.45 (d, J = 1.2 Hz, 3H), 1.56-1.40 (m, 2H), 1.39 (s, 9H), 1.21-
1.10 (m, 2H). 13C-NMR (75 MHz, CD3OD) : 175.1. 172.4, 163.2, 158.7, 158.0, 155.3, 155.2, 143.0, 
138.1, 130.5 (2C), 129.7 (2C), 128.0, 126.6, 117.8, 117.6, 113.9, 108.7, 81.0, 58.5, 54.8, 41.7, 38.6, 
30.8, 29.5, 28.7, 25.9, 24.3, 18.6. HRMS (ESI+) m/z calcd for C30H39N6O6 [M+H]+ 579.2931, found: 
579.2963. 
 
H-(D)-Phe-Arg-AMC·2HCl (7) 
  
To a suspension of Boc-(D)-Phe-Arg-AMC·HCl (6) (300 mg, max 0.5 mmol) in Et2O (20 mL) was 
added HCl in EtOAc (2 mL, 2.6 M). The reaction mixture was stirred 15 hours at room temperature. 
The resulting gum was dried in vacuo and re-suspended in Et2O (20 mL). The product was filtered off, 
washed with Et2O (2  10 mL) and dried in vacuo. Product 7 was obtained as an off-white solid 
(156 mg, 62% over 2 steps). 1H-NMR (300 MHz, CD3OD) : 7.78 (s, 1H), 7.60 (d, J = 8.7 Hz, 1H), 7.48 
(d, J = 8.5 Hz, 1H), 7.29-7.41 (m, 5H), 6.18 (s, 1H), 4.44 (m, 1H), 4.32 (br s, 1H), 3.22-3.13 (m, 4H), 
2.40 (s, 3H), 1.93-1.64 (m, 2H), 1.45-1.25 (m, 2H). 13C-NMR (75 MHz, CD3OD) : 172.5, 170.0, 163.3, 
158.6, 158.5, 155.3, 155.0, 143.1, 135.8, 130.7, 130.1, 128.8, 126.6, 117.3, 117.2, 113.7, 108.0, 55.8, 
55.6, 41.9, 38.7, 29.9, 26.3, 18.6. Anal. calcd. for C25H31N6O4 · 3.4 HCl; C 49.78% H 5.85% N 13.45%, 
measured C 49.80% H 5.71% N 13.42%.  
 
Boc-Pro-Arg-AMC·HCl (8) 
 
To a cooled solution (0 ºC) of H-Arg-AMC·2HCl (4) (202 mg, 0.5 mmol), DMAP (122 mg, 1.0 mmol), 
HOBt (74 mg, 0.55 mmol) and Boc-Pro-OH (118 mg, 0.55 mmol) in DMF (9 mL), was added EDC·HCl 
(105 mg, 0.55 mmol) in small portions. The mixture was allowed to warm to room temperature and 
was stirred for 16 hours. The DMF was removed in vacuo and purification of the product with counter-
current chromatography (EtOAc/BuOH/H2O, 25:25:50 v/v) afforded a light yellow powder (+100%, still 
some HOBt present, used as such in the next experiment) RF = 0.47 (BuOH/H2O/AcOH 4:1:1). 
1H-NMR (400 MHz, CD3OD) : 7.85 (d, J = 6.0 Hz, 1H), 7.72 (d, J = 8.7 Hz, 1H), 7.69 (t, J = 7.9 Hz, 
2H, HOBt), 7.50 (dd, J = 26.8, 7.4 Hz, 1H), 7.30-7.24 (m, 2H, HOBt), 6.25 (d, J = 1.3 Hz, 1H), 4.55 
(dd, J = 8.6, 5.3 Hz, 1H), 4.27 (dd, J = 8.7, 3.9 Hz, 1H), 3.28-3.19 (m, 2H), 2.46 (d, J = 1.2 Hz, 3H), 
2.32-2.19 (m, 1H), 2.08-1.60 (m, 7H), 1.43 (d, J = 24.1 Hz, 9H).  
 
H-Pro-Arg-AMC·2HCl (9) 
 
To a suspension of Boc-Pro-Arg-AMC·HCl (8) (300 mg, max 0.5 mmol) in Et2O (20 mL) was added 
HCl in EtOAc (2 mL, 2.6 M). The reaction mixture was stirred 15 hours at room temperature. The 
resulting gum was dried in vacuo and re-suspended in Et2O (20 mL). The product was filtered off, 
washed with Et2O (2  10 mL) and dried in vacuo. Product 9 was obtained as an off-white solid 
(181 mg, 66% over 2 steps). 1H-NMR (300 MHz, CD3OD) : 7.86 (d, J = 2.0 Hz, 1H), 7.73 (d, J = 
8.7 Hz, 1H), 7.49 (dd, J = 2.1, 8.7 Hz, 1H),  7.41-7.32 (m, 5H, HOBt), 6.26 (d, J = 1.3 Hz, 1H), 4.44 
(dd, J = 5.5, 8.7 Hz, 1H), 4.20 (t, J = 7.7 Hz, 1H), 3.22-3.10 (m, 4H), 2.46 (d, J = 1.3 Hz, 1H),1.86-1.77 
(m, 1H), 1.70-1.60 (m, 1H), 1.55-1.48 (m, 1H), 1.46-1.27 (m, 5H). 13C-NMR (75 MHz, CD3OD) : 
172.5, 171.7, 163.8, 158.5, 155.8, 155.1, 143.0, 126.9, 117.5, 113.6, 108.2, 61.0, 55.6, 48.2, 47.7, 
42.0, 31.3, 30.1, 26.3, 25.4, 18.7. Anal. calcd. for C25H31N6O4 · 3.5 HCl; C 45.60% H 5.80% N 14.73%, 
measured C 45.60% H 5.83% N 14.73% 
 
Boc-Val-Arg-AMC·HCl (10) 
 
General procedure for H-Arg-AMC coupling; quantities used: Boc-Val-OH (71.6 mg, 0.33 mmol), 
H-Arg-AMC (4, 134.3 mg, 0.33 mmol), HOBt (45 mg, 0.33 mmol), DMAP (80.0 mg, 0.66 mmol), 
CH2Cl2 (5 mL) and EDC·HCl (69.0 mg, 0.36 mmol). The DMF was removed in vacuo and purification 
of the product with counter-current chromatography (BuOH/H2O) afforded a pale yellow solid (+100%, 
still some HOBt present, used as such in the next experiment) RF = 0.58 (BuOH/H2O/AcOH 4:1:1). 
1H-NMR (400 MHz, CD3OD) : 7.83 (d, J = 2.1 Hz, 1H), 7.72 (d, J = 8.7 Hz, 1H), 7.69 (br t, 2H, HOBt), 
7.50 (dd, J = 2.1,  8.6 Hz, 1H), 7.30-7.23 (m, 2H, HOBt), 6.25 (q, J = 1.1 Hz, 1H), 4.56 (dd, J = 5.4, 
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8.6 Hz, 1H), 3.88 (d, J = 6.9 Hz, 1H), 3.24 (dd, J = 6.5, 13.8 Hz, 2H), 2.46 (d, J = 1.2 Hz, 3H), 2.08-
1.93 (m, 2H), 1.87-1.66 (m, 3H), 1.44 (s, 9H), 0.97 (t, J = 7.2 Hz, 6H). 13C-NMR (75 MHz, CD3OD) : 
175.0, 172.4, 163.3, 158.8, 155.41, 155.37, 155.30, 243.3, 126.8, 117.4, 117.2, 113.7, 108.1, 80.8, 
62.0, 42.0, 30.8, 30.3, 28.8 (3C), 26.5, 19.8, 18.7, 18.6. HRMS (ESI+) m/z calcd for C26H39N6O6 
[M+H]+ 531.2931, found: 531.2945. 
 
H-Val-Arg-AMC·2HCl (11) 
 
General procedure for Boc-deprotection, method B; quantities used: Boc-Val-Arg-AMC (10, 152 mg, 
0.30 mmol), CH2Cl2 (5 mL), TFA (0.4 mL, 2.5 mmol). After FCPC purification the product was obtained 
as a white solid (154 mg, 95% over 2 steps). RF = 0.31 (BuOH/H2O/AcOH 4:1:1). 1H-NMR (400 MHz, 
CD3OD) : 8.73 (d, J = 7.1 Hz, NH, 1H), 7.84 (d, J = 2.0 Hz, 1H), 7.71 (d, J = 8.7 Hz, 1H), 7.55 (t, J = 
5.5 Hz, NH, 1H), 7.50 (dd, J = 8.7 Hz, 1H), 6.24 (d, J = 1.2 Hz, 1H), 4.62-4.56 (m, 1H), 3.84 (d, J = 
5.7 Hz, 1H), 3.29-3.25 (m, 2H), 2.45 (d, J = 1.2 Hz, 3H), 2.27 (qd, J = 13.6, 6.7 Hz, 1H), 2.04-1.95 
(m, 1H), 1.93-1.68 (m, 3H), 1.08 (dd, J = 14.8 Hz, 6H). 13NMR (75 MHz, CD3OD) : 172.3, 170.0, 
163.4, 158.8, 155.44, 155.40, 143.5, 126.9, 117.3, 117.2, 113.8, 108.0, 59.7, 55.7, 42.2, 31.8, 30.3, 
26.55, 19.1, 18.8, 18.1. HRMS (ESI+) m/z calcd for C21H31N6O4 [M+H]+ 431.2407, found: 431.2421. 
 
Msc-Val-Arg-AMC·HCl (12) 
 
To a cooled solution (0 ºC) of H-Val-Arg-AMC·2HCl (11) (200 mg, 0.4 mmol) in DMF (10 mL) was 
added DiPEA (100 μL, 0.57 mmol) and N-[2-(methylsulfonyl)-ethoxycarbonyloxy]-succinimide (Msc-
OSu, 148 mg, 0.55 mmol) in small portions. The mixture was allowed to warm to room temperature 
and was stirred for 16 hours. The DMF was removed in vacuo and purification of the product with 
counter-current chromatography (BuOH/H2O) afforded a light yellow powder (166 mg, 68%) RF = 0.63 
(BuOH/H2O/AcOH 4:1:1). 1H-NMR (400 MHz, CD3OD) : 7.84 (d, J = 2.0 Hz, 1H), 7.73 (d, J = 8.7 Hz, 
1H), 7.53 (dd, J = 2.0, 8.7 Hz, 1H), 6.25 (d, J = 1.2 Hz, 1H), 4.58-4.51 (m, 2H), 4.48-4.42 (m, 1H), 3.94 
(d, J = 7.0 Hz, 1H), 3.47 (t, J = 5.6 Hz, 1H), 3.25 (qd, J = 6.7, 13.4 Hz, 2H), 3.05 (s, 3H), 2.67 (br s, 
1H, NH), 2.46 (d, J = 1.2 Hz, 3H), 2.13-1.94 (m, 2H), 1.88-1.65 (m, 3H), 1.01-0.98 (m, 6H). 13C-NMR 
(75 MHz, CD3OD) : 174.6, 172.4, 163.2, 158.6, 158.0, 155.31, 155.29, 143.2, 126.8, 117.3, 117.2, 
113.7, 108.0, 62.5, 59.7, 55.0, 54.8, 42.5, 42.0, 31.6, 30.2, 26.5, 19.7, 18.8, 18.6. HRMS (ESI+) m/z 
calcd for C25H37N6O8S [M+H]+ 581.2394, found: 581.2388. 
 
Btsc-Val-Arg-AMC.HCl (13) 
 
To a cooled solution (0 ºC) of H-Val-Arg-AMC·2HCl (11) (200 mg, 0.4 mmol) in DMF (10 mL) was 
added DiPEA (100 μL, 0.57 mmol) and N-(benzothiophene-sulfone-2-methyl)-N-succinimidyl 
carbonate (Btsc-OSu, 185 mg, 0.55 mmol) in small portions. The mixture was allowed to warm to room 
temperature and was stirred for 16 hours. The DMF was removed in vacuo and purification of the 
product with counter-current chromatography (BuOH/H2O) afforded an off-white powder (142 mg, 
52%) RF = 0.68 (BuOH/H2O/AcOH 4:1:1). 1H-NMR (400 MHz, CD3OD) : 7.75 (d, J = 2.0 Hz, 1H), 
7.69-7.64 (m, 2H), 7.56-7.50 (m, 2H), 7.47 (dd, J = 2.1, 8.6 Hz, 1H), 7.24-7.22 (m, 2H), 6.26 (d, J = 
1.2 Hz, 1H), AB-system: 5.28 + 5.06 (dd, J = 1.3, 14.7 Hz, 2H), 4.51 (dd, J = 4.7, 9.4 Hz, 1H), 3.98 
(d, J = 6.0 Hz, 1H), 3.23 (dt, J = 1.3, 6.8 Hz, 2H), 2.47 (d, J = 1.1 Hz, 3H), 2.22-2.13 (m, 1H), 2.08-
2.00 (m, 1H), 1.85-1.62 (m, 3H), 1.02 (dd, J = 7.0, 8.5 Hz, 6H). 13C-NMR (75 MHz, CD3OD) : 174.5, 
172.1, 163.3, 158.7, 158.4, 155.3, 155.2, 143.0, 140.7, 138.3, 135.2, 131.8, 130.7, 126.8, 126.7, 
122.0, 117.3, 113.7, 108.1, 63.0, 58.8, 55.0, 42.0, 31.4, 29.6, 26.6, 19.7, 18.62, 18.58. HRMS (ESI+) 
m/z calcd for C31H37N6O8S [M+H]+ 653.2394, found: 653.2391. 
 
Boc-Gly-Pro-OH (15) 
 
This compound was prepared according to a literature procedure:41  
Quantities used: H-Pro-OMe (1.30 g, 7.75 mmol), Boc-Gly-OH (1.26 g, 7.75 mmol), NMM (0.85 mL, 
7.75 mmol), HOBt (1.05 g, 7.75 mmol), EtOAc (30 mL) and DCC (1.68 g, 8.14 mmol). The product 
was purified by column chromatography (CH2Cl2/MeOH 9:1). Boc-Gly-Pro-OMe (14) was obtained as 
an off white semisolid (2.15 g, 90%). 1H-NMR (400 MHz, CD3OD) : 4.46 (dd, J = 8.7, 3.4 Hz, 2H), 
3.99-3.81 (m, 2H), 3.70 (s, 3H), 3.66-3.52 (m, 2H), 2.28-2.18 (m, 1H), 2.08-1.92 (m, 3H), 1.45 (s, 9H). 
LRMS (ESI+) m/z calcd for C13H22N2NaO5 [M+Na]+ 309.1, found: 309.1 Subsequent saponification of 
Boc-Gly-Pro-OMe (2.00 g, 7.50 mmol) in dioxane (13 mL), water (5 mL) using NaOH (2 mL, 2 M). The 
reaction was stirred for 16 hours at room temperature. After addition of HCl (1.5 mL, 2 M) the product 
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was extracted with CH2Cl2 (3  10 mL). The combined organic layers were dried over Na2SO4 and the 
solvents were removed in vacuo. The product was obtained as a white powder (1.61 g, 79%). 1H-NMR 
(400 MHz, CD3OD) : 4.40 (dd, J = 8.7, 3.4 Hz, 2H), 3.99-3.81 (m, 2H), 3.66-3.52 (m, 2H), 2.28-2.18 
(m, 1H), 2.08-1.92 (m, 3H), 1.45 (s, 9H). 13C-NMR (75 MHz, CD3OD) : 173.7, 168.3, 156.5, 78.7, 
58.6, 45.4, 41.5, 28.2, 26.8, 23.8. LRMS (ESI-) m/z calcd for C12H19N2O5 [M-H]- 271.1, found: 271.1, 
542.9 [2M-H]- 
 
Boc-Gly-Pro-Arg-AMC·HCl (16) 
 
To a cooled solution (0 ºC) of H-Arg-AMC (4) (202 mg, 0.5 mmol), Boc-Gly-Pro-OH (15) (150 mg, 
0.55 mmol), DMAP (122 mg, 1.0 mmol) and HOBt (73.7 mg, 0.55 mmol) in DMF (9 mL), EDC·HCl 
(116 mg, 0.55 mmol) was added in small portions. The solution was allowed to warm to room 
temperature and was stirred for 16 hours at room temperature after which the DMF was evaporated in 
vacuo. The crude material was purified using counter current chromatography (BuOH/H2O) to afford 
an off-white solid (205 mg, 70%) RF = 0.62 (BuOH/H2O/AcOH 4:1:1). 1H-NMR (400 MHz, CD3OD) : 
7.87 (d, J = 2.0 Hz, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.57 (dd, J = 8.8, 2.0 Hz, 1H), 6.25 (d, J = 1.2 Hz, 
1H), 4.55 (dd, J = 4.6, 9.6 Hz, 1H), 4.45 (dd, J = 5.0, 8.3 Hz, 1H), 3.93 (q, J = 17.0 Hz, 2H), 3.72-3.58 
(m, 2H), 3.25 (t, J = 7.1 Hz, 2H), 2.34 (d, J = 1.2 Hz, 1H), 2.33-2.25 (m, 1H), 2.11-1.94 (m, 4H), 1.87-
1.66 (m, 3H), 1.34 (s, 9H). 13C-NMR (75 MHz, CD3OD) : 174.9, 172.9, 172.5, 171.4, 163.2, 158.7, 
155.4, 155.2, 143.4, 226.7, 117.4, 117.3, 113.7, 108.2, 80.6, 62.4, 54.9, 48.0, 43.9, 41.9, 30.8, 29.8, 
28.7, 26.4, 26.0, 18.6. HRMS (ESI+) m/z calcd for C28H40N7O7 [M+H]+ 586.2989, found: 586.2973.  
 
H-Gly-Pro-Arg-AMC·2HCl (17) 
 
Compound 16 (200 mg, 0.35 mmol) was suspended in Et2O (20 mL) and HCl in EtOAc was added 
(2 mL, 2.6 M). This mixture was stirred for 16 hours and solvents were evaporated in vacuo. The crude 
material was purified by counter current chromatography (BuOH/H2O) and the product was obtained 
as a white powder (161 mg, 95%). 1H-NMR (400 MHz, CD3OD) : 7.87 (d, J = 2.0 Hz, 1H), 7.73 (d, J = 
8.8 Hz, 1H), 7.57 (dd, J = 2.0, 8.8 Hz, 1H), 6.25 (d, J = 1.2 Hz, 1H), 4.54-4.48 (m, 2H), 3.94 (q, J = 
12.0 Hz, 2H), 3.77-3.54 (m, 2H), 3.25 (t, J = 6.8 Hz, 2H), 2.45 (s, 3H) 2.32-2.25 (m, 1H), 2.08-1.65 
(m, 7H). 13C-NMR (75 MHz, CD3OD) : 172.6, 170.7, 165.0, 161.3, 156.7, 153.3, 141.4, 124.8, 115.6, 
115.4, 111.8, 106.2, 60.1, 53.6, 40.1, 39.9, 29.1, 28.0, 24.7, 23.8, 16.6. HRMS (ESI+) m/z calcd for 
C23H32N7O5 [M+H]+ 486.2465, found: 486.2500 
 
Boc-Ala-Arg-AMC·HCl (18) 
 
General procedure for H-Arg-AMC coupling; quantities used: Boc-Ala-OH (62.4 mg, 0.33 mmol), 
H-Arg-AMC (4, 134.3 mg, 0.33 mmol), HOBt (45 mg, 0.33 mmol), DMAP (80.0 mg, 0.66 mmol), 
CH2Cl2 (5 mL) and EDC·HCl (69.0 mg, 0.36 mmol). Yield; 150 mg (84%) light yellow solid. RF = 0.50 
(BuOH/H2O/AcOH 4:1:1). 1H-NMR (300 MHz, CD3OD) : 7.85 (d, J = 2.0 Hz, 1H), 7.71 (d, J = 8.7 Hz, 
1H), 7.53 (dd, J = 8.6, 1.7 Hz, 1H), 6.23 (d, J = 1.2 Hz, 1H), 4.54 (dd, J = 8.7, 5.0 Hz, 1H), 4.08 (q, J = 
7.2 Hz, 1H), 3.24 (dt, J = 6.9, 6.9, 3.6 Hz, 2H), 2.45 (d, J = 1.2 Hz, 3H), 2.05-1.59 (m, 4H), 1.43 
(s, 9H), 1.34 (d, J = 7.2 Hz, 3H). 13C-NMR (75 MHz, CD3OD) : 176.5, 172.5, 163.2, 158.7, 155.4, 
155.3, 143.3, 126.8, 117.4, 117.3, 113.7, 108.2, 80.9, 54.8, 52.1, 42.0, 30.8, 30.3, 28.8, 26.4, 18.6, 
18.1. HRMS (ESI+) m/z calcd for C24H35N6O6 [M+H]+ 503.2618, found: 503.2631.  
 
H-Ala-Arg-AMC·2HCl (19) 
 
General procedure for Boc-deprotection, method B; quantities used: Boc-Ala-Arg-AMC (18, 140.9 mg, 
0.25 mmol), CH2Cl2 (5 mL), TFA (0.4 mL, 2.5 mmol). Yield; 125 mg (95%) as a white solid. 1H-NMR 
(400 MHz, CD3OD) : 7.82 (s, 1H), 7.70 (d, J = 8.6 Hz, 1H), 7.46 (d, J = 7.9 Hz, 1H), 6.23 (s, 1H), 4.55 
(t, J = 6.1 Hz, 1H), 4.05 (q, J = 6.8, 6.5 Hz, 1H), 3.25 (t, J = 5.9 Hz, 2H), 2.45 (s, 3H), 2.04-1.91 
(m, 1H), 1.91-1.63 (m, 3H), 1.55 (d, J = 6.7 Hz, 3H). 13C-NMR (75 MHz, CD3OD) : 172.3, 171.3, 
163.2, 158.7, 155.4, 155.3, 143.3, 126.9, 117.4, 117.1, 113.8, 108.1, 68.2, 55.5, 42.1, 30.4, 26.5, 18.6, 
17.7. HRMS (ESI+) m/z calcd for C19H27N6NaO4 [M+Na]+ 425.1913, found: 425.1920. 
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Boc-Ala-Pro-OH (21) 
 
This compound was prepared according to a modified literature procedure:42 
Quantities used: Boc-Ala-OH (189 mg, 1.0 mmol), H-Pro-OMe·HCl (165 mg, 1.0 mmol), HOBt 
(136 mg, 1.0 mmol) and DiPEA (341 μL, 2 mmol) were dissolved in CH2Cl2 (10 mL) and the solution 
was cooled to 0 °C before adding EDC·HCl (210 mg, 1.1 mmol). The crude product was purified by 
column chromatography (CH2Cl2/ MeOH 9:1) to afford the product (20) as colorless oil (303 mg, 99%) 
RF = 0.59 (CH2Cl2/MeOH 9:1). 1H-NMR (400 MHz, CD3OD) : 4.48 (dd, J = 4.6, 8.6 Hz, 1H), 4.37 
(q, J = 7.0 Hz, 1H), 3.83-3.76 (m, 1H), 3.70 (s, 3H), 3.67-3.62 (m, 1H), 2.31-2.22 (m, 1H), 2.08-2.01 
(m, 2H), 1.99-1.93 (m, 1H), 1.43 (s, 9H), 1.29 (d, J = 7.0 Hz, 3H). LRMS (ESI+) m/z calcd for 
C14H24N2NaO5 [M+Na]+ 323.2, found: 323.0. Subsequent saponification of Boc-Ala-Pro-OMe (303 mg, 
1.0 mmol) in THF (20 mL), using NaOH (1 M, 2.2 mL) was performed at 0 °C. The reaction was 
warmed to room temperature and stirred for 16 hours. The reaction was quenched with HCl (2 M, 
3 mL) the product was extracted with CH2Cl2 (3  25 mL). The combined organic layers were dried 
over MgSO4 and the solvents were removed in vacuo. The product was obtained as a white solid 
(200 mg, 64%) RF = 0.14 (CH2Cl2/MeOH 9:1). 1H-NMR (300 MHz, CDCl3) : 6.15 (br s, 1H, OH), 5.41 
(d, J = 8.4 Hz, NH), 4.60 (dd, J = 4.3, 7.8 Hz, 1H), 4.50 (td, J = 7.1, 14.5 Hz, 1H), 3.78-3.75 (m, 1H), 
3.63-3.56 (m, 1H), 2.29-2.01 (m, 4H), 1.43 (s, 9H), 1.35 (d, J = 6.9 Hz, 3H). 13C-NMR (75 MHz, CDCl3) 
: 175.5, 174.1, 157.7, 80.6, 60.5, 49.2, 48.1, 30.1, 28.7, 25.9, 17.1. LRMS (ESI-) m/z calcd. for 
C13H21N2O5 [M-H]- 285.15, found: 285.07. 
 
Boc-Ala-Pro-Arg-AMC·HCl (22) 
 
General procedure for H-Arg-AMC coupling; quantities used: Boc-Ala-Pro-OH (144 mg, 0.5 mmol), 
H-Arg-AMC (4, 201 mg, 0.5 mmol), HOBt (74.3 mg, 0.5 mmol), DMAP (121.0 mg, 1.0 mmol), DMF 
(10 mL) and EDC·HCl (105.0 mg, 0.55 mmol). Yield; 261 mg (80%) light yellow solid. 1H-NMR 
(400 MHz, CD3OD) : 7.85 (d, J = 1.9 Hz, 1H), 7.70 (d, J = 8.7 Hz, 1H), 7.51 (d, J = 8.3 Hz, 1H), 7.26 
(d, J = 5.2 Hz, NH, 1H), 6.23 (d, J = 1.0 Hz, 1H), 4.53 (dd, J = 4.8, 8.6 Hz, 1H), 4.48 (dd, J = 5.2, 
7.8 Hz, 1H), 4.36 (q, J = 6.7 Hz, 1H), 3.82 (dd, J = 6.6, 16.2 Hz, 1H), 3.64 (dd, J = 6.6, 16.5 Hz, 1H), 
3.24 (t, J = 6.9 Hz, 2H), 2.45 (d, J = 0.9 Hz, 3H), 2.33-2.18 (m, 1H), 2.13-1.92 (m, 4H), 1.88-1.67 
(m, 3H), 1.43 (s, 9H), 1.29 (d, J = 7.0 Hz, 3H). 13C-NMR (75 MHz, CD3OD) : 174.7, 174.5, 172.4, 
163.2, 159.4, 158.7, 155.4, 155.3, 143.3, 126.8, (125.3, 125.2,), 117.4, 117.2, 113.7, 108.1, 80.7, 
61.9, 54.9, 49.8, 42.0, 30.6, 30.3, 28.8, 26.3, 26.2, 18.6, 17.0. LRMS (ESI+) m/z calcd for C29H41N7O7 
[M+H]+ 600.3, found: 600.2. 
 
H-Ala-Pro-Arg-AMC·2HCl (23) 
 
General procedure for Boc-deprotection, method A; quantities used: Boc-Ala-Pro-Arg-AMC (22, 
250 mg, 0.39 mmol), Et2O (10 mL), 2.6 M HCl in EtOAc (2 mL). The product was obtained as a pale 
yellow solid after counter current chromatography (BuOH/H2O/AcOH 4:5:1) (220 mg, 99%). 1H-NMR 
(300 MHz, CD3OD) : 7.84 (d, J = 1.7 Hz, 1H), 7.69 (d, J = 8.7 Hz, 1H), 7.49 (dd, J = 1.6, 8.6 Hz, 1H), 
6.22 (s, 1H), 4.60-4.50 (m, 2H), 4.28 (q, J = 6.6 Hz, 1H), 3.80-3.57 (m, 2H), 3.26 (d, J = 6.6 Hz, 2H), 
2.44 (s, 3H), 2.39-2.22 (m, 1H), 2.19-1.67 (m, 7H), 1.53 (d, J = 6.8 Hz, 3H). 13C-NMR (75 MHz, 
CD3OD) : 174.2, 172.5, 169.8, 163.2, 158.6, 155.4, 155.3, 143.3, (128.7, 127.8,), 126.8, 118.3, 
117.3, 117.2, 113.7, 111.7, 108.0, 61.7, 55.2, 48.7, 42.0, 30.7, 30.4, 26.4, 26.1, 18.6, 16.3. HRMS 
(ESI+) m/z calcd for C24H34N7O5 [M+H]+ 500.2621, found: 500.2620. 
 
Boc-Ala-Val-OH (25) 
 
This compound was prepared according to a modified literature procedure:43 
Boc-Ala-OH (189 mg, 1.0 mmol), H-Val-OMe·HCl (168 mg, 1.0 mmol), HOBt (136 mg, 1.0 mmol) and 
DiPEA (341 μL, 2 mmol) were dissolved in CH2Cl2 (10 mL) and the solution was cooled to 0 °C before 
adding EDC·HCl (210 mg, 1.1 mmol) to the solution. The reaction mixture was stirred for 30 minutes at 
room temperature and an additional 18 hours at room temperature. The mixture was quenched with 
HCl (2 M 10 mL) and the layers separated. The organic layer was washed with aq. NaHCO3 
(sat. 5 mL) and dried over Na2SO4. The drying agent was removed and the solvent was evaporated 
under reduced pressure. The product (24) was obtained as white solid (280 mg, 93%). 1H-NMR 
(400 MHz, CDCl3) : 6.68 (br d, J = 21.0 Hz, NH, 1H), 4.99 (br s, 1H), 4.52 (dd, J = 8.9, 8.9 Hz, 1H), 
4.18 (br s, 1H), 3.72 (d, J = 1.3 Hz, 3H), 2.20-2.12 (m, 1H), 1.44 (d, J = 2.8 Hz, 9H), 1.35 (t, J = 7.0 
Hz, 3H), 0.92 (t, J = 7.0 Hz, 3H), 0.88 (dd, J = 6.9 Hz, 3H). 13C-NMR (50 MHz, CDCl3) : 172.5, 172.3, 
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15737, 80.2, 56.9, 52.1, 50.1, 31.2, 28.3, 18.9, 17.6. LRMS (ESI+) m/z calcd for C14H23N2O5 [M+H]+ 
303.2, found: 302.9. Subsequent saponification of Boc-Ala-Val-OMe (280 mg, 0.93 mmol) in THF 
(20 mL), using NaOH (1 M, 1.85 mL) was performed at 0 °C. The reaction was warmed to room 
temperature and stirred for 16 hours. The reaction was quenched with HCl (2 M, 3 mL) the product 
was extracted with CH2Cl2 (3  25 mL). The combined organic layers were dried over MgSO4 before 
the solvents were removed in vacuo. The product was obtained as a white solid (202 mg, 70%) RF = 
0.15 (CH2Cl2/MeOH 9:1). 1H-NMR (300 MHz, CDCl3) : 6.88 (br s, 1H, NH), 5.17 (br s, 1H, OH), 4.54 
(dd, J = 4.8, 8.7 Hz, 1H), 4.23 (br s, 1H, NH), 2.33-2.16 (m, 1H), 1.43 (s, 9H), 1.35 (d, J = 7.0 Hz, 3H), 
0.95 (t, J = 7.0 Hz, 6H). 13C-NMR (75 MHz, CDCl3) : 174.9, 173.1, 155.9, 80.5,  57.1, 50.0, 31.0, 
28.3, 19.0, 17.5. LRMS (ESI-) m/z calcd for C13H23N2O5 [M-H]- 287.16, found: 287.13. 
    
Boc-Ala-Val-Arg-AMC·HCl (26) 
 
General procedure for H-Arg-AMC coupling; quantities used: Boc-Ala-Val-OH (25, 144 mg, 0.5 mmol), 
H-Arg-AMC (4, 201 mg, 0.5 mmol), HOBt (74.3 mg, 0.55 mmol), DMAP (121 mg, 1.0 mmol), DMF 
(10 mL) and EDC·HCl (105 mg, 0.55 mmol). The DMF was removed in vacuo and purification of the 
product with FCPC (BuOH/H2O) afforded a pale yellow solid (200 mg, 62%) RF = 0.69 (BuOH/H2O/ 
AcOH 4:1:1). 1H-NMR (400 MHz, CD3OD) : 7.84 (s, 1H), 7.68 (d, J = 8.7 Hz, 1H), 7.51 (d, J = 8.7 Hz, 
1H), 6.22 (s, 1H), 4.56 (dd, J = 4.8, 8.9 Hz, 1H), 4.19 (d, J = 6.7 Hz, 1H), 4.14-4.09 (m, 1H), 3.25 
(t, J = 6.8 Hz, 1H), 2.44 (s, 3H), 2.17-2.09 (m, 1H), 2.04-1.96 (m, 1H), 1.89-1.65 (m, 3H), 1.45 (s, 9H), 
1.33 (d, J = 7.1 Hz, 3H),1.00 (dd, J = 3.0, 5.7 Hz, 6H). 13C-NMR (50 MHz, CD3OD) : 176.4, 173.8, 
172.3, 163.2, 158.6, 157.9, 155.3, 143.3, 126.7, 117.3, 117.2, 113.7, 108.0, 80.8, 60.5, 55.0, 51.9, 
42.0, 31.9, 30.2, 28.7, 26.5, 19.8, 18.9, 18.8, 18.7. LRMS (ESI+) m/z calcd for C29H44N7O7 [M+H]+ 
602.33, found: 602.27. 
 
H-Ala-Val-Arg-AMC·2HCl (27) 
 
General procedure for Boc-deprotection, method A; quantities used: Boc-Ala-Val-Arg-AMC (26, 
195 mg, 0.30 mmol), Et2O (10 mL), 2.6 M HCl in EtOAc (1.5 mL). After counter current 
chromatography (BuOH/H2O) the product was obtained as an off-white solid (151 mg, 85%). 1H-NMR 
(400 MHz, CD3OD) : 8.41 (d, J = 7.5 Hz, 1H, NH), 7.85 (d, J = 1.7 Hz, 1H), 7.73 (d, J = 8.7 Hz, 1H), 
7.50 (dd, J = 8.6 Hz, 1H), 6.26-6.24 (m, 1H), 4.56-4.50 (m, 1H), 4.31-4.21 (m, 1H), 4.05 (q, J = 7.2 Hz, 
1H), 3.28-3.22 (m, 2H), 2.46 (d, J = 1.2 Hz, 3H), 2.21-1.93 (m,1H), 1.89-1.65 (m, 3H), 1.53 (d, J = 
7.0 Hz, 3H), 1.01 (dd, J = 6.9, 8.4 Hz, 6H). 13C-NMR (75 MHz, CD3OD) : 173.6, 172.5, 171.3, 163.2, 
158.6, 155.3, 155.2, 143.3, 139.9, 126.7, 117.2, 117.1, 113.6, 107.9, 60.6, 55.2, 49.6, 42.0, 31.9, 30.3, 
26.4, 19.8, 18.9, 18.6, 17.9. HRMS (ESI+) m/z calcd for C24H36N7O5 [M+H]+ 502.2778, found: 
502.2771. 
 
Boc-Ala-Gly-OH (29) 
 
This compound was prepared according to a literature procedure:44 
Quantities used: Boc-Ala-OH (945 mg, 5 mmol), H-Gly-OMe·HCl (628 mg, 5 mmol), HOBt (670 mg, 
5 mmol), NMM (0.55 mL, 5 mmol), EtOAc (20 mL) and DCC (1.08 g, 5.25 mmol, 1.05 equiv). After 
column chromatography (CH2Cl2/MeOH 9:1) the product (28) was obtained as a white solid (1.13 g, 
87%) RF = 0.46 (CH2Cl2/MeOH 9:1). 1H-NMR (400 MHz, CD3OD) : 4.11 (dd, J = 6.8, 13.9 Hz, 1H), 
3.94 (q, J = 17.6 Hz, 2H), 3.72 (s, 3H), 1.45 (s, 9H), 1.33 (d, J = 7.2 Hz, 3H). 13C-NMR (75 MHz, 
CD3OD) : 176.4, 171.6, 157.6, 80.7, 52.6, 51.5, 41.8, 28.7, 18.4. LRMS (ESI+) m/z calcd for 
C11H21N2O5 [M+H]+ 261.15, found: 260.95. Subsequent saponification of Boc-Ala-Gly-OMe (1.12 g, 
4.35 mmol) in THF (50 mL), using NaOH (2 M, 4.35 mL, 8.70 mmol) was performed at an initial 
temperature of 0 °C. The reaction was stirred for 16 hours at room temperature. After addition of 
hydrochloric acid (2 M, 7 mL) the product was extracted with EtOAc (2  75 mL). The combined 
organic layers were dried over MgSO4 before the solvents were removed in vacuo. The product was 
obtained as a white foam (800 mg, 75%). 1H-NMR (400 MHz, CD3OD) : 4.14-4.07 (m, 1H), 3.98-3.84 
(m, 2H), 1.44 (s, 9H), 1.32 (d, J = 7.3 Hz, 3H). LRMS (ESI-) m/z calcd for C10H17N2O5 [M-H]- 245.11, 
found: 245.19. 
 
Boc-Ala-Gly-Arg-AMC·HCl (30) 
 
General procedure for H-Arg-AMC coupling; quantities used: Boc-Ala-Gly-OH (29, 246 mg, 1.0 mmol), 
H-Arg-AMC (4, 403 mg, 1 mmol), DMAP (242 mg, 2.0 mmol), DMF (15 mL) and EDC·HCl (210 mg, 
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1.1 mmol). After counter current chromatography (BuOH/H2O) the product was obtained as a pale 
yellow solid (303 mg, 51%) RF = 0.41 (BuOH/H2O/AcOH 4:1:1). 1H-NMR (400 MHz, CD3OD) : 7.88 
(d, J = 1.3 Hz, 1H), 7.72 (d, J = 8.6 Hz, 1H), 7.57 (d, J = 8.9 Hz, 1H), 6.24 (s, 1H), 4.56 (dd, J = 8.6, 
4.9 Hz, 1H), 4.04 (q, J = 7.4 Hz, 1H), 3.89 (s, 2H), 3.22 (t, J = 6.9 Hz, 1H), 2.46 (s, 3H), 2.07-1.98 
(m, 1H), 1.89-1.63 (m, 3H), 1.55 (d, J = 7.1 Hz, 3H). 13C-NMR (75 MHz, CD3OD) : 176.3, 172.6, 
171.8, 171.4, 163.2, 158.7, 155.3, 143.2, 126.7, 117.4, 117.3, 113.7, 108.2, 80.8, 68.2, 54.9, 50.4, 
43.4, 42.1, 30.3, 28.8 (3C), 26.4, 18.6, 17.6. HRMS (ESI+) m/z calcd for C26H38N7O7 [M+H]+ 560.2819, 
found: 560.2839. 
 
H-Ala-Gly-Arg-AMC·2HCl (31) 
 
General procedure for Boc-deprotection, method A; quantities used: Boc-Ala-Gly-Arg-AMC (30, 
300 mg, 0.5 mmol), Et2O (20 mL), 2.6 M HCl in EtOAc (2 mL). After counter current chromatography 
(BuOH/H2O) the product was lyophilized from dioxane/H2O (10 mL, 1:1 v/v) and obtained as a white 
solid (229 mg, 86%). 1H-NMR (400 MHz, CD3OD) : 10.27 (s, 1H, NH), 8.68 (t, J = 5.6 Hz, 1H, NH), 
8.44 (d, J = 7.4 Hz, 1H, NH), 7.85 (s, 1H), 7.71 (d, J = 8.7 Hz, 1H), 7.53 (dd, J = 2.0, 8.7 Hz, 1H), 6.24 
(s, 1H), 4.59-4.54 (m, 1H), 4.10-3.97 (m, 3H), 3.28-3.24 (m, 2H), 2.46 (s, 3H), 2.05-1.96 (m, 1H), 1.91-
1.65 (m, 3H), 1.55 (d, J = 7.1 Hz, 3H). 13C-NMR (75 MHz, CD3OD) : 172.6, 171.8, 171.4, 163.2, 
158.7, 155.3, 143.2, 126.7, 117.4, 117.3, 113.7, 108.2, 68.2, 55.3, 50.4, 43.4, 42.1, 30.3, 26.4, 18.6, 
17.6. HRMS (ESI+) m/z calcd for C21H30N7O5 [M+H]+ 460.2306, found: 460.2301. 
 
Boc-Glu(OtBu)-Gly-OH (33a) 
 
A solution of Boc-Glu(OtBu)-OH (606 mg, 2 mmol) in EtOAc (10 mL) was cooled to 0 °C before adding 
N-hydroxysuccinimide (HOSu, 230 mg, 2 mmol) and 1,3-dicyclohexylcarbodiimide (DCC, 455 mg, 
2.2 mmol). The reaction was stirred at 0 °C for 1 hour and an additional 16 hours at room temperature. 
The DCU was filtered-off and the filtrate was washed with sat. NaHCO3 (10 mL) and brine (10 mL) 
after wich it was dried over MgSO4. Removal of the drying agent and subsequent evaporation of the 
solvent resulted in the product as a white solid (32) (708 mg, 89%) RF = 0.73 (n-heptane/EtOAc 3:7). 
The crude product was directly used in the next reaction.  
To a solution of H-Gly-OH (75 mg, 1.0 mmol) in H2O (5 mL) was added NaHCO3 (163 mg, 1.97 mmol). 
Boc-Glu(OtBu)-OSu (392 mg, 1.0 mmol) was dissolved in CH3CN (7.5 mL) and added drop wise to the 
solution containing H-Gly-OH and NaHCO3. The reaction mixture was stirred for 16 hours at room 
temperature. The reaction was quenched with HCl (1 M, 10 mL) and diluted with EtOAc (20 mL). The 
layers were separated and the organic layer was washed with brine (10 mL) and subsequently dried 
over MgSO4. Removal of the drying agent and evaporation of the solvents resulted in a white 
hygroscopic product (300 mg, 83%) RF = 0.36 (CH2Cl2/MeOH 9:1). 1H-NMR (400 MHz, CDCl3) : 7.19 
(br s, 1H), 5.55 (d, J = 8.1 Hz, 1H, NH), 4.35 (dd, J = 8.0, 13.3 Hz, 1H), 4.14-4.00 (m, 2H), 2.43-2.29 
(m, 2H), 2.14-2.03 (m, 1H), 1.59-1.84 (m, 1H), 1.44 (s, 9H), 1.43 (s, 9H). 13C-NMR (75 MHz, CDCl3) : 
173.0, 172.3, 171.9, 156.1, 81.2, 80.6, 53.6, 41.3, 31.7, 28.3, 28.0, 25.4. LRMS (ESI-) m/z calcd for 
C16H28N2O7 [M-H]- 359.2, found: 359.1. 
 
Boc-Glu(OtBu)-Gly-Val-Arg-AMC·HCl (34a) 
 
To a cooled solution (0 °C) of Boc-Glu(OtBu)-Gly-OH (72.0 mg, 0.2 mmol), H-Val-Arg-AMC (11, 
100.1 mg, 0.2 mmol) and DMAP (48.4 mg, 0.4 mmol) in DMF (5 mL) was added EDC·HCl (42.0 mg, 
0.22 mmol). The reaction was stirred at 0 °C for 1 hour and an additional 16 hours at room 
temperature. The solvent was then removed in vacuo and the crude product was purified by FCPC 
using n-BuOH/H2O. The product was obtained as a white solid (132 mg, 82%) RF = 0.71 
(BuOH/H2O/AcOH 4:1:1). 1H-NMR (400 MHz, CD3OD) : 7.87 (s, 1H), 7.72 (d, J = 8.7 Hz, 1H), 7.59 
(d, J = 8.8 Hz, 1H), 6.25 (s, 1H), 4.52 (dd, J = 4.7, 9.5 Hz, 1H), 4.15 (d, J = 6.5 Hz, 1H), 4.04 (dd, J = 
5.0, 9.0 Hz, 1H), 3.92 (dd, J = 16.2, 45.0 Hz, 2H), 3.27-3.23 (m, 2H), 2.46 (s, 3H), 2.30 (t, J = 7.4 Hz, 
2H), 2.22-2.13 (m, 1H), 2.09-1.97 (m, 2H), 1.93-1.66 (m, 4H), 1.44 (s, 9H), 1.42 (s, 9H), 1.01 (d, J = 
6.8 Hz, 6H). 13C-NMR (75 MHz, CD3OD) : 175.5, 173.7, 172.2, 172.1, 163.0, 158.3, 155.1, 155.0, 
143.0, 126.5, 117.1, 117.0, 113.5, 107.9, 81.6, 80.7, 60.9, 55.5, 54.8, 43.6, 41.7, 32.3, 31.0, 29.7, 
28.5, 28.1, 26.2, 19.4, 18.6, 18.3. LRMS (ESI+) m/z calcd for C37H57N8O10 [M+H]+ 773.42, found: 
773.27. 
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H-Glu(OH)-Gly-Val-Arg-AMC·2HCl (35) 
 
General procedure for Boc-deprotection, method B; quantities used: Boc-Glu(OtBu)-Gly-Val-Arg-AMC 
(34, 110 mg, 0.14 mmol), CH2Cl2 (15 mL), TFA (0.5 mL, 3.1 mmol). After FCPC purification the 
product was obtained as a white solid (82 mg, 95%). RF = 0.18 (BuOH/H2O/AcOH 4:1:1). 1H-NMR 
(400 MHz, CD3OD) : 8.44 (d, J = 7.3 Hz, 1H, NH), 8.17 (d, J = 7.4 Hz, 1H, NH), 7.83 (s, 1H), 7.72 
(d, J = 8.7 Hz, 1H), 7.51 (d, J = 8.8 Hz, 1H), 6.24 (s, 1H), 4.54 (dd, J = 7.1, 13.1 Hz, 1H), 4.25-4.22 
(m, 1H), 4.14-3.91 (m, 5H), 3.27-3.21 (m, 2H), 2.58-2.51 (m, 2H), 2.46 (s, 3H), 2.23-2.09 (m, 4H), 
2.03-1.94 (m, 1H), 1.88-1.63 (m, 3H), 0.99 (t, J = 5.9 Hz, 6H). 13C-NMR (75 MHz, CD3OD) : 175.8, 
174.0, 172.4, 171.4, 170.5, 163.3, 158.7, 155.4, 155.3, 143.3, 126.8, 117.4, 117.2, 113.7, 108.1, 60.7, 
55.1, 53.9, 43.3, 42.0, 31.9, 30.1, 27.7 (2C), 26.5, 19.7, 18.7, 18.6. HRMS (ESI+) m/z calcd for 
C28H41N8O8 [M+H]+ 617.3047, found: 617.3036. 
 
Boc-Glu(OtBu)-Gly-Gly-OH (33b) 
 
To a solution of H-Gly-Gly-OH (115.5 mg, 0.88 mmol) in H2O (5 mL) was added NaHCO3 (163 mg, 
1.97 mmol). Boc-Glu(OtBu)-OSu (32, 350 mg, 0.88 mmol, prepared according to the method 
described for compound (33a)) was dissolved in CH3CN (7.5 mL) and added drop wise to the solution 
of H-Gly-Gly-OH and NaHCO3. The reaction mixture was stirred for 16 hours at room temperature. 
The reaction was quenched with HCl (1 M, 10 mL) and diluted with EtOAc (10 mL). The layers were 
separated and the organic layer was washed with brine (10 mL) and subsequently dried over MgSO4. 
Removal of the drying agent and evaporation of the solvents resulted in the crude product (348 mg, 
96%) RF = 0.1 (n-heptane/EtOAc 3:7). 1H-NMR (400 MHz, CDCl3) : 7.53 (br s, 1H), 7.47 (br s, 1H), 
5.71 (br s, 1H), 4.21-4.14 (m, 1H), 4.10-3.89 (m, 5H), 2.39-2.34 (m, 2H), 2.16-2.03 (m, 1H), 1.97-1.85 
(m, 2H), 1.44 (s, 9H), 1.42 (s, 9H). 13C-NMR (75 MHz, CDCl3) : 173.1, 172.7, 170.4, 156.2, 80.7, 
80.1, 77.2, 54.3, 42.7, 31.7, 29.7, 28.3, 28.1, 27.4. HRMS (ESI+) m/z calcd for C18H31N3NaO8 [M+Na]+ 
440.2009, found: 440.2025. 
  
Boc-Glu(OtBu)-Gly-Gly-Val-Arg-AMC·HCl (34b) 
 
To a cooled solution (0 °C) of Boc-Glu(OtBu)-Gly-Gly-OH (33b, 208 mg, 0.5 mmol), H-Val-Arg-AMC 
(11, 240 mg, 0.48 mmol) and DMAP (117.1 mg, 0.96 mmol) in DMF (10 mL) was added EDC·HCl 
(101.2 mg, 0.53 mmol). The reaction was stirred at 0 °C for 1 hour and an additional 16 hours at room 
temperature. The solvent was then removed in vacuo and the crude product was purified by counter 
current chromatography using n-BuOH/H2O. The product was obtained as a white solid (270 mg, 65%) 
RF = 0.69 (BuOH/H2O/AcOH 4:1:1). 1H-NMR (400 MHz, CD3OD) : 7.90-7.85 (m, 1H), 7.74-7.55 
(m, 3H, prod.+DMAP), 7.28-7.23 (m, 1H, DMAP), 6.25 (s, 1H), 4.57-4.54 (m, 1H), 4.13 (d, J = 6.9 Hz, 
1H), 4.07-3.74 (m, 5H), 3.28-3.17 (m, 2H), 3.04 (s, 2H, DMAP), 2.46 (s, 3H), 2.34 (t, J = 7.3 Hz, 2H), 
2.21-2.12 (m, 1H), 2.09-1.94 (m, 2H), 1.90-1.65 (m, 4H), 1.44 (s, 18H), 1.01 (dd, J = 2.9, 6.4 Hz, 6H). 
LRMS (ESI+) m/z calcd for C38H57N9O11 [M+H]+ 816.4, found: 816.3. 
 
H-Glu(OH)-Gly-Gly-Val-Arg-AMC·2HCl (36) 
 
General procedure for Boc-deprotection, method A; quantities used: Boc-Glu(OtBu)-Gly-Gly-Val-Arg-
AMC (34b, 250 mg, 0.39 mmol), Et2O (10 mL), 2.6 M HCl in EtOAc (2 mL). After counter current 
chromatography (BuOH/H2O/AcOH 4:5:1) the product was obtained as a pale yellow solid (224 mg, 
60% over 2 steps). 1H-NMR (400 MHz, CD3OD) : 8.11 (d, J = 6.3 Hz, 1H, NH), 7.86 (s, 1H), 7.73 
(d, J = 8.5 Hz, 1H), 7.58 (d, J = 8.7 Hz, 1H), 7.00 (d, J = 6.3 Hz, 1H, NH), 6.25 (s, 1H), 4.56 (dd, J = 
4.6, 9.4 Hz, 1H), 4.18 (t, J = 6.0 Hz, 1H), 4.10-3.88 (m, 6H), 3.28-3.21 (m, 2H), 2.55 (dd, J = 7.6, 
16.1 Hz, 2H), 2.47 (s, 3H), 2.23-2.09 (m, 3H), 2.06-1.95 (m, 1H), 1.91-1.63 (m, 3H), 1.02-1.00 (m, 6H). 
13C-NMR (75 MHz, CD3OD) : 173.9, 172.2, 170.6, 170.2, 169.9, 169.1, 161.5, 156.7, 153.5, 153.3, 
141.3, 124.9, 115.3, 111.7, 106.4, 106.1, 59.0, 53.3, 52.1, 42.1, 41.7, 40.1, 29.7, 28.5, 28.1, 25.7, 
24.6, 17.9, 17.2, 16.8. Anal. calcd. for C30H43N9O9·4 HCl; C 43.97% H 5.75% N 15.38%, measured 
C 43.84% H 5.96% N 15.22% 
 
General procedure for the synthesis of compounds (37-39) 
 
To a cooled solution (0 ºC) of H-Gly-Gly-Arg-AMC·2HCl (2) (155 mg, 0.3 mmol) in a solvent (typically 
between 5-10 mL) was added Et3N (0.11 mL, 0.9 mmol, 3 equiv) and acid chloride (1.00-1.05 equiv). 
The reaction was stirred for 10 minutes at 0 °C and an addition period of time at room temperature. 
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After complete consumption of the starting material, the reaction was quenched with MeOH (3 mL). 
The solvents were removed under reduced pressure and the crude mixture was purified by counter 
current chromatography (BuOH/H2O) to afford the desired product.  
 
Ac-Gly-Gly-Arg-AMC·AcOH (37) 
 
Quantities used: acetylcloride (21 μL, 0.3 mmol), CHCl3 (3 mL), the reaction was stirred overnight at 
r.t. No full conversion was obtained, therefore acetic anhydride (28 μL, 0.3 mmol) was added and the 
reaction was stirred for an additional 72 hours. Purification and lyophilization gave the desired product 
as an off-white solid (73 mg, 47%). RF = 0.33 (BuOH/H2O/AcOH 4:1:1). 1H-NMR (400 MHz, CD3OD) : 
7.85 (d, J = 2.1 Hz, 1H), 7.71 (d, J = 8.7 Hz, 1H), 7.57 (dd, J = 2.1, 8.7 Hz, 1H), 6.23 (d, J = 1.3 Hz, 
1H), 4.54 (dd, J = 4.9, 9.5 Hz, 1H), 3.90 (d, J = 4.2 Hz, 2H), 3.85 (d, J = 2.3 Hz, 2H), 3.22 (dt, J = 2.3, 
6.9 Hz, 2H), 2.44 (d, J = 1.2 Hz, 3H), 1.99 (s, 3H (AcOH)), 1.90-1.79 (m, 1H), 1.76-1.59 (m, 3H). 
13C-NMR (75 MHz, CD3OD) : 179.6 (AcOH), 174.5, 173.0, 172.6, 172.1, 163.2, 158.8, 155.3, 143.2, 
126.7, 117.35, 117.33, 113.7, 108.2, 55.2, 44.2, 43.9, 42.0, 30.0, 26.4, 23.7, 22.6 (AcOH), 18.6. 
HRMS (ESI+) m/z calcd for C22H30N7O6 [M+H]+ 448.2258, found: 448.2258. 
 
EtSO2-Gly-Gly-Arg-AMC·½EtSO3H (38) 
 
Quantities used: ethanesulfonyl chloride (27.8 μL, 0.315 mmol, 1.05 equiv), CH3CN (10 mL), the 
reaction was stirred at r.t. for 30 min. and an additional 4 hours at 45 °C. Purification and lyophilization 
gave the desired product as an off-white solid (109 mg (68%)). RF = 0.42 (BuOH/H2O/AcOH 4:1:1). 
1H NMR (400 MHz, CD3OD) : 7.85 (d, J = 2.0 Hz, 1H), 7.71 (d, J = 8.7 Hz, 1H), 7.55 (dd, J = 2.1 Hz, 
8.7 Hz, 1H), 6.24 (d, J = 1.2 Hz, 1H), 4.55 (dd, J = 4.9, 9.1 Hz, 1H), 3.97 (s, 2H), 3.81 (s, 2H), 3.23 
(t, J = 7.1 Hz, 2H), 3.15 (q, J = 7.4 Hz, 2H), 2.81 (q, J = 7.4 Hz, 1H, EtSO3H), 2.46 (d, J = 1.2 Hz, 3H), 
2.04-1.96 (m, 1H), 1.88-1.64 (m, 3H), 1.33 (t, J = 7.4 Hz, 3H), 1.30 (t, J = 7.4 Hz, 2H, EtSO3H). 
13C NMR (75 MHz, CD3OD) : 173.0, 172.8, 172.0, 163.8, 158.4, 155.8, 155.0, 142.9, 126.8, 117.7, 
117.5, 113.6, 108.4, 55.2, 47.5, 46.7 (EtSO3H), 46.4, 43.7, 41.9, 29.9, 26.3, 18.7, 9.7, 8.4 (EtSO3H). 
HRMS (ESI+) m/z calcd for C22H32N7O7S [M+H]+ 538.2084, found: 538.2052. 
 
EtO2C-Gly-Gly-Arg-AMC·HCl (39) 
 
Quantities used: H-Gly-Gly-Arg-AMC·2HCl (2) (100 mg, 0.19 mmol), ethyl chloroformate (18 μL, 
0.19 mmol), CH2Cl2 (10 mL), the reaction was stirred for 18 hours at r.t. No full conversion was 
obtained, extra ethyl chloroformate (30 μL 0.32 mmol) was added and the reaction was stirred for an 
additional 72 hours. Purification and lyophilization gave the desired product as a white solid (53 mg, 
50%). RF = 0.43 (BuOH/H2O/AcOH 4:1:1). 1H-NMR (400 MHz, CD3OD) : 7.86 (d, J = 2.0 Hz, 1H), 
7.70 (d, J = 8.8 Hz, 1H), 7.55 (d, J = 8.9 Hz, 1H), 6.23 (s, 1H), 4.55 (dd, J = 4.2, 9.6 Hz, 1H), 4.06 
(q, J = 6.8 Hz, 2H), 3.91 (q, J = 16.6 Hz, 2H), 3.78 (s, 2H), 3.22 (t, J = 6.9 Hz, 2H), 2.44 (s, 3H), 1.19 
(t, J = 7.1 Hz, 3H), 2.06-1.95 (m, 1H), 1.87-1.79 (m, 1H), 1.77-1.59 (m, 2H). 13C-NMR (75 MHz, 
CD3OD) δ: 173.7, 172.5, 172.1, 166.8, 163.2, 158.7, 155.4, 155.3, 143.2, 126.8, 117.5, 117.4, 113.8, 
108.2, 62.5, 55.0, 45.3, 44.0, 42.0, 30.0, 26.4, 18.6, 14.9. HRMS (ESI+) m/z calcd for C23H32N7O7 
[M+H]+ 518.2363, found: 518.2362. 
 
CF3CO-Gly-Gly-Arg-AMC·HCl (40) 
 
To a cooled solution (0 ºC) of H-Gly-Gly-Arg-AMC·2HCl (2) (155 mg, 0.3 mmol) in dioxane (10 mL) 
was added Et3N (few drops). The reaction mixture was stirred at 0 ºC for 5 minutes before slowly 
adding trifluoroacetic acid anhydride (0.28 mL, 0.6 mmol). The temperature was raised to room 
temperature and the mixture was stirred for 16 hours. The reaction mixture was concentrated under 
reduced pressure and purified by counter current chromatography (BuOH/H2O) to afford a white 
powder (102 mg, 59%). RF = 0.45 (BuOH/H2O/AcOH 4:1:1). 1H-NMR (300 MHz, CD3OD) : 7.81 
(d, J = 2.0 Hz, 1H), 7.64 (d, J = 8.7 Hz, 1H), 7.47 (dd, J = 2.1, 8.7 Hz, 1H), 6.20 (d, J = 1.2 Hz, 1H), 
4.56 (dd, J = 5.0, 8.9 Hz, 1H), 4.04 (s, 2H), 3.97 (s, 2H), 3.23 (t, J = 6.9 Hz, 2H), 2.42 (d, J = 1.2 Hz, 
3H), 2.07-1.95 (m, 1H), 1.90-1.63 (m, 3H). 13C-NMR (75 MHz, CD3OD) : 172.5, 171.9, 171.1, 163.3, 
160.0 (d, J = 37.6, CF3C=O), 158.7, 155.3, 155.2, 143.1, 126.6, 117.4 (q, J = 286.4 Hz, CF3), 117.3, 
113.7, 108.1, 55.1, 43.9, 43.5, 42.0, 30.1, 26.4, 18.6. HRMS (ESI+) m/z calcd for C22H26F3N7NaO6 
[M+Na]+ 564.1794, found: 564.1830. 
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General procedure for the synthesis of compounds (42-44) 
 
To a cooled solution (0 ºC) of H-Gly-Gly-Arg-AMC·2HCl (2) (155 mg, 0.3 mmol), carboxylic acid 
(0.3 mmol, 1 equiv), DMAP (73.2 mg, 0.6 mmol, 2 equiv) in DMF (10 mL), EDC·HCl (63.0 mg, 
0.33 mmol, 1.1 equiv) was added slowly. The reaction mixture was stirred for 30 minutes at 0 °C and 
an additional 16 hours at room temperature. The solvent was reduced in vacuo and the crude mixture 
was purified by counter-current chromatography (BuOH/H2O) to afford the pure product.    
 
Furyl-Gly-Gly-Arg-AMC·HCl (42) 
 
Quantities used: furan-2-carboxylic acid (33.6 mg, 0.3 mmol). The product was obtained as a white 
solid after lyophilization from water/dioxane (10 mL 1:1 v/v) (61 mg, 35%). RF = 0.44 (BuOH/ 
H2O/AcOH 4:1:1). 1H-NMR (400 MHz, CD3OD) : 7.84 (s, 1H), 7.68-7.62 (m, 1H), 7.62 (s, 1H), 7.55 
(d, J = 8.6 Hz, 1H), 7.08 (d, J = 3.4 Hz, 1H), 6.54 (td, J = 1.9, 3.5 Hz, 1H), 6.24 (s, 1H), 4.57 (dd, J = 
4.5, 9.2 Hz, 1H), 4.05 (q, J = 16.4 Hz, 2H), 3.93 (s, 2H), 3.24 (t, J = 7.2 Hz, 1H), 2.44 (s, 3H), 2.10-
2.02 (m, 1H), 1.95-1.86 (m, 1H),1.80-1.65 (m, 2H).13C-NMR (75 MHz, CD3OD) : 173.1, 172.5, 172.1, 
163.3, 161.7, 158.7, 155.3, 148.6, 146.7, 143.1, 126.6, 117.4, 116.0, 113.7, 113.1, 108.2, 55.0, 44.2, 
43.9, 42.0, 29.9, 26.4, 18.6. HRMS (ESI+) m/z calcd for C25H30N7O7 [M+H]+ 540.2207, found: 
540.2217. 
 
Pyridyl-Gly-Gly-Arg-AMC·2HCl (43) 
 
Quantities used: pyridine-3-carboxylic acid (41 mg, 0.3 mmol). The product was obtained as a white 
solid after lyophilization from water/dioxane (10 mL 1:1 v/v) and HCl (2 M, 1 mL), yield 129 mg (69%). 
RF = 0.31 (BuOH/H2O/AcOH 4:1:1). 1H-NMR (400 MHz, CD3OD) : 8.96 (dd, J = 2.3, 0.8 Hz, 1H), 8.63 
(dd, J = 4.9, 1.6 Hz, 1H), 8.23 (ddd, J = 8.0, 2.3, 1.6 Hz, 1H), 7.79 (d, J = 2.0 Hz, 1H), 7.55 (d, J = 
8.6 Hz, 1H), 7.47 (ddd, J = 8.0, 5.0, 0.9 Hz, 1H), 6.23 (d, J = 1.2 Hz, 1H), 4.60 (dd, J = 9.5, 4.8 Hz, 
1H), 4.09 (dd, J = 33.5, 16.2 Hz, 2H), 3.95 (d, J = 2.6 Hz, 2H), 3.24 (dt, J = 6.9, 2.0 Hz, 2H), 2.43 
(d, J = 1.2 Hz, 3H), 2.13-2.05 (m, 1H), 1.97-1.88 (m, 1H), 1.81-1.67 (m, 2H).13C-NMR (75 MHz, 
CD3OD) : 173.1, 172.5, 172.1, 168.5, 163.2, 158.7, 155.2, 155.1, 152.9, 149.4, 143.1, 137.1, 130.9, 
126.6, 125.0, 117.3, 117.2, 113.7, 108.1, 55.0, 44.7, 44.2, 42.0, 29.9, 26.5, 18.6. HRMS (ESI+) m/z 
calcd for C26H31N8O6 [M+H]+ 551.2367, found: 551.2368. 
 
Norbornadiene-Gly-Gly-Arg-AMC·HCl (44) 
 
Quantities used: H-Gly-Gly-Arg-AMC·2HCl (2) (256 mg, 0.5 mmol), DMAP (122 mg, 1 mmol, 2 equiv), 
(68 mg, 0.5 mmol) bicyclo[2.2.1]hepta-2,5-diene-2-carboxylic acid34, EDC·HCl (105 mg, 0.55 mmol, 
1.1 equiv) and DMF (15 mL). The product was obtained as a white solid after lyophilization from 
water/dioxane (10 mL 1:1 v/v) (49 mg, 15%). RF = 0.44 (BuOH/H2O/AcOH 4:1:1). 1H-NMR (400 MHz, 
CD3OD) : 7.84 (d, J = 1.7 Hz, 1H), 7.68 (d, J = 8.7 Hz, 1H), 7.60 (d, J = 8.6 Hz, 1H), 7.43 (dd, J = 2.6, 
7.1 Hz, 1H), 6.78 (d, J = 19.4 Hz, 1H), 6.63 (d, J = 17.0 Hz, 1H), 6.23 (s, 1H), 4.56-4.52 (m, 1H), 3.96-
3.84 (m, 4H), 3.78 (d, J = 11.7 Hz, 1H), 3.64 (s, 1H), 3.22 (t, J = 6.9 Hz, 2H), 2.44 (s, 3H), 2.14-1.93 
(m, 3H), 1.79-1.59 (m, 3H). 13C-NMR (75 MHz, CD3OH) : 171.77, 171.72, 170.6, 170.2, 161.3, 156.8, 
153.4, 150.4, 144.0, 142.2, 141.3, 141.24, 141.21, 124.7, 115.5, 111.84, 111.77, 106.4, 53.1, 52.9, 
50.8, 49.4, 42.6, 42.3, 40.1, 27.9, 24.6, 16.6. HRMS (ESI+) m/z calcd for C28H34N7O6 [M+H]+ 
564.2571, found: 564.2570. 
 
Azido-acetic acid methyl ester (45)  
 
This compound was prepared according to a literature procedure:45 
Quantities used: methyl bromoacetate (6.5 g, 21.25 mmol) and NaN3 (2.92 g, 22.52 mmol) in dry DMF 
(5 mL). The product was obtained as a yellow oil (2.32 g, 95%). 1H-NMR (400 MHz, CDCl3) : 3.89 
(s, 3H) 3.81 (s, 1H). FT-IR max film (cm-1): 2098 (N3), 1259. 
 
Prop-2-ynyl-carbamic acid tert-butyl ester (46)  
 
This compound was prepared according to a modified literature procedure:46 
To a cold solution (0 ºC) of propargylamine (803 mg, 14.6 mmol) in CH2Cl2 (15 mL), a solution of 
Boc2O (2.67 g, 12.2 mmol) in CH2Cl2 (20 mL) was added drop wise over a period of 25 min. The 
mixture was warmed to room temperature and stirred for an additional 30 min. Solvents were removed 
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in vacuo and purification by column chromatography (EtOAc/n-heptane 1:10) afforded the product as 
a white solid (1.55 g, 68%). 1H-NMR (400 MHz, CDCl3) : 4.71 (br s, 1H), 3.93 (s, 2H), 2.22 (dt, J = 
2.5, 0.9 Hz, 1H), 1.46 (s, 9H).  
 
[4-(tert-Butoxycarbonylamino-methyl)-[1,2,3]triazol-1-yl] acetic acid methyl ester (47) 
 
To a solution of azido-acetic acid methyl ester (45) (345 mg, 3 mmol), prop-2-ynylcarbamic acid tert-
butyl ester (46) (465 mg, 3 mmol) and sodium ascorbate (238 mg, 1.2 mmol) in a mixture of water/ 
butanol (1:1 v/v, 5 mL), was added in small  portions CuSO4·5H2O (125 mg, 0.6 mmol). The mixture 
was stirred for 5 hours and after addition of water (10 mL) the product was extracted with ethyl acetate 
(3  10 mL). The combined organic layers were washed with water (10 mL) and brine (10 mL) before 
they were dried over Na2SO4. The solvent was removed in vacuo and the product was purified by 
column chromatography (EtOAc/n-heptane, 1:1) to afford a white solid (697 mg, 86%). RF = 0.43 
(EtOAc/n-heptane, 1:1). 1H-NMR (400 MHz, CDCl3) : 7.64 (s, 1H), 5.16 (s, 2H), 4.42 (d, J = 6.0 Hz, 
2H), 3.81 (s, 3H), 1.44 (s, 9H). 13C-NMR (75 MHz, CD3OD) : 169.9, 158.3, 147.3, 125.5, 80.5, 68.2, 
51.7, 36.7, 28.8. HRMS (ESI+) m/z calcd for C11H19N4O4 [M+H]+ 271.1406, found 271.1396. 
 
[4-(tert-Butoxycarbonylaminomethyl)-[1,2,3]triazol-1-yl] acetic acid (48) 
 
A solution containing compound 47 (540 mg, 2.00 mmol), dioxane (6.5 mL), water (2.5 mL) and NaOH 
(1 mL, 2 M) was stirred for 16 hours at room temperature. After addition of water (5 mL) the mixture 
was carefully acidified with 2 M HCl (1.5 mL) and the product was extracted with CH2Cl2 (3 × 10 mL). 
The combined organic layers were dried over Na2SO4 before solvents were removed in vacuo. The 
product was obtained as a white powder (369 mg, 72%). 1H-NMR (400 MHz, CD3OD) : 7.86 (s, 1H), 
5.25 (s, 2H), 4.32 (s, 2H), 1.44 (s, 9H). 13C-NMR (75 MHz, CD3OD) : 168.9, 158.3, 147.4, 125.4, 
80.5, 36.7, 28.8. HRMS (ESI+) m/z calcd for C10H17N4O4 [M+H]+ 257.1249, found 257.1239. 
 
Boc-Gly[triazole]Gly-Arg-AMC·HCl (49) 
 
To a cooled solution (0 ºC) of H-Arg-AMC·2HCl (4) (665 mg, 1.65 mmol), DMAP (402 mg, 3.29 mmol) 
and [4-(tert-butoxycarbonylaminomethyl)-[1,2,3]triazol-1-yl]acetic acid (48) (384 mg, 1.5 mmol) in DMF 
(15 mL), EDC·HCl (348 mg, 1.65 mmol) was added in small portions. The mixture was allowed to 
warm to room temperature and was stirred for 16 hours. The DMF was removed in vacuo and 
purification of the product with counter-current chromatography (BuOH/H2O) afforded a white powder 
(650 mg, 72%). 1H-NMR (400 MHz, CD3OD) : 7.89 (s, 1H), 7.79 (d, J = 1.8, 1H), 7.66 (d, J = 8.7, 1H), 
7.42 (dd, J = 8.6, 1.6, 1H), 6.21 (s, 1H), 5.28 (d, J = 4.6 Hz, 2H), 4.58 (dd, J = 8.3, 5.5 Hz, 1H), 4.31 
(s, 2H), 3.25 (dt, J = 6.8, 2.3 Hz, 2H), 2.43 (s, 3H), 1.77-1.63 (m, 2H), 2.05-1.80 (m, 2H), 1.41 (s, 9H), 
13C-NMR (75 MHz, CD3OD) : 172.3, 168.3, 168,2 163.2, 155.30, 155.27, 155.2, 147.3, 143.2, 126.7, 
125.7, 117.4, 117.3, 113.7, 108.2, 80.5, 55.4, 53.0, 42.0, 36.8, 30.4, 28.3, 23.3, 18.6. HRMS (ESI+) 
m/z calcd for C26H36N9O6 [M+H]+ 570.2789, found: 570.2819. 
 
H-Gly[triazole]Gly-Arg-AMC·2HCl (50) 
 
To a suspension of Boc-Gly[triazole]Gly-Arg-AMC (49) (640 mg, 1.06 mmol) in Et2O (10 mL), a 
solution of HCl in EtOAc was added (2 mL, 2.6 M). The mixture was stirred 4 days at room 
temperature. The solvent was removed in vacuo and the compound was purified using counter current 
chromatography (BuOH/H2O). The product was obtained as a white powder (500 mg, 87%). 1H-NMR 
(400 MHz, CD3OD) : 8.13 (s, 1H), 7.82 (d, J = 1.4 Hz, 1H), 7.68 (d, J = 8.7 Hz, 1H), 7.48 (ddd, J = 
10.7, 2.0, 0.7 Hz, 1H), 6.22 (s, 1H), 5.34 (d, J = 1.6 Hz, 2H), 4.52- 5.58 (m, 1H), 4.24 (s, 2H), 3.25 
(t, J = 6.5 Hz, 2H), 2.43 (s, 3H), 2.05-1.80 (m, 2H), 1.77-1.63 (m, 2H). 13C-NMR (75 MHz, CD3OD) : 
172.4, 168.1, 163.2, 155.32, 155.26, 143.1, 141.2, 127.3, 126.8, 117.4, 117.2, 55.6, 53.0, 43.4, 42.0, 
35.5, 30.4, 26.4, 18.6. HRMS (ESI+) m/z calcd for C21H28N9O4 [M+H]+ 470.2264, found: 470.2235. 
 
Et-malonyl-Gly-OtBu (51) 
 
To a cooled solution (0 ºC) of 3-ethoxy-3-oxopropanoic acid (132 mg, 1.0 mmol), glycine-tert-butyl 
ester (167 mg, 1.0 mmol), DMAP (242 mg, 2.0 mmol) in CH2Cl2 (10 mL), EDC·HCl (210 mg, 1.1 mmol, 
1.1 eq.) was added in small portions. The solution was allowed to warm to room temperature and was 
stirred for 16 hours. The reaction mixture was quenched with HCl (10 mL, 1 M) and the layers were 
separated. The water layer was extracted with CH2Cl2 (10 mL) and the combined organic layers were 
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dried over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (n-heptane/EtOAc 1:1) RF = 0.39. The product was obtained as a colorless oil 
(143 mg, 58%). 1H-NMR (400 MHz, CDCl3) : 7.59 (br s, 1H), 4.21 (q, J = 7.2, 2H), 3.96 (d, J = 5.2, 
2H), 3.34 (s, 2H), 1.47 (s, 9H), 1.29 (t, J = 7.2, 3H). 13C-NMR (75 MHz, CD3OD)  169.2, 168.6, 165.0, 
82.3, 62.6, 42.1, 40.9, 28.0, 14.0. LRMS (ESI+) m/z calcd for C11H19NO5 [M+H]+ 246.12, found: 246.1. 
 
Et-malonyl-Gly-OH (52) 
 
To a cooled solution (0 ºC) of Et-malonyl-Gly-OtBu (51) (143 mg, 0.58 mmol) in CH2Cl2 (10 mL) TFA 
(1 mL) was added. The reaction mixture was stirred at 0 ºC for 1 hour and 16 hours at room 
temperature. The solvent was evaporated and a mixture of dioxane/water (20 mL, 1:1 v/v) was added 
to the crude product. The mixture was lyophilized which resulted in an off-white solid (93 mg, 84%). 
1H-NMR (300 MHz, CD3OD) : 4.17 (q, J = 7.2, 2H), 3.79 (br s, 1H), 3.94 (s, 2H), 3.72 (s, 2H), 1.26 (t, 
J = 7.20, 3H). 13C-NMR (75 MHz, CD3OD) : 172.7; 171.3, 169.3, 62.5, 52.7, 42.0, 14.4. LRMS (ESI+) 
m/z calcd for C11H19NO5 [M+H]+ 190.07, found: 189.9.  
 
Et-malonyl-Gly-Arg-AMC·HCl (53) 
 
To a cooled suspension (0 ºC) of H-Arg-AMC·2HCl (4) (202 mg, 0.5 mmol), Et-malonyl-Gly-OH (52) 
(100 mg, 0.53 mmol), DMAP (122 mg, 1.0 mmol) in DMF (10 mL), EDC·HCl (105 mg, 0.55 mmol) was 
added in small portions. The solution was allowed to warm to room temperature and was stirred for 16 
hours after which the DMF was evaporated in vacuo. The crude material was purified by counter 
current chromatography (BuOH/H2O) and the product was obtained as a white powder (166 mg, 66%). 
1H-NMR (400 MHz, CD3OH) : 7.82 (d, J = 2.1 Hz, 1H), 7.67 (d, J = 8.7 Hz, 1H), 7.50 (dd, J = 4.9, 
8.7 Hz, 1H), 6.22 (d, J = 1.2 Hz, 1H), 5.49 (s, 2H), 4.58 (dd, J = 4.9, 9.0 Hz, 1H), 4.19 (q, J = 7.1 Hz, 
2H), 3.96 (d, J = 1.3 Hz, 2H), 3.65 (s, 2H), 3.23 (t, J = 7.1 Hz, 2H), 2.44 (d, J = 1.2 Hz, 3H), 2.06-1.97 
(m, 2H), 1.88-1.65 (m, 3H), 1.26 (t, J = 7.1 Hz, 3H). 13C-NMR (75 MHz, CD3OH) : 172.4, 171.7, 
170.1, 169.5, 163.0, 158.8, 155.1, 155.1, 143.2, 126.5, 117.3, 117.2, 113.6, 108.1, 62.6, 55.1, 44.1, 
42.9, 42.0, 30.1, 26.2, 18.5, 14.3. HRMS (ESI+) m/z calcd for C23H31N6O7 [M+H]+ 503.2254, found: 
503.2236. 
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Abstract 
 
This chapter describes a study to acquire fluorogenic substrates suitable for monitoring continuous 
thrombin generation. The new substrates are expected to perform better than the substrate that is 
commonly used at the moment, i.e. the commercially available tripeptide Z-Gly-Gly-Arg-AMC, which 
has poor water solubility and the substandard kinetic constants (KM and kcat). We determined the 
kinetic constants (KM, kcat) of the conversion of a series of 24 new fluorogenic substrates (Chapter 2) 
by thrombin (FIIa) and factor Xa (FXa). A first selection was made on the basis of these data. The 
suitability of the substrates was further assessed by a new tool, the so-called diagnostic plot. This plot 
is obtained from the fluorescence trace originating from the action of a known amount of enzyme 
(thrombin, factor Xa) at a known initial substrate concentration, by plotting the first derivative of 
fluorescence against the fluorescence intensity itself. The use of this plot for the selection of suitable 
substrates is described. Ten substrates were further tested as substrates in the thrombin generation 
assay. Evaluation of the acquired thrombograms showed that several substrates, including SQ68 
derivative Et-malonyl-Gly-Arg-AMC and N-functionalized Gly-Gly-Arg-AMC, could be potentially 
successful candidates for the replacement of the substrate currently in use.  
 
 
3 
Chapter 3 
 68
3.1. Introduction 
 
 
The diagnostics of haemostatic and thrombotic (H&T) diseases, the control of antithrombotic and 
substitution therapy, and the development of new antithrombotics are all put at a disadvantage by the 
fact that no adequate test exists for the haemostatic and thrombotic system. Clotting time tests such 
as prothrombin-time (PT)1 and activated partial thromboplastin time (aPTT)2 are frequently employed 
as a routine assessment of the coagulability of blood. However, measuring clotting times – indicative 
for the moment of onset of thrombin generation – does not indicate hypercoagulability and is 
insensitive to mild bleeding disorders. This is especially true since 95% of the thrombin formation 
responsible for hypercoagulation occurs after clot formation.3 Other techniques monitoring the 
functioning of the haemostatic system are thromboelastography4 (TEG, measuring the mechanical 
properties of a clotting medium) and the platelet function analyzer (PFA).5 These techniques, however, 
do not reflect the overall functioning of the haemostatic and thrombotic system either, and are more 
suitable for determining other specific aspects of coagulation.6 By far the most information on the 
functioning of the H&T system is gained by assessing the thrombin generation curve TGC (or 
thrombogram), i.e. the course of the thrombin concentration as it develops in clotting blood or plasma. 
In contrast to clotting times, the thrombogram measures both low and high reactivity of the clotting 
system and is sensitive to the action of all types of antithrombotic drugs, so that it can be used as a 
universal monitor of clotting function.7  
The concept of measuring thrombin generation dates back to 1953 when it was simultaneously 
described by Macfarlane & Biggs8, and Pitney & Dacie.9 Thrombin generation was measured via a two 
step protocol. First thrombin generation was triggered in a tube containing blood plasma whereupon at 
regular time-intervals the plasma was subsampled into a second tube containing a fibrinogen solution. 
By determining the clotting time in the second tube, an estimation of the amount of thrombin 
generated in time could be made. This method requires extraordinary skill and was highly time 
consuming. Hemker and coworkers therefore modified the classical approach by semi-automatically 
assessing the thrombin content of subsamples spectrophotometrically.10 During the 1990s the 
subsampling approach was modified by adding a thrombin-specific substrate with a low turnover 
number directly to the plasma and deriving the thrombin concentration in the plasma from the rate of 
substrate conversion.11 This substrate (SQ68) exhibited optimal kinetic parameters in terms of 
thrombin binding (KM) and rate of hydrolysis (kcat) and displayed no inhibitory activity against the 
prothrombinase complex or any other coagulation factor. This method, however, suffers from the 
major restriction that the optical density measurements could only be performed on optically clear 
media. Consequently, the complete removal of fibrinogen and blood cells from plasma was required, 
eliminating the recognition of any effect of fibrin and/or platelets on thrombin generation. The 
importance of measuring thrombin generation in platelet-rich plasma (PRP) is undisputed, since 
platelets are the physiological source for the phospholipids required for thrombin activation.12 
Therefore, further research in this field led to the complete replacement of the initially used 
chromogenic substrates by a second-generation, fluorogenic substrate Z-Gly-Gly-Arg-AMC, the 
substrate currently in use for thrombin generation determination. The main advantage of a 
fluorophore-based substrate is that the inevitable optical turbidity increase during measurement, due 
to fibrin formation, does not disturb the fluorescent signal. Consequently, thrombin generation can be 
measured in both platelet-poor and platelet-rich plasma13 as well as whole blood.14 With the use of a 
fluorogenic substrate another problem was encountered namely the non-linearity of the fluorescent 
signal and the thrombin activity. This problem was overcome by monitoring the substrate cleavage 
and comparing it to a constant known thrombin activity in a parallel non-clotting sample using 
calibrated automated thrombography.15   
 
The general form of a thrombin generation curve (TGC or thrombogram) is shown in Figure 3.1B. At 
the start of the coagulation only minute quantities of thrombin are present. This lag-phase, also called 
the initiation phase,3 is followed by an explosive rise in thrombin concentration (production phase). 
The time required for the off-set of extensive thrombin formation is known as the lag-time. Since clot 
formation starts with the rise of thrombin concentration, i.e. the end of the lag time, the clotting time 
approximately equals the lag time (A in Figure 3.1B). The slope of the TGC equals the maximum 
velocity (vmax) of thrombin formation during the production phase. The point where the velocity of 
thrombin formation equals the velocity of thrombin decay (i.e. peak maximum) is known as the peak 
height (B in Figure 3.1B). The final phase is the inactivation phase;3 here the antithrombin activity 
gains over prothrombin conversion, which gives rise to a decline in the amount of thrombin. The 
thrombogram thus provides specific parameters to describe the complete thrombin generation profile, 
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correlated with the different stages of coagulation. The three most important parameters are the lag-
time, peak height and the area under the curve or endogenous thrombin potential (ETP), which 
represents the amount of enzymatic work that can be performed by thrombin during its lifetime (C in 
Figure 3.1B). The ETP16 is derived from the term thrombin potential (TP) introduced by Hemker et al.17 
in 1993 to more accurately describe the overall effect of thrombin on clotting systems.  
 
 
Figure 3.1 A) Thrombin-time integral (curve C) is a composite of 2M-thrombin-time integral (curve B) 
and the free thrombin-time integral (curve A).18  B) The parameters of the thrombogram. A) Lag time 
(min), B) Peak height (nM), C) Endogenous thrombin potential (ETP = area under the curve 
(nM  min)), D) Slope (= vmax (nM/min)), E) The time-to-peak (ttP) provides information about the total 
length of the procoagulant phase (i.e. initiation, amplification and propagation, together).19 
 
A thrombin generation test will typically result in a graph (time vs. thrombin concentration) as depicted 
in Figure 3.1 A, curve C. Two molecular species with amidolytic activity contribute to the shape of this 
curve. This first is free thrombin (curve A) and the second is thrombin bound to 2-Macroglobulin 
(2M-T) (curve B). The latter arises from the fact that thrombin, when bound to 2M, although 
completely devoid of any known biological activity, retains its capacity to hydrolyze small substrates. 
Via mathematical processing the 2M-T activity can be calculated and subtracted from the composite 
curve C. This results in thrombin generation curve A from which the aforementioned parameters can 
be deduced. Studies have been performed to determine the average values of the most frequently 
used parameters (i.e. ETP, Peak height and Lag-time) in both platelet poor plasma (PPP) an platelet 
rich plasma (PRP), depicted in Table 3.1 (taken from ref 20). In addition, the variation between 
measurements either within an experiment, an individual or a population has been determined.   
 
Table 3.1 Normal value and variability 
  n Average StDev  CV (pop.)a CV (ind.)a CV (exp.)a 
PPP ETP (nM·min) 36 1879 284 15 4.5 2.5 
 Peak height (nM)  458 60 13 5.5 4.5 
 Lag-time (min)  3.1 1.4 47 8.1 5 
PRP ETP (nM·min) 24 1679 371 22 7.8 3 
 Peak height (nM)  117 42 35 8.3 3.5 
 Lag-time (min)  8.1 1.9 3 9.1 7 
a CV (coefficients of variation) measured for: pop. = inter population, ind. = inter individual, exp. = inter experiment 
 
The present day Thrombogram determination using the fluorogenic substrate Z-Gly-Gly-Arg-AMC still 
suffers from two serious disadvantages which have hampered the practical use of this test to its full 
potential. Besides the moderate kinetic parameters of the substrate, the poor solubility of the substrate 
in aqueous media demands the use of substantial amounts of DMSO, which, especially at higher 
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concentrations, influences the function of the blood platelets.21 Hence, the development of improved, 
water soluble, fluorogenic peptidic substrates may greatly enhance the efficiency and the applicability 
of the test. As mentioned in Chapter 2, the first substrate requirement is slow hydrolysis by thrombin 
(i.e. low kcat) enabling continuous measurement of thrombin generation. Secondly, the Michaelis 
constant (KM) should be high for two reasons. First, the occupancy of the enzyme by substrate must 
be low to minimize the inhibition effects. Since the KM value represents the substrate concentration at 
which half of the enzyme is saturated, the substrate concentration must be below KM. Secondly, the 
Michaelis constant (KM) should be high because the occupancy of the enzyme by substrate must be 
low to minimize inhibition effects. Notably the inhibition of the positive feedback of thrombin on its own 
formation because of the activation of factors V, VIII and XI and the negative feedback reactions 
resulting from the liaison between thrombomodulin and thrombin. As a rule of thumb at least a quarter 
of all thrombin should be in its free form, i.e. S < 3·KM. Another reason for not exceeding this limit is 
that thrombin breakdown by antithrombin (AT) is significantly slowed down, so that the time scale of 
the experiment would be unreasonably prolonged. 
Finally, the total amount of converted substrate must be sufficiently high to be easily measurable but 
not so high as to cause significantly lower conversion rates due to substrate exhaustion. These two 
requirements are met in a high KM value.22 Obviously, a prerequisite to all the structural modifications 
in the substrate is that the binding to thrombin still occurs in the desired way. However, apart from 
thrombin the clotting system consists of a dozen serine (pro)-enzymes coupled in an “enzyme–
proenzyme” cascade and several feedback loops (Chapter 1). If the substrate would significantly 
occupy the active center of one of the other enzymes in this mechanism, the physiological functioning 
would be disturbed. Thus, to determine thrombin activity accurately, it is highly important that the 
substrate does not exhibit any undesired inhibitory effects on the other components of the clotting 
system. Therefore, the prepared substrates (Chapter 2) will be investigated as to the kinetics of their 
interaction with components of the clotting system such as purified thrombin, α2-macroglobulin-
thrombin complex, factor Xa, and activated protein C. The most promising substrates will be further 
evaluated on their applicability in calibrated automated thrombography. 
 
 
3.2. Biological evaluation of fluorogenic peptide substrates 
 
 
For chemical reactions to occur in a biological environment the need of a catalyst is generally 
required. These catalysts are proteins (or protein-based molecules) called enzymes. An enzyme acts 
as catalyst for specific chemical reactions, converting a reactant (called substrate) into a specific set of 
products (see figure 3.2).23 Enzymes can catalyze both forward and backward reactions.  
 
 
 
Figure 3.2 Enzyme catalysis cascade. 
 
The relationship between substrate and enzyme concentration was first postulated by Henri.24 Later a 
model describing the enzyme kinetics was proposed by Michaelis and Menten25 (Scheme 3.1).  
 
E + S ES E + P
kon
koff
kcat
  
 
Scheme 3.1 Enzyme-catalyzed reaction sequence following Michaelis-Menten kinetics. 
 
First the substrate (S) binds to the enzyme (E) with a rate constant of kon, forming the enzyme-
substrate complex (ES). This complex can then either dissociate to the free enzyme and the 
unchanged substrate with a rate constant of koff, or the enzyme can catalyze the transformation of 
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substrate to the product (P) with a rate constant of kcat yielding the product and the free enzyme. The 
current derivation for enzyme kinetics is based on the quasi steady state approximation proposed by 
Briggs and Haldane.26 This approximation states that the concentrations of the intermediate 
complexes do not change. The rate of an enzymatic reaction is therefore only dependent on the 
substrate concentration and follows a hyperbolic function according to Michaelis-Menten equation 1. 
 
 
 
[E0] is the initial enzyme concentration and KM is the Michaelis constant (koff + kcat)/kon. The first order 
rate constant kcat is also known as the turn-over number (the number of substrate molecules that is 
converted by the enzyme into product molecules per time unit). High substrate concentrations lead to 
enzyme saturation and maximum reaction velocity. At high substrate concentrations, that is [S]  KM, 
[S] / ([S] + KM) approaches one, thus leading to the formula; vmax = kcat·[E0]. Substitution into the 
Michaelis-Menten equation results in equation 2 which can be used for the determination of the 
Michaelis constant. 
 
 
    
The Michaelis constant is the substrate concentration at which the reaction velocity is half the 
maximum value. Substitution of KM = [S] in equation 2 leads to v = ½ vmax. A high KM indicates a weak 
binding whereas a low KM indicates a strong binding. A graphical representation of the Michaelis-
Menten equation can be obtained by plotting the reaction velocity against substrate concentration, 
known as the Michaelis-Menten plot. An alternative representation is the Lineweaver-Burk plot, in 
which the reciprocal velocity (1/v) is plotted against the reciprocal substrate concentration (1/[S]).27 
 
Figure 3.3 Representation of the Michaelis-Menten plot (left) and the Lineweaver-Birk plot (right) to 
obtain kinetic constants KM, vmax and kcat. 
 
 
3.2.1  Requirements for fluorogenic substrates suitable for monitoring 
continuous thrombin generation 
 
The amino acid composition determines the specificity of the substrate and the complete chemical 
structure – including the leaving group – determines the kinetic constants of the hydrolysis by 
thrombin.28 The relation between kinetic constants and chemical structure is predetermined, though, 
cannot be predicted. In order to predict the behavior of a substrate in a TG experiment we therefore 
have to determine the kinetic parameters KM and kcat. Inversely, from the desired behavior we can 
already predict some restraints on these kinetic constants.  
In the first place we want to maintain a physiologically relevant thrombin generation mechanism. This 
implies that the amount of substrate present should not be so high as to compete successfully for 
thrombin with e.g. factor V, factor VIII or protein C and inhibit their feedback activations. It has been 
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shown that the normal thrombin generation mechanism is maintained as long as more than 25% of all 
thrombin remains free. In addition, binding of a larger fraction of the free thrombin disproportionately 
prolongs the experiment (> one hour) since thrombin inactivation takes more than four times longer 
than normal. The free fraction of thrombin equals KM/(KM+S) so 25% is bound at S = 3·KM. This leads 
to constraint 1: 
 
Constraint 1: S ≤ 3·KM 
 
Furthermore, conditions are required under which substrate consumption does not seriously diminish 
the rate of the reaction, i.e. the velocity during a thrombin generation experiment should not drop more 
than approximately 10% as a result of substrate depletion. With a limit of systematic error of 10% this 
would mean that the amount of product P < 0.10 is ideal for a substrate.29 The techniques for 
mathematical correction of the fluorescent signal work well if no more than half of the substrate is 
consumed, that is P < 0.5 for any substrate. The ideal substrate, however, does not need 
mathematical correction for substrate consumption. 
On the other hand, the amount of product formed should also be high enough to allow measurement 
of fluorescence. Under our experimental conditions this means that at least 100 µM of P should be 
formed.30 Hence, ideally 100 µM < Pend < 0.1 S0 (i.e. substrate concentration at t = 0), however, 
100 µM < Pend < 0.5 S0 is acceptable. This implies a substrate concentration ranging from 0.2 to 
1.0 mM. In combination with constraint 1 it furthermore implies that the ideal substrate would have a 
KM of minimally 66 µM (but preferably much higher). 
  
How much end product (Pend) can be expected in a normal thrombin generation experiment? 
 
The amount of enzymatic activity during a TG experiment in the absence of added substrate is 
equivalent to ~1.0 µM·min, e.g. the activity of 100 nM of thrombin acting for 10 minutes. Because the 
action of antithrombins is only directed to the free enzyme, in the presence of a substrate this value 
increases by a multiplication factor equal to the proportion of total enzyme over free enzyme, i.e. 
(KM+S)/KM. By substitution of S0 for S we allow a minimal overestimation of this fraction, so that 
(KM+S)/KM micromolar of thrombin acting during one minute should ideally not cause a decrease of 
more than 10% of the initial velocity. The amount of substrate converted by that amount of enzyme 
during that time can be approximated by calculating it from the rate equation, assuming maintenance 
of S0 at its original level. Because S0 will in fact decrease, the amount of product (P) is again 
somewhat overestimated. So Pend = kcat·(((KM+S0)S0/KM)/(KM+S0)) = kcat·(S0/KM) which results in the 
second constraint:   
 
Constraint 2: 100 µM < kcat·(S0/KM) < P·S0  
 
Where P = 0.1 in the ideal case and P < 0.5 as an absolute requirement. Here kcat is in inverse 
minutes. The apparent discordance of the dimensions is due to the fact that the formula kcat·(S0/KM) in 
fact reads kcat·(S0·ETP/KM), where ETP = 1 µM·min). In this formula both the values of 100 µM and P 
(when < 0.5) are arbitrary because they are dependent upon the available instruments, the degree of 
accuracy wanted and the method of signal handling.  
 
In actual practice, a useful substrate is water soluble, has a kcat ≥ 1 s-1, a KM ≥ 200 μM and can be 
used at S ≥ 200 μM. However, the higher the value of KM the better, provided that kcat also increases 
maintaining the constraint kcat ≥ KM/S.31 
 
 
3.2.2 Determination of kinetic parameters on thrombin (FIIa) 
 
The rate of hydrolysis of the synthesized peptidyl-AMC compounds 1-24 by thrombin (FIIa) was 
determined by monitoring the liberation of the fluorophore 7-amino-4-methyl-coumarin (AMC). The 
fluorescence increase was measured with a fluorometer equipped with a 390/460 filter set (excitation 
/emission). Experiments were performed in a BSA buffer at a temperature of 37 °C. In order to obtain 
a Michaelis-Menten plot measurements were performed at different substrate concentrations and a 
fixed enzyme concentration (FIIa). The kinetic parameters KM and kcat were obtained by determination 
of the initial reaction velocity (v0) and subsequent fitting of the data to the Michaelis-Menten equation. 
The exact enzyme concentration was determined using a chromogenic assay monitoring the 
conversion of chromogenic substrate S2238. A summary of the obtained data is given in Table 3.2. 
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Table 3.2 Kinetic parameters for 25 peptidyl-AMC compounds on activated thrombin (FIIa) 
determined in a BSA buffer at 37 °C.  
Entry Substrate [S] 
(μM) 
[E] 
(nM) 
KM  
(mM) 
kcat  
(s-1) 
vmax  
(M-1·s-1) 
1 H-Arg-AMC·2HCl 200-1400 191 -a -a -a 
2 H-(D)-Phe-Arg-AMC·2HCl1 200-1400 177 - a - a - a 
3 H-Val-Arg-AMC·2HCl 200-1400 173 1.09 0.03 27.5 
4 Msc-Val-Arg-AMC·HCl 200-1400 200 2.68 0.21 78.4 
5 Btsc-Val-Arg-AMC·HCl1 200-1400 193 0.36 0.04 111.1 
6 H-Ala-Arg-AMC·2HCl 50-1000 90 2.50 0.05 20.0 
7 H-Pro-Arg-AMC·2HCl 200-1400 202 0.96 0.08 83.3 
8 H-Gly-Pro-Arg-AMC·2HCl 200-1400 179 -b -b -b 
9 H-Ala-Pro-Arg-AMC·2HCl 50-1000 85 3.55 46.7 13·103 
10 H-Gly-Gly-Arg-AMC·2HCl 300-2100 176 1.93 4.69 2.4·103 
11 H-Gly-Gly-Arg-AMC·2HCl 200-1400 180 1.97 3.38 1.7·103 
12 H-EGVR-AMC·2HCl* 50-1000 88 1.78 0.30 168.5 
13 H-EGGVR-AMC·2HCl* 200-1400 195 2.33 0.19 81.5 
14 Et-malonyl-Gly-Arg-AMC·HCl 50-1000 87 1.66 6.99 4.2·103 
15 H-Gly-[triaz]-Gly-Arg-AMC·2HCl 50-1000 86 0.77 0.09 116.8 
16 CH3CO-Gly-Gly-Arg-AMC·HCl 50-1000 88 2.38 1.38 579.8 
17 CF3CO-Gly-Gly-Arg-AMC·HCl 50-1000 79 2.62 1.89 721.4 
18 Furyl-Gly-Gly-Arg-AMC·HCl2 1000 100-400 0.17 0.20 1.2·103 
19 Pyridyl-Gly-Gly-Arg-AMC·HCl2 1000 100-400 0.06 0.12 3.3·103 
20 EtSO2-Gly-Gly-Arg-AMC·HCl1 50-1000 84 0.80 1.51 538.8 
21 EtO2C-Gly-Gly-Arg-AMC·HCl 50-1000 85 0.74 1.03 1.3·103 
22 Norb-CO-GGR-AMC·HCl*,1 50-1000 98 0.23 0.18 782.0 
23 H-()Ala-Gly-Arg-AMC·2HCl 50-1000 81 0.55 0.90 1.64·103 
24 H-Ala-Val-Arg-AMC·2HCl 50-1000 108 9.48 5.10 538.0 
25 H-Ala-Gly-Arg-AMC·2HCl 50-1000 87 2.33 2.14 918.5 
26 Z-Gly-Gly-Arg-AMC·HCl3 - - 0.31 1.86 6.0103 
1) Substrate dissolved in DMSO; 2) Kinetic parameters determined by varying [E] and fixed [S]; 3) Kinetic data obtained from 
reference 15; * Amino acids are denoted by their three letter code;  a) Could not be determined; insufficient substrate 
conversion; b) Substrate hydrolysis was too fast. Norb = Norbornadiene 
 
A preliminary screen of the obtained data showed that the substrates used in entries 2, 5 and 24 were 
not suitable for TG testing since DMSO was required to dissolve these compounds. Furthermore, poor 
kinetic parameters were obtained for these compounds. Substrate EtSO2-Gly-Gly-Arg-AMC (entry 20) 
also required DMSO to be dissolved, but however, showed promising kinetic parameters. Further 
evaluation of the data showed that H-Arg-AMC, H-(D)-Phe-Arg-AMC, and H-Gly-Pro-Arg-AMC (entries 
1, 2 and 8) were either hydrolyzed too slow or too fast to determine KM and Kcat. In the case of H-Gly-
Pro-Arg-AMC) the turnover number was so high that the substrate will be completely consumed before 
thrombin generation is over. Substitution of the glycine unit at the P3 position for an alanine (i.e. 
entry 9) enabled the determination of KM and kcat, however, the obtained values did not allow TG 
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testing. For the dipeptidyl-AMC substrates R-Val-Arg, Ala-Arg and Pro-Arg (entries 3, 6 and 7) a kcat in 
the order of 0.03-0.21 s-1 was found, thus resulting in a too low fluorescent signal production in 
thrombin generation testing.    
The water soluble derivative of Z-Gly-Gly-Arg-AMC, i.e. H-Gly-Gly-Arg-AMC, showed favorable kinetic 
parameters in accordance with the previously described constraints for KM and kcat and vmax (entries 10 
and 11, highlighted in gray). This substrate fulfilled all the above mentioned criteria i.e. water soluble, 
a kcat ≥ 1 s-1, and a KM ≥ 200 μM. In addition to H-Gly-Gly-Arg-AMC, the N-terminus substituted 
derivatives (e.g. CH3CO-, CF3CO- and EtO2C-) also demonstrated excellent kinetic parameters 
(entries 18, 19 and 23), while the slightly larger and more aromatic substituents on the N-terminus (i.e. 
furyl and pyridyl) gave only moderate values for kcat and KM (entries 20 and 21). Surprisingly, 
exchanging of the amide bond between P2 and P3 in H-Gly-Gly-Arg-AMC for a triazole isostere32 
resulted in a complete loss of hydrolytic activity. In addition, the triazole moiety also affected the 
binding of this substrate in the active site of thrombin. Both fibrin analogues H-EGVR-AMC and H-
EGGVR-AMC gave good binding constants (1.78 mM and 2.33 mM, respectively), however, for both a 
poor rate of hydrolysis was found (0.30 and 0.19, respectively).  
SQ68 derivative, Et-malonyl-Gly-Arg-AMC, showed improved kinetic constants (KM = 1.66 mM and 
kcat = 6.99 s-1, entry 16) compared to SQ68 (KM = 0.83 mM and kcat = 0.46 s-1).11a Similar kinetic 
parameters were reported for DMMZ-Gly-Arg-pNA (KM = 0.90 mM and kcat = 6.0 s-1)11b compared to 
Et-malonyl-Gly-Arg-AMC. The increased binding affinity can thus largely be attributed to the lack of the 
dimethyl moiety at P2 and is not the result of the C-terminal coumarin moiety.  
 
 
Figure 3.4 Structures of SQ68, DMMZ-Gly-Arg-pNA and Et-Mal-Gly-Arg-AMC. 
 
Compounds bearing the structure AA-Gly-Arg-AMC, generally possess favorable kinetic parameters. 
However, beta-alanine derivative H-β-Ala-Gly-Arg-AMC performed significantly less than H-Ala-Gly-
Arg-AMC, displaying a lower binding constant (KM = 0.50 vs. 2.33 mM, respectively) and lower rate of 
hydrolysis (kcat = 0.90 vs. 2.14 s-1, respectively). A drastic effect on both the parameters was observed 
when the glycine residue of Ala-Gly-Arg-AMC was replaced by a valine residue (i.e. entry 26). Both KM 
and kcat increased. 
To summarize, substrates H-Gly-Gly-Arg-AMC, EtSO2-Gly-Gly-Arg-AMC, EtO2C-Gly-Gly-Arg-AMC, 
CH3CO-Gly-Gly-Arg-AMC, CF3CO-Gly-Gly-Arg-AMC, Et-malonyl-Gly-Arg-AMC, H-Ala-Val-Arg-AMC, 
H-Ala-Gly-Arg-AMC possessed suitable kinetic parameters (KM and kcat, highlighted gray in Table 3.2) 
and were subsequently tested on serine protease factor Xa to determine their kinetic behavior and 
selectivity. Although the substrates H-β-Ala-Gly-Arg-AMC, H-Ala-Pro-Arg-AMC, H-EGVR-AMC, H-Gly-
[triaz]-Gly-Arg-AMC, norbornadiene-GGR-AMC, did not fulfill the thrombin substrate requirements, 
they were screened for FXa activity in order to possibly find a selective FXa substrate.   
 
 
3.2.3 Determination of kinetic parameters on FXa 
 
To determine the thrombin specificity of the selected substrates, they were tested on another serine 
protease known to hydrolyze the arginine-fluorophore bond, namely factor Xa (FXa). Identical reaction 
conditions, as employed for the determination of KM and kcat on thrombin, were applied for the 
determination of KM and kcat on FXa. The substrate concentration was varied between 50-1000 μM or 
200-1400 μM while a fixed enzyme concentration was used (ranging from 30 to 80 nM). The applied 
FXa enzyme concentration was lower than the FIIa concentration since the presence of FXa in serum 
is on average a factor 20 lower than FIIa (i.e. concentration FXa in plasma is 10 nM).33 The exact FXa 
concentration was determined using a chromogenic assay monitoring the conversion of chromogenic 
substrate MeO2C-D-CHA-Gly-Arg-pNA (Pefachrome®Xa). The obtained results of the kinetic 
parameter determination are listed in Table 3.3.    
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Table 3.3 Kinetic parameters for 14 peptidyl-AMC compounds on activated factor X (FXa) 
determined in a BSA buffer at 37 °C. 
Entry Substrate [S] 
(μM) 
[E] 
(nM) 
KM  
(mM) 
kcat  
(s-1) 
vmax  
(M-1·s-1) 
1 H-Ala-Pro-Arg-AMC·2HCl 50-1000 80 5.43 0.06 11.1 
2 H-Gly-Gly-Arg-AMC·2HCl 200-1400 30 13.14 4.81 462.2 
3 H-EGVR-AMC·2HCl1 50-1000 80 -a -a -a 
4 Et-malonyl-Gly-Arg-AMC·HCl 50-1000 80 2.68 1.16 434.2 
5 H-Gly-[triaz]-Gly-Arg-AMC·2HCl 50-1000 80 -a -a -a 
6 EtSO2-Gly-Gly-Arg-AMC·HCl2 50-1000 80 1.96 0.53 272.3 
7 EtO2C-Gly-Gly-Arg-AMC·HCl 50-1000 80 6.50 1.05 161.5 
8 Norb-CO-GGR-AMC·HCl1,2 50-1000 80 1.95 0.10 51.3 
9 H-Ala-Val-Arg-AMC·2HCl 50-1000 80 -a -a -a 
10 H-Ala-Gly-Arg-AMC·2HCl 50-1000 80 8.80 0.2 22.7 
11 Z-Gly-Gly-Arg-AMC·HCl2 200-1400 30 0.71 4.47 6.29·103 
12 CH3CO-Gly-Gly-Arg-AMC·HCl 50-1000 73 11.0 24.00 2.81·103 
13 CF3CO-Gly-Gly-Arg-AMC·HCl 50-1000 66 3.39 4.48 1.32·103 
14 H-()Ala-Gly-Arg-AMC·2HCl 50-1000 70 25.14 9.78 389.1 
1) Amino acids are denoted in their three letter code; 2) Substrate dissolved in DMSO; a) Could not be determined; insufficient 
substrate conversion. Norb = norbornadiene 
 
No kinetic data could be obtained for substrates H-EGVR-AMC, H-Gly-[triaz]-Gly-Arg-AMC and H-Ala-
Val-Arg-AMC as a result of insufficient substrate conversion (entries 3, 5 and 9). For the latter 
substrate (H-Ala-Val-Arg-AMC) this is highly remarkable since a high rate of hydrolysis was found for 
thrombin (kcat = 5.10 s-1). This indicates that this substrate is highly thrombin specific. A similar effect 
was observed for H-Ala-Pro-Arg-AMC. This substrate was rapidly hydrolyzed by thrombin (kcat = 
46.7 s-1), however, on FXa the turnover number was reduced to nearly zero (i.e. 0.06 s-1). This effect 
can be attributed to the high specific binding of proline in the S2 binding site of thrombin, while FXa 
has a preference for aromatic amino acids at P2 (e.g. phenylalanine or tryptophan).34 For H-Gly-Gly-
Arg-AMC a high Michaelis constant was found (KM = 13.14 mM), i.e. poor FXa binding. The result 
indicated a 9-fold selectivity for FIIa over FXa of this substrate. Even more striking was the fact that 
the substrate currently in use for thrombin generation testing (Z-Gly-Gly-Arg-AMC) displayed only 
minor selectivity for FIIa over FXa (i.e. 0.31 mM over 0.71 mM). Comparison of H-Gly-Gly-Arg-AMC 
and Z-Gly-Gly-Arg-AMC, showed that the latter has a far greater affinity for FXa than H-Gly-Gly-Arg-
AMC (19-fold higher). Norbornadiene-CO-Gly-Gly-Arg-AMC (entry 8) showed moderate binding and a 
poor rate of hydrolysis. The affinity of Et-malonyl-Gly-Arg-AMC was slightly higher for FIIa than for FXa 
(1.66 and 2.68 mM, respectively), however, the rate of hydrolysis was significantly in favor of thrombin 
(6.99 s-1 for FIIa compared to 1.16 s-1 for FXa). Both EtSO2-Gly-Gly-Arg-AMC and EtO2C-Gly-Gly-Arg-
AMC (entries 6 and 7) are moderate FXa substrates and appear to have a preference for the thrombin 
active site.  The substrate Ala-Gly-Arg-AMC emerges as a thrombin selective substrate since both the 
FXa binding constant and turnover number are low (8.80 mM and 0.2 s-1, entry 10). Changing the 
amino acid residue at P3 from alanine to -alanine had a great effect on the binding of the substrate to 
FXa and moreover the rate of hydrolysis (9.78 s-1, entry 14). Though, the values obtained make it a 
poor FXa substrate and thus favorable for thrombin generation testing since appropriate kinetic 
constants were obtained for thrombin (see Table 3.2). Finally, the substrates bearing either an acetyl 
or a trifluoro-acetyl group at the N-terminus of Gly-Gly-Arg-AMC were both found to be good thrombin 
substrates. As it turned out CF3CO-Gly-Gly-Arg-AMC is also a rather good FXa substrate with a 
binding constant of 3.39 mM and a kcat of 4.48 s-1 (highlighted in gray). The acetyl-functionalized 
Gly-Gly-Arg-AMC, exhibited a high rate of hydrolysis (24.00 s-1), though the provided poor binding 
constant (11.0 mM) eliminates this compound as suitable FXa substrate.     
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3.3  A tool for rapid substrate utility screening; the diagnostic plot 
 
 
3.3.1 Introduction 
 
As previously reported by Hemker et al.,15 conversion of a signal curve into a curve of the course of 
thrombin activity requires continuous comparison to an activity curve obtained with a known amount of 
fixed thrombin activity (i.e. the use of 2M-thrombin complex as calibrator) followed by a step-by-step 
digital calculation procedure (see paragraph 3.5). To abolish continuous comparison using a calibrator 
and to circumvent complex mathematical processing, Hemker and Hemker recently developed a 
simple mathematical protocol that can be applied to determine the exact course of an enzymatic 
activity that develops and/or disappears in a reaction mixture (e.g. plasma) in time (in press). The 
enzymatic activity is probed through monitoring a signal obtained from a reaction product of an added 
substrate (either chromogenic or fluorogenic) that is hydrolyzed by a specific enzyme. The method 
enables to calculate the course of enzyme concentration in time, up to a certain and well defined 
fraction of the consumed substrate. It thus defines the concentration ranges of a substrate where it is 
applicable. This method is particularly useful for the determination of the course of thrombin in 
coagulating and lysing blood. Not only offers this method an analytical algorithm that abolishes the 
necessity of a simultaneous calibration curve in thrombin generation assessment, it also allows for 
rapid screening of useful thrombin substrates. 
 
 
3.3.2 Construction and usage of the diagnostic plot 
 
The following paragraphs elaborate on the use of this new method in thrombin generation testing 
using fluorogenic substrates. The method is a two step procedure in which first a diagnostic 
experiment is carried out to find the nature and the constants of an equation that applies in a given 
experimental situation. In the second step experimental data from an enzyme generation experiment 
(i.e. TG) are transformed into a quantitatively correct enzyme generation curve via the equation found 
in the first step. 
 
 
Figure 3.5 Left: diagnostic plot (straight line) of H-GGR-AMC (200 μM). Right: diagnostic plot 
(parabolic) of EtO2C-GGR-AMC (200 μM). 
 
This first step involves the construction of a so called “diagnostic plot” in order to determine three 
parameters i.e. vinit, the constant  and the limit of applicability Flim. This procedure needs to be 
performed only once for a defined experimental setup (vide infra). In this procedure a substrate is 
added to a fixed known amount of enzyme (e.g. 2M-thrombin complex) and conversion is monitored 
under identical conditions as will be applied in the thrombin generation experiment (i.e. substrate 
concentration, composition of the reaction medium and temperature), if possible until the substrate is 
exhausted (F = Fend). From the obtained fluorescent signal in time (F = f(t)), a plot of the first derivative 
dF/dt against the signal Fobs is constructed (the diagnostic plot), see Figure 3.5.  
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Unexpectedly it was found that this plot, in excellent approximation, is either a parabola or a straight 
line, either over the entire range of fluorescent signal measured (F0 to Fmax) or up to a certain limit (F0 
to Flim < Fmax). In both cases the highest value, i.e. the true initial reaction rate (vinit), is found at the 
intercept with the ordinate since dF/dt is at a maximum when no substrate has been consumed (St  
S0) and not enough product has appeared to disturb the measurement of further product. The constant 
 is the maximal signal that can be obtained when the reaction runs to completion and can be found 
as the intercept with the abscissa of the diagnostic function dF/dt = vinit·(1-(Fobs/)) or dF/dt = 
vinit·(1-(Fobs/)2).  
 
The limit of applicability Flim can be read from the 
diagnostic plot as the point where the diagnostic 
plot deviates from a straight line or a parabola 
(e.g. Figure 3.6). It should be recognized that the 
linear/parabolic relationship is an approximation 
that can only be used as far as it has shown to 
be valid, i.e. not beyond the highest fluorescence 
value measured (Figure 3.5) or beyond the value 
at which dF/dt does not deviate from the 
observed relation (Figure 3.6). 
 
In the second step of the procedure, the 
constants obtained from the diagnostic plot are 
used for the transformation of the TG data into 
correct enzyme concentrations. If the graph of 
dF/dt against F in the diagnostic plot gives a 
straight line (e.g. Figure 3.5, left) any 
experimental value of F (Fexp) can be trans-
formed into a corresponding “ideal” value (Fideal) 
by the transformation Fideal = -·ln(1-(Fexp/)).  
A thrombin generation curve (TGC) can then be 
constructed via E(t) = vinit·(dFideal/dt) = 
vinit·(d(-·ln(1-(Fexp/)))/dt). In this formula E(t) 
equals the thrombin concentration in time. If in the diagnostic plot dF/dt against F is a parabola 
(e.g. Figure 3.5, right) any experimental value of F (Fexp) can be transformed into a corresponding 
“ideal” value by the transformation Fideal = ·arctanh(Fexp/) (arctanh is the inverse function of the 
hyperbolic tangent). In this case the thrombin generation curve can be found via E(t) = vinit·(dFideal/dt) = 
vinit·(d(·arctanh(Fexp/))/dt). An example of the transformation of thrombin generation data using the 
arctanh-transform is described below for the fluorogenic substrate EtO2C-Gly-Gly-Arg-AMC. 
 
 
 
Figure 3.7 Left; Constant enzyme activity measurement using 2M-T complex and EtO2C-Gly-Gly-
Arg-AMC (1000 μM). Right; Diagnostic plot for EtO2C -GlyGly-Arg-AMC. The gray dots are the 
experimental data and the black line represents the enzyme potential.   
Figure 3.6 Diagnostic plot of H-Ala-Po-Arg-AMC 
(1000 M), with Flim at approximately 2900 
fluorescence units (i.e. the deviation from the 
straight line).  
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First a constant enzym activity measurement is performed under identical experimental conditions as 
will be applied for TG experiments (i.e. temp, [S] and medium). Subsequently the diagnostic plot is 
constructed from the fluorescence signal. From the diagnostic plot of EtO2C-Gly-Gly-Arg-AMC 
obtained with constant enzyme activity, the parameters vinit and  were extrapolated (Figure 3.7 right). 
For vinit a value of 53 AU/min was found and  was appromimately 3200. The parabola relationship in 
the diagnostic plot indicated that the curved experimental data (gray dots, Figure 3.7, left) could be 
transformed into straight lines (black line, Fig. 3.7 left) by applying the formula Fideal = -·arctanh 
((Fexp/)), using the previously assessed  value. 
 
 
 
Figure 3.8 Left; Thrombin generation performed in PPP with EtO2C-Gly-Gly-Arg-AMC. Identical 
experimental conditions were applied as for the constant enzyme activity measurement experiment 
(i.e. temp, [S] and medium). Right; thrombogram with gray circles corresponding to the total thrombin-
time curve, the gray dashed line is the 2M-thrombin-time curve and the black line corresponds to the 
free thrombin-time curve. 
 
Utilizing the same arctanh transform and value for , the fluorescent signal Fexp in a thrombin 
generation experiment (Figure 3.8 left, gray dots) could be transformed into an ideal fluorescent signal 
(Fideal), see Figure 3.8 left (black line). Subsequently, the thrombogram could be constructed by 
calculation of the first derivative of Fideal, however, first a scaling factor needed to be introduced to 
convert the arbitrary dF/dt values into nM thrombin. Since a constant enzyme concentration was used 
to construct the diagnostic plot (i.e. 100 nM human thrombin units) we can convert the fluorescent 
signal Fideal of the TG experiment into thrombin units using the scaling factor found via E/(dFideal/dt) = 
1.88 nM·min (Fideal from constant enzyme activity measurement, Figure 3.7). The result after 
differentation is a total thrombin-time curve (Figure 3.8 right, gray dots) which can be converted to the 
free thrombin-time curve (black line) by substracting the 2M-thrombin-time curve (gray dashed line).17 
Finally, integration of the free thrombin-time curve will give the endogenous thrombin potential (ETP). 
 
 
3.3.3 The diagnostic plot for substrate screening 
 
The diagnostic plot also allows to predict the performance of substrates in monitoring the thrombin 
generation. The diagnostic plot can be used for substrate screening, via assessment of the expected 
amount of product formation during a normal thrombin generation determination. The amount of 
product formed (or substrate consumed) is determined by the enzyme potential () i.e. by the 
concentration of enzyme multiplied by the time that it acts. In thrombin generation experiments this is 
known as the endogenous thrombin potential (ETP). The standard (normal) ETP value is 1 M·min.17 
The expected amount of product formation during normal ETP determination thus equals (KM+S)/KM  
1 M·min (i.e. theoretical ETP). In the experiment for the establishment of the diagnostic plot, the 
enzyme concentration (E) is constant (i.e. 2M-T complex, 100 nM thrombin), so that the course of the 
enzyme potential  = E·t is known and can be plotted as a function of F (see Figure 3.7 right, black 
line). This allows the determination of the value of  corresponding to Flim (i.e. the magnitude of the 
signal at the moment that the diagnostic plot deviates from a straight line or a parabola). Thus, the 
values of  (lim) refers to what extent this method can be applied with confidence. However, to assess 
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the appropriate enzyme potential corresponding to the normal ETP one needs to correct for the 
presence of the fluorogenic substrate KM/(KM+S) during a normal TG experiment. Consequently, the 
enzyme potential is found via  = KM/(KM+S)·[E]·t. By plotting this corrected ETP value against the 
obtained fluorescence we can now determine the fluorescent signal which would be obtained during a 
normal TG experiment. Since the ETP value is known for this experimental set-up (i.e. 1 M·min), one 
can easily predict whether the amount of fluorescence produced by a new substrate is sufficient.  
A suitable substrate, in a useful concentration range, can thus be defined as a substrate that 
generates a diagnostic plot that is either a straight line or a hyperbola. Furthermore, the amount of 
fluorescent signal at lim should be high enough to be measurable and the enzyme potential 
corresponding to that amount of fluorescent signal should be higher than the amount that needs to be 
measured in a TG experiment (typically 1 μM·min), preferably twice as high (i.e. 2  ETP).  
 
Constructing a diagnostic plot using different substrate concentrations allows to define the applicable 
concentration range in TG of a specific substrate. Ten compounds were tested at different substrate 
concentrations (typically 200, 400 and 600 μM) in the setup described under section 3.7.The obtained 
diagnostic plots are displayed in Figure 3.9. The graphs demonstrate that a straight line fit could be 
applied for five of the ten substrates tested. Some deviation of the straight line fit was found at high 
concentrations for H-Ala-Val-Arg-AMC and H-Ala-Pro-Arg-AMC. The remaining five substrates 
followed a perfect parabolic fit.  
 
     
     
     
 
Figure 3.9 Diagnostic plots. Dotted lines: dF/dt against F with best fitting line either a straight line or a 
parabolic line (data points: black, conc. = 200 μM; light gray, conc. = 400 μM; dark gray, conc. = 
600 μM). Solid lines: enzyme potential (colors correspond to previously mentioned concentrations). 
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Figure 3.9 continued 
 
     
 
       
 
     
 
Figure 3.9 continued. Data points: black, conc. = 200 μM; light gray, conc. = 400 μM; dark gray, 
conc. = 600 μM). Solid lines: enzyme potential (colors correspond to previously mentioned conc.). 
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To define the applicability of the ten different fluorogenic substrates in thrombin generation, the above 
mentioned criteria were applied to the diagnostic plots presented here. The first four substrates (i.e. 
H-Gly-Gly-Arg-AMC, H-Gly[Triaz]Gly-Arg-AMC, H-Ala-Pro-Arg-AMC and Ala-Val-Arg-AMC) failed to 
produce sufficient amounts of fluorescence (>100 FU) even at high concentrations. Both CH3CO-Gly-
Gly-Arg-AMC and CF3CO-Gly-Gly-Arg-AMC showed low fluorescence at substrate concentration of 
200 M, however, at higher concentration enough fluorescence was produced. The remaining four 
substrates (i.e. Et-Mal-Gly-Arg-AMC, EtO2C-Gly-Gly-Arg-AMC, -Ala-Gly-Arg-AMC and Msc-Val-Arg-
AMC) all gave adequate fluorescent signals at Flim (generally no deviation was observed) over the 
entire concentration range. The last mentioned six substrates possessed an lim value far greater than 
the preferred ETP value of 2 M·min (typically values ranged from 4-6 or higher). 
 
Table 3.4 Determination of the constant  and the theoretical ETP 
Substrate KM 
(μM) 
S 
(μM) 
E 
(nM) 
 Theoretical 
ETP (μM·min) 
none     1.0 
CH3CO-GGR-AMC 2380 1000 100 2550 1.42 
CF3CO-GGR-AMC 2620 1000 100 2300 1.38 
H-GGR-AMC 1930 1000 100 3850 1.31 
Msc-VR-AMC 2680 1000 100 2550 1.37 
EtMal-GR-AMC 1660 1000 100 3450 1.60 
β-AGR-AMC 2870 1000 100 2750 1.35 
H-AVR-AMC 9480 1000 100 1800 1.11 
EtO2C-GGR-AMC 740 1000 100 3200 2.35 
H-AGR-AMC 2330 1000 100 2250 1.43 
E = reconsituted α2M-T complex. KM was determined in a BSA buffer. 
 
Subsequently, diagnostic plots were constructed applying identical conditions as those applied in 
thrombin generation experiments using the substrates listed in Table 3.4 (typically [S] = 1000 M, [E] = 
2M-T = 100 nM, medium = PPP and the temperature = 37 °C). From these diagnostic plots obtained 
the  values were determined (see Table 3.4). In addition the theoretical ETP was determined via 
[(KM + [S]) / KM]  1.0 M·min (ETP value found in plasma) where the approximation was made that 
the KM in buffer equals the KM in plasma. It was demonstrated by Hemker and coworkers that this 
approximation holds for the fluorogenic substrate Z-Gly-Gly-Arg-AMC.15 The theoretical ETP value can 
then be compared to the actual obtained ETP (see paragraph 3.5) in order to determine the difference 
of KM in buffer and plasma. 
 
Evaluation of the diagnostic plot of Msc-Val-Arg-AMC displayed a large deviation of the parabolic fit at 
the high substrate concentration (see Figure 3.10 left) compared to the parabolic fits found at lower 
substrate concentrations. A silimar effect was observed for EtO2C-Gly-Gly-Arg-AMC, however, 
significantly less outspoken. A possible explanation for this effect might be the critical effect of 
temperature on enzyme activity and thus product formation. At the desired temperature (i.e. 37 °C) the 
initial velocity of product fomation will be maximal. If this temperature is not yet reached, resulting in a 
slow temperature increase, dF/dt will increase uptill the maximum velocity as is seen in the diagnostic 
plots of Msc-Val-Arg-AMC and EtO2C-Gly-Gly-Arg-AMC. Both substrates possessed an lim value far 
greater than the desired ETP value of 1 M·min (3.5 and > 6 for Msc-Val-Arg-AMC and EtO2C-Gly-
Gly-Arg-AMC respectively). 
The diagnostic plots of the other seven substrates showed no irregularities, giving either parabolic- or 
straight lines in all cases (see Figure 3.10 right, for reasons of readability only a small representative 
selection of the curves is displayed). 
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Figure 3.10 Diagnostic plots of several fluorogenic substrates at a concentration of 1000 M. Left; 
gray dots and line = Msc-Val-Arg-AMC, black dots and line = EtO2C-Gly-Gly-Arg-AMC. Right; black 
dots and line = H-Gly-Gly-Arg-AMC, dark gray dots and line = H--Ala-Gly-Arg-AMC, light gray dots 
and line = CH3CO-Gly-Gly-Arg-AMC. 
 
The obtained values for  which at a later stage will be used to transform the crude fluorescent signal 
of the thrombin generation experiments into ideal fluorescence, are listed in Table 3.4. All the 
substrates showed sufficient fluorescent signal at an ETP value of 1 M·min. Whether Flim is 
sufficiently high for practical purposes (typically above 100 FU) depends upon the enzymatic activity 
that is to be expected in an experiment (e.g. determination hyper- or hypocoagulation) and needs to 
be determined for each practical application. For comparison, the substrate H-Ala-Pro-Arg-AMC 
(depicted in Figure 3.6) has an ETP < 0.5 at Flim which is insufficient for TG measurements and thus 
this substrate is not suitable for thrombin generation testing. It might however be useful for the 
assessment of low ETP values which are encountered in haemophilia. 
 
 
Substrate CH3CO-Gly-Gly-Arg-AMC 
is particularly interesting since the 
diagnostic plot is near to horizontal 
(Figure 3.10 right, light gray dots), 
which predicts that the first derivative 
of the crude fluorescent signal will be 
near to a representation of the real 
thrombin generation curve as is 
shown in Figure 3.11.This indicates 
that nearly no correction of the 
fluorescent signal is required for the 
accurate determination of the 
amount of thrombin formed. 
 
 
 
 
 
Figure 3.11 Thrombin generation curve of the substrate CH3CO-Gly-Gly-Arg-AMC obtained via the 
standard calculation method (black line) and as a direct derivative of the fluorescence trace (circles). 
 
So far, the diagnostic plot has provided useful information on the behavior of the fluorogenic 
substrates under experimental conditions applied in TG assessment. Based on the  values and the 
shape of the diagnostic plot (straight or parabolic), at S = 1.0 M, practically all substrates qualified as 
suitable substrates for thrombin generation measurement. In the next paragraph the suitability of the 
fluorogenic substrates in thrombin generation is tested using calibrated automated thrombography. 
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3.4  Application of fluorogenic substrates in continuous thrombin 
generation 
 
 
Calibrated automated thrombography (CAT) has been applied for the determination of a fast variety of 
haemostatic defects such as hyper- and hypo-coagulability,35 bleeding tendencies36 and diagnosis of 
von Willebrand disease.37 In addition, the use of the CAT method allowed for screening and testing of 
new antithrombotics.38 However, reports describing the use of CAT for the screening of fluorogenic 
peptides suitable for thrombin generation testing are extremely limited. One of the few examples was 
reported by Ramjee who used a small series of fluorogenic peptides to monitor the effect on TG.14 The 
substrates used were not slow reacting substrates and thus were unsuitable for TG testing. 
 
In a typical thrombin generation experiment using CAT, every thrombin generation sample (TG well) is 
compared to a fixed amount of constant thrombin activity which is added to a parallel sample of the 
same plasma i.e. calibrator (CL well). From the resulting curve, the calibration factor at any level of 
fluorescence can be read and the exact thrombin concentration in the sample where TG is taking 
place can thus be calculated. Using continuous calibration significantly reduces the intra-individual 
experimental error from >15% to ~5%7 (also see Table 3.1).  
 
Initial attempts to perform continuous automated calibrated thrombin generation were conducted using 
water soluble H-Gly-Gly-Arg-AMC·2HCl. Based on the kinetic parameter screening and the diagnostic 
plot this substrate was expected to be a suitable substrate for TG testing. Thrombin generation was 
measured according to the protocol described by Hemker and coworkers.7 
The use of the fluorogenic substrate H-Gly-Gly-Arg-AMC in continuous measurement of thrombin 
generation required the transformation of the velocity of fluorescence change (dF/dt) into a thrombin 
concentration. This was done by monitoring the fluorescence increase caused by a known stable 
concentration of thrombin (i.e. 2M-thrombin complex). Although the 2M-T complex provides such a 
stable and constant thrombin concentration, it does not display a constant rate of fluorescence 
increase (see Figure 3.12 left). The curvature is a result of substrate consumption and the inner-filter 
effect (non-linearity of fluorescent intensity with increasing concentration). The experimental 
fluorescence (Fexp, gray dots) could be transformed into ideal fluorescence (Fideal, i.e. straight line) 
using the first term of a best fitted polynomial (i.e. y = y0 + ax + bx2 + cx2, dashed line in Figure 3.12 
left) corresponding to y = y0 + ax. 
 
 
 
Figure 3.12 Left frame: Fluorescent trace obtained by hydrolysis of H-Gly-Gly-Arg-AMC (1000 M) by 
100 nM 2M-T (calibrator) in PPP (gray dots). The dashed line is a best fit curve over the experimental 
data (i.e. gray dots). The black straight line represents the ideal fluorescence. Right frame: thrombin 
generation in PPP. The white circles represent the obtained fluorescence, the gray dots represent the 
converted fluorescence into thrombin units and the dashed line is the fitted thrombin concentration.        
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By plotting Fexp against Fideal (not shown) an exponential curve was obtained which was subsequently 
fitted to a fourth order polynomial (y = y0 + ax + bx2 + cx2 + dx3 + ex4). This polynomial and the 
obtained constants (a, b, c, d and e) were then used to convert the measured fluorescence of the 
thrombin generation experiment (i.e. gray dots in Figure 3.12 right) into ideal fluorescence (not 
shown). Since the ideal fluorescence in Figure 3.12 was calculated using a known amount of enzyme 
(i.e. 100 nM 2M-T), the first derivative of the ideal fluorescence could directly be transformed to 
thrombin units using the calibration factor (or scaling factor vide supra). The resulting progress-curve 
is the sum of the concentration of both thrombin and antithrombin complex 2M-T (Figure 3.1 A). The 
progress-curve can be fitted to a modified, so-called, W-function (equations 3 and 4). The essence of 
this fit procedure is described by Wagenvoord et al.39 and was found to fit any experimental TG curve 
within the limits of experimental error.  
 
 
 
In order to obtain a free thrombin progress curve the amount of 2M-T was subtracted from the 
experimental progress curve (described by Hemker et al.)16,17 The first derivative of the corrected 
fluorescence progress curve then gives the correct thrombin generation curve, depicted in Figure 3.13.  
This data was then fitted to the first derivative of the W-function to find the appropriate thrombin 
concentration (Figure 3.13, black line).  
 
As a result of high substrate concentration, less thrombin will be available for the binding of the natural 
substrate and the interaction with antithrombins.40 This results in an increase of the measured 
thrombogram and thus the amount of thrombin. We therefore investigated the effect of different 
substrate concentrations of H-Gly-Gly-Arg-AMC on thrombin generation (Figure 3.13, right). Indeed, 
with an increasing concentration of fluorogenic substrate (200-1200 M) an increase in the 
thrombograms was observed. With the increase of the peak-height, an increase of the ETP was also 
found. 
    
 
Figure 3.13 Thrombin generation curve for H-Gly-Gly-Arg-AMC (1000 M) in normal platelet poor 
plasma. The gray dots represent the derivative of the measured progress curve of Figure 3.12 (right, 
open circles) after correction for 2M-T activity. The black line is the calculated free thrombin curve 
using the constants obtained from the fitted curve of Figure 3.12 (right, black line). Right: Thrombin 
generation at different substrate concentrations, from light gray to dark gray; 1200 M, 1000 M, 800 
M, 600 M, 400 M and 200 M H-Gly-Gly-Arg-AMC. Insert: ETP versus substrate concentration. 
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A plot of the ETP against substrate concentration (insert Fig 3.13 right), showed an approximately 
linear relationship with an intercept at the ordinate (i.e. [S] = 0) corresponding to an ETP value of 
approximately 1000 nM·min, identical to the standard (normal) value.17 The influence of the substrate 
concentration on the ETP becomes negligible when the amount of free thrombin is calculated by 
correcting for the substrate concentration and binding constant via Tfree = [Ttot]  KM / (KM + [S]).15  
  
From the preliminary screening of kinetic parameters on FIIa and FXa and the diagnostic plots we 
selected 10 substrates for continuous thrombin generation assessment. The thrombograms were 
measured in normal platelet poor plasma with a final substrate concentration in the well of 1000 M 
according to the procedure described under methods. Thrombin generation was monitored during 
40 minutes after which the raw data was processed resulting in the thrombograms of which a selection 
is depicted in Figure 3.14. The obtained thrombograms do not show any deviation in shape with 
respect to the thrombogram obtained in platelet poor plasma using the substrate Z-Gly-Gly-Arg-AMC. 
This accounts for all the 10 substrates measured. In the case of Et-malonyl-Gly-Arg-AMC some 
scattering was observed at the end of the experiment and therefore only 30 minutes are displayed.   
 
The W-function fit procedure was applied to the thrombograms in order to appropriately determine the 
parameters of the measured thrombograms. For all the substrates a normal lag-time (between 2.25 
and 2.82 min.) and time-to-peak (between 4.50 and 6.27 min.) was observed suggesting that the 
clotting system does not suffer any inhibitory effects caused by the substrates. The reduced lag-time 
found for H-Gly-Gly-Arg-AMC can be caused by clotting factor activation, however, more research is 
required to investigate this phenomenon. Peak heights for Et-malonyl-Gly-Arg-AMC and EtCO2-Gly-
Gly-Arg-AMC are rather high as a result of the equally high ETP values found for these substrates. 
The remaining substrates all showed sufficiently high ETP values compared to ETP in plasma (1000 
nM·min). On average a slight decrease was observed for the values of the ETP, lag-time and peak-
height of these substrates compared to the values obtained for Z-Gly-Gly-Arg-AMC (Table 3.1). 
 
Table 3.5 Parameters calculated from the thrombograms obtained via CAT.a  
Compound Lag time (min) Peak (nM) ttPeak (min) ETP (nM·min) 
H-GGR-AMC 1.56 ± 0.13 211.6 ± 11.9 4.71 ± 0.20 1409.6 ± 79.5 
EtSO2-GGR-AMC 2.50 ± 0.01 226.4 ± 3.1 5.44 ± 0.11 1587.5 ± 26.7 
Et-malonyl-GR-AMC 2.50 ± 0.18 377.2 ± 14.3 5.31 ± 0.21 2024.0 ± 48.5 
EtO2C-GGR-AMC 2.56 ± 0.11 369.6 ± 4.9 5.19 ± 0.11 2548.0 ± 80.5 
H-AVR-AMC 2.25 ± 0.18 226.6 ± 3.6 4.50 ± 0.18 1288.0 ± 21.9 
H-AGR-AMC 2.44 ± 0.11 251.9 ± 3.3 5.12 ± 0.12 1487.8 ± 44.4 
CH3CO-GGR-AMC 2.32 ± 0.11 188.2 ± 7.8 5.89 ± 0.13 1360.3 ± 47.2 
CF3CO-GGR-AMC 2.76 ± 0.31 223.4 ± 4.1 6.27 ± 0.31 1566.5 ± 47.0 
H-β-AGR-AMC 2.69 ± 0.21 149.0 ± 10.2 6.27 ± 0.18 1198.3 ± 53.9 
Msc-VR-AMC 2.82 ± 0.27 215.7 ± 17.5 6.27 ± 0.43 1647.3 ± 50.5 
a Experiments are performed in quadruple. ttPeak = time-to-peak 
 
Comparison of the theoretical ETP values (Table 3.4) to the experimental ETP values (Table 3.5) 
demonstrated a highly correlated relation (R2 = 0.84) with on the mean 8% difference between the 
values. The normal ETP in plasma without substrate is around 1 µM·min. As a result of competition 
between the substrate and natural enzyme inhibitors, the ETP as a rule is increased by the presence 
of substrate. When in the absence of substrate it would be 0, then, in the presence of a concentration 
S of a substrate with a Michaelis constant of KM the ETP increases to s according to (KM+S)/KM.41 The 
experimental and theoretical ETP are to a high extent analogous, thus the Michaelis constant in 
plasma resembles the KM found in buffer. Exceptions are found for Et-malonyl-GR-AMC 
(2.02 vs.1.60), CF3CO-GGR-AMC (1.57 vs. 1.38) and Msc-VR-AMC (1.65 vs. 1.37). Measuring the 
ETP at different substrate concentrations and subsequent iteration of KM in the equation (KM+S)/KM 
until it is equal for all the ETP values will give the accurate KM in plasma for these substrates.  
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Figure 3.14 Selection of thrombograms obtained after thrombin generation measurement in normal 
platelet poor plasma at 37 °C during 40 min. using a substrate concentration of 1000 M. The 
parameters obtained from the thrombin generation curves are displayed in Table 3.5.  
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3.5  Conclusions 
 
 
Considering the primary criteria providing suitable substrates for thrombin generation testing (i.e. 
appropriate kinetic parameters on FIIa, FXa selectivity and water solubility), screening of the 
25 fluorogenic substrates resulted in five functional substrates. These substrates, H-Gly-Gly-Arg-AMC, 
CH3CO-Gly-Gly-Arg-AMC, EtCO2-Gly-Gly-Arg-AMC and H-Ala-Gly-Arg-AMC provided appropriate 
kinetic constants KM and kcat for thrombin and displayed high selectivity towards factor Xa. Good 
solubility in water, BSA buffer and plasma was found for all these substrates.  
The diagnostic plot demonstrated to be a convenient tool for rapid screening of thrombin specific 
fluorogenic substrates and for expedient transformation of data obtained by thrombin generation. 
Evaluation of a series of eleven fluorogenic substrates by means of the diagnostic plot demonstrated 
that eight substrates (generally at high [S]) were suitable for thrombin generation. Substrate CH3CO-
Gly-Gly-Arg-AMC proved to be particularly interesting since the obtained diagnostic plot is nearly 
horizontal, thereby circumventing the necessity for correction of the crude fluorescent signal.    
Thrombin generation measurements performed in PPP on a series of 10 fluorogenic substrates 
displayed proper thrombin generation curves; moreover the main parameters obtained from the 
thrombograms were comparable for the majority of substrates (Table 3.5) and similar to the values 
reported for Z-Gly-Gly-Arg-AMC. Some deviation was found for H-Gly-Gly-Arg-AMC (short lag-time) 
and the substrates Et-malonyl-Gly-Arg-AMC and EtCO2-Gly-Gly-Arg-AMC (high ETP). 
Comparison of theoretical and experimental ETP values for a series of substrates demonstrated a 
high degree of similarity, presumably as a result of identical binding constants of these substrates in 
plasma and buffer. 
From the 25 fluorogenic substrates synthesized, three substrates (i.e. CH3CO-Gly-Gly-Arg-AMC, 
EtCO2-Gly-Gly-Arg-AMC and H-Ala-Gly-Arg-AMC) possess desired kinetic parameters on FIIa, show 
good selectivity over FXa, are soluble in physiological media and produced appropriate thrombin 
generation curves. Therefore, these substrates are suitable candidates for the replacement of the 
substrate currently in use. However, extensive examination of the behavior of the above mentioned 
substrates on other clotting factors is required.   
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3.7 Experimental Section 
 
 
Chemicals 
 
Phospholipids consisted of a mixture of 20 mol% phosphatidylserine, 20 mol% phosphatidyl-
ethanolamine and 60 mol% phosphatidylcholine (Avanti, Alabaster, AL, USA). Recombinant 
relipidated tissue factor (rTF) not containing polybrene or Ca2+ was a kind gift from Dade Behring 
(Marburg, Germany). Human thrombin (hFIIa) and factor Xa (FXa) were a kind gift of Synapse BV 
(Maastricht, the Netherlands). The fluorogenic substrates were synthesised according to methods 
described in detail in Chapter 2. Fluorogenic substrate Z-Gly-Gly-Arg-AMC was purchased from 
Bachem AG (Bubendorf, Switzerland). All other chemicals were purchased from commercial 
recourses and used as such. 
 
 
Reagents 
 
Buffers:  
Four BSA buffers were used: ‘BSA5’ contains 20 mM HEPES, 140 mM NaCl, 0.02% NaN3 and 
5 mg/ml BSA (Sigma A-7030) at pH 7.35. ‘BSA60’ contains 20 mM HEPES, 0.02 % NaN3 and 60 
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mg/ml BSA at pH 7.35. ‘BSA60+’ contains 20 mM HEPES, 0.02 % NaN3, 60 mg/ml BSA at pH 7.35 
and NaCl (8.18 mg/mL).”BOA’ buffer contains 0.05 M Tris-HCl, 0.1 M NaCl and 0.5% egg albumin at 
pH 7.5. BSA was dissolved by adding it on top of the buffer without stirring to allow it to dissolve 
slowly. Next the buffer was filtered using a corning filter system 255 mL with 0.2 µm PES membrane. 
The buffers were stored in the freezer at -20 ºC. They were kept at room temperature during an 
experiment. 
 
Phospholipids (PL):  
The phospholipid suspension was obtained by sonication of the required amount of phospholipids for 
2  5 min. in cooled (0 °C) HEPES buffer to obtain a final concentration of 24 µM. The stocks were 
stored at -80 °C and kept at room temperature during an experiment. 
 
Substrate:  
A mixture of fluorescence substrate and CaCl2 (denoted FluCa) was prepared for each thrombin 
generation experiment as follows: to 875 μL of BSA5 buffer, at 37 °C, 100 μL of 1 M CaCl2 and 25 μL 
of a solution of the fluorogenic substrate (100 mM in BSA buffer42 (BSA60+)) were added and 
immediately vigorously mixed. 
 
Trigger (rTF):  
Trigger solution for the extrinsic system was composed of 300 pM rTF in HEPES buffer. 
 
Blood and Plasma:  
Blood was obtained through antecubital venipuncture (1 volume trisodium citrate 0.13 M to 9 volumes 
blood) from healthy consenting individuals. Free flow or minimal suction was employed; vacuum 
containers were avoided.  
Platelet rich plasma (PRP) was collected from the upper 3/4 volume of plasma supernatant, after 
centrifugation at 265 g for 10 min at room temperature. The platelets were counted (Beckman Coulter 
counter) and PRP was adjusted to 150  109 platelets/L with its own platelet poor plasma (PPP). PRP 
was always used within 1 h after venipuncture.  
PPP was prepared by centrifuging twice at 2900 g for 10 min at room temperature. In order to avoid 
contamination with procoagulant microparticles from aging platelets, PPP was prepared within 30 min 
after venipuncture. 
 
Calibrator, alpha-2-macroglobulin-thrombin complex (α2M-T):  
In order to obtain a stable thrombin-like activity in plasma, α2-macroglobulin-thrombin complex (α2M-T) 
was used, prepared as described previously (Hemker et al.).15 
 
 
Methods 
 
Determination kinetic parameters 
 
Typically 0.025 mmol fluorogenic substrate was dissolved in 0.25 mL BSA buffer (BSA 60+) to give a 
100 mM stock solution. From this stock solution a series of dilutions was prepared to give final 
substrate concentrations of 0, 50, 100, 200, 400, 600, 800 and 1000 M in the well. A thrombin (FIIa) 
solution of 0.6 M was prepared from a 4.5 M FIIa stock solution via dilution with BSA buffer (BSA5). 
To four wells of a round-bottom 96-well plate, 100 μL of each appropriate substrate concentration was 
added. The plate was placed in an Ascent fluorometer equipped with a 390/460 filter set (excitation 
/emission) and allowed to warm to 37 °C (approximately 5 min). 20 μL of 0.6 M enzyme solution was 
added to each well (100 nM FIIa end concentration in wells) (8  4 wells in total) to initiate hydrolysis. 
In a typical experiment fluorescence was measured during 40 min at 37 °C. The obtained data was 
organized in Microsoft® Excel and the kinetic parameters were obtained by fitting the data to the 
Michaelis-Menten equation. For the determination of Km and kcat the initial reaction velocity of the first 
10 min was used. The amidolytic activity was calculated by comparing the arbitrary fluorescence 
values to those of a calibration curve. 
 
Measurements for constructing diagnostic plots 
 
Typically 5.0 mol fluorogenic substrate was dissolved in 0.5 mL BSA buffer (BSA60+) to give a 
10 mM stock solution. From this stock solution a series of dilutions was prepared to give final 
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substrate concentrations in the well of 200, 400, 600 and 1000 M. An enzyme solution containing 
2M-thrombin complex was prepared via reconstitution of a lyophilized sample with 1 mL milliQ water 
(final human thrombin activity 600 nM). To each set of wells (16 per experiment) was added 80 L 
normal platelet poor plasma (NPPP) (4 substrate conc. in quadruple performed). Subsequently 20 L 
of the appropriate substrate concentration was added to a set of 4 wells ( 4 conc. = 16 wells). The 
96-well plate was to warm to 37 °C with an external plate-heater during 10 minutes (final temperature 
reached 33 °C). Next the 96-well plate was placed in an Ascent fluorometer set at a temperature of 37 
°C. The dispenser of the fluorometer was rinsed with warm enzyme solution (2M-T). At the start of an 
experiment the instrument dispense 20 L enzyme solution to all wells to be measured, which was 
registered as t = 0, after shaking for 10 sec. and fluorescence reading was started. After 40 min. the 
experiment was terminated and the obtained data were transferred to an appropriate software 
program for further processing to finally obtain the diagnostic plots. 
 
Fluorescence based measurement of thrombin activity 
 
A detailed experimental description of calibrated automated thrombin generation measurements is 
found in references 15 and 43. The development of fluorescence intensity from 7-amino-4-methyl-
coumarin (AMC) was typically measured in a 96-well plate fluorometer (Ascent reader, 
Thermolabsystems OY, Helsinki Finland) equipped with a 390/460 filter set (excitation/emission) and a 
dispenser. Immulon 2HB, round-bottom 96-well plates (Dynex) were used. Minimal four readings were 
performed per minute and experiments were carried out in quadruplicate unless otherwise indicated. 
To each well, 80 μL of NPPP was added. Wells in which TG was measured received 20 μL of buffer, 
containing the trigger but without Ca2+. Wells in which constant thrombin-like activity was to be 
measured received 20 μL of the α2M-T solution at the required concentration as indicated. For NPPP, 
the trigger consisted of 30 pM of recombinant tissue factor (rTF) and 24 μM phosphatidylserine / 
posphatidylcholine / phosphatidylethanolamine vesicles in HEPES-buffered saline. For PRP the trigger 
was 20 μL of 3 pM of rTF without additional PL. 
The 96-well plate was placed in the fluorometer and allowed to warm to 37 °C (minimal 10 min). The 
dispenser of the fluorometer was flushed with warm 100 mM CaCl2 solution, emptied, and then flushed 
with warm FluCa. At the start of the experiment, the instrument dispensed 20 μL of FluCa into all wells 
to be measured, which was registered as t = 0, after shaking for 10 sec. and fluorescence reading was 
started. After 40 min. the experiment was halted and the obtained data was exported to an appropriate 
software program for further processing. 
 
Determination exact enzyme concentration 
 
The exact enzyme concentration was determined by monitoring the conversion of a chromogenic 
substrate using a microplate reader (EL808, Bio-Tek Instruments Inc., Burlington, United States) 
measuring the absorption at 405 nm. The substrate used for FIIa and 2M-T activity measurements 
was S2238 (600 μM in 175 mM NaCl, 50 mM Tris.HCl (pH 7.9)) and for FXa the substrate used was 
Pefachrome® Xa (510 μM in 175 mM NaCl, 0.02% NaN3, 3.0 μM -NAPAP, 50 mM Tris.HCl (pH 7.9)). 
For the determination of the exact enzyme concentration (FIIa, 2M-T or FXa) the enzyme stock 
solution (used during the kinetic experiments) was diluted with ovalbumine buffer (BOA) to obtain a 
final concentration of 1.2 nM for FIIa and 2M-T, and 0.8 nM for FXa. Subsequently, four wells of a 
microtiter plate were filled with 100 μL diluted enzyme solution after which the plate was warmed to 37 
°C during 5-10 min. To each of the wells was added 20 μL of substrate (vide supra) using a 
multipipette. The microtiter plate was placed in a microplate reader set at 37 °C and the conversion of 
substrate was monitored during 5 min. The enzyme activity determinations were performed in triplo or 
quadruplo. Finally, the enzyme concentration was calculated using dedicated software.   
 
 
Data handling 
 
The raw data of optical density measurements were processed using KC Junior microplate data 
analysis software. Fluorescence measurements of thrombin activity were exported to SIGMAPLOT 
version 9.0 (Systat Software Inc., Point Richmond, CA, USA) or to EXCEL (Microsoft® Excel 2002 or 
higher) for further mathematical processing.  
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Toward Synthesis of Thrombin Substrates via 
Solid Phase Peptide Synthesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
 
For the rapid synthesis of water soluble, AMC-containing, thrombin substrate libraries a new strategy 
for solid phase peptide synthesis was devised. The methodology is based on solid phase peptide 
synthesis followed by a light-isomerization-induced ring closing release mechanism. For this strategy 
the AMC-precursor ((E)-3-(4-amino-2-hydroxyphenyl)but-2-enoic acid) was synthesized, containing an 
amine function for peptide synthesis and an acid functionality in order to create an ester linkage to a 
resin. This target molecule was synthesized via protection of 4-amino-2-hydroxy-acetophenone and 
subsequently applying a Horner-Wadsworth-Emmons reaction yielding both the E- and Z-but-2-
enoate. The E-isomer was hydrolyzed and deprotected in a single step, using TFA and catalytic HCl. 
Surprisingly, under the same conditions, the Z-isomer was deprotected, hydrolyzed and isomerized to 
the preferred E-isomer. After Fmoc-protection the desired AMC-precursor was obtained in an overall 
yield of 29% over 5 steps. This compound was linked to a Wang-Br resin with a loading of 0.40 
mmol/g determined by an Fmoc-test. Coupling of Fmoc-Ala-OH was successful, though subsequent 
O-allyl deprotection initially failed and thus requires further investigation. 
 
4 
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4.1 Introduction 
 
 
The use of 7-amino-4-methylcoumarin (AMC)-containing fluorogenic peptide substrates for the 
determination of protease activity and specificity is well recognized.1 More recently, arrays and 
position scanning libraries of AMC-containing peptide libraries were employed in rapid profiling of N-
terminal specificity of various proteases.2,3 In the field of thrombin generation testing the proteolytic 
activity is determined by using the thrombin specific fluorogenic peptide substrate Z-Gly-Gly-Arg-
AMC.4 Since this substrate suffers from poor water solubility and moderate kinetic parameters (KM and 
kcat) the need for substrates with enhanced chemical and biochemical properties is evident.  
As described in Chapter 2, the current synthesis of new fluorogenic thrombin substrates is impaired by 
the troublesome purification as a result of the guanidine moiety of the arginine side chain. Solid phase 
peptide synthesis (SPPS)5 of fluorogenic peptide substrates could circumvent the purification 
problems. A variety of resins and methods is available for the synthesis of C-terminal modified 
peptides.6 In most cases side chain anchoring is applied in combination with various linker systems. 
Bernhardt et al.7 were able to load an arginine derivative on a 2-chlorotrityl chloride resin via the 
guanidine side chain. However, cleavage from the resin led to a complex mixture of products. 
 
 
 
Figure 4.1 Methodologies for SPPS of arginine-AMC containing peptide substrates. 
 
A number of other methods describing the synthesis of Arg-AMC-containing fluorogenic substrates 
using SPPS have been reported (see Figure 4.1). Edwards et al.8 demonstrated the use of a CMtr-
group as linker molecule binding the arginine side-chain to a -alanine-functionalized Rink resin. 
Moreover, White9 demonstrated the use of a 3-carbaldehyde-indole-functionalized Rink-resin for the 
coupling of Fmoc-Orn-AMC. The resin was subsequently treated with N,N’-bis-Boc-thiourea to afford 
the resin-bound bis-Boc protected arginine-AMC derivative. The strategy employed by Hernandez et 
al.10 made use of an AMC-functionalized ornithine-isothiocyanate derivative which was coupled to a 
Rink-resin and subsequently converted to an arginine-AMC derivative. These methods suffer from two 
major disadvantages: first extensive synthesis is required for functionalization of the amino acid and/or 
resin and second, harsh deprotection conditions are required for substrate-resin cleavage. Moreover, 
linkage through hydrophobic side chain functionalities (leucine, phenylalanine, valine, etc.) will prove 
difficult, limiting the use of these strategies. 
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The lack of functional groups in AMC for direct resin coupling can be circumvented by the use of 
bifunctional fluorogenic 7-amino-4-carbamoylmethylcoumarin (ACC) possessing the required 
functionality to couple the fluorescent probe to a resin (see Figure 4.2). Ellman reported the synthesis 
of ACC11 and the use in combinatorial library synthesis for protease specificity profiling.12 Soon after, 
the groups of Tzougraki13 and Yao14 demonstrated the applicability of the ACC probe in solid phase 
peptide synthesis by coupling to a 2-chlorotrityl, Wang or Rink resin. However, subsequent coupling of 
arginine to the ACC-linked resin generally proceeded in low yields as a result of the low nucleophilicity 
of the amino-coumarin.12 Moreover, the presence of the carboxylate in ACC would complicate direct 
comparison with previously synthesized AMC-containing thrombin substrates. 
 
 
 
Figure 4.2 Application of ACC in SPPS. Different resins are used denoted by X.  
 
Considering the drawbacks of the currently available SPPS methods for the synthesis of fluorogenic 
peptide substrates we aimed to develop a new strategy for the synthesis of thrombin substrates using 
solid phase peptide synthesis. 
 
 
4.2 Design and synthesis of an Fmoc-protected AMC precursor 
 
 
We aimed to develop a new strategy for the synthesis of thrombin substrates using solid phase 
peptide synthesis (SPPS), followed by a ring-closing release mechanism, in which the fluorogenic 
thrombin substrate is released from the resin upon formation of the fluorophore (AMC). To this end 
AMC precursor I possessing the necessary functionality for peptide synthesis and linkage to a resin is 
required. Coupling to a resin and solid phase peptide synthesis will then lead to precursors II for new 
thrombin substrates as depicted in Scheme 4.1. 
 
 
 
Scheme 4.1 Strategy for SPPS of thrombin substrates starting from AMC precursor I. Cleavage from 
the resin by deprotection and light isomerization. 
 
Deprotection of the hydroxyl-protecting group of AMC-precursor II will lead to the stable E-configured 
intermediate III. Since this molecule is still the E-configured isomer no ring-closing will occur. Upon 
light-induced isomerization the E-isomer will convert into the Z-isomer (IV), which is a suitable 
configuration for ring closure. Ring-closing will instantaneously result in the cleavage of the thrombin 
substrate from the resin as shown in Scheme 4.1. Major advantages of this resin release methodology 
over the traditional solid phase peptide cleavage methods are the mild conditions employed (h) and 
the absence of residual scavenger compounds, thereby eliminating the need for further purification.  
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Several synthetic strategies were envisioned to yield the AMC precursor molecule (I). Starting from 2-
amino-5-nitrophenol, 2-iodo-5-nitrophenol can be prepared, which serves as a precursor for a 
Knochel, Heck or Sonogashira reaction (section 4.2.1). Starting from 4-amino-2-hydroxy-
acetophenone either a Wittig or Horner-Wadsworth-Emmons reaction can be performed (section 
4.2.2). The final steps enclose the hydrolysis of the ester functionality and deprotection of the amino-
protecting group followed by Fmoc-protection. Coupling of the linker molecule (I) to a resin and 
subsequent Fmoc solid phase peptide synthesis result in thrombin substrates that can then be 
obtained applying the deprotection and light isomerization strategy (vide supra). 
 
 
4.2.1 Metal catalyzed reactions 
 
The synthesis of key compound I was initially pursued via the introduction of an ,-unsaturated ester 
to O-protected 2-iodo-5-nitrophenol 1 using different metal-catalyzed reactions (Scheme 4.2). Both the 
Heck and Knochel reaction will directly lead to the desired methyl-substituted ,-unsaturated ester 2. 
A Sonogashira reaction will result in the alkynolate 3, which can then be transformed in the methyl-
substituted ,-unsaturated ester 2 via cuprate addition as shown in Scheme 4.2. Hydrolysis of the 
ester, reduction of the nitro-group, and protection of the amino-group with an Fmoc-group will 
ultimately lead to compound I. 
 
 
Scheme 4.2 Synthetic routes toward target compound I applying metal-catalyzed reactions. 
 
Starting from 2-amino-5-nitrophenol, 2-iodo-5-nitrophenol (1a) was obtained via a diazotransfer 
reaction, followed by nitrogen substitution producing compound 1a in a good yield (80%). Next, phenol 
1a was protected with a variety of protecting groups (PG) yielding compounds 1b-1d. Protection of the 
phenol with a tert-butyl group (i.e. 1b), however, turned out to be rather troublesome. A wide range of 
reactions was performed using different tert-butyl donors (tBu-Cl,15 tBu-Br,16 Boc2O,17 tBu-trichloro-
acetimidate17), in combination with different bases (K2CO3, DBU,18 nitrosopyrrolidine19) and/or other 
additives (TBAI,16 KI/CuI,20 Zn dust,21 Mg(ClO4)222), however, not producing the desired product. 
Fortunately, reacting compound 1a with isobutene gas and catalytic H2SO4 in a pressurized bottle 
gave compound 1a in a modest yield (20%). In our hands, however, it appeared very hard to 
reproduce this result. Both TiPS and methoxymethyl (MOM) protection of 2-iodo-5-nitrophenol gave 
the desired products 1c and 1d in excellent yields (81% and 98%, respectively).  
 
Next, the Heck reaction with ethyl crotonate and either 1a or 1b was performed applying various 
literature procedures.23, 24, 25, 26 Unfortunately, none of the performed reactions resulted in the formation 
of the desired products 2a or 2b, but instead, mainly homo-coupling was observed. The low reactivity 
of this particular Heck reaction can be attributed to two factors. First, there is a high rate of oxidative 
addition of the iodo-nitrophenol onto the palladium catalyst, resulting in the excessive formation of the 
homo-coupled product. Second, the sterically hindered ethyl crotonate competes with iodo-nitrophenol 
for binding to the palladium complex. Although an excess of ethyl crotonate was used, an even larger 
excess might be required for this reaction to produce the desired product (i.e. 2a or 2b).  
 
The second metal-catalyzed route leading to AMC precursor I was the Sonogashira reaction,27 which 
was performed on compound 1a and the O-protected 2-iodo-5-nitrophenols 1b, 1c and 1d to yield 
compounds 3a-3d. Reacting unprotected iodo-nitrophenol 1a with ethyl propiolate, following a 
literature procedure,28 gave the desired product 3a in a somewhat disappointing yield (17%). 
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Performing the Sonogashira reaction on O-protected 2-iodo-5-nitrophenols 1b, 1c and 1d gave only a 
trace amount of product 3b, and no 3c. Fortunately, MOM-protected 2-iodo-5-nitrophenol 1d gave 
compound 3d in a good yield (75%). Optimization of the Sonogashira reaction conditions for 
compound 1d demonstrated that THF in combination with different bases (i.e. K2CO3, Cs2CO3, DiPEA or 
Et3N), produced compound 3d in satisfying yields (72-89%). The best result was obtained using NMP 
and DiPEA, at a temperature of 65 °C for 7 hours, producing compound 3d in an excellent yield (95%). 
Having found an appropriate protocol for the Sonogashira coupling, the next step was the introduction 
of a methyl group via cuprate addition onto the acetylene functionality of 3d. However, employing 
different methylating agents (Me2CuLi29 or MeMgBr in combination with CuBr·SMe230) under various 
reaction conditions did not show any product formation. This approach was therefore also abandoned.  
 
Finally, a third metal catalyzed-reaction, a Negishi-type coupling, reported by Knochel et al. was 
employed.31 This reaction required ethyl 3-iodobut-2-enoate (5) as a reagent. This compound was 
obtained by reacting ethyl but-2-ynoate with NaI in AcOH, which gave a mixture of the Z-isomer 4 and 
E-isomer 5 in a ratio of 96:4 as shown in Scheme 4.3.32 Using the E-isomer of ethyl 3-iodo-but-2-
enoate (i.e. 5), the Negishi-type coupling was performed on compound 1d (Scheme 4.3). It was first 
converted into the corresponding Mg-reagent, followed by transmetallation with CuCN·2LiCl replacing 
the magnesium for copper. Finally, upon addition of ethyl 3-iodobut-2-enoate (5), an addition-
elimination reaction has to take place in order to produce 2d. Unfortunately, not the desired product 
was obtained, but solely 1-isopropyl-2-(methoxymethoxy)-4-nitrobenzene (not shown). 
 
 
 
Scheme 4.3 Conditions for synthesis of ethyl 3-iodobut-2-enoate and the Negishi-type coupling. 
 
Summarizing, in our hands the performed metal-catalyzed reactions with 2-iodo-5-nitrophenol and 
derivatives thereof appeared to be troublesome. Due to the difficulties encountered in the metal-
catalyzed synthesis of AMC precursor I, these routes were no further pursued. 
 
 
4.2.2 Wittig and Horner-Wadsworth-Emmons reactions 
 
Introduction of the crucial structural element in the AMC precursor I, the methyl-substituted 
,-unsaturated ester, was further explored using the Wittig and the Horner-Wadsworth-Emmons 
(HWE) reaction.  
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Scheme 4.4 Proposed synthesis of target molecule I applying either the Wittig or HWE reaction.  
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The former proceeds via an ylide phosphonium species,33 the latter utilizes a phosphonate-derived 
enolate as the reactive intermediate.34 For the application of the Wittig and HWE reaction in the 
synthesis of AMC precursor I complete protection of commercially available 4-amino-2-hydroxy-
acetophenone (i.e. structure VIII, Scheme 4.4) is required, which will then produce intermediate IX. 
Ester saponification, followed by the deprotection of the amine-protecting groups converts 
intermediate IX into structure X. Finally, Fmoc-protection will lead to compound I. 
 
Complete protection of 4-amino-2-hydroxy-acetophenone was required due to the fact that the HWE 
and Wittig reaction did not proceed without N- or O-protection. An appropriate protecting group of the 
hydroxyl is of great importance since it should withstand several reaction conditions. Preliminary 
removal of this protecting group could give rise to undesired ring closure after the HWE or Wittig 
reaction. The hydroxyl protecting group furthermore needs to be base stable to circumvent 
deprotection during the solid phase peptide synthesis, however, after SPPS the protecting group 
should be removed under mild conditions. In addition, the hydroxyl and the amine should be 
orthogonally protected to prevent undesired simultaneous deprotection. Complete protection of 4-
amino-2-hydroxy-acetophenone was explored employing two synthetic routes. Route A consists of the 
protection of the hydroxyl group prior to the amine group, while route B follows the opposite reaction 
sequence. Both routes yield the required, fully protected, 2-hydroxy-4-amino-acetophenone.  
 
A silyl-protecting group was preferred as a result of its stability under various conditions and the 
specific cleavage method (F¯).35 Therefore, several silyl-protecting groups, such as tert-butyl 
dimethylsilyl (TBDMS, 6), tert-butyl diphenylsilyl (TBDPS, 7) and tri-isopropylsilyl (TiPS, 8), were 
introduced following route A (Scheme 4.5). The silyl-protected products were obtained in moderate to 
good yields (33-75%), however, these yields were not always reproducible. After protecting the 
hydroxyl group, Boc-protection was performed giving compounds 9-11 in rather poor yields. 
 
 
 
Scheme 4.5 O-Silyl-protected 4-amino-2-hydroxy-acetophenone. Reagents and conditions: i) TBDMS-
Cl, imidazole, THF, r.t. 3 d; ii) TBDPS-Cl, imidazole, THF, 50 °C, 2 d; iii) TiPS-Cl, imidazole, DMF, 
50 °C, 48 h; iv) DMAP, Boc2O, CH2Cl2, r.t. 2-4 days. 
 
Introduction of a methyl-protecting group gave the desired compound 12 upon treatment of 4-amino-2-
hydroxy-acetophenone with 0.5 equivalents of dimethyl sulfate. The use of more dimethyl sulfate 
resulted in the formation of undesired N,O- di- and tri-substituted acetophenone derivatives. 
Subsequent Boc-protection of 12 gave fully protected 13 (Scheme 4.6)  
 
 
 
Scheme 4.6 Methyl- and Boc-protection of 4-amino-2-hydroxy-acetophenone. Reagents and 
conditions: i) 2-Butanone, dimethyl sulfate (0.5 equiv), K2CO3 (1 equiv), KOH (1 equiv), r.t., 3 d; ii) 
Boc2O, DMAP, CH2Cl2, r.t. 16 h. 
 
Starting with Boc-protection (i.e. route B) yielded a variety of products (14-17) which was dependant 
on the amount of Boc2O and DMAP, and the reaction time (Scheme 4.7). Mono Boc-protected amino-
acetophenone 14 was obtained in an excellent yield of 95% by adding four equivalents of DMAP and 
two equivalents of Boc2O and a reaction time of three days. Compound 15 (31%) and 16 (18%) were 
obtained using two equivalents of DMAP and three equivalents of Boc2O after stirring for 16 hours. 
Compound 17 was obtained in 64% yield in a two-step protocol. First, 4-amino-2-hydroxy-
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acetophenone was reacted with four equivalents of DMAP and two equivalents of Boc2O for 16 hours, 
subsequently, two additional equivalents of DMAP and three equivalents of Boc2O were added and 
the reaction was stirred for an additional 18 hours. Compound 15 and 16 were converted into 
compounds 14 and 17, respectively, via deprotection of the O-Boc-group using K2CO3 in MeOH.  
 
 
 
Scheme 4.7 Compounds obtained after Boc-protection. Reagents and conditions: i) 2 equiv Boc2O, 
4 equiv DMAP, CH2Cl2, r.t. 3 d; ii) 3 equiv Boc2O, 2 equiv DMAP, CH2Cl2, r.t. 16 h; iii) 2 equiv Boc2O, 
4 equiv DMAP, CH2Cl2, r.t. 16 h followed by 3 equiv Boc2O, 2 equiv DMAP, r.t. 18 h; iv) K2CO3, MeOH, 
r.t. 16 h. 
 
After Boc-protection, molecules 14 and 17 were subsequently O-silylated yielding compounds 9-11 
and 18-20 in moderate to good yields (64-91%) (Scheme 4.8).   
 
 
 
Scheme 4.8 O-silyl protection of N-Boc-protected compounds 14 and 17. Reagents and conditions: i) 
2.5 equiv TBDMS-Cl, 3 equiv imidazole, cat. DMAP, DMF, 40 °C, 16 h; ii) 2.5 equiv TBDPS-Cl, 
3 equiv imidazole, cat. DMAP, DMF, 40 °C, 16 h; iii)  2.5 equiv TiPS-Cl, 3 equiv imidazole, cat. DMAP, 
DMF, 50 °C, 6 h; iv) 2.5 equiv TBDPS-Cl, 3 equiv imidazole, cat. DMAP, DMF, r.t, 16 h; v) allyl 
bromide, K2CO3, DMF, r.t. 16 h. 
 
Table 4.1 Synthesis and yields of the fully protected 4-amino-2-hydroxy-acetophenones. 
Entry Route PG1 PG2 PG3 Product Yield (%)a 
1 One step Boc H Boc 15 31 
2 One step Boc Boc Boc 16 18 
3 Route A Boc Boc TBDMS 9  11 
4 Route A Boc Boc Me 13  35 
5 Route B Boc H/Boc TiPS 11/18 41b 
6 Route B Boc Boc TBDPS 10 48 
7 Route B Boc H TBDPS 19 49 
8 Route B Boc H Allyl 20 86 
a Overall yields, b inseparable mixture of PG2 = Boc and H 
Chapter 4 
 100
The reaction of compound 17 with TiPS-Cl resulted in an inseparable mixture of 11 and 18. The 
presence of the mono-Boc compound 18 can be explained by thermal decomposition of one of the 
Boc-groups due to the relative high temperature required for silylation. The allyl protection of 14 gave 
compound 20 in a near quantitative yield (91%). Table 4.1 summarizes the protection of 4-amino-2-
hydroxy-acetophenone via different reaction pathways resulting in compounds 9-11 and 18-20.  
 
The protected acetophenones were subsequently employed in the Wittig and HWE reactions. The 
stereochemical outcome of the HWE and Wittig reactions is mainly directed by the employed ylide. 
The explanation for this directing effect is found in the delocalization of the negative charge. The HWE 
reaction utilizes a stabilized enolate favoring the formation of the thermodynamically more stable 
E-isomer. The Wittig reaction, inversively, makes use of an unstabilized ylid and the outcome of this 
reaction is expected to be the kinetic product (e.g. an E/Z mixture).36 
 
To explore the optimal reaction conditions for the formation of structure IX (Scheme 4.4) various 
methods and reactants were employed. The conditions applied in method A, using 2-ethoxy-2-
oxoethyl (triphenyl)phosphonium bromide and Et3N in toluene, are typically employed in the Wittig 
reaction.37 The HWE reaction was performed with ethyl (diethoxyphosphoryl)acetate and NaH in THF 
(methods B38 and C). In method B two equivalents of the phosphonate and NaH were used, while in 
method C five equivalents of both reagents were employed. Method D utilized LiCl as reported by 
Masamune and Roush39,40 in which a lithium cation stabilized the ylid via complexation between the 
two oxygen atoms. As a result of this stabilizing effect deprotonation is facilitated allowing the use of a 
mild base (e.g. DBU or even K2CO3).41  
 
 
 
Table 4.2 Results of the Wittig and Horner-Wadsworth-Emmons reaction on compounds 9, 13, 15, 
16 and 19. 
Entry Substrate PG1 PG2 PG3 Method Product Yield (%) 
1 9 Boc Boc TBDMS B 21 -a 
2 9 Boc Boc TBDMS D 21 - 
3 13 Boc Boc Me B 22 27 
4 13 Boc Boc Me C 22 50 
5 15 Boc H Boc B 23 ND 
6 16 Boc Boc Boc A 24 - 
7 16 Boc Boc Boc B 24 20 
8 16 Boc Boc Boc D 24 - b 
9 19 Boc H TBDPS Cc 25 51(54)c 
Method A: 2 equiv Ph3PCH2CO2Et·Br, 2 equiv Et3N, toluene, 50 °C, 16 h – 10 d; method B: 2 equiv (EtO)2POCH2CO2Et, 2 
equiv NaH, dry THF, 55 °C, 16 h – 4 d; method C: 5 equiv (EtO)2POCH2CO2Et, 5 equiv NaH, dry THF, 55 °C, 3 days; method 
D: 2 equiv (EtO)2POCH2CO2Et, 2 equiv DBU, 3 equiv LiCl, MeCN, r.t. or  50 °C, 1 – 7 d; a compound 17 formed, b compound 
14 formed, ND = not determined; c 10 equiv of (EtO)2POCH2CO2Et) and NaH. 
 
A summary of the results for the Wittig and Horner-Wadsworth-Emmons reactions as performed on 
compounds 9, 13, 15, 16 and 19 is displayed in Table 4.2. Performing different HWE reactions on 
compounds 9 and 15 did not result in the formation of the desired products. Either decomposition of 
the starting material was observed (entry 1) or conversion was too low to be determined (entry 5). The 
formation of compound 22, employing method B, initially gave a moderate yield of 27% (entry 3). By 
increasing the amount of the phosphonate and NaH (i.e. employing method C) the yield improved up 
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to 50% (entry 4). Applying methods A, B and D on compound 16 gave mixed results. The Wittig 
reagent was not sufficiently reactive to give the desired product (24, entry 6). The use of mild HWE 
conditions (method D, entry 8) also failed to produce the desired product. Finally, applying method B 
resulted in the formation of 24 though in a disappointing 20% yield. Applying method C on compound 
19 yielded compound 25 in a reasonable yield (51%), but unfortunately, the use of 10 equivalents 
phosphonate and NaH did not significantly improve the yield any further (54%, entry 9). 
 
Although the E-configured product was the expected isomer for the HWE reaction, compounds 22, 24 
and 25 were obtained as an inseparable mixture of E- and Z-isomers. The composition of compound 
22 was determined by LC-MS in which two peaks with an identical mass were found in a ratio of 1 to 
19. Since the Z-isomer is the more sterically demanding isomer, it will presumably have less 
interaction with the C18-column thus resulting in a shorter retention time (corresponding to the peak 
with low intensity). Therefore we assume that the E-isomer is probably the predominant product, since 
this compound has the longest retention time and the highest intensity. 
 
Since the stereochemical composition of compound 24 could not be determined by 1H-NMR 
spectroscopy, a NOESY experiment was performed. Cross-peaks, caused by the NOE-effect, of the 
vinylic proton with either the methyl protons (i.e. Z-isomer) or the aromatic proton (i.e. E-isomer) are 
indicative for the E- and/or Z-isomer. However, since NOESY is a comparative method, reliable 
conclusions could only be obtained by measuring (and integrating the cross-peaks) of both isomers 
separately.42 For compound 24 both cross peaks were observed suggesting a mixture of E- and Z-
isomer. Nevertheless, the cross peak between the vinylic proton and methyl protons (indicative for the 
Z-isomer) can also be observed for the E-isomer, although, the intensity of this cross-peak was too 
large to be attributed to merely the E-isomer. Hence, the isomeric ratio of compound 24 remained 
unresolved. The E/Z ratio for compound 25 was determined by 1H-NMR spectroscopy since different 
chemical shifts for the vinylic protons as well as the methyl protons were observed for the E- and Z-
isomer (E/Z ratio (2:3)).  
 
The next step in the sequence towards AMC precursor I was the hydrolysis of the α,β-unsaturated 
ester of the HWE products 22, 24 and 25. Saponification of 24 was not attempted due to the base 
lability of the O-Boc-protecting group. Hydrolysis of compound 25 (Scheme 4.9) did not yield the 
desired carboxylic acid 26, but instead two other products were formed being the TBDPS-deprotected 
carboxylic acid 27 and AMC (20% and 79%, respectively, according to 1H-NMR). Since the reaction 
was performed with a mixture of the E- and Z-isomer, Boc-AMC (28) was also expected as a result of 
ring-closure of the Z-isomer, but this compound could not be detected. 
 
 
Scheme 4.9 Hydrolysis of compound 25 yielding compound 27 and AMC. 
 
 
 
Scheme 4.10 Hydrolysis and Boc-deproctection protocols for 22. Reagents and conditions: i) LiOH in 
THF/MeOH/H2O (7:5:5) r.t. 2 h Y = ND; ii) CH2Cl2, TFA, r.t. 16 h (99%). 
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Compound 22 was successfully converted into the carboxylic acid 29 using LiOH in a mixture of THF, 
MeOH and H2O (7:5:5) (Scheme 4.10). Also, the deprotection of the Boc groups using TFA in CH2Cl2 
yielded the desired product 30 in quantitative yield (Scheme 4.10). In order to cleave the methyl 
protecting group a reaction with BBr3 was performed in dry CH2Cl2 at -78 °C.43 Unfortunately first Boc-
deprotection occurred, generating compound 31. Prolonged reaction times led to the removal of the 
methyl group, immediately followed by full conversion to AMC as shown in Scheme 4.11. The full 
conversion of the E/Z mixture 22 to AMC implies that the E-configured double bond undergoes 
isomerization, possibly caused by the electron-donating effect of the free amine 31 which was 
generated by Boc-deprotection. 
 
  
 
Scheme 4.11 Methyl deprotection of compound 22 resulting in the formation of AMC. 
 
As a result of the problems encountered during the hydrolysis and deprotection of the HWE-products 
22, 24 and 25, mainly resulting in ring-closed products, we shifted our focus to N-bis-Boc-O-allyl 
protected acetophenone 20. This orthogonally protected compound requires mild conditions for both 
Boc- and allyl-deprotection. The HWE reagent was also changed from ethyl (diethoxyphosphoryl)-
acetate to tert-butyl (dimethoxyphosphoryl)acetate,44 which should allow acidic hydrolysis of the tert-
butyl ester using TFA in a later stage.  
 
 
Scheme 4.12 HWE-reaction of compound 20 resulting in the formation of compounds 32 and 33. 
 
Performing the HWE reaction using NaH gave the two possible isomers in a high overall yield (75%) 
(Scheme 4.12). The two isomers were separated by column chromatography yielding the E-isomer 32 
in 33% and the Z-isomer 33 in 42% yield. Isomers 32 and 33 gave distinct different chemical shifts in 
both 1H- and 13C-NMR. The configuration of both isomers was determined by NOESY analysis 
(Figures 4.3 and 4.4). Figure 4.3 shows the spectrum of the E-isomer (32, upper left corner) with the 
coupling of the protons at position 2 and 4 as expected for the E-isomer. In addition a relatively small 
coupling of the protons at position 2 and 3 was observed. This is presumably caused by the 
NOE-effect of the E-isomer since the protons at position 2 have different chemical shifts for the E- and 
Z-isomer (compare Figure 4.3 and 4.4). The spectrum of the Z-isomer (33, upper left corner) shows a 
clear coupling of the protons at position 2 and 3 and no coupling of the protons at position 2 and 4 as 
expected for the Z-isomer. By comparing the intensities of the cross-peaks of the protons at position 2 
and 3 for both isomers, the E/Z isomeric ratio could be determined and was found to be 2:3 which 
roughly corresponds to the isolated yields.  
 
Toward Solid Phase Peptide Synthesis 
 103
 
Figure 4.3 NOESY spectrum of the E-isomer 32. Cross-peaks are boxed. 
 
 
 
Figure 4.4 NOESY spectrum of the Z-isomer 33. Cross-peaks are boxed. 
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The tert-butyl ester hydrolysis and Boc-deprotection of compounds 32 and 33 proceeded in a single 
step using concentrated TFA and a catalytic amount of concentrated HCl (Scheme 4.13). The E-
isomer 32 gave complete deprotection overnight yielding compound 34 (99%), however, applying 
identical conditions on the Z-isomer 33 gave unexpected partial isomerization into the E-isomer 
resulting in a mixture of compounds 35 (30%) and 34 (70%) as depicted in Scheme 4.13.  
 
 
 
Scheme 4.13 Deprotection and isomerization of compounds 32 and 33 using TFA and catalytic HCl. 
 
A similar isomerization reaction and proposed mechanism for maleic acid to fumaric acid has been 
reported by Nozaki and Ogg.45 Scheme 4.14 (pathway A) shows the mechanism for isomerization of 
compound 33 according to the reported mechanism. Since CF3COO¯ and Cl¯ are both poor 
nucleophiles, an alternative mechanism, similar to the one proposed in Scheme 4.11, can take place 
(pathway B). Finally, protonation of the olefin is also a possible explanation for the isomerization of the 
Z-double to the E-double bond. 
 
  
 
Scheme 4.14 Suggested mechanism for isomerization of the Z-double bond of compound 33. 
 
To explore the possibility of complete isomerization of compounds 33 into the desired E-isomer 34 a 
series of kinetic 1H-NMR experiments were conducted (Scheme 4.15). 
 
 
Scheme 4.15 Kinetic 1H-NMR experiment for the deprotection and isomerization of compound 33.   
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The hydrolysis reaction was measured by monitoring the decrease of the tert-butyl signal, while the 
rate of isomerization was determined by comparison of the peaks corresponding to the protons at the 
allylic ether position (1 and 1* in Scheme 4.15).  
 
The experiment known to give isomerization (e.g. TFA and catalytic HCl) was repeated in deuterated 
THF at both 25 °C and 40 °C while monitoring the deprotection and the isomerization (Graph 4.1A). 
Initially the reaction was carried out at 25 °C giving rise to slow Z to E isomerization and incomplete 
deprotection. Surprisingly, raising the reaction temperature to 40 °C resulted in complete deprotection 
within 15 hours. After full conversion of 33 into the carboxylic acid and free amine 35 isomerization 
continued, demonstrating that the deprotected product can also be isomerized using acidic conditions. 
In both reactions the isomerization leveled off at approximately 60%. Changing the ratio of TFA and 
HCl (e.g. 1:1 ratio of TFA / HCl) resulted in a steady increase of both the amount of E-isomer and 
carboxylic acid during the course of the reaction (Graph 4.1B). It appeared however, that isomerization 
occurred prior to deprotection indicated by the slightly higher rate of isomerization compared to 
deprotection. Furthermore, no complete deprotection occurred and isomerization stopped at 
approximately 70% E-isomer formation. 
 
 
Graph 4.1 A) Kinetic experiments using 8 equiv TFA and catalytic HCl at 25 °C (open symbols) and 
40 °C (solid symbols). B) Kinetic experiment using 4 equiv TFA and 4 equiv HCl at 40 °C conversion 
monitored during 70 hours.  
 
 
Graph 4.2 A) Kinetic experiment using 8 equiv HCl at 40 °C, conversion monitored during 130 hours. 
B) Kinetic experiments using 8 equiv TFA at 40 °C (starting material contained 21% E-isomer).  
 
Using only an excess HCl did not significantly affect the rate of isomerization, although, deprotection in 
the absence of TFA appeared to be slower as shown in Graph 4.2A. Moreover, Graph 4.2A suggests 
a second order reaction rate for both the isomerization and the deprotection of compound 33 implying 
a concentration-dependence in compound 33 and acid (TFA or HCl) for both the isomerization and the 
deprotection. Applying an excess of TFA instead of HCl (Graph 4.2B) gave nearly no deprotection and 
a significant decrease of the isomerization rate. The results for the isomerization experiments are 
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summarized in Table 4.3. It seemed that both HCl and TFA can cause isomerization, however, 
isomerization is faster in the presence of HCl. For the deprotection a combination of TFA and catalytic 
HCl gave the best results (fast and complete conversion, entry 2). 
 
Table 4.3 Reaction conditions and results for deprotection/isomerization of compound 33 at 40 °C 
Entry Equiv 
HCl 
Equiv  
TFA 
Deprotection 
time (h) 
Isomerization 
time (h) 
Conversion 
to acid 
(E:Z)ini (E:Z)eq 
1a catalytic 8 60 60b 60% 0:1 1:4 
2 catalytic 8 9 60 100% 1:25 3:2 
3 4 4 40 70 40% 1:17 7:3 
4 8 0 120 65 90% 1:17 7:3 
5 0 8 0 63 0% 0:1 0:1 
a Reaction at 25 °C, b measurements were stopped before the equilibrium was reached. 
 
The final step toward the AMC-precursor I was the Fmoc-protection of compound 34 (Scheme 4.16). A 
variety of reaction conditions (i.e. solvent, base and reaction time) were screened to obtain optimal 
conditions for the Fmoc protection.46, 47, 48  Both Fmoc-OSu and Fmoc-Cl were employed as reagents 
in the synthesis of target compound 36. However, the use of Fmoc-OSu in combination with a wide 
range of bases (DBU, DMAP, 1 M NaOH, KOtBu and Et3N) in THF gave no reaction.  
 
 
Scheme 4.16 Fmoc-protection of compound 34 and the mixture of 34/35. 
 
Using Fmoc-Cl and pyridine in CH2Cl249 gave the best result, producing compound 36 in a reasonable 
yield (50%). Applying the same conditions on the inseparable mixture of 34 and 35 (see Scheme 4.15) 
gave compounds 36 (37%) and 37 (16%) after separation by column chromatography in an overall 
yield of 53%. Thus, the target AMC-precursor I in the form of compound 36 was produced in a five 
step reaction sequence in an overall yield of 29%.  
 
 
4.3 Solid phase peptide synthesis 
 
 
4.3.1 Resin loading 
 
In order to achieve the highest resin loading, three different resins, a 2-Cl-trityl chloride resin, a Wang 
resin and a Wang-Br resin were examined with respect to the loading of AMC-precursor 36 (Scheme 
4.17). After coupling of the substrate, the resin loading was determined using a so-called Fmoc-test.50 
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Scheme 4.17 Coupling of compound 36 to a 2-chlorotrityl-, Wang- or Wang-Br resin. 
 
The first attempts to couple substrate 36 to a resin were performed on the acid labile 2-Cl-trityl resin. A 
base was required to neutralize the HCl that was liberated during the coupling procedure to prevent 
preliminary cleavage of the product from the resin. Both DiPEA and K2CO3 were employed, but 
unfortunately no coupling to the resin occurred (as was determined by the Fmoc-test). Since the 
bulkiness of the trityl resin might have prevented successful coupling of 36, the less sterically 
demanding Wang resin was employed. This hydroxyl-functionalized resin can be loaded with 
compound 36 using coupling reagents in combination with a base to give material 42 (Scheme 4.17). 
Various coupling reagents were utilized (DIC, EDC, PyBOP and HBTU), however, solely EDC 
appeared to give loading of the resin (0.13 mmol/g (14%)). Finally, compound 48 and (4-bromo-
methylphenoxy)methyl polystyrene resin (Wang-Br resin) were mixed to obtain material 42. The 
reaction was performed using cesium iodide (CsI) and DiPEA in DMF according to a literature 
procedure.51 This time a reasonable loading of 0.37 mmol/g (37%) was obtained. In addition, the 
coupling of Z-isomer 37 was performed resulting in a similar loading as compared to the loading of the 
E-isomer (i.e. 0.31 mmol/g (31%)). 
 
An important factor in the determination of resin-loading via the Fmoc-test is the stability of the Fmoc 
protected compound. In general the Fmoc-protected amino acids are stable compounds, nevertheless, 
the stability of Fmoc-aniline is significantly lower. Hence, partial removal of the Fmoc-group during the 
resin coupling, affects the reliability of the values obtained by the Fmoc-test. Therefore the stability of 
the Fmoc-aniline 36 was tested in the presence of several bases (DMAP, K2CO3 and pyridine) which, 
in all cases, resulted in partial Fmoc deprotection. These results indicate that an Fmoc-test is not a 
reliable indicator for the determination of the resin coupling efficiency. Consequently, the Fmoc-group 
was removed yielding material 43 which was subsequently loaded with Fmoc-Ala-OH to produce 
material 44 as depicted in Scheme 4.18. After coupling of an Fmoc-protected amino acid a more 
stable Fmoc-group was introduced onto the resin which was reflected in a satisfactory loading of 
0.42 mmol/g over two steps (48%) according to the Fmoc-test performed on 44. The values for the 
loading of 42 compared to 44 determined via the Fmoc-test showed a difference of approximately 
17%. The correct loading of the resin is presumably closer to the values obtained for resin 44 than to 
the less accurate value of resin 42 due to the instability of the Fmoc group on an aromatic amine. 
 
 
 
Scheme 4.18 Coupling of Fmoc-Ala-OH to resin 43. Reagents and conditions: i) 20% piperidine in 
DMF, r.t., 2 h; ii) Fmoc-Ala-OH, DIPCDI, HOBt, DMF, r.t., 2 h.   
 
In addition, elemental analysis was performed on resin 44 to measure the percentage of nitrogen 
present. The loading determined by elemental analysis revealed a significantly higher loading 
(0.79 mmol/g (85%)) as compared to the Fmoc-test values. Comparing the loading determined via an 
Fmoc-test to the loading obtained by elemental analysis the outcome differs dramatically (45%). 
Although elemental analysis might be considered a more accurate method for the determination of the 
loading52 since no extensive sample preparation is necessary (as is required for the Fmoc-test), one 
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should be aware that encapsulation of starting material 36 by the resin can significantly increase the 
nitrogen content and thus the loading value. 
 
 
4.3.2 Toward substrate synthesis 
 
The success of our methodology for SPPS was greatly dependent on the allyl deprotection of AMC-
precursor 34. The deprotection of the allyl ether was initially attempted on both 34 and 35 using 
Pd(PPh3)4 and K2CO3 in MeOH (Scheme 4.19). As was expected, upon deprotection of Z-isomer 35 
quantitative formation of AMC was observed. Applying the same conditions on the E-isomer 34 did not 
result in the formation of the desired product 38, but instead isomerization followed by ring closure 
gave again AMC. The mechanism for the isomerization of the E double bond and subsequent AMC 
formation, as was observed for the deprotection of compound 22 (Scheme 4.11), presumably also 
plays a role in the allyl deprotection of compound 34.  
 
 
 
Scheme 4.19 Allyl deprotection reactions of 34, 35 and 39. 
 
To prevent the amine-induced isomerization, the amine function of 34 was protected with an electron 
withdrawing group (i.e. trifluoroacetyl) producing 39 in a quantitative yield. Subsequently, allyl 
deprotection was performed using Pd(PPh3)4 and K2CO3 to obtain compound 40 as depicted in 
Scheme 4.19. The successful formation of compound 40 confirmed that isomerization was caused by 
the electron-donating effect of the amine group. Since an electron-withdrawing group (i.e. an amino 
acid) is present on the amine function of the AMC-precursor, no isomerization should occur during the 
on-resin allyl deprotection. 
 
After the successful loading of the Wang-Br resin with AMC-precursor 36 the synthesis of Fmoc-Ala-
AMC was pursued using the developed solid phase peptide synthesis methodology. Every reaction 
step during the SPPS was checked by treatment of a small portion of the resin with TFA to cleave off 
the compound of interest which was then subsequently purified and analyzed. We envisioned a 
synthetic strategy as depicted in Scheme 4.20. After coupling of 36 to the Wang-Br resin (vide supra) 
the Fmoc group was removed to produce product 43. Compound 34 was obtained by cleaving a part 
of resin 43 with TFA, using ethanedithiol and TiPS as scavengers, demonstrating a successful 
coupling and Fmoc deprotection. Another fraction of resin 43 was used for deprotection of the allyl 
group by treatment with Pd(PPh3)4 and K2CO3. The allyl deprotection of 43 yielded AMC, indicating 
that allyl deprotection proceeded and the compound was immediately isomerized as a result of the 
electron-donating effect of the free amine (see also Scheme 4.19). The rest of resin 43 was used to 
couple Fmoc-Ala-OH to yield material 44. The amino acid coupling was also successful since 
compound 45 was obtained after cleavage from the resin and subsequent purification (25%). 
Unfortunately, the reactions toward compounds 47 (TFA cleavage) and 48 (light-isomerization) could 
not be performed since allyl deprotection of 46 using Pd(PPh3)4 and K2CO3 failed. 
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Scheme 4.20 Toward a synthesis of Fmoc-Ala-AMC (48) via SPPS. Reagents and conditions: i) 20% 
piperidine in DMF, r.t., 30 min; ii) TFA/H2O/TiPS/ethanedithiol 37:1:1:1, r.t., 30 min; iii) Pd(PPh3)4, 
K2CO3, MeOH/CH2Cl2 1:1, r.t., 2 h; iv) Fmoc-Ala-OH, DIC, HOBt, DMF, r.t., 16 h; v) UV-lamp, 
1,4-dioxane. 
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Scheme 4.21 Deprotection and resin cleavage of compound 44. 
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Using an organic base (i.e. morpholine, Scheme 4.21) also did not produce the desired product 47 
since the allyl-protected product 45 was recovered after the deprotection and TFA cleavage reaction. 
Therefore another method was employed using phenylsilane (PhSiH3) and Pd(PPh3)4 in dry CH2Cl2.53 
This method gave deprotection of the allyl protecting group, but cleavage of the peptide bond was a 
severe side-reaction, since AMC was found as the main product. In addition, minor quantities of Fmoc-
Ala-AMC (48) were observed possibly as a result of isomerization of compound 47 in the cleavage 
step due to the presence of TFA. Clearly further investigation is required to explore the optimal 
conditions for allyl deprotection. At this moment the use of PhSiH3 and Pd(PPh3)4 looks most 
promising, though additional research is necessary to circumvent cleavage of the amide bond.  
 
 
4.4. Conclusions 
 
 
Two synthetic strategies were explored in pursuit of the synthesis of N-Fmoc-(E)-3-(2-allyloxy-4-
aminophenyl)but-2-enoic acid, an AMC-precursor for solid phase peptide synthesis. The first 
methodology made use of various metal-mediated cross-coupling reactions (i.e. Heck, Knochel and 
Sonogashira) on 2-iodo-5-nitrophenol. Since these routes failed to produce the desired compounds a 
second strategy was applied which involved a Wittig or Horner-Wadsworth-Emmons reaction on fully 
protected 4-amino-2-hydroxy-acetophenones under different reaction conditions. This yielded in some 
cases the desired α,β-unsaturated ester, but saponification of the ethyl ester turned out to be 
troublesome. Introduction of a tert-butyl ester on N-Boc-O-allyl-amino-hydroxy-acetophenone 
(produced in excellent overall yield (87%)) proceeded smoothly, yielding both the E-isomer (42%) and 
Z-isomer (33%) of the α,β-unsaturated ester in an overall good yield (75%). Subsequent deprotection 
and saponification of the E-isomer (TFA with a catalytic amount of HCl) produced the desired product 
while deprotection of the Z-isomer (TFA/HCl 1:1) gave a fortunate unexpected isomerization producing 
an inseparable mixture of the E- and Z-isomer in a ratio of 7:3 (99%). Fmoc protection of the amine 
function of the E-isomer yielded target molecule N-Fmoc-(E)-3-(2-allyloxy-4-aminophenyl)but-2-enoic 
acid in moderate yield (50%). Fmoc-protection of the E/Z mixture resulted in a separable mixture of 
Fmoc-protected E-isomer (37%) and Z-isomer (16%) resulting in a total yield of 87% of the desired E-
isomer. 
The coupling of the Fmoc-protected AMC-precursor was performed on three different resins. No 
loading was observed for the 2-chlorotrityl resin and a poor loading (0.13 mmol/g (14%)) was found for 
functionalization of a Wang resin. In order to achieve a higher loading a Wang-Br resin was employed 
which allowed mild coupling conditions and simple capping. The loading of N-Fmoc-(E)-3-(2-allyloxy-
4-aminophenyl)but-2-enoic acid onto the Wang-Br resin was determined by an Fmoc-test (0.37 
mmol/g (40%)) however, the anilinic Fmoc group appeared to be somewhat unstable under the 
applied basic conditions thus compromising the reliability of the determination of the loading via the 
Fmoc-test. Consequently, loading was determined after coupling of an amino acid (Fmoc-Ala-OH) to 
the AMC-precursor-resin. To this end, an Fmoc-Ala-AMC-precursor functionalized resin was 
synthesized with a loading between the 0.5 mmol/g (57%) and 0.79 mmol/g (85%) according to Fmoc-
test and elemental analysis, respectively. Unfortunately, the on-resin deprotection of the allyl 
protecting group proved to be unsuccessful under several conditions. The allyl deprotection requires 
additional investigation in order to pursue the light-induced isomerization–ring closure methodology to 
harvest novel thrombin substrates. 
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4.6 Experimental section 
 
 
General experimental:  
 
See Chapter 2 section 7. 
 
 
Instrumentations 
 
Microwave reactions were carried out in a CEM Discover microwave.  
 
 
Methods and materials 
 
Wang-Br resin (01-64-0186) was purchased from Novabiochem and the Wang-OH resin (D-1250) and 
chloro-trityl resin (D-1965) from Bachem.  
 
 
Synthesis 
 
2-Iodo-5-nitrophenol (1a) 
 
Synthesized according to a literature procedure:54 
2-hydroxy-4-nitroaniline (154 mg, 1 mmol) was dissolved in DMSO (5 mL) and 30% 
H2SO4 was added. The mixture was heated for 2 hours at 50 °C. The mixture was then 
cooled to room temperature and a solution of NaNO2 (100 mg, 1.44 mmol) in H2O 
(2 mL) was added. The mixture was stirred for 1 hour at 0 °C. Next, a solution of NaI (450 mg, 
2.88 mmol) in water (2 mL) was added and the mixture was stirred for an additional hour at room 
temperature. EtOAc (30 mL) was added and the organic layer was washed with 10% NaHSO3 (2 × 
10 mL), H2O (2 × 20 mL) and brine (20 mL) and subsequently dried over MgSO4. The solvent was 
removed under reduced pressure and the crude product was purified by column chromatography 
(EtOAc/n-heptane, 1:4). The product was obtained as a yellow powder (210 mg, 80%) RF = 0.45 
(EtOAc/n-heptane, 1:2). 1H-NMR (400 MHz, CDCl3) : 7.87 (d, J = 8.7 Hz, 1H), 7.81 (d, J = 2.5 Hz, 
1H), 7.56 (dd, J = 8.7, 2.6 Hz, 1H). FT-IR max film (cm-1): 3490, 1497, 1324, 1014, 802, 733. LRMS 
(ESI-) m/z calcd. for C6H3INO3 [M-H]- 263.92, found 264.10. 
 
2-tert-Butoxy-1-iodo-4-nitrobenzene (1b) 
 
Synthesized according to a modified literature procedure: 55 
2-Iodo-5-nitrophenol (1a, 2.0 g, 7.5 mmol) was dissolved in 1,4-dioxane (30 mL) in a 
Grolsch beer bottle. The bottle was cooled to -30 °C and concentrated H2SO4 (1 mL) 
was added. Isobutylene (40 mL) was condensed and slowly added to the reaction 
mixture. The bottle was sealed and slowly warmed to room temperature. The mixture was left stirring 
for 3 days. The bottle was then cooled again to -30 °C for 1 hour and opened. The mixture was slowly 
warmed to room temperature and left stirring until all isobutylene was evaporated. The mixture was 
neutralized with 2 M NaOH (10 mL) and extracted with Et2O (6 × 40 mL). The organic layer was 
washed with H2O (3 × 60 mL) and brine (40 mL) and subsequently dried over MgSO4. The solvent was 
removed under reduced pressure. The obtained suspension was dissolved in 1,4-dioxane (10 mL) and 
lyophilized. The crude product was purified by column chromatography (EtOAc/n-heptane, 1:6). The 
product was obtained as yellow oil (0.46 g, 20%) RF = 0.6 (EtOAc/n-heptane, 1:6) 1H-NMR (400 MHz, 
CDCl3) : 7.97 (d, J = 8.6 Hz, 1H), 7.86 (d, J = 2.5 Hz, 1H), 7.62 (dd, J = 8.6, 2.5 Hz, 1H), 1.55 (s, 9H). 
13C-NMR (75 MHz, CDCl3) : 156.4, 148.2, 139.3, 117.7, 113.8, 102.4, 82.6, 28.6.  
 
O-TiPS-2-iodo-5-nitrophenol (1c) 
 
2-Iodo-5-nitrophenol (1a, 309 mg, 1.17 mmol) was dissolved in dry THF (10 mL). 
Imidazole (397 mg, 5.85 mmol) and TiPS-Cl (0.75 mL, 3.50 mmol) were added to 
the solution and the mixture was stirred for 4 hours at room temperature. The 
product was extracted using a mixture of EtOAc/H2O (1:1 v/v). The organic layer 
I
OHO2N
I
OtBuO2N
I
OTiPSO2N
Chapter 4 
 112
was dried over MgSO4, concentrated and purified by column chromatography (EtOAc/n-heptane, 1:9). 
The product was obtained as yellow oil (397 mg, 81%) RF = 0.8 (EtOAc/n-heptane, 9:1). 1H-NMR 
(300 MHz, CDCl3) : 7.94 (d, J = 8.6 Hz, 1H), 7.63 (d, J = 2.5 Hz, 1H), 7.53 (dd, J = 8.6, 2.5 Hz, 1H), 
1.35-1.42 (m, 3H), 1.16 (d, J = 7.2 Hz, 18H). 13C-NMR (75 MHz, CDCl3) : 156.2, 149.0, 139.9, 116.7, 
111.9, 99.4, 18.0, 12.9. HRMS (CI+) m/z calcd. for C15H25NO3ISi [M+H]+ 422.0649, found 422.0638. 
 
1-Iodo-2-(methoxymethoxy)-4-nitrobenzene (1d) 
 
Chloromethyl methyl ether (95 µL, 1.25 mmol) was added drop wise to a stirred 
solution of 2-iodo-5-nitrophenol (1a, 265 mg, 1 mmol) and DiPEA (0.25 mL, 
1.5 mmol) in dry CH2Cl2 (15 mL) at 0 °C under an argon atmosphere. After the 
solution was stirred at room temperature for 2 hours, the reaction mixture was 
diluted with CH2Cl2. The organic layer was washed with 2 M HCl (30 mL), saturated aqueous NaHCO3 
(30 mL), brine (30 mL) and subsequently dried over MgSO4. After evaporation of the solvent, the 
product was obtained as a light yellow powder (303 mg, 98%) RF = 0.5 (n-heptane/EtOAc, 3:1). 
1H NMR (400 MHz, CDCl3) : 7.97 (d, J = 8.6 Hz, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.63 (dd, J = 8.6, 
2.5 Hz, 1H), 5.34 (s, 2H), 3.53 (s, 3H). 13C-NMR (75 MHz, CDCl3)  : 156.6, 149.2, 139.8, 117.8, 109.0, 
95.8, 95.2, 56.8. HRMS (CI+) m/z calcd. for C8H9NO4I [M+H]+ 309.9577, found 309.9579. 
 
Ethyl 3-(2-hydroxy-4-nitrophenyl)-propiolate (3a) 
 
Synthesized according to a modified literature procedure: 28 
2-iodo-5-nitrophenol (1a, 265 mg, 1 mmol), PdCl2(PPh3)2 (14 mg, 0.02 mmol) 
and CuI (7.6 mg, 0.04 mmol) were dissolved in dry THF (5 mL) in a flame-
dried Schlenk tube under an argon atmosphere. DiPEA (0.36 mL, 3.7 mmol) 
and ethylpropiolate (0.19 mL, 2 mmol) were added and the mixture was stirred 
for 3 days at 70 °C. The reaction mixture was quenched with 2 M HCl (2 mL) 
and subsequently diluted with EtOAc (20 mL). The organic layer was washed with H2O (3 × 15 mL) 
and brine (15 mL) and subsequently dried over MgSO4. The crude product was purified by gradient 
column chromatography (EtOAc/n-heptane, 1:8  1:4). The product was obtained as yellow oil 
(40 mg, 17%) RF = 0.1 (EtOAc/n-heptane, 1:3). 1H-NMR (400 MHz, CDCl3) : 7.81 (dd, J = 8.4, 1.8 Hz, 
1H), 7.78 (t, J = 1.9 Hz, 1H), 7.35 (dd, J = 8.2, 1.6 Hz, 1H), 4.32 (dq, J = 7.2, 1.8 Hz, 2H), 1.36 (dt, J = 
7.2, 1.9 Hz, 3H). 13C-NMR (75 MHz, CDCl3) : 164.7, 152.9, 149.3, 134.7, 122.8, 122.4, 115.6, 105.7, 
61.9, 14.6. HRMS (ESI-) m/z calcd. for C11H8NO5 [M-H]- 234.0403, found 234.0408. 
 
Ethyl 3-(2-(methoxymethoxy)-4-nitrophenyl)propiolate (3d) 
 
General procedure for the synthesis of 3d: 
1-Iodo-2-(methoxymethoxy)-4-nitrobenzene (1d, 150 mg, 0.49 mmol), 
Pd(PPh3)2Cl2 (6.8 mg, 0.01 mmol) and CuI (3.7 mg, 0.02 mmol) were 
dissolved in a dry THF or NMP (10 mL). To this solution ethyl propiolate 
(0.20 mL, 1.94 mmol) and a base (K2CO3, DiPEA, CsCO3 or Et3N, 0.97 mmol) 
were added. The obtained mixture was stirred at 65 °C for 2 hours – 2 days. 
The product was extracted with EtOAc (2 × 20 mL) and washed with 1 M HCl (20 mL), whereupon it 
was dried over MgSO4. The product was purified by column chromatography (EtOAc/n-heptane, 1:5) 
RF = 0.55 (EtOAc/n-heptane, 1:2). The product was obtained as light yellow oil. 1H-NMR (400 MHz, 
CDCl3)  : 8.03 (d, J = 2.1 Hz, 1H), 7.87 (dd, J = 8.5, 2.1 Hz, 1H), 7.67 (d, J = 8.5 Hz, 1H), 5.35 (s, 2H), 
4.33 (q, J = 7.1 Hz, 2H), 3.54 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H). 13C-NMR (75 MHz, CDCl3) : 159.6, 
153.7, 149.7, 135.0, 116.8, 116.6, 110.0, 95.3, 87.7, 80.1, 62.6, 56.9, 14.2. HRMS (CI+) m/z calcd. for 
C13H14NO6 [M+H]+ 208.0821, found 208.0818. 
 
(Z)-Ethyl 3-iodobut-2-enoate (4) and (E)-ethyl 3-iodobut-2-enoate (5)  
 
Synthesized according to a literature procedure:32  
A suspension of NaI (2.2 g, 14.4 mmol) in acetic acid (3.8 mL, 57.6 
mmol) was added to ethyl-but-2-ynoate (0.96 mL, 9 mmol). The 
mixture was stirred for 16 hours at 115 °C. The mixture was diluted with EtOAc (20 mL) and 
neutralized with 2 M NaOH (18 mL). The organic layer was washed with H2O (3 × 15 mL) and brine 
(15 mL) before drying over MgSO4. The crude mixture was purified by column chromatography 
(Et2O/pentane, 1:18). 
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Analytical data for compound 4: colorless oil (1.2 g, 56%) RF = 0.2 (Et2O/pentane, 18:1). 1H-NMR 
(300 MHz, CDCl3) : 6.29 (q, J = 1.5 Hz, 1H), 4.22 (q, J = 7.2 Hz, 2H), 2.73 (d, J = 1.5 Hz, 3H), 1.30 
(t, J = 7.1 Hz, 3H). 13C-NMR (75 MHz, CDCl3) : 164.3, 125.6, 113.1, 60.5, 36.5, 14.2. 
Analytical data for compound 5: colorless oil (50 mg, 2.3%) RF = 0.5 (Et2O/pentane, 18:1). 1H-NMR 
(300 MHz, CDCl3) : 6.62 (dq, J = 1.5, 0.7 Hz, 1H), 4.15 (dq, J = 7.1, 0.6 Hz, 2H), 2.98 (dd, J = 1.5, 
0.7 Hz, 3H), 1.27 (dt, J = 7.2, 0.7 Hz, 3H). The stereochemistry was determined by NMR-spectroscopy 
(NOESY). In both spectra a coupling between the methyl protons and the vinylic proton was observed.  
 
O-TBDMS-4-amino-2-hydoxy-acetophenone (6) 
 
This compound was synthesized according to a modified literature procedure:56 
4-amino-2-hydroxy-acetophenone (151 mg, 1 mmol) was dissolved in THF 
(5 mL). Imidazole (1.02 g, 15 mmol) and TBDMS-Cl (750 mg, 5 mmol) were 
added. The mixture was stirred for 3 days at room temperature. The mixture was 
diluted with Et2O (30 mL), washed with H2O (2 × 20 mL), brine (20 mL) and 
subsequently dried over MgSO4. The solvent was removed under reduced pressure and the crude 
product was purified by column chromatography (EtOAc/n-heptane, 1:1). The product was obtained as 
a white powder (0.2 g, 75%). RF = 0.4 (EtOAc/n-heptane, 1:1). 1H-NMR (300 MHz, CDCl3) : 7.63 
(d, J = 8.5 Hz, 1H), 6.27 (dd, J = 8.5, 2.2 Hz, 1H), 6.08 (d, J = 2.2 Hz, 1H), 3.97 (br s, 2H), 2.53 
(s, 3H), 1.02 (s, 9H), 0.28 (s, 6H). 
 
O-TBDPS-4-amino-2-hydroxy-acetophenone (7) 
 
Synthesized according to a modified literature procedure:56  
4-amino-2-hydroxy-acetophenone (151 mg, 1 mmol) was dissolved in dry THF 
(10 mL). Imidazole (1.0 g, 15 mmol) and TBDPS-Cl (1.5 mL, 5 mmol) were added 
and the reaction mixture was stirred for 2 days at 50 °C. The mixture was diluted 
with Et2O (2 × 30 mL), washed with H2O (3 × 30 mL) and brine (2 × 30 mL) and 
subsequently dried over MgSO4. The crude product was purified by column chromatography 
(EtOAc/n-heptane, 1:2). The product was obtained as a white solid (130 mg, 33%) RF = 0.3 
(EtOAc/n-heptane, 1:2). 1H-NMR (400 MHz, CDCl3) :  7.76 (t, J = 1.5 Hz, 2H), 7.74 (d, J = 1.6 Hz, 
2H), 7.64 (d, J = 8.5 Hz, 1H), 7.47-7.37 (m, 6H), 6.16 (dd, J = 8.5, 2.1 Hz, 1H), 5.67 (d, J = 2.1 Hz, 
1H), 3.56 (br s, 2H), 2.74 (s, 3H), 1.08 (s, 9H). 13C-NMR (75 MHz, CDCl3) : 197.7, 157.2, 151.0, 
135.3, 132.7, 132.2, 130.0, 128.0, 120.7, 107.9, 105.9, 31.7, 26.4, 19.3. HRMS (ESI+) m/z calcd. for 
C24H28NO2Si [M+H]+ 390.1889, found 390.1893. 
 
O-TiPS-4-amino-2-hydroxy-acetophenone (8) 
 
Synthesized according to a modified literature procedure:57  
4-amino-2-hydroxy-acetophenone (151 mg, 1 mmol) was dissolved in dry DMF 
(5 mL). Imidazole (136 mg, 2 mmol) was added and the mixture was stirred for 
10 min. TiPS-Cl (250 μL, 1.1 mmol) was added and the mixture was stirred at 
50 °C for 48 hours. The mixture was extracted with Et2O (30 mL) and washed with 
H2O (3 × 20 mL) and brine (20 mL) and subsequently dried over MgSO4. The crude product was 
purified by column chromatography (EtOAc/n-heptane, 1:4). The product was obtained as a yellow 
solid (160 mg, 52%) RF = 0.1 (EtOAc/n-heptane, 1:4). 1H-NMR (400 MHz, CDCl3) : 7.65 (d, J = 
8.5 Hz, 1H), 6.26 (dd, J = 8.5, 2.2 Hz, 1H), 6.07 (d, J = 2.2 Hz, 1H), 3.94 (br s, 2H), 2.57 (s, 3H), 1.14 
(d, J = 7.4 Hz, 18H), 0.83-0.91 (m, 3H). 13C-NMR (75 MHz, CDCl3) : 197.8, 158.1, 151.7, 132.8, 
120.8, 107.8, 104.4, 31.2, 18.0, 13.5. FT-IR max film: (cm-1): 3356, 2837, 1588, 1459, 1359, 1272, 
1204, 983, 828, 677. HRMS (ESI+) m/z calcd. for C17H30NO2Si [M+H]+ 308.2046, found 308.2045.  
 
General procedure for Boc-protection of compounds 9-11: 
 
O-Silyl-protected 4-amino-2-hydroxy-acetophenone (0.56 mmol) was dissolved in CH2Cl2 (20 mL) and 
DMAP (110 mg, 0.8 mmol) was added. The mixture was stirred for 5 min. after which di-tert-butyl-
carbonate (247 mg, 1.1 mmol) was added to the mixture. The mixture was stirred for 2-4 days at room 
temperature after which the solvent was removed under reduced pressure and the product was 
purified by column chromatography (EtOAc/n-heptane, 1:2).  
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N,N´-Bis-Boc-O-TBDMS-4-amino-2-hydroxy-acetophenone (9) 
 
Product 9 was obtained as a white powder (40 mg, 15%). RF = 0.75 (EtOAc/n-heptane, 1:2). 1H-NMR 
(300 MHz, CDCl3) : 7.54 (d, J = 8.3 Hz, 1H), 6.72 (dd, J = 8.3, 1.9 Hz, 1H), 6.59 (d, J = 1.9 Hz, 1H), 
2.53 (s, 3H), 1.34 (s, 18H), 0.93 (s, 9H), 0.19 (s, 6H). LRMS (ESI+) m/z calcd. for C24H40NO6Si [M+H]+ 
466.26, found 466.10. 
 
N,N´-Bis-Boc-O-TBDPS-4-amino-2-hydroxy-acetophenone (10) 
 
Product 10 was obtained as a white solid (50 mg, 15%) RF = 0.44 (EtOAc/n-heptane, 1:4). 1H-NMR 
(400 MHz, CDCl3) : 7.76-7.65 (m, 4H), 7.59 (d, J = 8.3 Hz, 1H), 7.46-7.33 (m, 6H), 6.67 (dd, J = 8.3, 
1.3 Hz, 1H), 6.30 (d, J = 1.7 Hz, 1H), 2.77 (s, 3H), 1.20 (s, 18H), 1.07 (s, 9H). 13C-NMR (75 MHz, 
CDCl3) : 200.0, 154.5, 150.5, 142.8, 135.2, 131.5, 130.2, 129.9, 128.1, 127.7, 120.9, 120.0, 82.6, 
31.7, 27.9, 27.7, 26.4, 14.1. HRMS (ESI+) m/z calcd. for C34H44NO6Si [M+H]+ 590.2938, found 
590.2925. 
 
N,N´-Bis-Boc-O-TiPS-4-amino-2-hydroxy-acetophenone (11) 
 
Product 11 was obtained as a white solid (16 mg, 6%) RF = 0.35 (EtOAc/n-heptane, 1:4). 1H-NMR 
(400 MHz, CDCl3) : 7.64 (d, J = 8.3 Hz, 1H), 7.12 (d, J = 1.8 Hz, 1H), 6.83 (dd, J = 8.7, 1.9 Hz, 1H), 
6.50 (br s, 1H), 2.63 (s, 3H), 1.52 (s, 9H), 1.12 (d, J = 4.71 Hz, 18H), 0.83-0.91 (m, 3H). 
 
O-Methyl-4-amino-2-hydroxy-acetophenone (12) 
 
Synthesized according to a modified literature procedure:58  
4-amino-2-hydroxy-acetophenone (50 mg, 0.33 mmol) was dissolved in 2-butanone 
(5 mL). Dimethylsulfate (55 μL, 0.16 mmol), K2CO3 (138 mg, 1 mmol) and KOH 
(38 mg, 0.66 mmol) were added. The mixture was stirred at room temperature for 
3 days. The mixture was poured into ice-water and left stirring for 16 hours. The 
mixture was extracted with Et2O (2 × 20 mL) and washed with H2O (3 × 20 mL) and brine (20 mL) and 
subsequently dried over MgSO4. The solvent was removed under reduced pressure and the crude 
product was purified by column chromatography (EtOAc/n-heptane, 1:1). The product was obtained as 
a white solid (30 mg, 55%) RF = 0.2 (EtOAc/n-heptane, 1:1). 1H-NMR (400 MHz, CDCl3) : 7.75 (d, J = 
8.5 Hz, 1H), 6.26 (dd, J = 8.5, 2.1 Hz, 1H), 6.16 (d, J = 2.1 Hz, 1H), 4.06 (br s, 2H), 3.86 (s, 3H), 2.54 
(s, 1H). 13C-NMR (75 MHz, CDCl3) : 197.1, 161.7, 152.4, 133.0, 118.3, 106.9, 96.8, 55.2, 31.7. 
HRMS (ESI+) m/z calcd. for C9H12NO2 [M+H]+ 166.0868, found 166.0871. 
 
N,N’-Bis-Boc-O-methyl-4-amino-2-hydroxy-acetophenone (13) 
 
Compound 12 (0.56 g, 3.4 mmol) was dissolved in CH2Cl2 (30 mL) and DMAP 
(2.0 g, 14.3 mmol) was added. The mixture was stirred for 5 min. after which 
di-tert-butyl carbonate (4.4 g, 20.4 mmol) was added and the reaction mixture was 
stirred for 16 hours. After dilution with EtOAc (50 mL), the organic layer was 
washed with H2O (3 × 50 mL) and brine (50 mL) and subsequently dried over 
MgSO4. The crude product was purified by column chromatography (EtOAc/n-heptane, 1:4). The 
product was obtained as a white powder (0.8 g, 64%) RF = 0.25 (EtOAc/n-heptane, 1:4). 1H-NMR 
(300 MHz, CDCl3) : 7.75 (dd, J = 8.2, 0.5 Hz, 1H), 6.80 (ddd, J = 8.2, 1.9, 0.8 Hz, 1H), 6.78 (d, J = 
1.3 Hz, 1H), 3.90 (s, 3H), 2.61 (d, J = 0.5 Hz, 3H), 1.45 (s, 18H). 13C-NMR (75 MHz, CDCl3) : 198.8, 
159.1, 151.4, 143.9, 130.7, 120.1, 111.4, 83.2, 55.7, 31.8, 27.9. HRMS (ESI+) m/z calcd. for 
C19H27NNaO6 [M+Na]+ 388.1736, found 388.1736. 
 
N-Boc-4-amino-2-hydroxy-acetophenone (14) 
 
4-Amino-2-hydroxy-acetophenone (300 mg, 2 mmol) and DMAP (1 g, 8 mmol) 
were dissolved in CH2Cl2 (20 mL) and the mixture was stirred for 5 min. before 
di-tert-butyl carbonate (0.88 g, 4 mmol) was added. The reaction mixture was 
stirred for 3 days after which the mixture was washed with H2O (3 × 30 mL) and 
brine (30 mL) and subsequently dried over MgSO4. The solvent was evaporated 
and the crude product was purified by column chromatography (EtOAc/n-heptane, 1:4). Compound 14 
was obtained as a white solid (480 mg, 95%) RF = 0.3 (EtOAc/n-heptane, 1:4). 1H-NMR (400 MHz, 
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CDCl3) : 12.51 (s, 1H), 7.64 (d, J = 8.8 Hz, 1H), 6.98 (dd, J = 8.7, 2.1 Hz, 1H), 6.93 (d, J = 2.2 Hz, 
1H), 6.65 (s, 1H), 2.57 (s, 3H), 1.53 (s, 9H). 13C-NMR (75 MHz, CDCl3) : 203.4, 162.4, 150.5, 144.9, 
130.6, 118.3, 117.9, 116.9, 83.9, 27.4, 26.3. FT-IR max film (cm-1): 3321, 2975, 1739, 1618, 1532, 
1368, 1290, 1234, 1139. HRMS (ESI+) m/z calcd. for C13H18NO4 [M+H]+ 252.1236, found 252.1235. 
 
N,O-Bis-Boc-4-amino-2-hydroxy-acetophenone (15) and N,N’,O-tris-Boc-4-amino-2-hydroxy-
acetophenone (16) 
4-Amino-2-hydroxy-acetophenone (151 mg, 1 mmol) and 
DMAP (289 mg, 2.1 mmol) were dissolved in CH2Cl2 and 
the mixture was stirred for 5 min. before di-tert-butyl 
carbonate (654 mg, 3 mmol) was added. The mixture was 
stirred overnight at room temperature after which the 
solvent was removed under reduced pressure and the crude mixture was purified by column 
chromatography (EtOAc/n-heptane, 1:3).  
Analytical data for compound 15: white solid (110 mg, 31%) RF = 0.4 (EtOAc/n-heptane, 1:2). 1H-NMR 
(400 MHz, CDCl3) : 7.80 (d, J = 8.6 Hz, 1H), 7.36 (d, J = 2.1 Hz, 1H), 7.22 (dd, J = 8.6, 2.2 Hz, 1H), 
6.66 (br s, 1H), 2.53 (s, 3H), 1.57 (s, 9H), 1.52 (s, 9H). 13C-NMR (75 MHz, CDCl3) : 195.8, 151.8, 
150.9, 143.4, 131.7, 124.9, 114.9, 112.6, 84.0, 81.6, 29.3, 28.2, 27.7.  HRMS (ESI+) m/z calcd. for 
C18H26NO6 [M+H]+ 352.1736, found 374.1760. 
Analytical data for compound 16: white solid (80 mg, 18%) RF = 0.5 (EtOAc/n-heptane, 1:2). 1H-NMR 
(400 MHz, CDCl3) : 7.80 (d, J = 8.4 Hz, 1H), 7.10 (dd, J = 8.4, 2.1 Hz, 1H), 7.01 (d, J = 2.0 Hz, 1H), 
2.58 (s, 3H), 1.56 (s, 9H), 1.42 (s, 18H). 13C-NMR (75 MHz, CDCl3) : 196.2, 150.6, 149.2, 145.7, 
134.3, 129.8, 127.2, 124.7, 122.6, 83.7, 83.0, 27.4. HRMS (ESI+) m/z calcd. for C23H33NNaO8 [M+Na]+ 
474.2104, found 474.2091. 
 
N,N’-Bis-Boc-4-amino-2-hydroxy-acetophenone (17) 
 
4-Amino-2-hydroxy-acetophenone (1 g, 6.6 mmol) and DMAP (1.9 g, 13.9 mmol) 
were dissolved in CH2Cl2 and the mixture was stirred for 5 min. before di-tert-butyl 
carbonate (4.3 g, 19.8 mmol) was added. The mixture was stirred overnight at room 
temperature. An additional amount of DMAP (1.9 g, 13.9 mmol) and di-tert-butyl 
carbonate (4.3 g, 19.8 mmol) were added and the reaction was stirred for another 
16 hours. The solvent was removed under reduced pressure and the crude mixture was purified by 
column chromatography (EtOAc/n-heptane, 1:3). The product was obtained as a white solid (1.5 g, 
64%) RF = 0.4 (EtOAc/n-heptane, 1:3) 1H-NMR (300 MHz, CDCl3) : 12.31 (br s, 1H), 7.72 (d, J = 
8.5 Hz, 1H), 6.78 (d, J = 2.0 Hz, 1H), 6.71 (dd, J = 8.5, 2.1 Hz, 1H), 2.63 (s, 3H), 1.44 (s, 18H). 
13C-NMR (75 MHz, CDCl3) : 195.8, 151.9, 151.4, 150.9, 131.7, 124.8, 114.9, 112.6, 114.9, 112.6, 
84.0, 81.5, 29.3, 28.1, 27.7. HRMS (ESI+) m/z calcd. for C18H25NNaO6 [M+Na]+ 374.1580, found 
374.1575. 
 
N,N’-Bis-Boc-O-TBDMS-4-amino-2-hydroxy-acetophenone (9) 
 
Synthesized according to a modified literature procedure:56 
Compound 17 (350 mg, 1 mmol) was dissolved in THF (10 mL). Imidazole 
(1.02 g, 15 mmol) and TBDMS-Cl (750 mg, 5 mmol) were added. The mixture 
was stirred for 16 hours at room temperature. The reaction mixture was diluted 
with Et2O (30 mL), washed with H2O (2 × 20 mL), brine (20 mL) and 
subsequently dried over MgSO4. The solvents were removed under reduced pressure and the crude 
product was purified by column chromatography (EtOAc/n-heptane, 1:9). The product was obtained as 
a white powder (320 mg, 70%). RF = 0.5 (EtOAc/n-heptane, 1:9). Analytical data vide supra. 
 
N,N’-Bis-Boc-O-TBDPS-4-amino-2-hydroxy-acetophenone (10) 
 
Synthesized according to a modified literature procedure:57  
Compound 17 (200 mg, 0.57 mmol) was dissolved in DMF (15 mL) and 
imidazole (116 mg, 1.71 mmol) and DMAP (catalytic) were added. The reaction 
mixture was stirred for 10 min. whereupon TBDPS-Cl (414 µL, 1.4 mmol) was 
added and the mixture was stirred for an additional 16 hours at 40 °C. The 
product was extracted with Et2O (40 mL) and washed with 2 M HCl (2 × 20 mL), H2O (3 × 30 mL) and 
brine (30 mL) and subsequently dried over MgSO4. The solvent was evaporated under reduced 
BocHN
O
OBoc Boc2N
O
OBoc
Boc2N
O
OH
O
OTBDMSBoc2N
O
OTBDPSBoc2N
Chapter 4 
 116
pressure and the mixture was purified by column chromatography (EtOAc/n-heptane, 1:4) to obtain 
compound 10 as a white solid (250 mg, 75%) RF = 0.7 (EtOAc/n-heptane, 1:1). Analytical data vide 
supra.  
 
N,N’-Bis-Boc-O-TiPS-4-amino-2-hydroxy-acetophenone (11) and N-Boc-O-TiPS-4-amino-2-
hydroxy-acetophenone (18) 
These compounds were synthesized according to a 
modified literature procedure:57  
Compound 30 (100 mg, 0.28 mmol), imidazole (57.2 mg, 
0.84 mmol) and DMAP (catalytic) were dissolved in dry 
DMF (5 mL) and stirred for 10 min. Next, TiPS-Cl 
(123 μL, 0.7 mmol) was added slowly and the mixture was stirred for 6 hours at 50 °C. The reaction 
mixture was extracted with Et2O (20 mL), washed with H2O (3 × 20 mL) and brine (20 mL) and 
subsequently dried over MgSO4. The crude product was purified by column chromatography 
(EtOAc/n-heptane, 1:4). An inseparable mixture of the mono- and bis-Boc protected compound was 
obtained (80 mg, 63%) RF = 0.37 (EtOAc/n-heptane, 1:4). 
Analytical data for compound 11: 1H-NMR (400 MHz, CDCl3) : 7.66 (d, J = 8.6 Hz, 1H), 6.75 (dd, J = 
8.1, 1.7 Hz, 1H), 6.64 (d, J = 1.9 Hz, 1H), 2.60 (s, 3H), 1.38 (s, 18H), 1.14 (d, J = 4.8 Hz, 18H), 0.83-
0.91 (m, 3H). 
Analytical data for compound 18: 1H-NMR (400 MHz, CDCl3) : 7.64 (d, J = 8.3 Hz, 1H), 7.12 (d, J = 
1.8 Hz, 1H), 6.83 (dd, J = 8.7, 1.9 Hz, 1H), 6.50 (br s, 1H), 2.63 (s, 3H), 1.52 (s, 9H), 1.12 (d, J = 4.71 
Hz, 18H), 0.83-0.91 (m, 3H). 
 
N-Boc-O-TBDPS-4-amino-2-hydroxy-acetophenone (19) 
 
Synthesized according to a modified literature procedure:57  
Compound 14 (190 mg, 0.75 mmol), imidazole (153 mg, 2.25 mmol) and 
DMAP (one spatula tip) were dissolved in dry DMF (10 mL). After stirring for 
10 minutes TBDPS-Cl (550 μL, 1.85 mmol) was added and the reaction 
mixture was stirred overnight. The reaction mixture was diluted with Et2O 
(40 mL) and subsequently washed with 2 M HCl (20 mL), H2O (3 × 30 mL) and brine (30 mL) and 
finally dried over MgSO4. The solvent was evaporated under reduced pressure and the crude product 
was purified by column chromatography (EtOAc/n-heptane, 1:4) to obtain compound 19 (190 mg, 
52%) RF = 0.4 (EtOAc/n-heptane, 1:4). 1H-NMR (400 MHz, CDCl3) : 7.68 (d, J = 6.5 Hz, 4H), 7.52 
(d, J = 8.3 Hz, 1H), 7.37-7.27 (m, 6H), 6.68 (dd, J = 8.4, 1.8 Hz, 1H), 6.44 (dd, J = 1.8, 0.6 Hz, 1H), 
2.70 (s, 3H), 1.55 (s, 9H), 1.08 (s, 9H). 13C-NMR (75 MHz, CDCl3) : 200.3, 154.4, 150.5, 142.1, 
135.4, 134.8, 131.7, 130.2, 127.9, 127.6, 120.9, 120.2, 83.0, 31.5, 27.6, 26.6, 19.4.  
 
N-Boc-2-allyloxy-4-amino-acetophenone (20) 
 
Synthesized according to a modified literature procedure:59 
Compound 14 (1.05 g, 4.1 mmol), K2CO3 (890 mg, 6.3 mmol) and allylbromide 
(0.97 mL, 5.74 mmol) were dissolved in DMF (20 mL). The mixture was stirred 
overnight and subsequently poured into water (50 mL). The mixture was 
extracted with EtOAc (3 × 50 mL), washed with H2O (3 × 50 mL), brine (50 mL) 
and subsequently dried over MgSO4. The solvent was evaporated under reduced pressure to afford 
compound 20 as a white solid (1.09 g, 91%) RF = 0.3 (EtOAc/n-heptane, 1:4). 1H-NMR (300 MHz, 
CDCl3) : 7.77 (d, J = 8.5 Hz, 1H), 7.45 (d, J = 1.8 Hz, 1H), 6.65 (dd, J = 8.5, 2.0 Hz, 1H), 6.63 (br s, 
1H), 6.25-5.88 (m, 1H), 5.46 (qd, J = 17.3 1.6 Hz, 1H), 5.33 (qd, J = 10.5, 1.3 Hz, 1H), 4.66 (td, J = 
5.5, 1.4 Hz, 2H), 2.61 (s, 3H), 1.53 (s, 9H). 13C-NMR (75 MHz, CDCl3) : 197.5, 159.2, 151.7, 143.4, 
132.0, 131.3, 122.1, 118.0, 109.5, 101.4, 80.8, 69.1, 31.6, 27.8. FT-IR max film (cm-1): 3723, 3282, 
2980, 1718, 1649, 1584, 1532, 1411, 1156, 832. HRMS (ESI+) m/z calcd. for C16H22NO4 [M+H]+ 
292.1549, found 292.1552. 
 
N,N’-Bis-Boc-O-methyl-ethyl-3-(4-amino-2-hydroxyphenyl)but-2-enoate (22) 
 
Synthesized according to a modified literature procedure:38  
60% NaH on mineral oil (880 mg, 11 mmol) was suspended in dry THF 
(5 mL) and triethylphosphonoacetate (5.52 mL, 11 mmol) was added slowly. 
The solution was stirred for 15 min., until gas formation ceased. A solution of 
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13 (0.8 g, 2.2 mmol) in THF was added slowly after which the reaction mixture was stirred for 3 days 
at 55 °C. The reaction was quenched with H2O (30 mL) and extracted with EtOAc (2 × 40 mL). The 
organic layers were combined and washed with H2O (3 × 30 mL) and brine (30 mL) and subsequently 
dried over MgSO4. The solvents were removed under reduced pressure and the crude product was 
purified by column chromatography (EtOAc/n-heptane, 1:4). The product was obtained as a white 
solid (470 mg, 49%) RF = 0.35 (EtOAc/n-heptane, 1:4). 1H-NMR (300 MHz, CDCl3) : 7.12 (d, J = 
8.0 Hz, 1H), 6.75 (dd, J = 8.0, 2.0 Hz, 1H), 6.69 (d, J = 1.9 Hz, 1H), 5.90 (q, J = 1.3 Hz, 1H), 4.20 (q, 
J = 7.1 Hz, 2H), 3.81 (d, J = 3.7 Hz, 3H), 2.47 (d, J = 1.4 Hz, 3H), 1.46 (s, 18H), 1.30 (t, J = 7.1 Hz, 
3H). 13C-NMR (75 MHz, CDCl3) : 166.7, 156.4, 155.8, 151.9, 140.2, 128.7, 120.1, 119.5, 116.9, 
108.8, 82.9, 59.7, 55.5, 30.9, 27.9, 19.7, 18.4, 14.3. FT-IR max film (cm-1): 2971, 1709, 1601, 1515, 
1368, 1156, 668. HRMS (ESI+) m/z calcd. for C23H33NNaO7 [M+Na]+ 458.2155, found 458.2128. 
 
N,N’,O-Tris-Boc-ethyl-3-(4-amino-2-hydroxyphenyl)but-2-enoate (23) 
 
Synthesized according to a modified literature procedure:38  
60% NaH on mineral oil (14 mg, 0.31 mmol) was suspended in dry THF 
(5 mL) and triethylphosphonoacetate (78.2 μL, 0.154 mmol) was added 
slowly. The reaction mixture was stirred until gas formation ceased 
whereupon a solution of 16 (70 mg, 0.154 mmol) in dry THF (2 mL) was 
added slowly after which the mixture was stirred for 4 days at 55 °C. The reaction mixture was diluted 
with EtOAc (20 mL), washed with H2O (2 × 20 mL) and brine (20 mL) and subsequently dried over 
MgSO4. The solvent was removed under reduced pressure and the crude product was purified by 
column chromatography (EtOAc/n-heptane 1:4). The product was obtained as a white powder (15 mg, 
20%) RF = 0.55 (EtOAc/n-heptane, 1:2). 1H-NMR (400 MHz, CDCl3) : 7.22 (d, J = 8.2 Hz, 1H), 7.03 
(dd, J = 8.2, 2.1 Hz, 1H), 6.97 (d, J = 2.1 Hz, 1H), 5.91 (q, J = 1.3 Hz, 1H), 4.20 (q, J = 7.1 Hz, 2H), 
2.46 (d, J = 1.4 Hz, 3H), 1.50 (s, 9H), 1.43 (s, 18H), 1.30 (t, J = 7.1 Hz, 3H). 13C-NMR (75 MHz, 
CDCl3) : 165.8, 152.2, 150.9, 146.9, 139.3, 127.9, 124.9, 122.0, 120.0, 83.3, 82.7, 59.4, 29.2, 27.4, 
22.2, 19.0, 13.8. FT-IR max film (cm-1): 2967, 1757, 1709, 1255, 1148, 611. HRMS (ESI+) m/z calcd. 
for C27H39NNaO9 [M+Na]+ 544.2523, found 544.2508. 
 
N-Boc-O-TBDPS-ethyl-3-(4-amino-2-hydroxyphenyl)but-2-enoate (24) 
 
Synthesized according to a modified literature procedure:38  
60% NaH on mineral oil (720 mg, 18 mmol) was suspended in dry THF 
(20 mL) and triethylphosphonoacetate (4.5 mL, 18 mmol) was added 
slowly. The solution was stirred for 15 min. until gas formation ceased. A 
solution of compound 19 (880 mg, 1.8 mmol) in THF was added slowly 
after which the reaction mixture was stirred for 3 days at 55 °C. The reaction was quenched with H2O 
(30 mL) and extracted with EtOAc (2 × 40 mL). The organic layers were combined and washed with 
H2O (3 × 30 mL) and brine (30 mL) and subsequently dried over MgSO4. The solvents were removed 
under reduced pressure and the crude product was purified by column chromatography (EtOAc/n-
heptane, 1:9). The product was obtained as a mixture of the E- and Z-isomer (ratio 2:3) as a white 
solid (540 mg, 54%) RF = 0.65 (EtOAc/n-heptane, 1:9).  
E-isomer: 1H-NMR (400 MHz, CDCl3) : 7.79-7.61 (m, 6H), 7.36-7.43 (m, 6H), 6.95 (d, J = 8.3 Hz, 1H), 
6.02 (d, J = 1.5 Hz, 1H), 4.02 (q, J = 7.1 Hz, 2H), 2.23 (d, J = 1.4 Hz, 3H), 1.31 (t, J = 6.1, 3H), 0.99 
(s, 1H). Z-isomer: 1H-NMR (400 MHz, CDCl3) : 7.79-7.61 (m, 6H), 7.36-7.43 (m, 6H), 7.08 (d, J = 8.4 
Hz, 1H), 6.02 (d, J = 1.5 Hz, 1H), 4.22 (q, J = 7.3 Hz, 2H), 2.57 (d, J = 1.3 Hz, 3H), 1.26 (t, J = 7.1, 
3H), 1.03 (s, 1H). LRMS (ESI+) m/z calcd. for C33H41NNaO5 [M+Na]+ 582.3, found 582.1. 
 
N,N’-Bis-Boc-O-methyl-3-(4-amino-2-hydroxyphenyl)but-2-enoic acid (29) 
 
Compound 22 (50 mg, 0.11 mmol) was dissolved in a mixture of 
THF/MeOH/H2O (0.7/0.5/0.5 mL). LiOH (11 mg, 0.22 mmol, 54 wt%) was 
added at 0 °C and the mixture was stirred for 30 min. The reaction mixture 
was warmed to room temperature and stirred for an additional 2 days. The 
reaction was diluted with H2O (10 mL) and washed with EtOAc (3 × 10 mL). 
The water layer was acidified with 2 M HCl to pH 5 and subsequently extracted with EtOAc (3 × 
10 mL). The organic layer was washed with H2O (3 × 15 mL) and brine (15 mL) and subsequently 
dried over MgSO4. The solvent was removed under reduced pressure and the product was obtained 
as a brown solid (yield not determined) RF = 0.2 (EtOAc/n-heptane, 1:2). 1H-NMR (400 MHz, CDCl3) : 
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7.07 (d, J = 8.2 Hz, 1H), 6.70 (dd, J = 8.2, 2.1 Hz, 1H), 6.55 (s, 1H), 5.95 (q, J = 1.3 Hz, 1H), 3.82 
(s, 3H), 2.48 (d, J = 1.3 Hz, 3H), 1.53 (s, 9H). 13C-NMR (75 MHz, CDCl3) : 171.1, 158.4, 157.1, 145.1, 
140.1, 129.1, 128.6, 118.7, 109.9, 101.8, 80.8, 55.5, 28.3, 20.0. FT-IR max film (cm-1): 3334, 2975, 
1679, 1597, 1506, 1251, 1143, 663. HRMS (ESI+) m/z calcd. for C16H21NNaO5 [M+Na]+ 330.1317, 
found 330.1305. 
 
Ethyl 3-(4-amino-2-methoxyphenyl)but-2-enoate (30) 
 
Synthesized according to a modified literature procedure: 60 
Compound 22 (40 mg, 0.1 mmol) was dissolved in CH2Cl2 (5 mL) and cooled 
to 0 °C. TFA (80.4 μL, 0.5 mmol) was added and the mixture was warmed to 
room temperature and stirred for 16 hours. The reaction was neutralized with 
2 M NaOH (0.3 mL) and diluted with EtOAc (40 mL). The layers were 
separated and the organic layer was washed with H2O (3 × 20 mL) and brine (20 mL) and 
subsequently dried over MgSO4. The crude product was purified by column chromatography 
(EtOAc/n-heptane, 1:1). The product was obtained as a white solid (20 mg, 99%) RF = 0.4 (EtOAc/n-
heptane, 1:1). 1H-NMR (300 MHz, CDCl3) : 6.98 (dd, J = 7.6, 0.7 Hz, 1H), 6.25 (d, J = 2.2 Hz, 1H), 
6.22 (s, 1H), 5.91 (q, J = 1.3 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 3.77 (s, 3H), 3.76 (br s, 2H), 2.47 
(d, J = 1.3 Hz, 3H), 1.29 (t, J = 7.1 Hz, 3H). 13C-NMR (75 MHz, CDCl3) : 167.1, 157.7, 156.5, 148.1, 
130.0, 123.3, 117.8, 106.7, 98.4, 59.5, 55.3, 19.9, 14.4. HRMS (ESI+) m/z calcd. for C13H18NO3 
[M+H]+ 236.1287, found 236.1292.  
 
N-Boc-(E)-tert-butyl-3-(2-allyloxy-4-amino-phenyl)but-2-enoate (32) and N-Boc-(Z)-tert-butyl-3-
(2-allyloxy-4-amino-phenyl)but-2-enoate (33) 
 
These compounds were synthesized according to a 
modified literature procedure:44 
Primary to use the oil of the 60% NaH on mineral 
oil (567 mg, 14.4 mmol) was removed using 
n-heptane and pentane under schlenk conditions. 
NaH was dissolved in dry THF (50 mL) and 
dimethyl tert-butoxycarbonyl-methylphosphonate (4.0 mL, 14.4 mmol) was added slowly. The mixture 
was stirred for 30 min. whereupon a solution of 20 (900 mg, 3.1 mmol) in dry THF (20 mL) was added 
slowly. The reaction stirred overnight at 55 °C after which it was quenched with H2O (50 mL) and 
extracted with EtOAc (2 × 100 mL). The organic layers were combined and washed with H2O (3 × 
50 mL), brine (50 mL) and subsequently dried over MgSO4. The crude mixture was purified by column 
chromatography (EtOAc/n-heptane, 1:9).  
Analytical data for compound 32 (E-isomer): yellow oil (400 mg, 33%) RF = 0.25 (EtOAc/n-heptane, 
1:9). 1H-NMR (CDCl3, 300 MHz) : 7.22 (s, 1H), 7.06 (d, J = 8.1 Hz, 1H), 6.70 (d, J = 7.6 Hz, 1H), 6.53 
(br s, 1H), 5.99-6.09 (m, 1H), 5.82 (s, 1H), 5.41 (d, J = 17.3 Hz, 1H), 5.26 (d, J = 10.9 Hz, 1H), 4.55 
(d, J = 4.1 Hz, 2H), 2.45 (s, 3H), 1.52 (s, 9H), 1.50 (s, 9H). 13C-NMR (CDCl3, 300 MHz) : 166.4, 
156.1, 154.7, 152.5, 139.6, 132.8, 129.3, 128.1, 120.7, 117.4, 110.1, 102.9, 80.7, 79.7, 69.1, 28.3, 
19.6. FT-IR max film (cm-1): 3732, 3321, 2980, 1696, 1523, 1428, 1364, 1242, 1143. HRMS (ESI+) m/z 
calcd. for C22H31NNaO5 [M+Na]+ 412.2100, found 412.2114. 
Analytical data for compound 33 (Z-isomer): white solid (510 mg, 42%) RF = 0.2 (EtOAc/n-heptane, 
1:9). 1H-NMR (CDCl3, 300 MHz) : 7.20 (s, 1H), 6.91 (d, J = 8.1 Hz, 1H), 6.72 (d, J = 7.8 Hz, 1H), 6.53 
(br s, 1H), 5.95-6.05 (m, 1H), 5.85 (s, 1H), 5.38 (d, J = 17.3 Hz, 1H), 5.23 (d, J = 10.5 Hz, 1H), 4.53 
(d, J = 4.1 Hz, 2H), 2.09 (s, 3H), 1.51 (s, 9H), 1.25 (s, 9H). 13C-NMR (CDCl3, 300 MHz) : 164.9, 
154.5, 152.1, 150.3, 138.4, 132.7, 128.0, 125.2, 120.5, 116.5, 109.6, 102.5, 80.0, 79.0, 68.5, 29.2, 
27.9, 25.5. FT-IR max film (cm-1): 3732, 3321, 2980, 1696, 1523, 1428, 1364, 1242, 1143. HRMS 
(ESI+) m/z calcd. for C22H32NO5 [M+H]+ 390.2281, found 390.2299. 
 
(E)-3-(2-(allyloxy)-4-aminophenyl)but-2-enoic acid (34) 
 
Synthesized according to a modified literature procedure:60  
Compound 32 (350 mg, 0.9 mmol) was dissolved in CH2Cl2 (50 mL) followed 
by the addition of TFA (630 μL, 3.6 mmol) and concentrated HCl (3 drops). The 
reaction was stirred at room temperature for 16 hours. The solvent was 
evaporated and the crude product compound was lyophilized from H2O 
(20 mL) to obtain compound 34 (260 mg, 99%) RF = 0.5 (CH2Cl2/MeOH, 9:1). 1H-NMR (400 MHz, 
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CD3OD) : 7.21 (d, J = 7.8 Hz, 1H), 6.72 (d, J = 1.9 Hz, 1H), 6.68 (dd, J = 8.2, 1.9 Hz, 1H), 6.15-5.99 
(m, 1H), 5.85 (dd, J = 1.3, 0.6 Hz, 1H), 5.42 (ddd, J = 5.0, 3.1, 1.5 Hz, 1H), 5.28 (ddd, J = 9.9, 2.6, 1.4 
Hz, 1H), 4.61 (dd, J = 4.9, 1.4 Hz, 2H), 2.44 (s, 3H). 13C-NMR (75 MHz, CD3OD) : 169.8, 157.8, 
156.3, 135.7, 133.9, 131.2, 130.6, 121.0, 118.1, 115.0, 107.6, 70.5, 20.1. FT-IR max film (cm-1): 3754, 
3304, 2919, 1670, 1532, 1363, 1234, 1139, 620. HRMS (ESI+) m/z calcd. for C13H16NO3 [M+H]+ 
234.1130, found 234.1132. 
 
(E)-3-(2-(allyloxy)-4-aminophenyl) but-2-enoic acid (34) and (Z)-3-(2-(allyloxy)-4-aminophenyl) 
but-2-enoic acid (35)  
 
These compounds were synthesized according to a 
modified literature procedure:60  
Compound 33 (890 mg, 2.3 mmol) was dissolved in THF 
(40 mL) followed by the addition of concentrated HCl 
(2.1 mL, 19 mmol) and TFA (5 drops). The mixture was 
stirred at 40 °C for 5 days. The solvent was evaporated 
and the crude product was lyophilized from H2O (20 mL) to obtain a mixture of compounds 34 and 35 
(550 mg, 99%). An E/Z ratio of 7:3 was obtained according to 1H-NMR analysis.  
Analytical data for compound 34 vide supra. 
Analytical data for compound 35: RF = 0.45 (CH2Cl2/MeOH, 9:1). 1H-NMR (400 MHz, CD3OD) : 7.17 
(d, J = 8.6 Hz, 1H), 7.00-6.85 (m, 2H), 6.12-5.99 (m, 1H), 6.01 (d, J = 1.5 Hz, 1H), 5.47-5.36 (m, 1H), 
5.29-5.23 (m, 1H), 4.59 (dd, J = 4.9, 1.5 Hz, 2H), 2.14 (s, 3H). 13C-NMR (75 MHz, CD3OD) : 168.8, 
156.8, 153.4, 134.9, 133.8, 131.1, 130.5, 120.8, 117.8, 115.8, 108.3, 70.4, 26.2, 20.0. FT-IR max film 
(cm-1): 3754, 3304, 2919, 1670, 1532, 1363, 1234, 1139, 620. HRMS (ESI+) m/z calcd. for C13H16NO3 
[M+H]+ 234.1130, found 234.1129. 
 
General experimental for the isomerization and deprotection of 33 followed by 1H-NMR spectroscopy: 
 
Compound 33 (11.6 mg, 0.03 mmol) was dissolved in THF-d8 (0.5 mL) and TFA and/or HCl (various 
equivalents) were added. The mixture was shortly mixed and directly transferred to an NMR tube. 
NMR spectra were recorded on a Varian Inova 400 MHz NMR spectrometer at 25 °C or 40 °C, 
following a preset time schedule. 
 
N-Fmoc-(E)-3-(2-allyloxy-4-aminophenyl)but-2-enoic acid (36) 
 
Synthesized according to a modified literature procedure:61  
A mixture of compound 34 (386 mg, 1.44 mmol) and pyridine (111.3 μL, 
1.44 mmol) dissolved in CH2Cl2 (50 mL) was stirred for 5 min. at room 
temperature before adding Fmoc-Cl (375 mg, 1.44 mmol). The reaction 
was stirred for 16 hours after which the crude mixture was diluted with 
CH2Cl2 (30 mL) and washed with H2O (2 × 40 mL). The water layers were combined and extracted 
with CH2Cl2 (5 × 50 mL). The organic layers were combined and washed with brine (200 mL) and 
subsequently dried over MgSO4. The crude product was purified by gradient column chromatography 
(EtOAc/n-heptane, 1:4  EtOAc/n-heptane 1:1) to obtain compound 36 as a white solid (320 mg, 
50%) RF = 0.2 (EtOAc/n-heptane, 1/1). 1H-NMR (400 MHz, CDCl3) : 7.82 (d, J = 7.3 Hz, 2H), 7.71 (d, 
J = 7.3 Hz, 2H), 7.41 (t, J = 7.6 Hz, 2H), 7.33 (t, J = 7.3 Hz, 2H), 7.23 (s, 1H), 7.06 (d, J = 8.0 Hz, 1H), 
6.94 (s, 1H), 6.13-5.98 (m, 1H), 5.87 (d, J = 0.9 Hz, 1H), 5.41 (dd, J = 17.4, 1.6 Hz, 1H), 5.25 (dd, J = 
10.6, 1.5 Hz, 1H), 4.56 (dd, J = 14.3, 5.2 Hz, 2H), 4.49 (d, J = 6.9 Hz, 2H), 4.29 (t, J = 6.6 Hz, 2H), 
2.38 (s, 3H). 13C-NMR (75 MHz, CDCl3) : 169.3, 157.9, 156.1, 153.1, 143.6, 141.3, 132.7, 132.3, 
129.3, 127.8, 127.1, 124.8, 120.0, 118.8, 118.1, 117.6, 110.0, 103.1, 69.1, 66.7, 47.1, 20.0. FT-IR max 
film (cm-1): 3330, 3075, 2932, 1692, 1592, 1519, 1402, 1204, 1091, 1005, 741. HRMS (ESI+) m/z 
calcd. for C28H25NNaO5 [M+Na]+ 478.1630, found 478.1626. 
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N-Fmoc-(E)-3-(2-allyloxy-4-aminophenyl)-but-2-enoic acid (36) and N-Fmoc-(Z)-3-(2-allyloxy-4-
aminophenyl)but-2-enoic acid (37)  
 
Synthesized according to a modified literature 
procedure: 61 
A mixture of compound 34 and 35 (ratio 7:3, 
550 mg, 2.1 mmol) was dissolved in CH2Cl2 
(20 mL) and pyridine (193 μL, 2.5 mmol) was 
added. The mixture was stirred for 5 min. after 
which Fmoc-Cl (645 mg, 2.5 mmol) was added and the reaction was stirred for an additional 18 hours. 
The reaction mixture was diluted with CH2Cl2 (20 mL) and washed with H2O (2 × 30 mL). The water 
layers were combined and extracted with CH2Cl2 (5 × 30 mL). The organic layers were combined and 
washed with brine (100 mL) and subsequently dried over MgSO4. The crude product was purified by 
gradient column chromatography (EtOAc/n-heptane, 1:4  1:1  CH2Cl2/MeOH, 9:1) to obtain 
compound 36 as a white solid (350 mg, 37%) and compound 37 as orange oil (150 mg, 16%). 
Analytical data for compound 36: analysis vide supra.  
Analytical data for compound 37: RF = 0.45 (MeOH/CH2Cl2, 1:9). 1H-NMR (400 MHz, CD3OD) : 7.79 
(d, J = 7.5 Hz, 2H), 7.69 (d, J = 7.4 Hz, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.31 (t, J = 7.4 Hz, 2H), 7.19 
(s, 1H), 6.93 (br s, 2H), 6.11-5.95 (m, 1H), 5.92 (s, 1H), 5.37 (dd, J = 17.0, 1.4 Hz, 1H), 5.20 (dd, J = 
10.5, 1.5 Hz, 1H), 4.48 (d, J = 4.9 Hz, 2H), 4.5 (d, J = 6.80 Hz, 2H), 4.3 (t, J = 6.7 Hz, 2H), 2.1 (s, 3H). 
13C-NMR (75 MHz, CD3OD) : 169.7, 156.9, 155.7, 154.2, 145.3, 142.7, 140.8, 134.7, 129.6, 128.9, 
128.2, 126.5, 126.2, 121.0, 120.1, 117.3, 111.7, 104.5, 70.1, 67.8, 30.7, 26.6. FT-IR max film (cm-1): 
3330, 3075, 2932, 1692, 1592, 1519, 1402, 1204, 1091, 1005, 741. HRMS (ESI+) m/z calcd. for 
C28H25NNaO5 [M+Na]+ 478.1630, found 478.1594. 
 
(E)-3-(2-(allyloxy)-4-(2,2,2-trifluoroacetamide)phenyl)but-2-enoate (39) 
 
Synthesized according to a modified literature procedure:62 
Compound 34 (120 mg, 0.5 mmol) was dissolved in THF (5 mL) followed 
by the addition of TFAA (192 μL, 0.55 mmol). The reaction was stirred for 
30 min. at room temperature after which it was diluted with EtOAc (20 mL) 
and washed with H2O (3 × 20 mL) and brine (20 mL) and subsequently 
dried over MgSO4. The solvents were evaporated under reduced pressure to afford compound 39 
(180 mg, 99%) RF = 0.5 (CH2Cl2/MeOH, 9:1). 1H-NMR (CD3OD, 400 MHz) : 7.44 (s, 1H), 7.16-7.25 
(m, 2H), 6.14-6.01 (m, 1H), 5.87 (s, 1H), 5.43 (d, J = 17.4 Hz, 1H), 5.29 (d, J = 10.5 Hz, 1H), 4.59 
(d, J = 5.2 Hz, 2H), 2.45 (s, 3H). 13C-NMR (75 MHz, CD3OD) : 170.0, 157.1, 157.0, 156.3, 139.0, 
134.2, 132.0, 130.2, 127.0, 120.6, 118.0, 115.5, 114.1, 106.7, 70.3, 20.2. 19F-NMR (282 MHz, CD3OD) 
: -77.23. FT-IR max film (cm-1): 3283, 2933, 1714, 1689, 1601, 1537, 1498, 1174. HRMS (ESI+) m/z 
calcd. for C15H15F3NO4 [M+H]+ 330.0953, found 330.0966. 
 
(E)-3-(2-Hydroxy-4-(2,2,2-trifluoroacetamide)phenyl)but-2-enoate (40) 
 
Synthesized according to a modified literature procedure:63 
Compound 39 (20 mg, 0.06 mmol) was dissolved in MeOH (2 mL) and 
Pd(PPh3)4 (3.72 mg, 0.006 mmol) was added. After stirring 5 min., K2CO3 
(49.5 mg, 0.36 mmol) was added and the resulting mixture was stirred for 
an additional 1.5 hours. 2 M HCl was added until a pH of 6 was reached 
after which the mixture was diluted with EtOAc (20 mL). The organic layer was washed with H2O (3 × 
10 mL) and brine (10 mL) and subsequently dried over MgSO4. The crude product was purified by 
column chromatography (initially EtOAc/n-heptane, 1:4; then CH2Cl2/MeOH, 9:1) to obtain compound 
40 as a yellow solid (5 mg, 30%) RF = 0.3 (CH2Cl2/MeOH, 9:1). 1H-NMR (300 MHz, CD3OD) : 7.36 
(d, J = 2.0 Hz, 1H), 7.13 (d, J = 8.3 Hz, 1H), 7.02 (dd, J = 8.3, 2.1 Hz, 1H), 5.93 (d, J = 1.1 Hz, 1H), 
2.46 (d, J = 1.4 Hz, 3H). 13C-NMR (75 MHz, CD3OD) : 171.0, 156.4, 156.1, 138.7, 130.3, 129.8, 
120.8, 119.3, 113.0, 109.6, 19.8. 19F-NMR (282 MHz, CD3OD) : -77.20. FT-IR max film (cm-1): 3278, 
2902, 1841, 1709, 1562, 1208, 1160, 607. HRMS (ESI+) m/z calcd. for C12H10F3NNaO4 [M+Na]+ 
312.0460, found 312.0433. 
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General methods for resin loading 
 
Wang-OH resin: 
To a solution of compound 36 (20 mg, 0.042 mmol) in dry DMF (6 mL) was added DMAP (5.1 mg, 
0.042 mmol), Wang-OH resin (20 mg, 0.9-1.2 mmol/g) and EDC·HCl (16.8 mg, 0.084 mmol). The 
reaction was shaken for 16 hours at room temperature after which the remaining unfunctionalized 
end-groups were capped via the addition of acetic acid anhydride (7.9 μL, 0.084 mmol) and piperidine 
(8.3 μL, 0.084 mmol) and an additional 30 min. stirring at room temperature.  
 
Wang-Br resin: 
To a solution of compound 36 or 37 (100 mg, 0.21 mmol) in dry DMF (5 mL) was added CsI (114 mg, 
0.44 mmol), DiPEA (160 μL, 0.92 mmol) and Wang-Br resin (400 mg, 1.6 mmol/g). The mixture was 
shaken for 16 hours after which MeOH (1 mL) and DiPEA (800 µL, 4.8 mmol) were added and the 
mixture was shaken for 30 min. in order to cap the unfunctionalized end-groups of the Wang-Br resin. 
 
Resin loading was calculated via equation 1 where Abssample is the absorption of the sample at 
290 nm, Absref is the absorption of 20% piperidine in DMF at 290 nm, m is the mass of the weighed 
resin and loadmeas is the loading. The theoretical loading (loadtheor) of the resin can be determined via 
equation 2. This theoretical loading differs per step since the mass of the resin changes during 
synthesis, therefore the calculation of loadtheor needs to be performed for each step.64 In this equation 
loadin is the initial theoretical loading and ΔMw is the molecular weight gain in g/mmol. The yield of the 
coupling can then be determined via equation 3. 
 
m

 1.65
AbsAbs
load refsamplemeas   Equation 1 
 
 inwintheor loadΔM1
1loadload   Equation 2 
 
100%
load
loadY
theor
meas   Equation 3 
 
For example the theoretical loading of the Wang-Br resin with compound 36: 
loadin = 1.60 mmol/g, MW 36 = 455.17 g/mol, MW Br = 78.92 g/mol and ΔMw = 376.25 g/mol. So the 
mass difference per mmol is thus 0.376 g. Substitution into equation 2 results in a theoretical loading 
of 1.0 mmol/g.   
 
 6.1760.31
16.1loadtheor   
 
In addition elemental analysis was performed on a resin measuring the percentage of nitrogen 
present. The loading was determined according to equation 4, where pn was the measured percentage 
of nitrogen and Mn is the molar mass of nitrogen. 
 
n
n
M100
1000pL 
  Equation 4 
 
N-Fmoc-(L)-Ala-(2-allyloxy-4-aminophenyl-but-2-enoic acid (45) 
 
Compound 58 was synthesized by standard solid-phase methods 
using a Wang-Br resin.51 Compound 36 (100 mg, 0.21 mmol), CsI 
(114 mg, 0.44 mmol) and DiPEA (160 μL, 0.96 mmol) were mixed 
with Wang-Br resin (400 mg, 1.6 mmol/g). The mixture was shaken 
for 16 hours after which MeOH (1 mL) and DiPEA (800 µL, 
4.8 mmol) were added and the mixture was shaken for 30 min. in 
order to cap the unfunctionalized end-groups of the Wang resin. The resin was filtered and washed 
repeatedly with DMF (5 × 5 mL), H2O (2 × 5 mL), MeOH (3 × 5 mL) and CH2Cl2 (5 × 5 mL). The 
ON
H
O
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loading of the resin was determined via an Fmoc-test (0.37 mmol/g (37%)). Subsequently a solution of 
piperidine in DMF (20% (v/v), 5 mL) was added and the mixture was shaken for 30 min. to remove the 
Fmoc protecting group. The resin was filtered and washed with DMF (5 × 5 mL) whereupon Fmoc-Ala-
OH (185 mg, 0.6 mmol), 1 M HOBt in DMF (810 µL, 0.81 mmol) and 1 M DIPCDI in DMF (720 µL, 
0.72 mmol) were added. This mixture was shaken for 16 hours. The reagents were filtered off and the 
resin was repeatedly washed with DMF (5 × 5 mL), H2O (2 × 5 mL), MeOH (3 × 5 mL) and CH2Cl2 (5 × 
5 mL). The loading of the resin was determined via an Fmoc-test (0.50 mmol/g (57%)). The 
functionalized resin (100 mg) was subsequently shaken in a mixture of TFA/TiPS/ethane dithiol/H2O 
(95:2.5:2.5:2.5, 1 mL) to cleave the product from the resin. The crude product was purified using 
column chromatography (initially EtOAc/n-heptane, 1:1, then CH2Cl2/MeOH, 9:1) to obtain 45 as a 
yellow oil (5 mg, 25%) RF = 0.15 (CH2Cl2/MeOH, 1:1). 1H-NMR (400 MHz, CD3OD) : 7.79 (d, J = 
7.2 Hz, 2H), 7.68 (t, J = 7.7 Hz, 2H), 7.38 (t, J = 7.2 Hz, 2H), 7.31 (d, J = 6.2 Hz, 2H), 6.70 (d, J = 
8.4 Hz, 1H), 6.37-6.35 (m, 1H), 6.28 (dd, J = 8.3, 2.2 Hz, 1H), 6.20-5.96 (m, 1H), 6.08 (s, 1H), 5.24 
(dd, J = 11.7, 3.9 Hz, 2H), 4.55 (d, J = 4.7 Hz, 2H), 4.51 (t, J = 5.3 Hz, 1H), 4.38 (d, J = 7.2 Hz, 1H), 
4.23 (dd, J = 13.6, 5.8 Hz, 2H), 2.43 (d, J = 1.2 Hz, 3H), 1.40 (d, J = 7.1 Hz, 3H). LRMS (ESI+) calcd. 
for C31H31N2O6 [M+H]+ 527.22, found 527.20. 
 
N-Fmoc-(L)-Ala-AMC (48) 
 
Compound 48 was synthesized by standard solid-phase methods 
described for compound 45. The functionalized Wang resin (100 mg, 
loading: 0.50 mmol/g) was loaded into a high pressure vial and 
suspended in CH2Cl2 (3 mL). After the addition of PhSiH3 (50 µL, 
0.40 mmol) and Pd(PPh3)4 (8 mg, 0.007 mmol) the vessel was capped 
and the mixture was shaken for 30 min. The resin was washed with CH2Cl2 (5 × 5 mL), H2O (3 × 
5 mL), MeOH (3 × 5 mL) and again with CH2Cl2 (5 × 5 mL). The resin was subsequently shaken in a 
mixture of TFA/TiPS/ethane dithiol/H2O (95:2.5:2.5:2.5, 2 mL) to cleave the product from the resin. 
The crude product was purified by column chromatography (EtOAc/n-heptane, 1:1) to obtain 48 as 
yellow oil (3 mg, 16%) RF = 0.15 (EtOAc/n-heptane, 1:1). 1H-NMR (400 MHz, CDCl3) : 8.82 (br s, 1H), 
7.76 (d, J = 7.5 Hz, 2H), 7.66 (d, J = 1.5 Hz, 1H), 7.58 (d, J = 7.5 Hz, 2H), 7.47 (t, J = 10.9 Hz, 2H), 
7.39 (t, J = 7.6 Hz, 2H), 7.29 (t, J = 7.2 Hz, 2H), 6.19 (s, 1H), 5.42 (br s, 1H), 4.49 (d, J = 7.3 Hz, 2H), 
4.41 (br s, 1H), 4.22 (t, J = 6.9 Hz, 1H), 2.40 (s, 3H), 1.48 (d, J = 7.0 Hz, 3H). HRMS (ESI+) m/z calcd. 
for C28H25N2O5 [M+H]+ 469.1764, found 469.1760.  
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CuAAC Chemistry as a Tool in the Synthesis of  
a Macrocyclic Coumarin-Containing Tripeptide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
 
A convergent synthesis of a cyclic peptide substrate is described for the quantitative fluorescence 
determination of thrombin generation. To this end, a bifunctional amino- and azidomethylene-
functionalized coumarin was synthesized and coupled to Boc-protected arginine. A pair of dipeptide 
fragments was prepared by introduction of an alkyne-bearing substituent at the N-terminus of a Gly-
Pro peptide fragment. Subsequent condensation of either of the alkyne-functionalized dipeptides to 
the Arg-AAMC fragment resulted in linear precursors for macrocyclization. Solution phase copper-
catalyzed 1,3-dipolar cycloaddition was employed for the macrocyclization resulting in cyclo-[-Gly-Pro-
Arg-AMC-[triazole]- spacer-]. Kinetic parameters KM and kcat were determined for the cyclic peptide 
and compared to the previously synthesized linear peptide H-Gly-Pro-Arg-AMC, showing a decreased 
binding affinity and a comparable rate of hydrolysis. 
 
 
5 
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5.1 Introduction 
 
 
Cyclic peptides form an interesting lead for drug discovery due to their conformational strain which 
generally results in increased metabolic stability, selectivity and biological activity.1,2,3,4 In the field of 
research centered around thrombosis, macrocyclic structures also gained the interest of scientists with 
the discovery of macrocyclic thrombin inhibitors. Cyclotheonamide A and B (Ct A and Ct B, Figure 5.1) 
were the first macrocyclic thrombin inhibitors found,  obtained from a Japanese marine sponge of the 
genus Theonella.5 After a few years the stereochemistry was reassigned as a result of the first total 
synthesis described by Schreiber et al.6 After the discovery of these potent thrombin inhibitors several 
papers described the total synthesis7,8,9 or analogues10,11 of Ct A and Ct B.  
 
 
 
Figure 5.1 Structures of cyclotheonamide A and B (1 and 2, respectively), analogues of 
cyclotheonamide (3 a-j, n = 3-8, X = O or H/OH and R = Ph or Bz) and non-natural cyclic thrombin 
inhibitors (4 and 5). 
 
The potency of cyclic thrombin inhibitors12 prompted several groups to explore the biological activity of 
non-natural cyclic compounds as thrombin inhibitors.13,14,15 The main difficulty in the synthesis of 
macrocyclic inhibitors is the cyclization reaction.16 For penta- and especially tetrapeptides the 
cyclization of the native L-configured linear precursors is known to be extremely difficult. Various 
methods for macrocyclization, such as lactonization or lactam formation,17 disulfide formation,18 ring-
closing metathesis19,13b or cyclization with the use of auxiliaries20 have been reported. 
With the introduction of the copper-catalyzed variant of the Huisgen 1,3-dipolar cycloaddition,21,22 also 
referred to as copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction, a versatile and mild 
ligation method was established which rapidly found application in various fields of chemistry.23 The 
CuAAC reaction has had a particularly great impact on peptidomimetics.24 Studies have shown that a 
1,2,3-triazole can be a suitable mimic for an amide bond in peptides25, moreover, the obtained 
1,4-connected 1,2,3-triazole ring can serve as a β-turn mimic.26 Recently, the CuAAC has been 
applied as a tool for macrocyclization both in solution27 and on solid phase.28  
A method for measuring the effect of thrombin inhibitors on the haemostatic system is the thrombin 
generation test (TGT) devised by Hemker et al.29 Substrates used in the thrombin generation test are 
frequently linear, flexible, tripeptides bearing a C-terminal fluorophore (AMC). Upon amide hydrolysis 
by thrombin, the fluorophore is released thereby providing a direct measure for the thrombin activity. In 
Chapter 3, we described the extremely rapid hydrolysis of peptide H-Gly-Pro-Arg-AMC in the thrombin 
active site. For the thrombin generation test, however, slow reacting substrates are required for 
accurate and prolonged measurements. Thrombin has two peptide loops located on the surface 
around the active site. These two loops, the insert loop and the autolysis loop,30 restrict access of 
macromolecular substrates to the relatively deep active site of thrombin.11 We reasoned that 
constraining the linear peptide H-Gly-Pro-Arg-AMC in a more bulky macrocyclic conformation might 
hamper entry into the thrombin active site as a result of the steric repulsion by the two peptide loops. 
Macrocylization of the tripeptide could therefore decrease the affinity of the substrate for the binding 
pocket of thrombin resulting in improved kinetic parameters (higher KM and lower kcat) suitable for 
thrombin generation testing. The use of click chemistry as an efficient cyclization method was 
envisioned for constructing the cyclic version of the linear peptide H-Gly-Pro-Arg-AMC. Apart from 
kinetic parameters improvement, the cyclic peptide might also play an important role in retaining the 
solubility of AMC in physiological media. The moderate solubility of AMC in aqueous solutions was 
found to interfere with the accurate assessment of enzyme activities as a result of fluorescent 
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quenching. Furthermore, liberated AMC can act as a competitive inhibitor of thrombin at higher 
concentrations.31 Several methodologies have been developed in order to increase the solubility of 
AMC, i.e. synthesis of coumarins containing water-solublizing functionalities32,33 or incorporation of the 
fluorophore in-between two peptide fragments.34,35 We envisaged the integration of the fluorophore in 
a cyclic structure as a new methodology to overcome the poor solubility of AMC in physiological 
media. Since the hydrolysis of the Arg-AMC bond will not liberate AMC as a result of the triazole 
linkage to the tripeptide backbone, precipitation and undesired competitive inhibition of AMC is 
expected to be prevented.  
 
 
5.2 Design and synthesis of macrocyclic Gly-Pro-Arg-AMC 
 
 
Two macrocyclic thrombin-specific substrates 6a and 6b were envisioned as depicted in Scheme 5.1. 
Compounds 6 contain a tripeptide motif, a coumarin fluorophore, an alkyl spacer and a triazole moiety.    
 
 
 
Scheme 5.1 Retrosynthesis of cyclo-[-Gly-Pro-Arg-AMC-[triazole]-spacer-] (6) 
 
Retrosynthetic analysis of 6 leads to the linear peptides (7), containing both an alkyne and an azide, 
the requisite functionalities for the proposed macrocyclization step by copper-catalyzed azide-alkyne 
cycloaddition. Optimal convergency of the route is obtained by splitting the linear peptide into a 
coumarin-functionalized arginine residue (8) and an alkyne-containing Gly-Pro peptide (9a or 9b). For 
coupling of an alkyne tail to the Gly-Pro peptide unit, a methylene-linked, more rigid, alkyne chain was 
envisaged, as well as a more flexible O-containing alkyne chain. The arginine residue is attached to 
an aminocoumarin decorated with an azide functionality at the methylene position. Due to the fact that 
there is no commercial source for this 7-amino-4-azidomethylenecoumarin (AAMC, 14) we devised a 
synthetic route as described in the next section.  
 
    
5.2.1 Synthesis of AAMC and Arg-AAMC 
 
The H-Arg-AAMC fragment was the first synthon required for the synthesis of the cGPR-AMC peptide. 
Unlike 7-amino-4-methyl-coumarin (AMC), 7-amino-4-azidomethylene-coumarin (AAMC, compound 
14 in Scheme 5.1) is not commercially available and therefore a synthetic route was devised. 
Methodologies, such as the Lewis acid catalyzed Pechmann condensation36 and microwave-assisted 
Pechmann cyclizations37,38 are frequently employed in the synthesis of coumarins. Starting from 3-
Chapter 5 
 128
aminophenol both the Lewis acid-catalyzed and the microwave-assisted Pechmann condensation 
were explored in order to obtain amino-chloromethylcoumarin 12 (ACMC). A protective group was 
found to be requisite, since direct Pechmann condensation of 3-aminophenol under a variety of 
conditions turned out to be fruitless. Therefore, the amine functionality of 3-aminophenol was 
protected with five different protecting groups, in reasonable to good yields, as depicted in Table 5.1.  
 
H2N OH NH
OH N
H
O O
Cl
OH2N O
Cl
10 a-e 11 a-e 12
i ii iii
PG PG
 
 
Table 5.1 Synthesis of 7-amino-4-chloromethylenecoumarin 12 
Entry PG 10 Yield (%) 11 Yield (%) 12 Yield (%) 
a Fmoc 83 5 NP 
b Bz 41 - NP 
c Cbz 51 - NP 
d EtO2C 54 70 - 
e MeCO 99 20 72 
NP = not performed; - = no reaction; i = acid chloride or acetic anhydride, base, solvent, various conditions; ii = ethyl 4-
chloro-acetoacetate, strong acid, various conditions; iii = various conditions. 
 
Since the projected next step was an acid-catalyzed Pechmann condensation, the protecting group 
needed to be compatible with acid. The protected aminophenol derivatives 10a-e were subsequently 
subjected to the Pechmann condensation reaction,39 typically involving stirring in a 60% solution of 
sulfuric acid. For Fmoc-protected aminophenol 10a, a disappointing 5% yield after 18 days of stirring 
at room temperature was obtained. Elevated temperatures did not significantly improve the rate of 
conversion but led to formation of by-products. Addition of co-solvents such as diethyl ether or THF 
resulted in full consumption of the starting materials but without formation of the desired coumarin. 
Both the benzyl- (10b) and carbobenzyloxy- (10c) protected m-aminophenol did not give the desired 
product either under the conditions mentioned above.  
 
Gratifyingly, condensation of N-ethoxycarbonyl-3-aminophenol (10d) with ethyl 4-chloroaceto-acetate 
in 60% sulfuric acid gave coumarin 11d in a satisfactory yield (70%) after precipitation from ice-water. 
Lastly, N-acetyl-protected aminophenol 10e was cyclized to form chlorocoumarin 11e, but despite 
complete disappearance of the starting material, the desired product was obtained in a moderate yield 
(20%).  
 
Deprotection of compound 11d was considered to be straightforward as numerous literature 
procedures describe the cleavage of N-ethyl carbamates with a variety of bases at elevated 
temperature.40  However, several reaction conditions were explored (Table 5.2) affording mostly 
mixtures of unidentifiable compounds, since compound 11d showed high intolerance toward 
nucleophilic bases. In some cases treatment with a hydroxide base gave modest amounts of 
4-hydroxymethylenecoumarin as a result of nucleophilic substitution of the chloride (entries 2 and 4). 
An alternative deprotecting method is hydrolysis with TBAF.41 Treatment of compound 11d with an 
excess of TBAF at room temperature or elevated temperatures (Table 5.2, entries 6 and 7) did not 
result in product formation, instead, only starting material was recovered.  
 
Due to the fact that deprotection of the N-ethyl carbamate coumarin remained futile, formation of 
AAMC 14 was pursued by deprotection of the N-acetylcoumarin. According to literature the acetyl 
protecting group is readily cleaved under acidic conditions.42 Analogously, deprotection of compound 
11e with hydrochloric acid in 2-propanol at elevated temperatures produced 7-amino-4-chloromethyl-
coumarin (12) in good yield (72%). 
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Table 5.2 Conditions for N-ethyl carbamate deprotection of compound 11da 
Entry Reagents Temp. Time S D/U B 
1 10 M NaOH 120 °C 16 h    
2 1 M NaOH, THF  r.t. 16 h    
3 K2CO3, MeOH r.t. 2 d    
4  2 M LiOH, THF  r.t. 3 d    
5 KOH in MeOH 70 °C 16 h    
6 TBAF in THF (5 equiv) 80 °C 5 h    
7 TBAF in THF (5 equiv) r.t. 16 h     
a Test-reactions, yield = ND. S = Starting material; D/U = decomposition/unidentifiable material; B = by-product.  
 
The last step in the synthesis of AAMC was nucleophilic displacement of the chloride by an azide. 
Various reaction conditions were explored using N-ethoxycarbonyl-4-chloromethyl-coumarin (11d) as 
a test substrate (Table 5.3). The similarity in polarity of the product azidocoumarin and the starting 
material required full conversion as separation was impossible. Furthermore, purification difficulties of 
the products demanded a clean conversion and minimization of by-product formation.  
 
Table 5.3 Reaction conditions for the transformation for both compound 11d and 12 into 
azidomethylcoumarin 
Entry 
 
Compound 
 
Temp. 
(°C) 
Time 
(hours) 
Solvent 
 
NaN3 
(equiv) 
P 
(%)a 
S  
 
B 
 
1b 11d 20 16 MeCN 2.1       
2 11d 20 48 MeCN 1.2     
3 11d 60 16 MeCN 1.2     
4c 11d 20 72 MeCN 1.0     
5 11d 20 16 mix A 1.2    
6 11d 80 16 mix A 1.0     
7 11d 20 16 Dioxane 2.0      
8 11d 20 16 DMF 1.2     
9 11d 20 3 NMP 2.0      
10 11d 0 → 20 16 DMF 1.2 85     
11 11d 0 → 20 2 NMP 1.2 82     
12 12 0 → 20 2 NMP 1.2     
13 12 20 16 mix B 5.0 70   
14 12 20 32 mix C 5.0 95   
a Isolated yields; b Additive: CF3SO2Cl; c Additive: LiI; mix A = H2O/Acetone (1:1), mix B = H2O/MeCN (1:1), mix C = 
MeCN/Acetone (1:1); P = product, S = starting material and B = by-products  
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Entries 1-4 in Table 5.3 show the substitutions performed in acetonitrile (varying time, temperature, 
and equivalents of NaN3) resulting in formation of compound 15. However, under these conditions 
considerable amounts of starting material remained present and/or by-products were formed (not 
identified). Changing the solvent to a mixture of H2O/acetone (mix A) at elevated temperatures (entries 
5 and 6) gave full conversion of the starting material, although an increased amount of by-products 
was found. The use of either DMF or NMP (entries 8 and 9, respectively) resulted in complete 
conversion of the starting material and only minute quantities of by-product. By-product formation was 
completely suppressed by addition of sodium azide at 0 °C, generating the product in high yield (82%, 
entry 11, Table 5.3). The reaction could also be performed in DMF (entry 10, Table 5.3), however, 
requiring a prolonged reaction time.  
Under the optimal conditions for chloride substitution (Table 5.3, entry 11), 7-amino-4-chloro-
methylenecoumarin 12 was transformed to 7-amino-4-azidomethylcoumarin 14 (Table 5.3, entry 12). 
Unexpectedly, NMP turned out not to be the ideal solvent, since considerable by-product formation 
was again observed. Therefore, two other solvent mixtures were explored (mix B and C, entries 13 
and 14, respectively). Eventually it was found that stirring coumarin 12 with five equivalents of sodium 
azide in a mixture of acetonitrile and acetone (mix C) produced the key intermediate 7-amino-4-
azidomethylcoumarin (14) in an excellent yield (95%, Table 5.3, entry 14). 
 
A second pathway towards key intermediate 7-amino-4-azidomethylcoumarin (14) involved a reversed 
order of deprotection and substitution (Scheme 5.2), i.e. first azide substitution followed by acetyl 
removal. Thus, conversion of acetylated compound 11e into azidocoumarin 13 was performed using 
the same procedure as described for the N-ethoxycarbonyl-protected coumarin (Table 5.3, entry 11). 
Next, deprotection of azidocoumarin 13 afforded 7-amino-azidomethylcoumarin (14) in a good yield 
(66%, Scheme 5.2), although more by-products were observed compared to acetyl deprotection of N-
acetyl-7-amino-4-chloromethylcoumarin (11e). Therefore, the most straightforward synthetic route 
towards 7-amino-4-azidomethyl-coumarin (14) is the sequence involving deprotection prior to 
substitution. 
 
 
Scheme 5.2 Two complementary synthetic pathways for the synthesis of 7-amino-4-azidomethyl-
coumarin (AAMC). 
 
 
 
Scheme 5.3 Synthesis of synthon H-Arg-AAMC (8) using AAMC (14). 
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Finally, the fluorescent probe AAMC (14) was coupled to Boc-protected arginine leading to Boc-Arg-
AAMC (16, Scheme 5.3). Coupling was performed via a mixed anhydride intermediate of the arginine 
carboxylic acid and phosphoryl chloride. Purification of the product with silica-based column 
chromatography was impossible due to the high affinity of the polar guanidine function of arginine for 
silica gel. Counter-current chromatography proved to be an efficient technique, Boc-Arg-AAMC (16) 
was obtained in a reasonable yield (41%). Subsequent Boc-deprotection of compound 17 using 
trifluoroacetic acid in dichloromethane afforded the first synthon 8. 
 
 
5.2.2 Synthesis of C- and O-linked alkyne-functionalized Gly-Pro  
 
The copper-catalyzed 1,3-dipolar cycloaddition macrocyclization requires both an azide and an 
acetylene functionality. Having synthesized the azide-functionalized synthon 8, next two acetylene-
containing dipeptides (synthons 9a and 9b) were prepared.  
 
Scheme 5.4 3-Butynyloxycarbonyl-containing glycine-proline fragment.  
 
Synthesis of synthon 9a (Scheme 5.4) commenced with coupling of 3-butyn-1-yl chloroformate to 
unprotected glycine. The pH was kept between 9.5 and 10.5 to prevent undesired polymerization. 
After acid-base extraction, N-butynyloxycarbonylglycine 17 was obtained in excellent yield (95%). 
Next, coupling of L-proline methyl ester to 17 was performed under standard peptide coupling 
conditions, to afford N-butynyloxycarbonyl-Gly-Pro-OMe (18) in reasonable yield (64%). Finally, 
hydrolysis of the methyl ester gave the desired synthon N-butynyloxycarbonyl-Gly-Pro-OH (9a) in 
good yield (70%).  
 
Scheme 5.5 Hexynoyl containing glycine-proline fragment. 
 
For the synthesis of synthon 9b (Scheme 5.5), peptide coupling of glycine methyl ester with hexynoic 
acid was followed by hydrolysis of the methyl ester 19, to give compound 20 in good yield (77%). A 
second peptide coupling reaction was performed to link proline tert-butyl ester to the N-
hexynoylglycine fragment 20, resulting in smooth formation (97% yield) of N-hexynoyl-O-tert-butyl-
proline-glycine 21. The last step involved acid-catalyzed saponification of the tert-butyl ester to afford 
synthon 9b in excellent yield (99%). 
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With key intermediates (8 and 9a/b) in hand, the coupling of these fragments was required to obtain 
linear peptides 7a and 7b (Scheme 5.6). To this end, coupling reactions were performed utilizing EDC, 
HOBt and DMAP. Coupling of N-butynyloxycarbonyl-Gly-Pro-OH (9a) to H-Arg-AAMC (8) gave N-
butynyloxycarbonyl-Gly-Pro-Arg-AAMC (7a) in a rather low yield (24%). Coupling of N-hexynoyl-Gly-
Pro-OH (9b) and H-Arg-AAMC (8) proceeded slightly better as N-hexynoyl-Gly-Pro-Arg-AAMC (7b) 
was obtained in a yield of 54% after purification with counter-current chromatography. 
 
 
 
Scheme 5.6 Coupling of synthons resulting in the linear peptides 7a and 7b 
 
 
5.2.3 Macrocyclization via Cu-catalyzed azide-alkyne cycloaddition 
 
The most challenging step in the synthesis of cyclo-[-Gly-Pro-Arg-AMC-[triazole]-spacer-] was the 
intramolecular Cu(I)-catalyzed 1,3-dipolar cyclo-addition reaction (Scheme 5.7).  
  
 
 
Scheme 5.7. Macrocyclization of linear precursors 7a and 7b via an intramolecular azide-alkyne 
cycloaddition reaction. 
 
Several methods for copper-catalyzed macrocyclization are known in literature (vide supra). However, 
since we anticipated that the elevated temperatures often employed could result in decomposition of 
compounds 7a and 7b, attention was focused on intramolecular azide-alkyne cycloaddition under mild 
conditions.43 Reactions were performed under high dilution (< 0.001 M) and at relatively low 
temperatures (Table 5.4). First, the 1,3-dipolar cycloaddition under the action of copper(I) bromide and 
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in toluene gave multiple products, though not the desired 
one (entry 1). When CuSO4 was used in combination with sodium ascorbate in a solvent mixture of 
butanol/water again multiple products were formed, including the desired cyclic product (entry 2). 
Identification of the crude products with 1H-NMR spectroscopy was complicated due to complexation 
of copper ions to the guanidine moiety giving rise to broadening of the signals. A convenient way to 
get around this problem involves pressure-promoted cycloaddition without copper.44 Consequently, a 
high pressure experiment was performed (Table 5.4, entry 3), but unfortunately a variety of products 
were formed. The use of copper-wire activated by Et3N (entry 4) required prolonged heating, leading 
to product formation as well as by-product formation. Macrocyclization reactions performed with 
compound 7b proceeded more successfully, giving clean conversions to the desired product 6b 
according to TLC analysis (entries 5 and 6). However, the unprotected side-chain of arginine again 
hindered purification and thus isolation of the product.  
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Table 5.4 Copper catalyzed macrocyclization reactions with linear peptides 7a and 7ba 
Entry Compound Conditions Time Temp S P B 
1 7a CuBr, DBU, toluene 48 h 40 °C    
2 7a CuSO4, Na-Asc., tBuOH/H2O 16 h 40 °C    
3 7a DMFb 5 d 50 °C    
4 7a Cu-wire, Et3N, MeOH/MeCNc 7 d 65 °C    
5 7b CuI, TBTAd, Et3N, DMF 18 h 40 °C    
6 7b Cu-wire, Et3N, MeCN 18 h 40 °C    
a Test-reactions, yield = ND. b Reaction performed at 15 kPa, no additives, c Ref 45, d TBTA = tris-(benzyltriazolylmethyl) 
amine, S = starting material, P = product, B = by-product 
 
 
Considering the basic character of the guanidine moiety, it is not unlikely that the copper-catalyzed 
process is significantly hampered by the affinity of copper-ions for basic amines. Therefore, Boc-
protection of the guanidine was performed prior to macrocyclization (Scheme 5.8). Addition of four 
equivalents of di-tert-butyl dicarbonate resulted in the formation of multiple products (mono-, di- and 
trisubstituted guanidine), of which the bis Boc-protected compound 22 appeared to be the major 
product (50%). 
 
 
 
Scheme 5.8 Guanidine protection, macrocylization and deprotection strategy to obtain cyclo-[Gly-Pro-
Arg-AMC-[triazole]-spacer-] (6b). 
 
A series of test reactions for intramolecular 1,3-dipolar cycloaddition of compound 22 were performed 
in different deuterated solvents to monitor the appearance of a triazole proton. Potential dimer or 
trimer formation was checked by mass spectrometry. Thus, reaction of compound 22 in the presence 
of a CuBr/PMDETA complex (10 equiv) at 35 °C in DMSO-d6 during 14 hours afforded a minor triazole 
peak as observed by 1H-NMR spectroscopy. In contrast, TLC-analysis showed full conversion and 
according to mass spectroscopy no dimers or trimers were formed. When the same reaction was 
performed in deuterated THF or DMF, no triazole peak was observed. Moreover, TLC-analysis of the 
reaction in DMF showed significant by-product formation. In THF, after 14 hours, TLC-analysis 
showed approximately 50% conversion and no dimer or trimer formation was detected by mass 
spectrometry. Therefore, macrocyclization was performed on a larger scale in THF at 40 °C for 7 
hours. After preparative TLC, cyclo-[-Gly-Pro-Arg-AMC-[triazole]-spacer-] (23) was obtained (23%). In 
the last step, the Boc-protecting groups were removed to provide the final product 6b in quantitative 
yield. 
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5.3 Biological evaluation of cyclo-[-Gly-Pro-Arg-AMC-[triazole]-
spacer-]  
 
 
A general method to determine the kinetic parameters KM and kcat was described in Chapter 3. As a 
result of the rapid substrate consumption by activated thrombin, a slightly modified procedure was 
used to determine the kinetic constants for the linear peptide 24 and the cyclic peptide 6b (Figure 5.2).  
 
 
 
Figure 5.2 Hydrolysis of linear peptide H-Gly-Pro-Arg-AMC (24) by thrombin resulting in H-Gly-Pro-
Arg-OH and AMC and hydrolysis of cyclo-[-Gly-Pro-Arg-AMC-[triazole]-spacer-] (6b) results in 25. 
 
In brief, kinetic parameters were determined by monitoring the fluorescence increase in time as a 
result of the hydrolysis of the arginine-coumarin bond. The fluorescence counts were subsequently 
converted to AMC concentrations using a calibration curve. Plotting of the calculated AMC 
concentration versus time gave curves as depicted in Graph 5.1A.  
 
Graph 5.1 A) Normalized plots of the hydrolysis of the linear and cyclic peptide at a substrate 
concentration of 600 μM where (▲) = linear peptide (24), conc. FIIa = 1.04 μM and (♦) = cyclic peptide 
(6b), conc. FIIa = 0.50 μM; B) Determination of kinetic parameters for cyclic peptide (6b) from 
Michaelis-Menten plot.  
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While complete substrate consumption was observed after approximately 3 minutes for the linear Gly-
Pro-Arg peptide, complete substrate consumption for the cyclic Gly-Pro-Arg peptide required more 
than 10 minutes. The curves did not allow linear regression processing so that the initial rate constants 
were determined via non-linear regression by fitting of the data to a 6th order polynomial. 
 
  
Graph 5.2 Determination of kinetic parameters for H-Gly-Pro-Arg-AMC (24) form A) Michaelis-Menten 
plot, B) Lineweaver-Burk plot. 
 
As a result, the obtained initial rate constants for the cyclic peptide 6b were plotted against the 
different concentrations (see Graph 5.1B). Utilizing the Michaelis-Menten equation on the 
experimental data, both kinetic constants KM and kcat were extracted from the fitted data (Table 5.5, 
entry 1). Following the same procedure for the linear peptide 24, we found that poor overlap of the 
fitted data with the experimental data (Graph 5.2A) hampered accurate determination of the kinetic 
parameters (Table 5.5, entry 2). A clear example is the lower kcat found for the linear peptide in 
comparison to the cyclic peptide (17.7 and 23.3, respectively), despite the fact that Graph 5.1A clearly 
shows that the hydrolysis rate of the linear peptide is greater than the rate of hydrolysis of the cyclic 
peptide. To assess the kinetic constants more accurately, a Lineweaver-Burk plot was constructed by 
plotting the reciprocal substrate concentrations against the reciprocal velocities. The slope of the 
obtained linear line equals kcat and from the x-intercept, the KM could be determined (x = -1/KM). 
Statistical analysis showed a tolerable R2 of 0.97. From calculations, a KM value of 746.9 μM and a kcat 
of 29.3 s-1 were obtained for the linear peptide 24 (Table 5.5, entry 3).  
 
Table 5.5 Kinetic parameters for the linear peptide 24 and cyclic peptide 6b 
Entry Substrate E (µM) KM (µM) kcat (s-1) vmax (M·s)-1 
1 cyclo[Pro-Arg-AMC-ψ(triazole)-Gly] (6b) 0.45 3693.9 23.3 6308 
2 a H-Gly-Pro-Arg-AMC (24) 1.11 443.4 17.7 39968 
3 b H-Gly-Pro-Arg-AMC (24) 1.11 746.9 29.3 39228 
a Calculated via Michaelis-Menten method, b Calculated via Lineweaver-Burk method, E = FIIa, vmax = kcat / KM 
 
The cyclic conformation slowed down the rate of substrate hydrolysis slightly compared to the linear 
conformation (kcat = 23.3 and 29.3, respectively), but nevertheless remained high. Comparing the 
binding affinity for the active site of thrombin for both the cyclic and linear peptide, a significant 
reduction was observed (KM = 3693.9 versus 746.9 for 6b and 24, respectively). Therefore, it must be 
concluded that the kinetic parameters for the cyclic peptide 6b are not suitable for application in the 
thrombin generation test.       
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5.4 Conclusions 
 
 
Macrocyclization of a linear azide and alkyne-containing peptide was successful and resulted in the 
formation of cyclo-[Gly-Pro-Arg-AMC-[triazole]-spacer-]. Initial cyclization experiments failed probably 
as a result of coordination of copper to the basis guanidine moiety, but could be circumvented by 
protection of the amines with Boc-protecting groups.  
The alkyne-bearing peptides 9a and 9b were synthesized in excellent yields following a 
straightforward synthetic route. The synthesis of the second precursor needed for the linear peptides, 
H-Arg-AAMC, was more challenging, in particular the fluorophore 7-amino-4-azidomethyl-coumarin 
(AAMC). However, proper conditions were found for the synthesis of 7-amino-4-chloromethylcoumarin 
(ACMC), followed by azido substitution to give AAMC. Coupling to arginine proceeded smoothly to 
give H-Arg-AAMC in good yield.  
Biological evaluation of both the linear and cyclic peptide demonstrated that the cyclic peptide had 
improved kinetic properties, as expected. Nevertheless, a high rate of hydrolysis by thrombin hindered 
accurate determination of KM and kcat via Michaelis-Menten kinetics. By construction of a Lineweaver-
Burk plot, the rate of hydrolysis (kcat) for both peptides could be determined and was found to be in the 
same order of magnitude. However, as a result of the macrocyclic (bulky) shape of the cyclic peptide, 
the binding constant (KM) went up with a factor 5 compared to the linear peptide. Other cyclic peptides, 
consisting of different amino acid sequences, may display improved kinetic parameters, in particular 
kcat, suitable for thrombin generation testing.      
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5.6 Experimental section 
 
 
General experimental: 
 
See Chapter 2 section 7 
 
 
Instrumentations 
 
Microwave reactions were carried out in a CEM Discover microwave. Fluorescence experiments were 
typically measured in a 96-well plate fluorometer (Ascent reader, Thermolab systems OY, Helsinki 
Finland) equipped with a 390/460 filter set (excitation/emission). 
 
 
Methods and materials 
 
Human thrombin (hFIIa) and alpha-2-macroglobulin-thrombin complex (2M-T) were supplied by 
Synapse BV (Maastricht, the Netherlands). 
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Synthesis 
 
The synthesis of compound 24 is described in Chapter 2. 
 
 
N-(9-Fluorenylmethoxycarbonyl)-3-aminophenol (10a) 
 
To a suspension of 3-aminophenol (545 mg, 5.00 mmol) in Et2O 
(45 mL) was quickly added 9-fluorenylmethyloxycarbonyl chloride 
(Fmoc-Cl 0.65 g, 2.50 mmol). The suspension was stirred for 16 hours 
at room temperature after which remaining solid material was removed 
by filtration. The solvent was removed under reduced pressure to 
afford a white solid (1.37 g, 83%). 1H-NMR (400 MHz, CDCl3) : 7.78 
(d, J = 7.5 Hz, 2H), 7.62 (dd, J = 7.5, 0.9 Hz, 2H), 7.42 (ddt, J = 7.5, 1.1, 0.7 Hz, 2H), 7.33 (dt, J = 7.5, 
1.2 Hz, 2H), 7.13 (t, J = 8.1, Hz, 2H), 6.71 (s, 1H), 6.61 (br s, 1H), 6.55 (dd, J = 8.1, 1.8 Hz, 1H), 5.23 
(br s, 1H), 4.57 (d, J = 4.4 Hz, 2H), 4.27 (t, J = 6.4 Hz, 1H). 13C-NMR (75 MHz, CD3OD) : 157.2, 
134.6, 141.2, 129.6, 127.6 (2C), 127.0 (2C), 124.8 (2C), 119.8 (2C), 110.9, 110.4, 66.5, 46.9. LRMS 
(ESI+) m/z calcd. for C21H18NO3 [M+H]+ 332.1, found: 332.0. 
 
N-Phenylacetyl-3-aminophenol (10b)  
 
Prepared according to a modified literature procedure:46 
To a suspension of 3-aminophenol (2.18 g, 20 mmol) in Et2O (175 mL) was 
quickly added phenylacetyl-chloride (2.02 mL, 20 mmol). The mixture was 
stirred for 48 hours followed by removal of the remaining solid material via 
filtration. The organic layer was washed with 1 M NaOH (3  10 mL) and dried over anhydrous 
Na2SO4. Solvent was removed in vacuo to afford an off-white powder (1.86 g, 41%). 1H-NMR 
(400 MHz, DMSO-d6) : 10.01 (br s, 1H), 9.34 (br s, 1H), 7.55-7.29 (m, 4H), 7.28-7.21 (m, 1H), 7.17 (t, 
J = 2.1 Hz, 1H), 7.05 (t, J = 8.1 Hz, 1H), 6.95 (ddd, J = 8.1, 1.9, 1.0 Hz, 1H), 6.43 (ddd, J = 8.0, 2.4, 
1.0 Hz, 1H), 3.60 (s, 2H). LRMS (ESI+) m/z calcd. for C14H14NO2 [M+H]+ 228.1, found: 228.0. 
 
N-Carbobenzyloxy-3-aminophenol (10c) 
 
Prepared according to a literature procedure:47 
Quantities used; 3-aminophenol (2.5 g, 23 mmol), benzyl chloroformate 
(2.0 g, 11.5 mmol), Et2O (175 mL). The product was obtained as a white 
powder (2.85 g, 51 %). 1H-NMR (400 MHz, DMSO-d6) : 9.62 (s, 1H), 9.33 
(s, 1H), 7.41 (m, 5H), 7.02 (t, J = 8.1 Hz, 1H), 7.01 (t, J = 2.0 Hz, 1H), 6.85 
(ddd, J = 8.3, 1.9, 0.9 Hz, 1H), 6.38 (ddd, J = 8.1, 2.4, 1.0 Hz, 1H), 5.13 (s, 2H). LRMS (ESI+) m/z 
calcd. for C14H14NO3 [M+H]+ 244.1, found: 244.0. 
 
N-Ethoxycarbonyl-3-aminophenol (10d) 
 
Prepared according to a literature procedure:40c 
Quantities used; 3-aminophenol (12.8 g, 117 mmol), ethyl chloroformate (25.6 g, 
237 mmol), Et2O (450 mL) and Et3N (1 mL). The product was obtained as white 
crystals (11.4 g, 54%). 1H-NMR (400 MHz, CDCl3) : 7.33 (br, 1H), 7.13 (t, J = 
8.1 Hz, 1H), 6.66 (dd, J = 2.0, 0.8 Hz, 1H), 6.64 (dd, J = 2.0, 0.8 Hz, 1H), 6.57 (ddd, J = 8.1, 2.4, 0.8 
Hz, 1H), 6.19 (br, 1H), 4.23 (q, J = 7.1 Hz, 2H), 1.31 (t, J = 6.8 Hz, 3H). LRMS (ESI+) m/z calcd. for 
C9H12NO3 [M+H]+ 182.1, found: 182.1.   
 
N-Acetyl-3-aminophenol (10e) 
 
Prepared according to a literature procedure:48 
Quantities used; 3-aminophenol (10.9 g, 0.10 mol) acetic anhydride (21.3 mL, 
0.22 mol) The product was obtained as a light brown powder (15.0 g, 99%). 
1H-NMR (400 MHz, CD3OD) : 7.15 (t, J = 2.1 Hz, 1H), 7.08 (t, J = 8.2 Hz, 1H), 
6.91 (ddd, J = 8.1, 2.0, 1.0 Hz, 1H), 6.52 (ddd, J = 8.1, 2.4, 1.0 Hz, 1H), 2.09 (s, 3H). LRMS (ESI+) 
m/z calcd. for C8H10NO2 [M+H]+ 152.1, found: 152.0. 
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N-Ethoxycarbonyl-7-amino-4-chloromethylcoumarin (11d) 
 
Prepared according to a literature procedure:49 
Quantities used; ethyl 4-chloroacetoacetate (2.3 g, 14.4 mmol) 
N-ethoxycarbonyl-3-aminophenol (10d) (2.0 g, 12 mmol) and H2SO4 (40 mL, 
60% in H2O). The product was obtained as a light pink powder (2.4 g, 70%). 
1H-NMR (400 MHz, DMSO-d6) : 10.19 (br, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.59 
(d, J = 1.9 Hz, 1H), 7.42 (dd, J = 8.8, 2.0 Hz, 1H), 6.51 (s, 1H), 4.97 (s, 2H), 4.17 (d, J = 7.1 Hz, 
1H),1.26 (t, J = 7.1 Hz, 1H). LRMS (ESI+) m/z calcd. for C13H13ClNO4 [M+H]+ 282.1, found: 282.1.  
 
N-Ethoxycarbonyl-7-amino-4-azidomethylcoumarin (15) 
 
To a solution of N-ethoxycarbonyl-7-amino-4-chloromethylcoumarin (11d) 
(281 mg, 1 mmol) in cold NMP (0 ºC, 10 mL) was added NaN3 (78 mg, 
1.2 mmol). The solution was stirred for one hour at 0 °C before warming to 
room temperature. After an additional two hours stirring, the reaction mixture 
was poured into a mixture of EtOAc (20 mL) and 0.5 M HCl (10 mL). The 
mixture was transferred to a separation funnel and washed with EtOAc (2  10 mL) after which the 
organic layers were collected and dried over anhydrous Na2SO4. The solvents were removed under 
reduced pressure to afford the product as a yellow powder (237 mg, 82%). 1H-NMR (400 MHz, 
DMSO-d6) : 10.18 (s, 1H), 7.63 (d, J = 8.8 Hz, 1H), 7.58 (d, J = 2.0 Hz, 1H), 7.40 (dd, J = 8.7, 2.1 Hz, 
1H), 6.35 (s, 1H), 4.80 (s, 2H), 4.17 (q, J = 7.1 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H). 13C-NMR (75 MHz, 
CD3OD) : 162.0, 156.0, 155.1, 151.5, 144.8, 126.4, 115.9, 113.5, 112.4, 112.4, 106.3, 106.1, 62.3, 
51.3, 15.2. HRMS (ESI+) m/z calcd. for C13H13N4O4 [M+H]+ 289.0973, found: 289.0922. FT-IR max film 
(cm-1):  2107 (N3), 1718, 1697, 1614, 1238. 
 
N-Acetyl-7-amino-4-chloromethylcoumarin (11e) 
 
Ethyl 4-chloroacetoacetate (1.8 g, 11.12 mmol) was added to a solution of 
N-acetyl-3-aminophenol (10e) (1.4 g, 9.27 mmol) in H2SO4 (30 mL, 70% in 
H2O). The suspension was stirred for 4 days at 45 °C. The mixture was 
transferred to a separation funnel and the product was extracted with EtOAc 
(3  35 mL). Solid material was filtered off and the filtrate was dried over 
anhydrous Na2SO4 after which the solvent was removed in vacuo. The product was purified two times 
by column chromatography (MeOH/CH2Cl2 1:9) and was obtained as brown powder (465 mg, 20%). 
1H-NMR (400 MHz, DMSO-d6) : 10.42 (s, 1H), 7.81 (d, J = 2.0 Hz, 1H), 7.78 (d, J = 8.7 Hz, 1H), 7.47 
(dd, J = 8.8, 2.1 Hz, 1H), 6.54 (s, 1H), 4.98 (d, J = 0.7 Hz, 2H), 2.10 (s, 3H). 13C-NMR (75 MHz, 
DMSO-d6) : 169.1, 159.8, 154.0, 150.4, 142.8, 125.7, 115.0, 112.9, 112.1, 105.5, 41.1, 24.1. HRMS 
(ESI+) m/z calcd. for C12H11ClNO3 [M+H]+ 252.0428, found: 252.0433. 
 
7-Amino-4-chloromethylcoumarin (12) 
 
To a solution of concentrated HCl (0.20 mL) in 2-propanol (1 mL) was added N-
acetyl-7-amino-4-chloromethylcoumarin (11e) (200 mg, 1.20 mmol). The solution 
was heated to reflux and stirred for 16 hours. The mixture was then cooled to room 
temperature and subsequently transferred to a separation funnel. After addition of 
H2O (5 mL), the product was extracted with EtOAc (2  15 mL). The combined 
organic layers were washed with H2O (10 mL) and dried over Na2SO4 after which the solvents were 
removed in vacuo. The product was obtained as a brown solid. (181 mg, 72%). 1H-NMR (400 MHz, 
DMSO-d6) : 4.87 (d, J = 0.6 Hz, 2H), 6.17 (s, 1H), 6.22 (br s, 2H), 6.44 (d, J = 2.2 Hz, 1H), 6.59 (dd, 
J = 8.7, 2.2 Hz, 1H), 7.48 (d, J = 8.7 Hz, 1H). 13C-NMR (75 MHz, CD3OD/DMSO-d6) : 157.7, 154.9, 
153.3, 127.1, 113.0, 109.3, 108.4, 100.6, 42.3. HRMS (ESI+) m/z calcd. for C10H9ClNO2 [M+H]+ 
210.3022, found: 210.0322. 
 
N-Acetyl-7-amino-4-azidomethylcoumarin (13) 
 
To a solution of N-acetyl-7-amino-4-chloromethylcoumarin (11e) (175 mg, 
0.70 mmol) in cold NMP (0 °C, 8 mL) was added NaN3 (54 mg, 0.83 mmol). 
The solution was stirred for one hour and allowed to warm to room 
temperature. After an additional two hours stirring the reaction was poured into 
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a separation funnel containing EtOAc (40 mL) and H2O (40 mL). The mixture was washed several 
times with H2O (10 mL) after which the organic layer was dried over anhydrous Na2SO4. The solvent 
was evaporated under reduced pressure and the product was obtained as brown powder (89 mg, 
49%). 1H-NMR (400 MHz, DMSO-d6) : 10.43 (s, 1H), 7.79 (d, J = 2.0 Hz, 1H), 7.66 (d, J = 8.7 Hz, 
1H), 7.45 (dd, J = 8.7, 2.1 Hz, 1H), 6.39 (t, J = 1.2 Hz, 1H), 4.81 (d, J = 1.2 Hz, 1H), 2.10 (s, 1H). 
13C-NMR (75 MHz, CD3OD) : 169.4, 159.9, 154.0, 142.9, 125.5, 115.2, 112.4, 11.4, 105.6, 49.6, 24.2. 
HRMS (ESI+) m/z calcd. for C12H10N4NaO3 [M+Na]+ 281.0651, found: 281.0648. 
 
7-Amino-4-azidomethylcoumarin (14) 
 
Method A: To a suspension of NaN3 (1.14 g, 17.5 mmol) in acetone and acetonitril 
(1:1 v/v, 70 mL), 7-amino-4-chloromethylcoumarin (12) (730 mg, 3.5 mmol) was 
added. The mixture was stirred for 48 hours after which the solvent was 
evaporated in vacuo. The mixture was suspended in EtOAc (35 mL) and the 
precipitated salts were removed by filtration. The resulting organic layer was dried 
over Na2SO4 and the solvents were removed under reduced pressure. The product was obtained as a 
brown powder (725 mg, 95%).  
 
Method B: To a solution of concentrated HCl (0.1 mL) in 2-propanol (0.5 mL), N-acetyl-7-amino-4-
azidomethylcoumarin (13) (77 mg, 0.3 mmol) was added. The solution was heated to reflux for 
16 hours after which the reaction mixture was allowed to cool to room temperature and was 
transferred to a separation funnel. After addition of water (10 mL) the product was extracted two times 
with EtOAc (10 mL). The organic layers were washed with brine (5 mL) and dried over Na2SO4. The 
solvent was removed in vacuo and the product was obtained as a brown powder (43 mg, 66%). 
1H-NMR (400 MHz, DMSO-d6) : 7.48 (d, J = 2.1 Hz, 1H), 6.58 (dd, J = 8.7, 2.2 Hz, 1H), 6.44 (d, J = 
2.1 Hz, 1H), 6.23 (br s, 2H), 6.18 (s, 1H), 4.87 (d, J = 0.7 Hz, 2H). 13C-NMR (75 MHz, CD3OD) : 
164.2, 157.5, 154.9, 152.7, 126.5, 113.2, 108.6, 107.7, 51.6. HRMS (ESI+) m/z calcd. for C10H9N4O2 
[M+H]+ 217.0726, found: 217.0730. FT-IR max film (cm-1): 2569, 2116, 1688, 1601, 1320, 849, 603. 
 
Boc-Arg-7-amino-4-azidomethylcoumarin·HCl (16) 
 
To a cooled solution (-15 °C) of Boc-protected arginine (328 mg, 
1.00 mmol) and 7-amino-4-azidomethylcoumarin (14) (216 mg, 
1.00 mmol) in pyridine (3 mL) was added drop wise phosphoryl chloride 
(102 mg, 1.1 mmol). The mixture was stirred for 5 min at -15 °C and was 
allowed to warm to room temperature and stirred for an additional hour. 
The solvent was evaporated under reduced pressure and purification was 
performed two times using counter current chromatography 
(n-BuOH/H2O) to obtain the product as a white powder (208 mg, 41%). 
1H-NMR (400 MHz, CD3OD) : 7.86 (d, J = 2.0 Hz, 1H), 7.68 (d, J = 8.6 
Hz, 1H), 7.50 (d, J = 8.6 Hz, 1H), 6.44 (s, 1H), 4.73 (s, 2H), 3.23 (t, J = 6.8 
Hz, 2H), 1.90 (s, 1H), 1.82-1.62 (m, 3H), 1.46 (s, 9H). 13C-NMR (75 MHz, CD3OD) : 173.6, 162.6, 
158.7, 158.0, 155.7, 151.7, 151.6, 143.6, 126.2, 117.3, 144.8, 113.0, 108.3, 81.0, 56.4, 51.4, 42.1, 
30.6, 28.7, 26.5. HRMS (ESI+) m/z calcd. for C21H29N8O5 [M+H]+ 473.2261, found: 473.2285. 
 
H-Arg-7-amino-4-azidomethylcoumarin·TFA (8) 
 
To a suspension of Boc-Arg-7-amino-4-azidomethylcoumarin (16) (295 mg, 
0.58 mmol) in CH2Cl2 (20 mL) was added trifluoroacetic acid (TFA, 0.5 mL, 
6.7 mmol). The suspension was stirred for 48 hours after which the solvent 
and excess TFA were removed in vacuo to afford a orange/brown powder 
(299 mg, 86%). 1H-NMR (400 MHz, CD3OD) : 7.96 (d, J = 2.0 Hz, 1H), 
7.72 (d, J = 8.7 Hz, 1H), 7.56 (dd, J = 8.7, 2.1 Hz, 1H), 6.47 (t, J = 1.2 Hz, 
1H), 4.74 (d, J = 1.3 Hz, 2H), 3.27 (t, J = 6.9 Hz, 2H), 2.15-2.02 (m, 
2H),1.85-1.68 (m, 2H). 13C-NMR (75 MHz, CD3OD) : 169.0, 162.5, 158.7, 
155.6, 151.6, 142.9, 126.3, 117.3, 115.2, 113.2, 108.4, 54.9, 51.4, 41.8, 
29.8, 25.6. HRMS (ESI+) m/z calcd. for C16H23Cl2N8O3 [M+H]+ 445.1270, 
calcd. for C16H21N8O3 [M+H]+ 373.1734, found: 373.1747. FT-IR max film (cm-1): 3339, 3170, 2142, 
1701, 1662, 1610, 1584, 1528, 1416, 1394, 1225, 1001, 858. 
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N-Butyn-3-yl-oxycarbonyl-Gly-OH (17) 
 
Prepared according to a modified literature procedure:50 
To a solution of glycine (150 mg, 2 mmol) in H2O (15 mL), 3-butynyl 
chloroformate (265 mg, 2 mmol) was added drop wise whilst keeping the pH 
between 9.5 and 10.5 with a 2 M NaOH solution. The reaction was monitored 
until the pH was stable and then stirred for 72 hours. The solution was transferred to a separation 
funnel and washed two times with EtOAc (10 mL) after which the water layer was acidified with 2 M 
HCl (3 mL). The product was extracted from the water layer with EtOAc (2  10 mL). The combined 
organic layers were dried over MgSO4 after which the solvent was removed in vacuo. The product was 
obtained as a yellow oil (332 mg, 97%). 1H-NMR (400 MHz, CDCl3) : 5.26 (br s, 1H), 4.21 (t, J = 
6.7 Hz, 2H), 4.04 (d, J = 5.7 Hz, 2H), 2.54 (dt, J = 6.7, 2.6 Hz, 2H), 2.01 (t, J = 2.7 Hz, 1H). 13C-NMR 
(75 MHz, CDCl3): 173.7, 156.1, 77.2, 69.9, 63.2, 42.4, 19.3. HRMS (ESI+) m/z calcd. for C7H10NO4 
[M+H]+ 172.0610, found: 172.0605. 
 
N-Butyn-3-yl-oxycarbonyl-Gly-Pro-OMe (18) 
 
To a cooled mixture (0 °C) of N-butynyloxycarbonyl-Gly-OH (17) 
(150 mg, 0.88 mmol), proline methyl ester (113 mg, 0.88 mmol), N-
Me-morpholine (NMM, 89 mg, 0.88 mmol) and N-hydroxybenzotriazole 
(HOBt, 118 mg, 0.88 mmol) in EtOAc (5 mL), DCC (180 mg, 0.92 mmol) 
was added in small portions. The mixture was stirred for 30 min at 0 °C 
and an additional 16 hours at room temperature. DCU was filtered off 
and the filtrate was transferred to a separation funnel and washed with saturated Na2CO3 (2  5 mL). 
The combined aqueous layers were washed with EtOAc (3  5 mL) and the combined organic layers 
were dried with Na2SO4 where after the solvent was removed in vacuo. The product was purified by 
column chromatography (EtOAc/MeOH 20:1) to afford a yellow oil (159 mg, 64%). 1H-NMR (400 MHz, 
CD3OD) : 4.46 (dd, J = 8.7, 4.0 Hz, 1H), 4.12 (dt, J = 6.9, 2.3 Hz, 2H), 3.96 (q, J = 17.2 Hz, 2H), 3.70 
(s, 3H), 3.45-3.65 (m, 2H), 2.51 (dt, J = 6.9, 2.7 Hz, 2H), 2.30 (t, J = 2.7 Hz, 1H), 2.28-2.18 (m, 1H), 
2.11-1.86 (m, 3H). LRMS (ESI+) m/z calcd. for C13H18N2O5 [M+H]+ 283.1, found: 283.1.  
 
N-Butyn-3-yl-oxycarbonyl-Gly-Pro-OH (9a) 
 
N-Butynyloxycarbonyl-Gly-Pro-OMe (18) (158 mg, 0.56 mmol) was 
dissolved in a mixture of dioxane (13 mL), H2O (5 mL) and a 2 M NaOH 
solution (2 mL) was added. The mixture was stirred for 16 hours at room 
temperature. EtOAc (10 mL) was added to the reaction mixture and it 
was transferred to a separation funnel. The aqueous layer was acidified 
with 2 M HCl (2 mL) and washed with EtOAc (3  10 mL). The combined 
organic layers were dried over MgSO4 before the solvent was removed in vacuo. The product was 
purified with gradient column chromatography (MeOH/ CH2Cl2 1:9 → 1:1) and the product was 
obtained as yellow oil. (105 mg, 70%). 1H-NMR (400 MHz, CD3OD) : 2.11-1.86 (m, 3H), 2.28-2.18 (m, 
1H), 2.30 (t, J = 2.7 Hz, 1H), 2.51 (dt, J = 6.9, 2.7 Hz, 2H), 3.45-3.65 (m, 2H), 3.96 (q, J = 17.2 Hz, 
2H), 4.12 (dt, J = 6.9, 2.3 Hz, 2H), 4.46 (dd, J = 8.7, 4.0 Hz, 1H). LCMS analysis: purity +99%, MS 
(ESI+) m/z calcd. for C12H17N2O5 [M+H]+ 269.1, found: 269.0. 
 
N-Butyn-3-yl-oxycarbonyl-Gly-Pro-Arg-7-amino-4-azidomethylcoumarin·HCl (7a) 
 
To a cooled solution (0 °C) of N-butynyloxycarbonyl-Gly-Pro-OH (9a) 
(113 mg, 0.42 mmol), H-Arg-7-amino-4-azidomethyl-coumarin (8) 
(252 mg, 0.42 mmol), HOBt (57 mg, 0.42 mmol) and DMAP (103 mg, 
0.42 mmol) in DMF (10 mL), EDC·HCl (89 mg, 0.46 mmol) was slowly 
added in small portions. The mixture was allowed to warm to room 
temperature and was stirred for an additional 16 hours. The DMF was 
removed under reduced pressure and purification was performed three 
times using counter current chromatography (BuOH/H2O) to give the 
product as a yellow powder (66 mg, 24%). 1H-NMR (400 MHz, CD3OD) 
: 7.94 (s, 1H), 7.64 (s, 2H), 7.34 (br s, 1H), 7.12 (br s, 1H), 6.42 (s, 
1H), 4.71 (s, 2H), 4.51-4.58 (m, 1H), 4.42-4.47 (m, 1H), 3.80-4.05 (m, 
4H), 3.55-3.75 (m, 2H), 3.23 (t, J = 6.4 Hz, 2H), 2.36 (t, J = 6.8 Hz, 2H), 
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2.26-2.32 (m, 1H), 2.25 (t, J = 2.8 Hz, 4H), 1.92-2.10 (m, 4H), 1.63-1.86 (m, 4H), MALDI-TOF (ESI+) 
m/z calcd. for C28H35N10O7 [M+H]+ 623.2690, found: 623.2733, calcd for C28H34NaN10O7 [M+Na]+ 
645.2510, found: 645.2515. 
 
N-Hex-5-ynoyl-Gly-OMe (19) 
 
To a cooled solution (0 °C) of H-Gly-OMe·HCl (687.5 mg, 5.5 mmol), 
5-hexynoic acid (0.6 mL, 5.5 mmol), and DMAP (1.21 g, 10 mmol) in CH2Cl2 
(50 mL), EDC·HCl (1.05 g, 5.5 mmol) was slowly added in small portions. 
The mixture was kept at 0 °C for 30 min and an additional 16 hours at room 
temperature. The reaction mixture was poured into 60 mL of 1 M HCl and extracted with CH2Cl2 (2  
50 mL). The combined organic layers were washed with sat. NaHCO3 (2  50 mL) and dried over 
Na2SO4. CH2Cl2 was removed under reduced pressure to afford the product as a light yellow oil 
(980 mg, 97%). 1H-NMR (400 MHz, CDCl3) : 6.00 (br s, 1H, NH), 4.05 (d, J = 5.2 Hz, 2H), 3.77 (s, 
3H), 2.40 (t, J = 7.4 Hz, 2H), 2.29 (dt, J = 2.7, 6.8 Hz, 2H), 1.98 (t, J = 2.7 Hz, 1H), 1.88 (p, J = 7.1 Hz, 
2H). 13C-NMR (75 MHz, CDCl3) : 172.4, 170.4, 83.4, 69.2, 52.4, 41.2, 34.6, 24.0, 17.8. HRMS (ESI+) 
m/z calcd. for C9H14NO3 [M+H]+ 184.0974, found: 184.0972. 
 
N-Hex-5-ynoyl-Gly-OH (20) 
 
Compound 19 (550 mg, 3 mmol) was dissolved in THF (30 mL) and cooled to 
0 °C. An aqueous solution of NaOH (1 M, 6 mL) was added drop wise. The 
reaction mixture was stirred for 30 min at 0 °C and an additional 30 min at 
room temperature. The volume of the reaction was reduced to 50% before 
aqueous HCl (1 M, 10 mL) and EtOAc (20 mL) were added. The layers were 
separated after which the water layer was washed with EtOAc (2  20 mL). The organic layers were 
combined and dried over MgSO4. After filtration of MgSO4 the solvents were removed under reduced 
pressure. The crude product was re-dissolved in EtOAc (30 mL) and an aqueous solution of NaHCO3 
(1 M, 20 mL) was added. After extraction and separation, the water layer was acidified with aqueous 
HCl (2 M, 15 mL) and extracted with EtOAc (2  30 mL). The combined organic layers were dried over 
MgSO4 and after filtration evaporated under reduced pressure. The product was obtained as slightly 
yellow solid (507 mg, 77%). 1H-NMR (400 MHz, CDCl3) : 6.19 (br s, 1H, NH), 5.36 (br s, 1H, COOH), 
4.09 (d, J = 5.3 Hz, 2H), 2.43 (t, J = 7.4 Hz, 2H), 2.29 (dt, J = 2.7, 6.8 Hz, 2H), 1.99 (t, J = 2.7 Hz, 1H), 
1.88 (p, J = 6.9 Hz, 2H). 13C-NMR (75 MHz, CD3OD/CDCl3) : 173.4, 171.6, 83.2, 69.0, 40.9, 34.4, 
24.0, 17.6. HRMS (ESI+) m/z calcd. for C8H11NO3 [M+H]+ 170.0817, found: 170.0817.  
 
N-Hex-5-ynoyl-Gly-Pro-OtBu (21) 
 
Compound 20 (169 mg, 1.0 mmol), H-Pro-OtBu (180 mg, 1.05 mmol) 
and DMAP (242 mg, 2 mmol) were dissolved in CH2Cl2 (15 mL) and 
cooled to 0 °C. To the cooled solution EDC·HCl (210 mg, 1.1 mmol) 
was added slowly after which the reaction was stirred for 30 min at 0 °C 
and overnight at room temperature. The reaction mixture was quenched 
with aqueous HCl (2 M, 20 mL) and the layers were separated. The 
water layer was extracted with CH2Cl2 (2  20 mL) and the combined organic layers were dried over 
Na2SO4. After filtration the solvent was removed under reduced pressure. The product was obtained 
as a yellow oil (315 mg, 97%) 1H-NMR (400 MHz, CDCl3) S-cis/trans isomers observed; : 6.51 (br s, 
1H), 4.40 (dd, J = 8.6, 3.5 Hz) + 4.25 (dd, J = 8.2, 2.8 Hz) 2H, AB-system: 4.10 + 3.96 (dd, J = 17.7, 
4.6 Hz) + AB-system: 4.07 + 3.72 (dd, J = 17.2, 3.5 Hz) 2H, 3.67-3.61 (m) + 3.60-3.53 (m) + 3.48- 3.42 
(m) 2H, 2.37 (t, J = 7.4 Hz) + 2.36 (t, J = 7.4 Hz) 2H, 2.27-2.22 (m, 2H), 2.21-1.97 (m, 4H), 1.95 (t, J = 
2.7 Hz, 1H), 1.89-1.82 (m, 2H), 1.46 (s) + 1.45 (s) 9H. 13C-NMR (75 MHz, CDCl3) : 171.7, 170.4, 
166.8, 166.3, 82.9, 82.6, 81.2, 68.7, 59.2, 58.8, 46.2, 45.5, 41.6, 41.3, 34.3, 30.9, 28.6, 27.5, 24.0, 
23.7, 21.7, 17.5. HRMS (ESI+) m/z calcd. for C17H27N2O4 [M+H]+ 323.1971, found: 323.1966.  
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N-Hex-5-ynoyl-Gly-Pro-OH (22) 
 
Compound 21 (315 mg, 0.97 mmol) was dissolved in CH2Cl2 (15 mL) and 
TFA (1.5 mL, 20.2 mmol) was added. The reaction was stirred for 16 
hours at room temperature. The solvent and excess TFA were removed 
under reduced pressure after which the crude product was re-dissolved 
in CH2Cl2 (30 mL) and an aqueous solution of NaHCO3 (1 M, 20 mL) was 
added. After extraction and separation, the water layer was acidified with aqueous HCl (2 M, 15 mL) 
and extracted with CH2Cl2 (2  30 mL). The combined organic layers were dried over MgSO4 and after 
filtration evaporated under reduced pressure. The product was obtained as slightly brown oil (290 mg, 
99%). 1H-NMR (400 MHz, CDCl3) : 9.29 (br s, 1H), 7.16 (br s, 1H), 4.53 (dd, J = 8.3, 4.0 Hz, 1H), AB-
system: 4.19 + 4.04 (dd, J = 17.6, 4.6 Hz, 2H), 3.57 (m, 2H), 2.45 (t, J = 7.8 Hz, 2H), 2.21 (dt, J = 6.8 
Hz, 2H), 2.33-2.14 (m, 2H), 2.07 (m, 2H), 1.94 (t, J = 2.6 Hz, 1H), 1.82 (m, 2H). 13C-NMR (75 MHz, 
CD3OD) : 175.7, 175.6, 169.5, 84.3, 70.2, 60.5, 47.4, 42.6, 35.6, 30.2, 25.9, 25.7, 18.7. HRMS (ESI+) 
m/z calcd. for C13H19N2O4 [M+H]+ 267.1345, found: 267.1349. 
 
N-[(N-Hex-5-ynoyl)-Gly-Pro-Arg]-7-amino-4-azidomethylcoumarin·TFA (9b)  
 
N-hex-5-ynoyl-Gly-Pro-OH (22) (133 mg, 0.5 mmol) and H-Arg-7-
amino-4-azidomethylcoumarin·2TFA (8) (295 mg, 0.5 mmol) were 
dissolved in DMF (15 mL) and cooled to 0 °C. DMAP (121 mg, 
1.0 mmol) and EDC·HCl (105 mg, 0.55 mmol) were added to the 
cooled solution which was subsequently stirred for 30 min at 0 °C 
before allowing the mixture to warm to room temperature. The reaction 
mixture was stirred for an additional 16 hours at room temperature after 
which the solvent was removed under reduced pressure. The crude 
mixture was purified by counter current chromatography (n-BuOH/H2O 
1:1) to afford a white solid (200 mg, 54%) RF = 0.36 (BuOH/AcOH/H2O 
4:1:1). 1H-NMR (400 MHz, CD3OD) : 7.92 (d, J = 1.8 Hz, 1H), 7.70-
7.63 (m, 2H), 6.42 (s, 1H), 4.72 (d, J = 0.9 Hz, 2H), 4.54 (dd, J = 9.7, 
4.5 Hz, 1H), 4.47 (dd, J = 8.6, 4.8 Hz, 1H), 4.15 + 3.94 (AB-system, J = 
16.7, 2H), 3.79-3.74 (m, 1H), 3.70-3.64 (m, 1H), 3.25 (dt, J = 6.8, 6.8, 6.7 Hz, 2H), 2.42-2.22 (m, 4H), 
2.18 (t, J = 2.6 Hz, 1H), 2.13 (dt, J = 7.0, 2.6 Hz, 2H), 2.09-1.97 (m, 4H), 1.91-1.60 (m, 6H). 13C-NMR 
(75 MHz, CD3OD) : 176.2, 174.9, 172.5, 171.0, 162.6, 158.7, 155.7, 151.6, 143.6, 126.1, 117.5, 14.9, 
113.1, 108.4, 84.1, 70.2, 62.5, 54.90, 54.84, 51.45, 43.2, 41.9, 35.5, 30.8, 29.7, 26.5, 26.0, 25.7, 18.7. 
HRMS (ESI+) m/z calcd. for C29H37N10O6 [M+H]+ 621.2897, found: 621.2882. FT-IR max film (cm-1): 
3287, 2941, 2111, 1653, 1610, 1528, 1420, 1195, 1135.   
 
N-[(N-Hex-5-ynoyl)-Gly-Pro-Argω,ω’(bis-Boc)]-7-amino-4-azidomethylcoumarin (22) 
 
Compound 7b (57 mg, 77.0 μmol) was dissolved in THF (1.5 mL) and 
DMAP (18.6 mg (0.15 mmol) was added. The reaction mixture was 
cooled to 0 °C and (Boc)2O (67.1 mg, 0.31 mmol) was added slowly. 
The mixture was stirred at 0 °C for 30 min and an additional 72 hours 
at r.t. The solvent was removed under reduced pressure and the 
crude mixture was purified by column chromatography 
(CH2Cl2/MeOH 9:1) to afford the ω,ω’bis-(Boc) product as a white solid 
(50 mg, 79%). 1H-NMR (400 MHz, CD3OD) : 7.92 (dd, J = 6.6 Hz, 
1H), 7.74 (ddd, J = 8.6, 3.0, 2.0  Hz, 1H), 7.65 (d, J = 8.6 Hz, 1H), 
6.43 (s, 1H), 4.73 (d, J = 0.9 Hz, 2H), 4.47 (m, 2H), 4.12 (d, J = 
16.4 Hz, 1H), 3.96 (dd, J = 16.8, 4.2 Hz, 1H), 3.80-3.73 (m, 1H), 
3.68-3.62 (m, 1H), 3.46-3.38 (m, 1H), 2.40-2.20 (m, 4H), 2.16 (t, J = 
2.6 Hz, 1H), 2.12 (ddt, J = 7.0, 4.3, 2.7 Hz, 2H), 2.08-1.98 (m, 6H), 
1.88-1.58 (m, 4H), 1.52 (d, J = 2.9 Hz, 9H), 1.46 (s, 9H) 13C-NMR (75 MHz,CD3OD) : 175.9, 174.8, 
172.7, 170.9, 162.6, 160.7, 157.6, 155.6, 154.1, 151.6, 143.6, 126.0, 117.4, 114.7, 112.9, 108.3, 85.3, 
84.5, 84.2, 80.4, 70.3, 62.6, 55.4, 51.4, 45.5, 43.2, 41.3, 35.4, 30.8, 29.6-29.5 (d), 28.7, 28.3, 27.1-
27.0 (d), 26.0, 25.6, 18.7. HRMS (ESI+) m/z calcd. for C39H53N10O10 [M+H]+ 821.3946, found: 
821.3939. 
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Cyclo-[-N-(N-(1,2,3-triazol-4-yl)-butanoyl-glycyl-prolyl-arginylω,ω’(bis-Boc))-7-amino-4-
methylenecoumarin-] (23) 
 
Compound (22) (47 mg, 57.6 μmol) was dissolved in dry and 
degassed (N2) THF (25 mL) and kept under a nitrogen atmosphere. 
A volume of 5 mL of a stock solution containing CuBr (85 mg, 
576 μmol) and N,N,N’,N’,N’’-pentamethyl- diethylenetriamine 
(PMDETA) (105 mg, 576 μmol) in dry and degassed (N2) THF (50 
mL) was slowly added to the reaction (a color change of yellow to 
green was observed). The reaction mixture was warmed to 40 °C and 
stirred for 7 hours and subsequently quenched with MeOH (10 mL). 
The solvents were removed under reduced pressure and the crude 
mixture was purified by preparative TLC (CH2Cl2/MeOH 9:1) to afford 
a light yellow solid (11 mg, 23%). 1H-NMR (400 MHz, CD3OD) : 8.33 
(dd, J = 4.2, 2.1 Hz, 1H), 7.79 (s, 1H), 7.30 (ddd, J = 8.6, 5.7, 2.1 Hz, 
1H), 6.77 (d, J = 8.76 Hz, 1H), 6.65 (s, 1H), 6.09 + 5.49 (AB-system, J = 15.3, 2H), 4.57-4.53 (m, 1H), 
4.32 (dd, J = 8.8, 5.8 Hz, 1H), 4.24 + 3.86 (AB-system, J = 17.2 Hz, 2H), 3.70 (t, J = 6.7 Hz, 2H), 3.61-
3.57 (m, 1H), 3.40-3.34 (m, 1H), 2.73 (t, J = 5.8 Hz, 2H), 2.38-2.11 (m, 3H), 2.06-1.92 (m, 2H), 1.89-
1.78 (m, 4H), 1.71-1.56 (m, 4H), 1.51 (d, J = 14.5 Hz, 9H), 1.43 (d, J = 3.3 Hz, 9H).  13C-NMR 
(75 MHz, CD3OD) : 175.6, 174.9, 172.4, 171.2, 162.3, 157.7, 156.24, 156.15, 148.9, 148.5, 143.4, 
125.3, 125.0, 117.6, 117.4, 114.4, 108.3, 85.4, 84.5, 80.4, 68.9, 63.64, 63.60, 54.8, 54.7, 52.8, 47.8, 
45.4, 42.9, 41.3, 35.3, 31.0, 28.7, 28.3, 27.4, 27.1, 26.3, 26.1, 25.1. HRMS (ESI+) m/z calcd. for 
C39H53N10O10 [M+H]+ 821.3946, found: 821.3942. FT-IR max film (cm-1): 3304, 2976, 2928, 2872, 
1722, 1645, 1567, 1143, 1057. 
 
Cyclo-[-N-(N-(1,2,3-triazol-4-yl)-butanoyl-glycyl-prolyl-arginyl)-7-amino-4-methylenecoumarin-] 
·2HCl (6b) 
 
A solution of 23 (10 mg, 12.2 μmol) in Et2O (2.5 mL) was treated with 
0.5 mL 2.6 M HCl in EtOAc. The clear solution became a suspension 
upon stirring for 72 hours. The solvents were removed by a nitrogen 
airflow and the remaining solid was dried in vacuo to yield a yellow 
solid (8 mg, 99%). 1H-NMR (400 MHz, CD3OD) : 9.17 (s, 1H, NH), 
8.29 (s, 1H), 8.13 (s, 1H), 7.34 (d, J = 8.8 Hz, 1H), 6.86 (d, J = 8.8 Hz, 
1H), 6.69 (s, 1H), 6.15 + 5.60 (AB-system, J = 15.1 Hz, 1.3, 2H), 4.53 
(dd, J = 10.8, 3.7 Hz, 1H), 4.33 (dd, J = 8.0, 6.3 Hz, 1H), 4.25 + 3.95 
(AB-system, J = 17.7 Hz, 2H), 3.73 (m, 1H), 3.59 (m, 1H), 3.21 (t, J = 
6.7 Hz, 2H), 2.81 (m, 2H), 2.43-2.36 (m, 1H), 2.27-2.13 (m, 1H), 2.09 
(dt, J = 6.2, 12.4 Hz, 2H), 1.94-178 (m, 4H), 1.75-1.54 (m, 4H). 
13C-NMR (75 MHz, CD3OD) : 175.5, 175.1, 172.3, 171.4, 162.3, 158.7, 
156.2, 148.7, 143.4, 125.6, 125.3, 117.7, 117.6, 114.5, 108.4, 63.7, 54.3, 53.0, 47.9, 43.0, 41.9, 35.2, 
31.1, 30.8, 28.5, 26.9, 26.13, 26.10, 24.9. HRMS (ESI+) m/z calcd. for C29H37N10O6 [M+H]+ 621.2898, 
found: 621.2851. 
 
 
Biological evaluation 
 
Determination kinetic parameters for H-Gly-Pro-Arg-AMC·2HCl (24): 
 
The following solutions were prepared and stored at the indicated temperatures: 
 
Substrate: H-GPR-AMC (55.7 mg, 0.1 mmol) was dissolved in 1.0 mL BSA60+ buffer (bovine serum 
albumin, Sigma, A-7030, 60 mg/mL containing NaCl (8.18 mg/mL)) to give a 100 mM stock solution. 
From this stock solution a series of dilutions was prepared (total volume of 500 μL) to give final 
substrate concentrations in the well of 0, 200, 400, 600, 800, 1000, 1200, and 1400 M. The dilutions 
were kept at 37 °C. 
Fluo: Z-Gly-Gly-Arg-AMC (61.5 mg, 0.1 mmol, Bachem, I-1140) was dissolved in 1.0 mL DMSO to 
give a 100 mM stock solution. 7.5 μL of the 100 mM stock solution and 292.5 μL BSA60 buffer (NOT 
containing NaCl) were shortly vigorously mixed to give a Fluo-solution of 2.5 mM. The solution was 
kept at room temperature. 
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h-Thrombin: A solution of 1.2 M activated humane thrombin (denoted hFIIa) was prepared from an 
18.8 M hFIIa stock solution via dilution with BSA5 buffer (5 mg/mL). The hFIIa solution was kept at 
0 °C. Prior to use it was warmed to 37 °C. 
Calibrator: Lyophilized 2-MT complex (Thrombinoscope BV, The Netherlands) was reconstituted in 
1 mL deionised water to give a final enzyme concentration of 600 nM. The calibrator solution was kept 
at 0 °C. Prior to use it was warmed to 37 °C. 
 
A set of four wells of an Immulon 2HB, round-bottom 96-well plate, was filled with 100 μL of each 
appropriate substrate concentration (total 4  8 wells, quadruple measurement). A set of four wells in a 
96 wells plate was filled with 80 μL BSA5 buffer followed by 20 μL of Fluo solution. The 96 wells plate 
was placed in an Ascent reader, Thermolab systems OY fluorometer equipped with a 390/460 filter set 
(excitation /emission), and allowed to warm to 37 °C (approximately 5 minuites). To all the wells 
containing substrate, 20 μL of 0.6 M hFIIa solution was then added to initiate hydrolysis (200 nM end 
concentration hFIIa in wells, 4  8 wells in total). To the wells containing the Fluo-solution, 20 μL of 
calibrator was added to initiate hydrolysis. In a typical experiment fluorescence was measured 
continuously during 40 minutes at 37 °C. The obtained data was organized in Microsoft Excel® and the 
kinetic parameters were obtained by fitting the data to the Michaels-Menten equation. For the 
determination of KM and kcat the initial reaction velocity of the first 10 minutes was used. The amidolytic 
activity was calculated by comparing the arbitrary fluorescence values to those of an AMC-calibration 
curve. Results of different experiments were compared by correcting the amidolytic activity of each 
experiment with the amidolytic activity found for the calibrator which was measured in the same 
96 wells plate.  
 
Determination kinetic parameters for cyclo-[-N-(N-(1,2,3-triazol-4-yl)-butanoyl-glycyl-prolyl-arginyl)-7-
amino-4-methylenecoumarin-]·2HCl (6b): 
 
Using the experimental procedure as described vide supra with slight modifications: 
 
The following solution was prepared and stored at the indicated temperature: 
 
Substrate: cyclo(-GPR-AMC-[triazole]-spacer-) (1.4 mg, 0.025 mmol) was dissolved in 0.25 ml BSA60+ 
buffer (bovine serum albumin, Sigma, A-7030, 60 mg/mL containing NaCl (8.18 mg/mL)) to give a 
100 mM stock solution. From this stock solution a series of dilutions was prepared (total volume of 
500 μL) to give final substrate concentrations in the well of 0, 50, 100, 200, 400, 600, 800 and 1000 
M. The dilutions were kept at 37 °C. 
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Abstract 
 
A serious drawback in current calibrated automated thrombography is the complex mathematical 
processing required for adequate determination of the endogenous thrombin potential. The processing 
is required since an ongoing increase in fluorescence is observed after thrombin generation is 
completed, which is the result of continuous hydrolysis of small fluorogenic thrombin substrates by the 
anti-thrombin complex alpha-2-macroglobulin-thrombin (2M-T). To circumvent the undesired 
secondary hydrolysis mechanism we constructed three types of polymer-peptide hybrids containing a 
thrombin specific fluorogenic tripeptide attached to either poly(ethylene glycol), poly(methyl 
methacrylate)-graft-poly(ethylene glycol) or polystyrene. The polymer chains induce steric hindrance 
prevents the peptide fragment from entering the 2M-thrombin complex thus avoiding hydrolysis. Both 
the peptide-poly(PEGMA) construct and the PEG-peptide are expected to form tangle ball structures, 
while the PS-peptide is expected to form spherical aggregrates. The amphiphilic behavior of the PS-
GGR-AMC construct resulted in the formation of vesicular structures (typically 200-500 nm up to 2 μm) 
upon suspension of a THF solution in water.* These macromolecular architectures, and the other 
polymer-peptide biohybrid structures, were subjected to hydrolysis by thrombin in order to determine 
their kinetic parameters and thus their suitability for thrombin generation assessment.    
 
 
Reference 
*   Published in modified form; A. (Ton) J. Dirks, Sander S. van Berkel, Nikos S. Hatzakis, Joost A. Opsteen, Floris L. van 
Delft, Jeroen J. L. M. Cornelissen, Alan E. Rowan, Jan C. M. van Hest, Floris P. J. T. Rutjes and Roeland J. M. Nolte, 
Chem. Commun. 2005, 4172-4174. 
 
6 
Chapter 6 
 148
6.1 Introduction 
 
 
Thrombin formation, and thus coagulation, is controlled by the interplay of both prothrombins and 
antithrombins. Prothrombins (e.g. prothrombinase) convert prothrombin into thrombin while 
antithrombins in a later stage inactivate thrombin. Besides antithrombins, alpha-2-macroglobulin (2M) 
plays an important role in the deactivation of thrombin via its encapsulation.1 Although the thrombin 
active-site remains active upon encapsulation, the hydrolysis of the natural substrate (i.e. fibrinogen) 
and the conversion of proenzymes by thrombin can no longer be performed as a result of steric 
impediment. However, small chromogenic and fluorogenic thrombin substrates, such as those used to 
determine the endogenous thrombin potential,2 are still able to reach the thrombin active-site resulting 
in ongoing continuous signal increase long after thrombin generation is over.3 Since the ETP 
determination is based on the amount of fluorescence generated by ‘free thrombin’, the continuous 
hydrolysis of small substrates generated by the thrombin bound 2M complex (2M-T) induces a 
necessity for additional mathematical correction for the appropriate determination of the ETP. To 
overcome the undesired hydrolysis of fluorogenic thrombin substrates by 2M-T, macromolecular 
substrates (i.e. polymer-peptides) can be employed to circumvent hydrolysis by 2M-T. The size and 
hydrodynamic volume of polymer-peptides averts the substrate from entering the 2M-T complex and 
thus prevents hydrolysis. Consequently, only the hydrolysis of fluorogenic substrates by free thrombin 
formed in time is monitored, leading to simplification of the mathematical determination of the 
endogenous thrombin potential. 
 
 
6.1.1 2-Macroglobulin-Thrombin complex 
 
Human 2-macroglobulin is a large plasma glycoprotein assembled from four identical 180-kDa 
subunits which are disulfide-linked in pairs to form two protomers. These protomers are consecutively 
held together by noncovalent interactions to form the 720-kDa 2-macroglobulin structure 
(Figure 6.1).4, 5  
H
H
H
H
assembly process
 
 
Figure 6.1 Assembly process of individual subunits via dimer protomers to tetrameric 
2-macroglobulin (partially from; S. R. Feldman et al., PNAS, 1985, 5700-5704, ref 5). 
 
Human 2-macroglobulin can bind, non-specifically, all four major classes of proteases (serine-, 
cysteine-, aspartic acid-, and metalloproteases).6 Studies on protease binding have demonstrated that 
most of the smaller proteases bind to 2M in a 2:1 protease-to-inhibitor ratio (Figure 6.2 C) while larger 
proteases such as chymotrypsin and plasmin bind to 2M in a 1:1 ratio.7 These binary incomplete 
transformed complexes are also found for thrombin upon binding to 2-M (i.e. 1 mol of thrombin per 
mol of 2-M, Figure 6.2D).5  
Macromolecular Fluorogenic Substrates 
 149
 
Figure 6.2 Schematic representation of different 2M models. A) The native tetrameric complex. B) 
Conformational change of the complex. The small arrows denote the positions postulated for the 
receptor-recognition sites. C) Protease trapping by the 2M complex (2:1 ratio presented). D) 
Thrombin binding to 2M in a 1:1 ratio. (from: S. R. Feldman et al., PNAS, 1985, 5700-5704, ref 5).  
 
Each subunit of 2M contains an approximately 40-residue long amino acid sequence termed “the bait 
region”, which is responsible for the binding of the proteases. Within this bait-region a four amino acids 
chain forms the functionally important internal thiol ester bond between Cys949 and Glu952, which 
rapidly undergoes nucleophilic attack (see Figure 6.3).4   
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Figure 6.3 Structure and reactions of the internal -cysteinyl--glutamyl thiol ester. 
 
The structurally constrained 15-membered thiolactone is presumably in equilibrium with its open-chain 
lactam form (this isomerization has been shown for model thiol ester peptides8). In the proteolytically 
activated state the thiol ester is highly susceptible to nucleophilic attack by a wide range of 
predominantly nitrogen nucleophiles (e.g. the side of lysine) resulting in the formation of the 
substituted Glu residue.9  
 
Reaction of 2M with proteases results in the cleavage of the bait region giving rise to conformational 
changes of the 2M complex. Such conformational changes can already be induced by small 
nucleophilic primary amines such as methylamine or hydroxylamine.10 Human 2-macroglobulin exists 
in two well defined, highly distinct conformations, however, as a result of the dynamics and the size of 
the 2M-thrombin complex and the different shapes that are associated with it, no crystal structure of 
this complex is known to date. Various electron microscopy techniques have been employed to 
determine the conformational changes of 2M, including electron microscopy combined with image 
analysis11, and Fab-labeled cryoelectron microscopy.4 Electron micrographs showed that native 2M 
appears as a Cyrillic “H” (ж) as is depicted in Figure 6.1. Furthermore, data obtained by this technique 
was used to estimate the size of the 2M-T complex to be approximately 195  135  130 Å (height, 
width and depth, respectively). The opening between the arms at the top-side was found to be 
approximately 40 Å.4 The size of the macromolecular substrates should thus be greater than 4 nm to 
prevent the substrate from entering the 2M-T complex and being hydrolyzed by thrombin. 
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6.1.2 Macromolecular biohybrids  
 
As mentioned above one of the problems of the thrombin generation test is cleavage of the available 
chromogenic and fluorogenic substrates by in vivo inactive 2-macroglobulin-bound thrombin, leading 
to overestimation of thrombin generation. The calibrated automated thrombography (CAT) method 
accounts for this problem by using a mathematical algorithm correcting for the assumed contribution of 
2M-thrombin. Hortin et al.12 introduced the concept of macromolecular chromogenic substrates for the 
selective determination of protease activity of unbound chymotrypsin, trypsin and thrombin with 
respect to the corresponding 2-macroglobulin-protease complexes, by functionalization of protease-
selective peptides with poly(ethylene glycol) tails.  
The results obtained by Hortin demonstrate that improvement of the substrate composition as well as 
optimization of the kinetic parameters is required in order to implement macromolecular peptide 
substrates in the thrombin generation test. First, the chromogenic protease specific peptides need to 
be replaced by fluorogenic thrombin specific peptides possessing suitable kinetic parameters. Since 
the linear PEG-peptide applied by Hortin gave variable results, the second intended improvement is 
the substitution of the linear PEG-polymer by a closed packed brush poly(PEG-methacrylate) polymer 
(poly(PEGMA) or P(PEGMA)) in order to increase the hydrodynamic volume of the substrate and thus 
the selectivity for unbound thrombin over the 2M-thrombin complex. 
Another approach to circumvent the undesired hydrolysis by the 2M-thrombin complex is the use of 
functional amphiphilic block copolymers, consisting of a hydrophobic polymer part and a hydrophilic 
fluorogenic peptide part. These polymer-peptide amphiphiles may be of particular interest because 
macromolecular amphiphiles generally form stable assemblies with sizes well exceeding the size 
required to prevent hydrolysis by the 2-M-T complex (i.e. 4 nm).  
Biohybrid amphiphiles constructed from polymers coupled to peptides13 or proteins14 have 
demonstrated to be functional self-assembled materials.15 A common approach to prepare such 
biohybrid amphiphiles is to equip the N- or C-terminus of a peptide with one or more hydrophobic 
polymer chain(s) which has also been shown to create effective self-assembling biohybrids.16,17 
Although the synthesis of peptide-polymer hybrids can be challenging, recent advances in conjugation 
methodology have furnished several powerful techniques to synthesize well-defined peptide-polymer 
conjugates.18 For example, building up a polymer from a functional macroinitiator is an elegant 
approach to synthesize peptide-polymer conjugates. However, for the synthesis of amphiphilic 
peptide-polymer conjugates it may be more favorable to synthesize both blocks under optimized 
conditions and link them together after individual characterization by specific techniques. A 
prerequisite of such a modular approach is an effective coupling strategy to conjugate the two blocks, 
and in this respect the copper-catalyzed azide-alkyne cycloaddition (CuAAC)19 is a particularly useful 
reaction. This prototypical ‘click reaction’ has been proven to be a valuable tool for almost all fields of 
chemistry, and materials science in particular.20  
Since the tripeptide H-Gly-Gly-Arg-AMC has been demonstrated to be a suitable substrate for the 
application in the thrombin generation test (TGT) to diagnose thrombosis (see Chapter 3), we 
envisioned biohybrid amphiphiles consisting of a tripeptidic polar headgroup (-Gly-Gly-Arg-) tagged 
with a 7-amino-4-methyl coumarin (AMC) moiety and a hydrophobic polystyrene (PS) tail to induce 
amphiphilicity which might lead to macromolecular self-assembly. The synthesis of PS-Gly-Gly-Arg-
AMC amphiphiles can be achieved via the copper catalyzed azide-alkyne cycloaddition reaction of 
alkyne-functionalized H-Gly-Gly-Arg-AMC and -azido terminated PS. The alkyne-functionalized 
peptide part can be readily prepared from H-Gly-Gly-Arg-AMC (for synthesis see Chapter 2) and the 
synthesis of the polymer block can be achieved by controlled atom transfer radical polymerization 
(ATRP) followed by end group modification. After studying the amphiphilic behavior of the polymer-
peptides, the amphiphiles will be subjected to thrombin and 2M-T complex to determine both the rate 
of hydrolysis and the degree of selectivity. 
 
 
6.2 Synthesis of polymer-peptides 
 
 
We envisioned different types of polymer-peptide constructs to circumvent the hydrolysis by the 2M-T 
complex (Figure 6.4). These constructs are composed of a polymer chain, either poly(ethylene glycol), 
poly(PEG-methacrylate) or polystyrene, functionalized with a fluorophore-containing peptide fragment 
being either -Gly-Gly-Arg-AMC, -Gly-Pro-Arg-AMC or -Ala-Pro-Arg-AMC. PEGylation of these peptides 
was carried out using commercially available methoxy-PEG-p-nitrophenol-carbonate in the presence 
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of a base. The synthesis of the polystyrene and poly(PEG-methacrylate) blocks was readily achieved 
by atom transfer radical polymerization (ATRP)21 followed by end group modification. In this protocol, 
ATRP allows for the straightforward variation of the polymer length, but moreover, also several 
functionalities can be introduced at the -terminus of the polymer by employing functional initiators. 
Building up a polymer from a functional initiator followed by end group modification(s) thus provides 
access to hetero telechelic polymers and allows for the preparation of (a)symmetrically functionalized 
biohybrid amphiphiles.  
 
 
 
Figure 6.4 Polymer-peptide constructs (PEG, P(PEGMA) and PS).  
 
 
6.2.1 Linear and brushed PEG-peptide conjugates 
 
The process of PEG conjugation to either peptides or proteins, known as PEGylation, is a procedure 
of growing interest in both biotechnology and therapeutical science.22 As a result, a large variety of 
methods for the conjugation of PEG to either peptides or proteins is currently available.23 The use of 
PEG-containing polymer-peptides is related to the favorable properties of this type of polymer. Alpha-
methoxy-PEG (mPEG) is an inert, uncharged polymer that can take on an extended random-coil 
conformation with a high excluded volume per molecular weight. In addition, these polymers are highly 
soluble in water and organic solvents facilitating peptide coupling and post-synthetic application.24  
Application of the commercially available PEGylated thrombin substrate mPEG5000(CH2)2CO2-Gly-Gly-
Arg-AMC (1) showed good selectivity for FIIa over the 2M-T complex and was readily soluble in 
aqueous media.25 The kinetic parameters of substrate 1 on 2M-T complex revealed a moderate rate 
of hydrolysis (kcat = 0.045 s-1) and a poor binding constant (KM = 12.5 mM), compared to a good 
binding constant for FIIa (KM = 1.17 mM) though a somewhat low rate of hydrolysis (kcat =  0.46 s-1).25 
Since the rate of hydrolysis of this PEG-peptide was rather low, the amount of released fluorescence 
in the thrombin generation assay was only moderate. A polymer-peptide substrate bearing a peptide 
fragment with a higher rate of hydrolysis compared to compound 1 is therefore desirable. The kinetic 
parameters of various fluorogenic substrates as described in Chapter 3 revealed that both H-Gly-Pro-
Arg-AMC (2) and H-Ala-Pro-Arg-AMC (4) possess suitable high kcat values. We therefore aimed to 
synthesize the linear PEG-peptides mPEG-Gly-Pro-Arg-AMC (3) and mPEG-Ala-Pro-Arg-AMC (5) 
assuming an increased rate of hydrolysis by thrombin and thus increasing the fluorescence intensity.  
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Scheme 6.1 Functionalization of peptides 2 and 4 with methoxy-PEG-p-nitrophenol-carbonate. 
 
Introduction of the mPEG was envisaged using the p-nitrophenylcarbonate activated mPEG5000.26 To 
this end, the selected peptide fragments (2 and 4) were PEGylated by stirring a solution of peptide and 
commercially available mPEG-p-nitrophenol-carbonate in the presence of a base for 48 hours. The 
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highly polar products were obtained both in high purity and high yield (97% and 87% for 3 and 5, 
respectively) after purification by counter-current chromatography (n-BuOH/H2O).  
 
In order to enlarge the hydrodynamic volume of the polymer-peptides, therewith increasing the 
selectivity for thrombin over the 2M-T complex, a graft polymer was constructed, consisting of a 
poly(methacrylate) polymer backbone and PEG brushes grafted to the backbone polymer. ATRP was 
considered the most favorable polymerization technique because of the high tolerance towards 
different functional groups and monomer types as well as impurities; moreover, the reaction can be 
performed under mild reaction conditions.27 Two different initiators were chosen to start the 
polymerization, namely tert-butyl--bromo-isobutyrate and tert-butyl-12-hydroxy-4,7,10-trioxa-
dodecanoate--bromo-isobutyrate (6). The ethylene glycol spacer was introduced for distancing the 
peptide from the envisaged bulky P(PEGMA) polymer in order to facilitate conjugation of the peptide 
fragment to the polymer. Initiator 6 was obtained via the quantitative coupling of tert-butyl 12-hydroxy-
4,7,10-trioxadodecanoate to 2-bromo-2-methylpropanoyl bromide in the presence of Et3N 
(Scheme 6.2).  
  
 
 
Scheme 6.2 Synthesis of hetero-telechelic spacer-initiator 6. 
 
Starting from two types of hetero-telechelic initiators the polymerization of the mPEG-methacrylate 
monomer was carried out in deuterated DMSO in order to follow the conversion. The catalytic system 
in this reaction was a CuBr-bipyridine (bpy) complex in a molar ratio of [CuBr]/[bpy] 1:2.28  The 
resulting P(PEGMA) polymers 7 and 9 were obtained in reasonable yields (58% and 50% for 7 and 9, 
respectively) and polydispersity (DPI = 1.19 and 1.20 for 7 and 9, respectively). To determine the 
molecular weight of the brush polymers MALDI-ToF, GPC and NMR analysis were performed. Due to 
the complexity of the polymers MALDI-ToF failed to produce an appropriate mass spectrum. GPC 
analysis gave a number average molecular weight (Mn) of approximately 26100 for polymer 7, 
corresponding to n = 24, and a Mn of 36300, corresponding to n = 30 for polymer 9. However, since no 
calibration set for P(PEGMA) was available the reported masses were based on a PS calibration set 
and therefore not accurate. Determination of the molecular weight by 1H NMR analysis also turned out 
to be troublesome due to overlap and broadening of the peaks. Comparison of the integral values of 
the tert-butyl ester protons and the CH2 + CH3 protons of the polymethacrylate backbone resulted in a 
number of repeating units (n) of 14 for polymer 7 and n = 20 for polymer 9. 
 
 
 
Scheme 6.3 ATRP polymerization of PEG-methacrylate using CuBr/bpy as a catalyst and initiators 6 
or tert-butyl 2-bromo-2-methylpropanoate. 
 
Next, tert-butyl ester deprotection was performed on hetero-telechelic polymers 7 and 9 yielding the 
-carboxylic acid derivatives 8 and 10 (95% and 88% respectively, Scheme 6.3). Polymers 8 and 10 
were subsequently decorated with different tripeptides via a peptide coupling reaction (Scheme 6.4). 
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Since the polymer chain might have an influence on the kinetic parameters of the polymer-peptide 
conjugate, the previously applied substrates 2, 4 and H-Gly-Gly-Arg-AMC (11), with varying kinetic 
parameters, were selected to be coupled to the P(PEGMA)-polymers. To ensure straightforward work-
up and purification of the product, the reaction conditions for the coupling of the peptides to the 
carboxylic acid of the P(PEGMA) polymers were devised to obtain the pure products after a simple 
extraction procedure. To this end, an excess (1.5 equiv) of the water soluble tripeptide was used to 
ensure complete conversion of the P(PEGMA) polymer. The water soluble coupling reagent EDC·HCl 
was used in combination with DMAP which, in a protonated state, also dissolves in water. After 
completion of the reaction, the mixture can thus be poured into a slightly acidic aqueous solution 
whereupon the product can be extracted using an organic solvent leaving all other reagents in the 
aqueous solution.    
 
 
 
Scheme 6.4 Synthesis of peptide-(spacer)-P(PEGMA) conjugates 12-17.  
 
Unexpectedly, the reaction between the carboxylic acid of P(PEGMA) 10 and peptides 2, 4 or 11 did 
not result in the formation of peptide-P(PEGMA) constructs 12-14 according to TLC analysis, 1H-NMR 
and UV-Vis spectroscopy. Since the carboxylic acid is in close proximity of the bulky brush polymer, 
coupling is presumably significantly hindered by the steric bulk.   
 
Conversely, decoration of the spacer-functionalized P(PEGMA) polymer 8 with tripeptides 2, 4 or 11 
proceeded smoothly which gave, after 18 hours, completion of the reaction according to TLC analysis. 
Work-up as described vide supra furnished the desired polymer-peptide biohybrids 15-17. The degree 
of functionalization of HO-spacer-P(PEGMA) (8) with the different peptide fragments was determined 
by UV-Vis spectroscopy by comparing the absorption of a peptide-AMC compound (i.e. 2, 4 or 11) to 
the absorption of the corresponding polymer-peptide-AMC compound at a specific substrate 
concentration (see experimental section). In contrast with TLC analysis, the results obtained with 
UV-Vis spectroscopy showed functionalization of polymer 8 with H-Gly-Gly-Arg-AMC of 74%, and only 
52% for both H-Gly-Pro-Arg-AMC and H-Ala-Pro-Arg-AMC. Perhaps this difference can be attributed 
to the high sensitivity of the UV spectrometer compared to TLC UV-analysis.  
 
 
6.2.2 PS-peptide conjugates with different linker systems 
 
Previous research on PS-peptide amphiphiles29 illustrated an elegant solid phase methodology for the 
coupling of the peptide fragment to polystyrene chains. Conversely, we focussed on a solution phase 
methodology since the peptide fragment required the presence of the AMC fluorophore at the 
C-terminus and thus could not be constructed on solid support.30 The synthesis of the peptide part 
(H-Gly-Gly-Arg-AMC, 11) is described in detail in Chapter 2. Subsequent alkyne functionalization of 
the tripeptide block was achieved by linking the N-terminus with 3-butynyl chloroformate 
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(Scheme 6.5). Terminal azide-functionalized PS of well-defined lenght (Mn = 4150 Da, PDI = 1.15) 
was readily synthesized using atom transfer radical polymerization (ATRP) and subsequent end group 
modification with azidotrimethylsilane and tetra-butylammonium fluoride (TBAF).31 The peptide and 
polymer blocks were then linked together under CuAAC conditions in THF (Scheme 6.5). Initial 
attempts using CuSO4/ascorbic acid as the catalytic system in THF/water mixtures were unsuccessful. 
We reasoned that this might be caused by the coordinating nature of copper ions to the arginine 
residue of the peptide fragment and therefore we examined the CuBr/PMDETA complex as the 
catalyst in pure THF at 35 °C. Although the peptide is only poorly soluble in THF the reaction was 
complete in 36 hours, as was judged from TLC.  
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Scheme 6.5 CuAAC reaction of alkyne-Gly-Gly-Arg-AMC (18) and PS-N3 (20). 
 
 
 
Figure 6.5 SEC traces of PS-N3 (18) and PS-Gly-Gly-Arg-AMC (21) at  = 254 nm and  = 330 nm.  
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Furthermore, size exclusion chromatography (SEC) in combination with UV detection (AMC group, 
abs = 330 nm) clearly showed the formation of the coupled product 21 (Figure 6.5). Broadening of the 
signal was observed for the product presumably caused by its amphiphilic behavior. Formation of the 
amphiphile was further confirmed by MALDI-TOF mass spectrometry, which revealed a clear shift in 
the molecular weight distribution with respect to the starting PS-N3. In addition, end group analysis of 
the molecular mass distribution was in line with the presence of the tripeptide (see experimental 
section). 
 
Starting from a polymer bearing both an azide and a carboxylic acid end group (i.e. 25a, Scheme 6.6), 
allows to sequentially couple two peptide segments, creating a biohybrid ABA-type triblock copolymer 
which can be considered a macromolecular bolaamphiphile. These bolaamphiphiles are an interesting 
class of amphiphiles that have been used to create monolayer membrane (MLM) vesicles but are also 
capable of forming several other useful assemblies.32 
The construction of peptide-PS-peptide biohybrid bolaamphiphilic materials required the synthesis of 
hetero-telechelic polystyrene. To this end, PS 22, bearing a tert-butyl-protected acid on one terminus 
and a bromide on the other end, was prepared by ATRP of styrene starting from tert-butyl-2-bromo-
isobutyrate (Scheme 6.6). Employing typical ATRP conditions for styrene (CuBr/PMDETA in 10% 
anisole, 90 °C) resulted in the well-defined precursor polymer 22 with two different lengths; n = 21 and 
49, both with a narrow molecular weight distribution (PDI ~ 1.1) as was determined by size exclusion 
chromatography (SEC). Deprotection of the tert-butyl ester end group proceeded smoothly with 
trifluoroacetic acid (TFA) and resulted in carboxylic acid-functionalized PS (100% and 75% for 23a 
and 23b, respectively) as was shown by FT-IR and 1H NMR spectroscopy. The acid functionality could 
be used for further derivatization, e.g. with the N-terminus of a peptide, directly resulting in biohybrid 
amphiphiles (vide infra). 
 
 
 
Scheme 6.6 Synthesis of hetero-telechelic PS derivatives. 
 
In addition, the bromide end group of PS 22 could also be readily substituted for an azide via reaction 
with Me3SiN3 and tetra-butylammonium fluoride (TBAF) in THF (Scheme 6.6). A complete conversion 
was indicated by the shift in the 1H NMR spectrum of the neighboring hydrogen from  = 4.5 ppm to  
= 4.0 ppm, for the bromide and azide end groups, respectively. The resulting -tert-butyloxycarbonyl-
-azido PS 24, could then be linked to alkyne-functionalized building blocks such as peptide 18 
applying CuAAC conditions (vide infra). Furthermore, the -terminus could also be deprotected using 
TFA in CH2Cl2 to yield -carboxy--azido PS 25 which is ready for functionalization on both ends. 
Preparation of this type of PS enables the construction of biohybrid bolaamphiphiles by sequential 
functionalization with peptides 11 and 18 (see Scheme 6.7). 
 
Synthesis of the bolaamphiphile 27 could be achieved via two complementary routes outlined in 
Scheme 6.7. Starting with a peptide coupling between compound 11 and -carboxy--azido PS 25a 
(route A), led to polymer-peptide 26 in a high yield (83%). Linking the alkyne-functionalized peptide 18 
to compound 26 was pursued by using the copper-catalyzed azide alkyne cycloaddition (CuAAC) 
reaction. To ensure complete solubility of all reaction partners, the coupling was carried out in DMF as 
a solvent. Since the results with CuBr/PMDETA suggested that coordination of copper to the arginine 
residue slightly hampered the coupling reaction of PS-N3 and peptide 18, the more strongly 
coordinating CuBr/tris(2-dimethylamino)ethyl)amine (Me6TREN) complex was used as a catalyst. 
Stirring 4 days at 35 °C resulted in the formation of bolaamphiphile 27 according to TLC and FT-IR 
analysis. However, purification of the product by preparative TLC and subsequent removal of the 
remaining copper-ions by extensive washing with an aqueous solution of ethylenediaminetetra-acetic 
acid (EDTA) failed to produce the desired pure product. 
 
Chapter 6 
 156
OO
H
N
O
N
H
HN
HN NH2
O H
N
O
N
H NH
H
N
O
N
H
O
HN
HN NH2
H
N
O
O O
O
O
N
O
n
NN
27 Route A (ND)
Route B (65%)
N
H
H
N
O
N
H
O
HN
HN NH2
H
N
O
O O
O
O
N
O
21RO
NN
28 R = tBu (64%)
29 R = H (33%)
CuBr/Me6TREN
DMF, 40 °C, 2 d
18
11 + 29
O
21RO
N3
24a R= tBu
25a R = H
pyBOP, DiPEA
DMF, r.t., 18 d
11
O
21HO
N3
25a
OO
H
N
O
N
H
HN
HN NH2
O H
N
O
N
H
N3
O
21
26 (83%)
CuBr/Me6TREN
DMF, 35 °C, 4 d
18
Route A:
Route B:
N N
'Me6TREN'
3
DMF
pyBOP
r.t. 18 h
 
 
Scheme 6.7 Routes to biohybrid bolaamphiphile 27 starting from hetero-telechelic PS 25a 
 
In order to circumvent purification difficulties as encountered after the second step of route A, we 
reversed the reaction sequence (route B) starting with the CuAAC reaction between azido-terminated 
PS (24a or 25a) and peptide 18. Polymer-peptides 28 and 29 were thus prepared analogous to the 
method described for the coupling of PS 26 and peptide 18 (Scheme 6.7, route A). After stirring for 48 
hours at 40 °C under an inert atmosphere, TLC analysis indicated completion of the reaction. To 
remove the catalyst, the reaction mixture was washed with an EDTA solution (0.067 M) before further 
purification by silica gel chromatography was applied. The polymer-peptide hybrid 28 was isolated in a 
reasonable yield (64%), 
comparable to previously obtained 
results. The coupling of PS 25a 
and peptide 18 led to compound 
29 in an isolated yield of 33%. The 
-carboxylic acid of polymer-
peptide 29 was subsequently used 
in the coupling to peptide 11, 
utilizing pyBOP as a coupling 
reagent, affording the desired 
bolaamphiphile 27 after purification 
by preparative TLC (65%). MALDI-
ToF mass spectrometry showed a 
clear shift in molecular weight 
distribution which was in good 
agreement with the expected mass 
(Figure 6.6). 
Figure 6.6 MALDI-ToF mass spectra of HOOC-PS21-Pept 29 
(bottom) and Pept-PS21-Pept 27 (top). 
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6.2.3 Amphiphilic behavior of biohybrid polymer-peptides 
 
The aggregation behavior (and size) of polymer-peptides 21, 26 and 27 in aqueous media was 
investigated to ensure that the synthesized products were appropriate macromolecular fluorogenic 
substrates (i.e. capable of forming micellar or vesicular architectures)33 suitable for the thrombin 
generation test.  
 
 
Figure 6.7 Vesicle formation of PS-Gly-Gly-Arg-AMC (21) studied by TEM (A, B, D) and SEM (C).30 
 
Assembly of the PS-Gly-Gly-Arg-AMC biohybrid amphiphile 21 was studied both directly after injection 
of a THF solution of PS-peptide 21 in water, and after standing for 18 hours at room temperature. The 
formation of vesicular structures, with an average size of 300 nm, was observed by transmission 
electron microscopy (TEM) (Figure 6.7A and B) and scanning electron microscopy (SEM) (Figure 
6.7C). The size of the aggregates was found to increase in time going from 150-500 nm up to 2 m 
after 18 hours (Figure 6.7D). 
 
To induce self-assembly of peptide-polymer hybrids 26-28, two procedures were employed; (i) 
injecting a THF solution of the polymer-peptide hybrids into water (to a final THF content of 9% v/v), 
and (ii) dialyzing the polymer-peptides against water starting from a solution in THF. Both methods 
resulted in cloudy mixtures, and TEM revealed the formation of spherical aggregates with a rather 
large size distribution (30-500 nm) (Figure 6.8). Some of the larger assemblies contained a hole 
revealing an empty interior (indicated by the arrows in Figure 6.8A). Besides the holes, it was noted 
that other defects such as disrupted membranes were also present for some of the larger aggregates 
of biohybrid 28 (Figure 6.8B). 
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Figure 6.8 TEM images of A) peptide-PS21-N3 26; B) tBu-ester-PS21-peptide 28 and C) Pept-PS21-Pept 
27. D) Cryo-SEM image of Pept-PS21-Pept 27. Assemblies from Pept-PS21-Pept 27 were prepared by 
dialysis of the sample solution in DMF against water. The arrows and numbers in the TEM image 
indicate the areas from which a 3-fold magnification is depicted on the upper right.  
 
Preparation of TEM samples for bolaamphiphile 27 using the same method as for the regular 
amphiphiles (placing a grid on top of the amphiphile solution, followed by the removal of excess water 
with paper) showed no assembly. Drop-casting an aggregate solution of bolaamphiphile 27 onto a grid 
and subsequent drying resulted in TEM images such as displayed in Figure 6.8C. The obtained 
structures seemed to be a network of collapsed spherical assemblies. Several of the spherical sub-
structures appeared to be hollow, suggesting that initially vesicular assemblies were obtained for the 
bolaamphiphile. Imaging using cryo-SEM gave a more clear picture of the assembly of bolaamphiphile 
27 (Figure 6.8D). Performing additional DLS measurements on Pept-PS21-Pept (27) samples showed 
spherical assemblies with a radius somewhat larger than those for the PS-peptide amphiphiles 21, 26 
and 28. In contrast to the assembly of PS-GGR-AMC (21), the average size of the aggregates 26-28 
was found not to increase significantly upon standing for a longer period of time. 
 
 
6.3 Biological evaluation of polymer peptide conjugates 
 
 
6.3.1 Biological evaluation of the PS-peptide biohybrids 
 
The selectivity of the vesicular amphiphiles of either the amide-linked PS-peptide (26) or the triazole 
linked PS-peptide (28) was assessed by subjecting BOA-buffer solutions (BOA = buffer ovalbumine) 
containing either conjugate 26 or 28 to both thrombin and 2M-thrombin complex (2M-T) and monitor 
the development of fluorescence in time. 
Monitoring the fluorescence as a function of time for amide-linked PS21-Gly-Gly-Arg-AMC (26, 
Figure 6.9, left frame), an insignificant increase was observed for both the thrombin- and 2M-T-
containing solution. Besides the minute change in fluorescence no selectivity was observed. A 
possible explanation might be the poor appropriate aggregates formation of PS-peptide 26 in a BOA-
buffer solution. This problem can be overcome by dissolving pre-formed vesicles, obtained via 
lyophilization of a PS-peptide containing H2O/THF solution, in buffer. The results obtained after 
subjecting the pre-formed vesicles to a thrombin and 2M-T-containing solution (Figure 6.9, middle 
frame) indicated that, although most likely vesicular structures were present in solution, no hydrolysis 
had taken place. Studying the fluorescence development of triazole-linked PS-peptide 28 upon 
hydrolysis by either thrombin or 2M-T complex, an unexpected decrease was observed (Figure 6.9 
right frame). This effect can be attributed to an incomplete vesicle formation or increasing 
temperature. The temperature effect was also observed for the blank experiment making this a 
probable cause of the fluorescence decrease.34 The second phenomenon (i.e. incomplete vesicle 
formation) can cause a decline of fluorescence as a result of stacking of the AMC molecules resulting 
in fluorescence quenching.35 Since the decrease of fluorescence is significantly stronger for the 
PS-peptide-AMC-containing solutions compared to the blank experiment, vesicle formation might be a 
second effect causing the initial fluorescence decrease. 
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Figure 6.9 Determination of the selectivity of PS21-peptide biohybrids 26 and 28 (358 M) for human 
thrombin (147 nM) over 2M-T (100 nM). 
 
In order to investigate the ability of thrombin to hydrolyze -Gly-Gly-Arg-AMC at the surface of the 
vesicular aggregates, an experiment was devised, measuring time-resolved fluorescence over the 
wavelength range 300-600 nm. First the hydrolysis of the amide linkage between arginine and AMC of 
the water soluble thrombin substrate H-Gly-Gly-Arg-AMC (11) by thrombin was monitored, which 
caused a distinct change in the fluorescence emission spectrum of the coumarin moiety 
(Figure 6.10A). The fluorescence emission at 380 nm, corresponding to the arginine-linked AMC, 
decreased in time, while concurrently an increase in fluorescence was observed at 440 nm, which 
corresponds to unbound AMC. Subjecting the PS-peptide assemblies (prepared from 26) to thrombin, 
gave no change in the fluorescence emission (Figure 6.10B). Moreover, increasing the concentration 
of thrombin (i.e. going from 1 M to 4.4 M) also did not result in hydrolysis of the polymer-peptide 
vesicles. This could be caused by fluorescence quenching of the fluorophore when present in the 
hydrophobic polystyrene bilayer.  
Control experiments in which AMC was added to the assemblies (not shown) indicated that even if the 
fluorophore would be included in the membrane, it would still be possible to detect its presence. 
Therefore, the obtained results demonstrate that thrombin is unable to hydrolyze the Arg-AMC bond 
when present in the vesicular assemblies. This could either be due to the close packing of the 
peptides or an unfavorable interaction between the highly hydrophobic PS chain and the enzyme. 
Mixing of PS and peptide-functionalized PS could overcome the close packing of the peptide head 
group thus making them more accessible for hydrolysis. It should be noted that the packing of 
peptides in assemblies of bolaamphiphile 11 is expected to be even higher than for the other 
amphiphiles because it was found that the fluorescence of AMC was partially quenched upon self-
assembly. No further investigation of the other PS-biohybrid amphiphiles was therefore undertaken.  
 
 
 
Figure 6.10 Fluorescence emission spectra (λexc = 325 nm) of; A: H-GGR-AMC (11) (1.0 M) and 
thrombin (FIIa, 1.0 M) in PBS buffer monitored at 37 °C. B: Pept-PS21-N3 (26) assemblies (16.0 M) 
and thrombin (FIIa, 1.0-4.4 M) in PBS buffer monitored at 37 °C. 
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6.3.2 Biological evaluation of the PEG-peptide biohybrids 
 
Next, we focused on the kinetic behavior of the linear and brushed PEG-containing polymer peptides. 
Since the PEG-containing polymer-peptides possess a high degree of water solubility it was possible 
to make a sufficiently high concentration range allowing accurate determination of the kinetic 
parameters KM and kcat of the substrates on human thrombin (Table 6.1). 
 
Table 6.1 Kinetic parameters of peptidyl AMC substrates and homologous PEG-peptide substrates. 
Compound [E] (M) [S] (M) KM (mM) kcat (s-1) vmax (M-1·s-1) 
H-Gly-Gly-Arg-AMC (11)a 0.18 200-1400 1.97 3.38 1.7·103 
H-Gly-Pro-Arg-AMC (2)b 1.11 200-1000 0.44 17.7 39.9·103 
H-Ala-Pro-Arg-AMC (4)a 0.09 50-1000 3.55 46.7 13.0·103 
mPEG-GGR-AMC (1) 0.10 100-1000 1.17 0.46 0.39  103 
mPEG-GPR-AMC (3) 0.10 118-944 0.45 16.4 36.0  103 
mPEG-APR-AMC (5) 0.48 25-800 0.14 1.27 11.3  103 
AMC-RGG-spacer-P(PEGMA) (15) 0.49 25-800 -c -c -c 
AMC-RPG-spacer-P(PEGMA) (16) 0.49 25-800 -d -d -d 
AMC-RPA-spacer-P(PEGMA) (17) 0.45 25-800 0.45 3.22 7.15  103 
a Data obtained from Chapter 3; b Data obtained from Chapter 5; c Could not be determined; d Irreproducible data.   
 
Comparison of the kinetics of mPEG-Gly-Gly-Arg-AMC and H-Gly-Gly-Arg-AMC showed no great 
difference in binding affinity (1.17 and 1.97M, respectively), however, a 7-fold decrease in the rate of 
hydrolysis was observed. Notably, the mPEG component did not affect the kinetic parameters of the 
substrate H-Gly-Pro-Arg-AMC resulting in similar values for KM or kcat. Against all expectations we 
found a strikingly large effect of the mPEG tail on H-Ala-Pro-Arg-AMC reducing the binding affinity a 
factor 25 (3.55 and 0.14 M for 4 and 5, respectively) and the rate of hydrolysis 37-fold (46.7 versus 
1.27 s-1 for 2 and 3, respectively). It is apparent that the influence of mPEG coupled to small peptides 
is highly variable and strongly dependent on the individual substrates, as was also observed by 
Hortin et al.12  
 
Figure 6.11 A) Kinetic experiment of AMC-RGG-spacer-P(PEGMA) in the concentration range of 
25-500 M. The arrows indicate the increase and decrease of fluorescence depending on the applied 
concentration. B) Maximum fluorescence (Fmax on t = 40 min.) versus concentration (C = 0 = blank 
experiment).  
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By changing to the more bulky P(PEGMA) polymer peptides 15-17 we found that determination of the 
kinetic parameters for compounds 15 and 16 was not possible. Measuring the fluorescence intensity 
as a result of the hydrolysis of AMC-RGG-spacer-P(PEGMA) (15) by thrombin, gave unexpectedly low 
values which increased and decreased with concentration (Figure 6.11A).  Moreover, a concentration 
dependent fluorescence maximum was observed with an optimum at a substrate concentration of 100 
M by plotting Fmax versus concentration (Figure 6.11B). A possible explanation for this phenomenon 
might be the restricted diffusion of thrombin at higher polymer-peptide concentrations as was also 
observed with increasing fibrin concentration during thrombin generation in clotting plasma.36  
 
An attempt to determine the kinetic parameters of polymer-peptide 16 failed since no reproducible 
data could be obtained. Conversely, assessment of kinetic parameters for AMC-RPA-spacer-
P(PEGMA) (17) gave good results. Surprisingly we found an increase of both KM and kcat in 
comparison with mPEG-Ala-Pro-Arg-AMC (0.45 vs. 0.14 and 3.22 vs. 1.27 for 17 vs. 5, respectively).  
 
After the kinetic parameter determination of the PEG-containing polymer peptides, the selectivity of 
these substrates for human FIIa over the 2M-thrombin complex was explored. Selectivity of the 
mPEG5000-peptide substrates (1, 3 and 5) was determined by monitoring the fluorescence increase 
during 20 minutes as a result of hydrolysis by either human thrombin (hFIIa) or the 2M-thrombin 
complex. The results, displayed in Graph 6.1A-C, showed a high degree of selectivity of mPEG5000-
Gly-Gly-Arg-AMC (1) for thrombin (Graph 6.1A). The amount of fluorescence was rather low however, 
which could be the result of the low substrate concentration (200 M). mPEG5000-Gly-Pro-Arg-AMC (3) 
generated a sufficient amount of fluorescence, however, a slight loss of selectivity was noticed (Graph 
6.1B). Substrate mPEG5000-Ala-Pro-Arg-AMC (Graph 6.1C) was found unsuited since poor selectivity 
was perceived and complete substrate consumption was reached within four minutes (far before 
thrombin generation would be completed).  
 
Subsequently, we focussed on the determination of the selectivity of the peptide-spacer-P(PEGMA) 
conjugates 15-17 shown in Graph 6.1D-F. A remarkable effect was observed when using P(PEGMA)-
functionalized Gly-Gly-Arg-AMC conjugate 15. A complete reversal of selectivity was found 
(Graph 6.2D), which to some extent, might explain the poor rate of hydrolysis by hFIIa (Figure 6.1A).    
A similar reversed effect was observed for both P(PEGMA) polymers 16 and 17, as both substrates 
were hydrolyzed much more rapidly by the 2M-T complex than by hFIIa. Full substrate conversion by 
2M-T was achieved after eight minutes for 16 and after only four minutes for 17. Both substrates 
showed no selectivity for one of the proteases since significant substrate hydrolysis by thrombin was 
also apparent. 
 
The reason for this behavior is still unclear at present but could be related to the repelling effect of the 
PEG-tails of the P(PEGMA) polymer on thrombin since poly(ethylene glycol) has demonstrated to be 
effective in retarding thrombin adsorption to unnatural surfaces (i.e. wells and glass tubes) by 
markedly reducing the adsorption rate.37 In addition, it has been shown that protein adsorption 
decreases dramatically with increasing graft density of PEG on various substrates, and thus should 
this effect be profoundly present in the P(PEGMA) polymers. 
 
Moreover, PEG is used to precipitate proteins by excluding the protein molecules from regions of 
solvent.38 At critical concentrations, PEG polymers selectively precipitate proteins without denaturing 
them at room temperature and are thus well suited for use in protein fractionation.39 Hence, if this 
precipitation process has a greater effect on the small free thrombin compared to the bulky 2M-T 
complex, then reversed selectivity could be observed. Finally, tuneable lower critical solution 
temperature (LCST) behavior has been observed for P(PEGMA) polymers depending on the initial 
composition of different monomers used.40 Although, with the high PEG-methacrylate monomer 
concentration in the P(PEGMA) polymer, the LCST temperature is expected to be high (> 37 °C), 
polymer length, polymer end-groups and the salt concentration all can have a significant effect on the 
LCS temperature. 
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Graph 6.1 Substrates tested on h-FIIa (100 nM) and 2M-T (152-260 nM) to determine selectivity. 
Left; mPEG5000-peptides 1 (200 M), 3 (0.95 mM) and 5 (1.0 mM). Right; peptide-spacer-P(PEGMA) 
15 (1.0 mM), 16 (1.0 mM) and 17 (1.0 mM). 
 
 
To investigate the reversed selectivity of AMC-RGG-spacer-P(PEGMA) (15) in more detail, the effect 
of the polymer-peptide substrate on the hydrolysis of chromogenic substrate DEMZ-Gly-Arg-pNA (see 
also Chapter 3, DEMZ = diethylmalonic acid monomethyl ester) by thrombin was studied. Mixtures of 
DEMZ (25 µl, final concentration 0.25 mM) and substrate 15 (0-10 µl, final concentrations ranging from 
0 to 60 µM) were added to wells containing 100 µl thrombin (final concentration 100 nM). The reaction 
was started upon the addition of the DEMZ + substrate 15 mixture after which the OD increase at 
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405 nm was followed during 30 minutes (Figure 6.12, left). From the initial slopes of the optical density 
measurements the rate of hydrolysis of DEMZ-Gly-Arg-pNA was calculated and plotted against the 
concentration of polymer peptide 15 (Figure 6.12, right). 
 
 
 
Figure 6.12 Left: Thrombin induced p-nitro-aniline (pNA) formation in the presence of substrate 15. 
Right: rate of hydrolysis of DEMZ-Gly-Arg-AMC versus concentration of polymer-peptide 15. 
 
 
As expected, a steady formation of p-nitro-aniline was observed as a result of hydrolysis of DEMZ-Gly-
Arg-pNA in the absence of polymer-peptide 15. To our surprise we found a decrease in p-nitro-aniline 
formation with an increasing polymer-peptide concentration (Figure 6.12, left). Plotting the initial rate 
constants against the concentration of AMC-Arg-Gly-Gly-spacer-P(PEGMA) (15) clearly showed full 
inhibition of thrombin, and thus pNA production, at a concentration of 35 M of 15. Since the protease 
selectivity test with substrate 15 was performed with a concentration of 1.0 mM, it is thus likely that 
complete thrombin inhibition resulted. For the other two substrates (16 and 17) the high rate of 
hydrolysis caused by the thrombin selective peptide fragments presumably competes with the 
inhibition by the P(PEGMA)-peptide thus resulting in the observation of significant hydrolysis by 
thrombin compared to the 2M-T complex. Further research is required to investigate the nature of this 
inhibition behavior of the peptide-spacer-P(PEGMA) substrates 16 and 17. 
 
Finally, thrombin generation experiments in normal pooled platelet poor plasma were performed with 
the linear mPEG-peptides 1 and 3 to investigate their behavior in a physiological medium. Thrombin 
generation experiments were performed following the calibrated automated thrombography (CAT) 
protocol described by Hemker et al.41 Using a substrate concentration of 1.0 mM, thrombin generation 
was performed at 37 °C during 40 minutes after which the crude data was processed to obtain the 
standard thrombin generation parameters (i.e. ETP, peak height, time-to-peak and lag time). 
Analyzing the thrombin generation curve obtained with mPEG-Gly-Gly-Arg-AMC (Figure 6.13, left), 
showed that minimal mathematical processing was required in order to obtain a suitable ETP value.    
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Figure 6.13 Thrombin generation curves measured in NPPP with mPEG5000-Gly-Gly-Arg-AMC (left) 
and mPEG5000-Gly-Pro-Arg-AMC (right). The dark dots represent the crude signal; the light dots 
represent the corrected data (corrected for 2M-T), and the black line is the fitted curve of the 
corrected data.   
 
The measured fluorescence was converted to thrombin units (nM), followed by subsequent 
differentiation of the signal resulting in the crude thrombin generation curve (dark dots) which needs 
little to no correction for the hydrolysis by the 2M-T complex. Performing a fit-procedure on the 
corrected data (light dots) enabled accurate determination of the endogenous thrombin potential 
(ETP). The TGC reflected lower values for the lag-time and time-to-peak compared to H-Gly-Gly-Arg-
AMC (see Chapter 3) and somewhat higher values for the peak height and ETP (Table 6.2). 
 
 
Table 6.2 Parameters calculated from the thrombograms obtained via CAT.  
Compound Lag time (min) Peak (nM) ttPeak (min) ETP (nM·min) 
H-GGR-AMC (11)a 1.56 ± 0.13 211.6 ± 11.9 4.71 ± 0.20 1409.6 ± 79.5 
mPEG5000-GGR-AMC (1) 1.14 ± ND 430.0 ± ND 3.54 ± ND 1721.0 ± ND 
mPEG5000-GPR-AMC (3) 1.44 ± ND 190.0 ± ND 4.88 ± ND 1910.0 ± ND 
a Experiment was performed in quadruple. ttPeak = time-to-peak 
 
 
The TGC of mPEG5000-Gly-Pro-Arg-AMC (3) required considerably more processing since the crude 
signal (dark dots) did not reach a zero-level end-point, indicative for hydrolysis by the 2M-T complex. 
Correction for the 2M-T activity (light dots) followed by a subsequent fit procedure (black line) allowed 
for determination of the thrombogram parameters (Table 6.2). Comparison of the thrombogram 
parameters of both mPEG-peptides demonstrated significant differences in all of the obtained values. 
Moreover, a distinct difference in shape as well as accuracy was apparent which required additional 
measurements to increase the accuracy and to unravel the underling mechanism of the change in 
curve shape. We suggest that interactions of the polymer with fibrinogen thus lowering its contents 
can be one of the causes for the peak lowering and broadening. The effect of decreasing 
concentration fibrinogen effecting the thrombin generation curve, as described vide supra, has been 
described by Hemker and coworker41 and thus could be further investigated.  
 
 
 
Macromolecular Fluorogenic Substrates 
 165
6.4 Conclusions 
 
 
Nine different polymer-peptide biohybrids were successfully synthesized, constructed from either 
poly(ethylene glycol), poly(PEG methacrylate) or polystyrene, coupled to either H-Gly-Gly-Arg-AMC, 
H-Gly-Pro-Arg-AMC or H-Ala-Pro-Arg-AMC. The PEG-containing fluorogenic substrates were 
synthesized in high yields starting from methoxy-PEG-p-nitrophenol-carbonate and the appropriate 
AMC-containing peptide fragment in a straightforward substitution reaction.  
Performing an ATRP on PEG-methacrylate monomer resulted in the graft-copolymer poly(PEGMA). 
Subsequent coupling of a peptide fragment did not result in the desired polymer-peptide adduct, 
presumably as a result of steric hindrance. Introduction of an ethylene glycol spacer on the PEG-
methacrylate monomer followed by ATRP and attachment of a peptide fragment furnished the desired 
AMC-peptide-spacer-P(PEGMA) construct. 
A modular build-up procedure was applied for the synthesis of PS-peptide amphiphiles. Both -
functionalized PS and hetero-telechelic PS were prepared via controlled polymerizations using ATRP.  
Hetero-telechelic PS enabled different synthetic approaches toward peptide-PS hybrid amphiphiles by 
making use of CuAAC or peptide coupling chemistry. Hence, the same precursor polymer was tailored 
for both coupling techniques, employing either alkyne-functionalized -Gly-Gly-Arg-AMC or the native 
peptide as the complementary part.  
The amphiphilic behavior of the PS-peptide conjugates was studied by means of TEM and SEM 
revealing spherical aggregates with dimensions corresponding to vesicular architectures.  
The obtained macromolecular fluorogenic substrates were subsequently subjected to thrombin and 
2-M-thrombin complex to determine both the rate of hydrolysis and the degree of selectivity. The 
PS-peptide conjugates did not show any hydrolysis by either thrombin or 2M-T, presumably as a 
result of the poor aggregate formation in protein-containing buffer solutions. The hydrophilic PEG-
peptide constructs were hydrolyzed by thrombin and showed peptide dependent kinetics. mPEG-Gly-
Gly-Arg-AMC displayed suboptimal kinetic parameters (low kcat), but a high degree of selectivity for 
thrombin over 2M-T. Substitution of the peptide fragment (GGR) for either -Gly-Pro-Arg-AMC or -Ala-
Gly-Arg-AMC resulted in favorable binding constants (KM), however, the rate of hydrolysis (kcat) was in 
both cases too high. Moreover, a decrease of the selectivity for thrombin over 2M-T was observed for 
mPEG-Gly-Pro-Arg-AMC which was even more profound for mPEG-Ala-Gly-Arg-AMC. 
Determination of the kinetic properties of the bulky P(PEGMA)-peptides was troublesome as a result 
of the inexplicable Michaelis-Menten curves. Surprisingly, upon subjection of the P(PEGMA)-peptides 
to both thrombin and 2M-T a complete reversal of selectivity was observed, with AMC-RGG-spacer-
P(PEGMA) being a completely selective 2M-T substrate. Further investigation of these results is 
required to determine the mode of action of the P(PEGMA) substrates. Preliminary thrombin 
generation experiments indicated that mPEG5000-Gly-Gly-Arg-AMC is a promising substrate since no 
correction for 2M-T hydrolysis was required (not present) thus simplifying mathematical processing 
for acquiring appropriate thrombin generation curves and parameters.    
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6.6 Experimental section 
 
 
General experimental: 
 
See Chapter 2 section 7. 
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Instrumentations 
 
Molecular weight distributions were measured using sixe exclusion chromatography (SEC) on a 
Shimadzu Liquid Chromatograph LC-10AD, equipped with a guard column and a PL gel 5 m mixed D 
column (Polymer Laboratories) with refraction index detector RID-10A en UV-VIS spectrophotometer 
SPD-10AV ( = 254 nm and  = 330 nm) detection using THF (1 mL/min at 35 °C), NMP (1 mL/min at 
65 °C) or chloroform (1.00 mL/min at 30 °C) as a solvent. Polystyrene (PS) standards in the range of 
580 to 377400 Da were used for calibration (For the peptide-polymer conjugates an apparent Mn is 
reported based on a PS calibration set). Gas chromatography spectra were measured on a Hewlett 
Packard HP5890 series II equipped with a HP1 column and conditions: start temperature 50 °C 
(5 min), rate 15 °C/min, end temperature 200 °C (10 min). Fluorescence measurements were 
performed on a Perkin Elmer luminescence spectrometer LS 55 equipped with a RM6 Lauda 
temperature controller fixed at 37 °C, using a 1 cm path-length quartz cuvette. TEM images were 
obtained using a JEOL JEM 1010 microscope (60 kV) equipped with a charge-coupled device (CCD) 
camera. SEM images were obtained using a JEOL JSM T300 microscope operating at 30 kV. 
 
 
Methods and materials 
 
The water used for the self-assembly studies was deionized using a Labconco Water Pro PS 
purification system. Styrene was distilled under reduced pressure prior to use. Anhydrous DMF was 
obtained from Biosolve. Dialysis tubing (regenerated cellulose membrane) with a molecular weight 
cut-off (MWCO) of 3 kDa was obtained from Spectra/Por. Thrombin solution (4.4 μM) was kindly 
donated by the University of Maastricht. mPEG5000(CH2)2CO-Gly-Gly-Arg-AMC (1) was purchased 
from Pentapharm (Basel, Switzerland).  
 
 
Synthesis 
 
The synthesis of tripeptides H-Gly-Gly-Arg-AMC (11), H-Gly-Pro-Arg-AMC (2) and H-Ala-Pro-Arg-AMC 
(4) is described in detail in Chapter 2. 
 
mPEG-(CH2)2-CO2-Gly-Pro-Arg-AMC (3) 
 
To a solution of H-Gly-Pro-Arg-AMC·HCl (40.1 mg, 0.072 mmol) in DMF (5 mL) was added DiPEA 
(12.5 μl, 0.18 mmol) and methoxy-PEG-p-nitrophenol-carbonate (395 mg, 0.08 mmol, MW 5000). The 
solution was stirred for 48 hours after which the solvent was removed in vacuo. The product was 
purified by counter-current chromatography (n-BuOH/H2O) and was obtained as an off-white solid 
(388 mg, 97%). 1H-NMR (400 MHz, D2O) : 7.65 (d, J = 8.8 Hz, 1H), 7.58 (d, J = 2.0 Hz, 1H), 7.40 
(dd, J = 8.8, 2.0 Hz), 6.25 (s, 1H), 4.32-4.40 (m, 2H), 3.94 (q, J = 12.0 Hz, 2H), 3.82-3.99 (m, 2H), 
3.35-3.80 (br, 540H), 3.24 (s, 3H), 3.11 (t, J = 6.8 Hz, 2H), 2.45 (s, 3H), 2.11-2.27 (m, 1H), 1.51-195 
(m, 7H). Accu-TOF MS: calc for 3 (n=109): 2683.0487 [M+H+Na]2+, found; 2684.2161 [M+H+Na]2+.  
 
mPEG-(CH2)2-CO2-Ala-Pro-Arg-AMC·HCl (5) 
 
To a solution of H-Ala-Pro-Arg-AMC·HCl (41.0 mg, 0.072 mmol) in DMF (5 mL) was added DiPEA 
(12.5 μl, 0.18 mmol) and methoxy-PEG-p-nitrophenol-carbonate (395 mg, 0.08 mmol, MW 5000). The 
solution was stirred for 48 hours after which the solvent was removed in vacuo. The product was 
purified by counter-current chromatography (n-BuOH/H2O) and was obtained as an off-white solid 
(350 mg, 87%). 1H-NMR (400 MHz, D2O) : 7.71 (d, J = 8.4 Hz, 1H), 7.63 (s, 1H), 7.40 (d, J = 8.3 Hz, 
1H), 6.29 (s, 1H), 4.51-4.44 (m, 3H), 4.21 (m, 3H), 3.26 (t, J = 6.8 Hz, 2H), 3.95-3.46 (br m, 645H) 
2.43 (s, 3H), 2.35 (m, 1H), 2.10-1.63 (m, 7H) 1.34 (d, J = 6.7 Hz, 3H). GPC (NMP): Mn = 6017, PDI = 
1.06. Accu-TOF MS: calc for 5 (n=109): 2690.5605 [M+H+Na]2+ found; 2691.1145 [M+H+Na}2+  
 
tert-Butyl-12-oxo-3,6,9,13-tetraoxapentadecyl 2-bromo-2-methylpropanoate (6) 
 
In a flame dried Schlenk tube tert-butyl-12-hydroxy-4,7,10-dodecanoate 
(380 L, 1.44 mmol) was dissolved in CH2Cl2 (9.0 mL) and Et3N 
(300 L, 2.15 mmol, 1.5 equiv) was added. The reaction mixture was 
stirred for 10 min at 0 °C after which 2-bromo-2-methylpropanoyl 
O O
O
O
3
O
Br
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bromide (210 L, 1.70 mmol, 1.2 equiv) was added drops wise. The mixture was warmed to room 
temperature and stirred for 18 hours. The reaction mixture was diluted with EtOAc (100 mL) and 
washed with saturated NH4Cl (2  50 mL). The organic layer was dried over Na2SO4 and subsequently 
evaporated in vacuo. After purification by column chromatography (EtOAc/heptane 1:1) the product 
was obtained as a white solid (480 mg, 99%). 1H-NMR (300 MHz, CD3OD) : 4.34-4.31 (m, 2H), 3.76-
3.59 (m, 12H), 2.50 (t, J = 6.6 Hz, 2H), 2.00 (s, 3H), 1.94 (s, 3H), 1.44 (s, 9H). 13C-NMR (75 MHz, 
CD3OD) : 172.8, 172.7, 81.7, 71.7, 71.62, 71.56, 71.4, 69.8, 67.9, 66.3, 57.1, 37.3, 31.2, 28.4. HRMS 
(ESI+) m/z calcd for C17H31BrNaO7 [M+Na]+ 449.1151, found: 449.1168. 
 
tert-Butyl-12-oxo-3,6,9,13-tetraoxapentadecyl 2-methylpropanoate-P(PEGMA) (7) 
 
A Schlenk tube filled with CuBr (10.1 mg, 0.071 mmol) and 2,2’-bipyridine (21.9 mg, 0.14 mmol, 
2 equiv) was three times evacuated and flushed with argon. A solution of PEG-methacrylate 
(monomer) (2.06 g, 1.87 mmol, 30.0 equiv) dissolved in DMSO-d6 (5.0 mL) was flushed with Argon for 
1 hour and was subsequently added to the Schlenk after which the reaction mixture was placed at 
60 °C. At t = 0, compound 6 (initiator) (34.0 mg, 0.080 mmol, 1 equiv) in 0.2 mL DMSO-d6 was added 
and the reaction was monitored by NMR spectroscopy until 100% conversion was reached. The 
reaction was cooled to room temperature and subsequently quenched via addition of CH2Cl2 
(100 mL). The reaction mixture was washed with H2O (10 mL) and 0.067 M EDTA solution (225 mL). 
The organic layer was dried with Na2SO4 and after filtration and evaporation of the solvents the 
residue was dissolved in methanol and precipitated in Et2O. Decantation and drying yielded the 
polymer as a white solid (1.45 g, 58%). 1H-NMR (300 MHz, CDCl3) : 4.07 (br s, 52H), 3.87 (t, J = 
4.7 Hz, 14H), 3.77-3.47 (br m, 2927H), 3.44-3.34 (m, 119H), 2.49 (t, J = 6.5 Hz, 2H), 1.44 (s, 9H), 1.12 
(s, 3H), 1.09-0.70 (br m, 70H). Number of repeating units (n) was determined by 1H-NMR (n = 14). 
GPC (NMP): Mn = 26.1 kg/mol, PDI = 1.20.  
 
Carboxylic acid terminated 12-hydroxy-4,7,10-dodecane-P(PEGMA) (8) 
 
To 1.16 g of polymer 7 in CH2Cl2 (5 mL) was added TFA (3.5 mL, 46.0 mmol, excess) and the reaction 
was stirred for 18 hours. The reaction was washed with saturated NaHCO3 solution (3  35 mL) and 
the organic layer was subsequently dried with Na2SO4. After filtration and evaporation of the solvent 
the desired polymer was obtained as a white solid (0.99 g, 88%).1H-NMR (300 MHz, CDCl3) : 4.07 
(br s, 60H), 3.87 (t, J = 4.7 Hz, 14H), 3.80-3.46 (br m, 4341H), 3.41-3.35 (m, 158H), 2.59 (t, J = 
6.5 Hz, 2H), 1.25 (s, 3H), 1.13 (s, 3H), 1.08-0.68 (br m, 91H). GPC (NMP): Mn = 25.4 kg/mol, PDI = 
1.21. 
 
tert-Butyl ester terminated P(PEGMA) (9) 
 
A Schlenk tube filled with CuBr (9.4 mg, 0.066 mmol) and 2,2’-bipyridine (bpy) (20.0 mg, 0.128 mmol, 
2 equiv) was three times evacuated and flushed with Argon. A solution of PEG-methacrylate 
(monomer) (1.99 g, 1.81 mmol, 30.0 equiv) dissolved in DMSO-d6 (5.0 mL) was flushed with Argon for 
1 hour and was subsequently added to the Schlenk after which the reaction mixture was placed at 
60 °C. At t = 0, tert-butyl--bromo-isobutyrate (initiator) (12 µl, 0.065 mmol, 1 equiv) was added and 
the reaction was monitored by NMR spectroscopy until 100% conversion was reached. The reaction 
was cooled to room temperature and subsequently quenched via addition of CH2Cl2 (100 mL). The 
mixture was washed with H2O (10 mL) and 0.067 M EDTA solution (225 mL). The organic layer was 
dried with Na2SO4 and after filtration and evaporation of the solvents the residue was dissolved in 
methanol and precipitated in Et2O. Decantation and drying yielded the polymer as a white solid 
(1.41 g, 50%). 1H-NMR (300 MHz, CDCl3) : 4.06 (br s, 87H), 3.88-3.84 (m, 30H), 3.79-3.48 (br m, 
4100H), 3.41-3.35 (m, 164H), 1.93 (br s, 3H), 1.40 (br s, 9H), 1.11-0.68 (m, 113H). Number of 
repeating units (n) was determined by 1H-NMR (n = 20). GPC (NMP): Mn = 36.3 kg/mol, PDI = 1.19. 
 
Carboxylic acid terminated P(PEGMA) (10) 
 
To 1.00 g of polymer 22 in CH2Cl2 (5 mL) was added TFA (4.0 mL, 52.6 mmol, excess) and the 
reaction was stirred for 18 hours. The reaction was washed with saturated NaHCO3 solution (3  
35 mL) and the organic layer was subsequently dried with Na2SO4. After filtration and evaporation of 
the solvent the desired polymer was obtained as a white solid (0.95 g, 95%). 1H-NMR (300 MHz, 
CDCl3) : 4.60 (br s, 97H), 3.88-3.85 (m, 28H), 3.77-3.46 (br m, 5510H), 3.43-3.33 (m, 239H), 1.24 
(s, 6H), 1.17-0.63 (br m, 141H). GPC (NMP): Mn = 29.7 kg/mol, PDI = 1.32. 
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General procedure for the synthesis of peptide-spacer-P(PEGMA) conjugates (15-17): 
 
To HO-spacer-P(PEGMA) (8, 312 mg, 9.510-3 mmol) dissolved in DMF (5.0 mL) was added the 
appropriate amount of peptide (0.0141 mmol, 1.5 equiv), i.e. 7.29 mg for H-Gly-Gly-Arg-AMC· 2HCl, 
7.86 mg for H-Gly-Pro-Arg-AMC·2HCl or 8.05 mg for H-Ala-Pro-Arg-AMC·2HCl. The reaction mixture 
was cooled to 0 °C and DMAP (4.8 mg, 0.039 mmol, 4.0 equiv) and EDC·HCl (2.5 mg, 0.013 mmol, 
1.1 equiv) were subsequently added. After 30 min. the mixture was warmed to room temperature and 
stirred for 18 hours. The reaction mixture was diluted with CH2Cl2 (15.0 mL) and was washed with 
saturated NH4Cl solution (2  10 mL). The organic layer was dried with Na2SO4 and subsequently 
filtrated, evaporated and lyophilized from H2O/dioxane (1:1 v/v).  
 
The degree of functionalization was determined by UV-Vis spectroscopy. The different peptides were 
dissolved in H2O to obtain concentrations of 0.025 mg/mL. The polymer-peptide samples were 
dissolved in H2O generating concentrations of 0.680 mg/mL for polymer-GGR-AMC, 0.615 mg/mL for 
polymer-GPR-AMC and 0.655 mg/mL for polymer-APR-AMC. Next, the absorption at 324 nm was 
measured for all the samples and the concentration peptide-AMC was determined. Comparison of 
these values with the theoretical concentration (determined via MWpep/(MWtot  conc.)) gave the 
degree of functionalization. The obtained results are summarized in Table 6.3. 
 
Table 6.3 Determination of the degree of functionalization.* 
Compound Conc. 
mg·mL-1 
Abs 
324 nm 
Conc. 
pep-AMC 
Theor. conc. 
mg·mL-1 
Function. 
% 
H-GGR-AMC (11) 0.025 0.507    
H-GPR-AMC (2) 0.025 0.622    
H-APR-AMC (4) 0.025 0.660    
AMC-RGG-spacer-P(PEGMA) (15) 0.680 0.166 0.0082 0.011 74 
AMC-RPG-spacer-P(PEGMA) (16) 0.615 0.142 0.0057 0.011 52 
AMC-RPA-spacer-P(PEGMA) (17) 0.655 0.165 0.0062 0.012 52 
* Samples dissolved in H2O and measured on a Varian Cary 50 spectrophotometer using a quartz cuvette 
 
 
N-3-Butyn-1-yl-Gly-Gly-Arg-AMC (18) 
 
To a solution of H-Gly-Gly-Arg-AMC·2HCl (11, 258.5 mg, 0.5 mmol) in a H2O/dioxane mixture (5:1, 
v/v) was added 2M NaOH until the pH reached 9-10. Under a nitrogen atmosphere 3-butyn-1-yl 
chloroformate (62.3 µL 0.55 mmol) was added and the mixture was allowed to stir for 5 hrs at room 
temperature. Completion of the reaction was monitored by TLC: BuOH/H2O/AcOH (4:1:1). The product 
was lyophilized and purified by counter current chromatography using an n-BuOH/H2O system. After 
purification the product was obtained as a white solid (yield 185 mg, 63%). RF = 0.48 
(BuOH/H2O/AcOH, 4:1:1). 1H-NMR (300 MHz, CD3OD) : 7.88 (d, J = 1.8 Hz, 1H), 7.73 (d, J = 8.7 Hz, 
1H), 7.57 (dd, J = 8.8, 2.1 Hz, 1H), 6.25 (d, J = 1.2 Hz, 1H), 4.58 (dd, J = 9.0, 4.8 Hz, 1H), 4.12 (dt, J = 
6.8, 1.5 Hz, 2H), 3.92 (d, J = 7.8 Hz, 2H), 3.80 (s, 2H), 3.24 (t, J = 7.0 Hz, 2H), 2.50 (td, J = 6.9, 
3.5 Hz, 2H), 2.48 (d, J = 1.2 Hz, 3H), 2.30 (t, J = 2.3, 1H), 2.09-1.95 (m, 1H), 1.92-1.65 (m, 3H). 
13C-NMR (75 MHz, CD3OD)  (ppm): 173.5, 172.5, 172.1, 163.2, 158.7, 155.4, 155.3, 143.4, 126.8, 
117.5, 117.4, 113.8, 108.3, 107.6, 71.1, 64.5, 55.0, 45.3, 43.9, 42.0, 30.1, 26.4, 19.9, 18.6. HRMS 
(ESI+) m/z calcd for C25H31N7NaO7 [M+Na]+ 564.2483, found: 564.2467. 
 
-Bromo-polystyrene (19) 
 
CuBr (72.1 mg, 0.50 mmol) was placed in a Schlenk tube fitted with a stopper, evacuated and back-
filled with argon. This procedure was repeated three times. After the evacuating cycles the stopper 
was replaced by a septum. Anisole (0.6 ml), N,N,N’,N’,N”-pentamethyl diethylenetriamine (PMDETA, 
87.5 mg, 0.50 mmol) and styrene (3.11 g, 29.9 mmol) were added and the reaction mixture was 
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cooled in an ice bath. Subsequently, 1-bromoethylbenzene (92.9 mg, 0.50 mmol) was added and the 
reaction mixture was purged with argon for 5 min. and warmed to 90 °C. Samples were taken 
periodically for conversion analysis by gas chromatography. The polymerisation was stopped after 
450 min. (64% conversion) by cooling and exposing the catalyst to air. The reaction mixture was 
diluted with CHCl3 and washed with an aqueous ethylenediaminetetraacetic acid (EDTA) solution 
(0.065 M) in order to remove the copper catalyst. The organic layer was dried over MgSO4 and 
concentrated under reduced pressure. The polymer was precipitated in methanol, yielding a white 
solid which was dried under vacuum. 1H-NMR (CDCl3, 300 MHz) : 7.36-6.38 (br. m, arom H), 4.48 
(br. m, CH2-CH(Ph)-Br), 2.17-1.24 (br. m, backbone CH2 , CH), 1.11-1.02 (br. s, H3C-CH(Ph)-CH2). 
FT-IR max film (cm-1): 3019, 2925, 2837, 2008, 1943, 1865, 1796, 1597, 1493, 1450. SEC (THF): Mn = 
4.15 kg/mol, PDI = 1.15. 
 
-Azido-polystyrene (20) 
 
To a solution of PS-Br (1.83 g, 0.44 mmol) in THF (10 ml) were added azidotrimethylsilane (445.2 mg, 
3.86 mmol) and TBAF (4 ml of 1 M solution in THF, 4 mmol). The reaction mixture was stirred 
overnight at room temperature under a nitrogen atmosphere and the polymer was precipitated in 
methanol, yielding a white solid which dried under vacuum (1.72 g, 94%). 1H-NMR (CDCl3, 300 MHz) 
: 7.36-6.38 (br. m, arom H), 3.91 (br. m, CH2-CH(Ph)-N3), 2.17-1.24 (br. m, backbone CH2, CH), 1.11-
1.02 (br. s, H3C-CH(Ph)-CH2). FT-IR max film (cm-1): 3019, 2925, 2837, 2090, 2008, 1943, 1865, 1796, 
1597, 1493, 1450. SEC (THF): Mn = 4.15 kg/mol, PDI = 1.15. MALDI-TOF MS: see Figure 6.14A. 
 
PS-triazole-Gly-Gly-Arg-AMC (21) 
 
N-3-Butyn-1-yl-Gly-Gly-Arg-AMC (18, 6.4 mg, 0.011 mmol) and PS-N3 (20, 40.2 mg, 0.010 mmol) 
were placed in a Schlenk vessel. After the vessel was evacuated and back-filled with argon for three 
times the materials were suspended in THF (0.5 ml). CuBr (3.2 mg, 0.022 mmol) and PMDETA 
(5.4 L, 0.023 mmol) were dissolved in THF (0.5 ml) and argon purging for 5 min. prior to addition to 
the reaction. The mixture was stirred under an argon atmosphere for 18 hrs. The reaction was 
monitored by TLC analysis (CH2Cl2) tripeptide 18 RF = 0.05, PS 20 RF = 0.95 and PS-Gly-Gly-Arg-
AMC stripes from bottom to front). A minute amount of Cu(0) was added and the mixture was allowed 
to stir under an argon atmosphere for an additional 18 hrs. After dilution with CH2Cl2 the mixture was 
washed twice with an aqueous EDTA solution (0.065 M). The organic phase was concentrated under 
reduced pressure and filtered over silica gel using CH2Cl2 as the mobile phase (ca. 10 mL). Upon 
addition of MeOH a milky substance was obtained which was concentrated under reduced pressure 
yielding an off-white solid (24 mg, 51%). Note: the moderate yield is due to the difficult isolation of the 
product. 1H-NMR (DMF-d7, 400 MHz) : 7.40-6.20 (br. m, arom H), 6.10 (br. s, (CH3)C=CH AMC), 5.18 
(br. m, triazole-CH(Ph)-CH2), 4.09 (br. m, CH2-CH2-O-CO), 2.27 (br. s, (CH3)C=CH AMC) 2.20-1.20 
(br. m, backbone CH2, CH), 1.00-0.90 (br. s, H3C-CH(Ph)-CH2). SEC (CHCl3, UV detection  = 330 
nm): Mn = 3.9 kg/mol, PDI > 1.45. MALDI-TOF MS: see Figure 6.14B. 
 
 
 
Figure 6.14 MALDI-TOF spectra of PS-N3 (A) and PS-Gly-Gly-Arg-AMC (B). 
 
The mass of the end groups can be derived from a molecular weight distribution by plotting the 
molecular mass against number of repeating units (N). Consequently, the intercept (N = 0) affords the 
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mass of the end groups. Using the peak at N = 26 as a reference also N for the other peaks was 
determined and a plot of mass versus N was constructed. Linear regression (using Origin 6.1 
software) of this dataset resulted in the following equation:  
 
Mass = 104.07 * N + 689.98  
 
Herein 104.07 corresponded to the mass of one repeating unit of styrene (calc. 104.06) and the 
intercept of 689.98 was in line with the initiator (calc 105.07) plus the -Gly-Gly-Arg-AMC end group 
(calc 583.24) and an additional proton.  
 
-tert-Butyl ester--bromo-polystyrene (22a,b) 
 
A Schlenk tube with CuBr (1 equiv) was three times evacuated and flushed with Argon. A mixture of 
styrene, 10% anisole (IS) and PMDETA (1 equiv) flushed with Argon was added and the reaction 
mixture was placed at 90 °C. At t = 0 the initiator, tert-butyl--bromo-isobutyrate (1 equiv) was added. 
The conversion of the reaction was monitored with gas chromatography (GC) until 67% of conversion 
was reached. The reaction was stopped by cooling and exposing the catalyst to air and subsequent 
dilution with CH2Cl2. The mixture was washed with 50 mL of 0.067 M EDTA solution. After evaporation 
of the organic layer the residue was dissolved in CH2Cl2 and precipitated in MeOH. Filtration and 
drying yielded the desired polystyrene (tBuO2C-PSn-Br) as a white solid.  
For 22a (n = 21): 10 mL (87.4 mmol, 30 equiv) styrene, 1.0 mL IS (10%), 421 mg (2.94 mmol, 
1.0 equiv) copper bromide and 0.7 mL (2.95 mmol, 1.0 equiv) PMDETA. At t = 0, 0.55 mL (2.95 mmol, 
1.0 equiv) initiator, tert-butyl--bromo-isobutyrate, was added. Filtration and drying yielded polystyrene 
(tBuCO2-PS21-Br) as a white solid (3.9 g, 96%). 1H-NMR (300 MHz, CDCl3) : 7.26-6.90 (br m, 62H), 
6.84-6.32 (br m, 47H), 4.41 (br s, 1H), 2.52-1.36 (br m, 70H), 0.98-0.69 (br m, 6H). SEC (THF) Mn = 
2260 kDa, PDI = 1.11  
For 22b (n = 49): 129.4 mg (0.90 mmol, 1 equiv) CuBr, 5.0 mL (43.7 mmol, 49 equiv) styrene, 0.5 mL 
(10%) anisole (IS) and 214 µl (0.90 mmol, 1 equiv) of PMDETA. At t = 0, 170 µL (0.91 mmol, 1 equiv) 
initiator, tert-butyl--bromo-isobutyrate, was added. Filtration and drying yielded polystyrene (tBuO2C-
PS49-Br) as a white solid (2.9 g, 95%). 1H-NMR (300 MHz, CDCl3)  (ppm): 7.26-6.90 (br d, 148H), 
6.84-6.32 (br m, 94H), 4.41 (br s, 1H), 2.55-1.96 (br m, 157H), 0.94-0.71 (br m, 6H). SEC (THF) Mn = 
5330 kDa, PDI = 1.13 FT-IR (solid) cm-1: 3023, 2920, 1720, 1600, 1491, 1450, 1065, 907, 754, 696. 
 
-Carboxylic acid--bromo-polystyrene (23a,b) 
 
To 1.0 g (1 equiv) of polystyrene (22a or 22b) in 15 mL CH2Cl2 was added TFA (0.65 mL (50 equiv) 
and the reaction mixture was stirred for 18 hours. After washing twice with 50 mL of a saturated 
NaHCO3 solution and evaporation of the organic layer the residue was dissolved in CH2Cl2 and 
precipitated in MeOH. Filtration and drying yielded the acid terminated polystyrene (PS) as a white 
solid; 23a: 738 mg, 100%, SEC (THF) Mn = 2290, PDI = 1.12, MALDI-ToF MS; calcd for 23a [M+H]+ 
2352, found: 2350. 23b: 716 mg, 72% SEC (THF) Mn = 5350 kDa, PDI = 1.14. FT-IR (solid) cm-1: 
3027, 2962, 2917, 1698, 1600, 1491, 1450, 1066, 904, 754, 696. 
 
-tert-Butyl ester--azido polystyrene (24a,b) 
 
To 1.0 g (1 equiv) of polystyrene (23a or 23b) in 10 mL dry THF in a nitrogen atmosphere 350 µL 
(7.7 equiv) of TMS-N3 and 3.6 mL (7.7 equiv) of a 1M TBAF solution in THF were added. After stirring 
for 18 hours at room temperature the solvent was evaporated and the residue was precipitated from 
CH2Cl2 in MeOH. After filtration and washing with MeOH (2) and subsequent drying, the product was 
obtained as a white solid (24a: 917 mg (90%), 24b: 664 mg (84%)). 1H-NMR (300 MHz, CDCl3) : 
7.36-6.38 (br. m, arom H), 3.95 (br. m, CH2-CH(Ph)-N3), 2.17-1.24 (br. m, backbone CH2 , CH and 
tBu), 0.97-0.84 (br. m, CO-C(CH3)2-CH2. FT-IR (solid) cm-1: 3024, 2920, 2092 (N3), 1719, 1600, 1492, 
1451, 1131, 1027, 905, 755, 696. For 24a: SEC (THF) Mn = 2380 kDa, DPI = 1.10, MALDI-ToF MS; 
calcd for 24a [M+H]+ 2371, found; 2393 [M+Na]+. For 24b: SEC (THF) Mn = 5460 kDa, DPI = 1.12, 
MALDI-ToF MS; calcd for 24b [M+H]+ 5288, found; 5310 [M+Na]+  
 
-Carboxylic acid--azido-polystyrene (25a) 
 
To 400 mg polystyrene 24a in 10 mL CH2Cl2 was added TFA 0.28 mL (50 equiv) and the mixture was 
stirred for 18 hours. TLC analysis showed residual starting material so additional TFA (0.2 mL) was 
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added and the mixture was stirred for an additional 8 hours. After washing with saturated NaHCO3 
solution (2  50 mL) and evaporation of the organic layer the residue was dissolved in CH2Cl2 and 
precipitated in MeOH. Filtration and drying yielded acid terminated polystyrene 25a as a white solid 
(301 mg, 78%) 1H-NMR (300 MHz, CDCl3)  (ppm): 7.22-6.30 (br m, 114H), 3.94 (br s, 1H, COOH), 
2.41-1.24 (br m, 66H), 1.01-0.84 (br m, 6H), SEC (THF) Mn = 2540, DPI = 1.10, MALDI-ToF MS; calcd 
for 25a [M+H]+ 2315, found; 2338 [M+Na]+ FT-IR (solid) cm-1: 3027, 2962, 2920, 2092 (N3), 1719, 
1600, 1492, 1450, 1066, 904, 754, 696. 
 
-AMC-Arg-Gly-Gly--azido polystyrene (26) 
 
To a cooled solution (0 °C) of PS 25a (52 mg, 0.023 mmol) and peptide 11 (20 mg, 0.039 mmol 
(2.0 equiv)) dissolved in 7 mL DMF was added DiPEA (18 µL, 0.11 mmol (4.0 equiv)). After stirred at 
0 °C for 10 min, PyBOP was added (32 mg, 0.062 mmol (2.6 equiv)). After 30 min the reaction mixture 
was warmed to rt and stirred for 18 hours. The reaction mixture was then diluted with CH2Cl2 and 
washed once with 10 mL saturated NaHCO3 solution. After evaporation of the organic layer the 
residue was purified by means of column chromatography (CH2Cl2/MeOH 9:1 v/v). The product was 
obtained as a white solid 53 mg (83%)  SEC (NMP) Mn = 7050, DPI = 1.06, MALDI-ToF MS; calcd for 
26 [M+H]+ 2744, found; 2744 
 
-tert-Butyl ester--triazole-Gly-Gly-Arg-AMC polystyrene (28) 
 
A solution of PS 24a (22 mg, 0.01 mmol) and peptide 18 (6 mg, 0.01 mmol) dissolved in 5 mL extra 
dry DMF was N2-flushed during 5 min. After flushing with nitrogen 1.0 mL (2.0 equiv) of a stock 
solution of CuBr and Me6TREN in extra dry flushed DMF (5.8 mg CuBr and 11.3 mg Me6TREN in 
2.0 mL DMF) was added, after which the reaction was placed at 35 °C under an N2-atmosphere. The 
reaction was stopped after 48 hours, diluted with CH2Cl2 (5 mL) and washed once with 10 mL of 
0.067 M EDTA solution. After evaporation of the organic layer the residue was purified by means of 
column chromatography (CH2Cl2/MeOH 9:1 v/v). Conjugate 28 was obtained as a yellowish solid 
18 mg (64%). SEC (NMP) Mn = 6720 kDa, DPI = 1.07, MALDI-ToF MS; calcd for 28 [M+H]+ 2914, 
found; 2933 [M+Na]+ 
 
-Carboxylic acid--triazole-Gly-Gly-Arg-AMC polystyrene (29) 

A solution of PS 25a (21 mg, 0.01 mmol) and peptide 18 (6 mg, 0.01 mmol) dissolved in 5 mL extra 
dry DMF was N2-flushed during 5 min. After flushing with nitrogen 1.0 mL (2.0 equiv) of a stock 
solution of CuBr and Me6TREN in extra dry flushed DMF (5.8 mg CuBr and 11.3 mg Me6TREN in 
2.0 mL DMF) was added, after which the reaction was placed at 35 °C under an N2-atmosphere. The 
reaction was stopped after 48 hours, diluted with CH2Cl2 (5 mL) and washed once with 10 mL of 
0.067 M EDTA solution. After evaporation of the organic layer the residue was purified by means of 
column chromatography (CH2Cl2/MeOH 9:1 v/v). Conjugate 29 was obtained as a slightly yellowish 
solid 8.9 mg (33%). SEC (NMP) Mn = 4345, DPI = 1.56, MALDI-ToF MS; calcd for 29 [M+H]+ 2858, 
found; 2856 

-AMC-Arg-Gly-Gly--triazole-Gly-Gly-Arg-AMC polystyrene (27) 
 
Method A: 
 
Under Schlenk conditions -peptido--azido polystyrene (26, 29 mg, 0.01 mmol) and peptide 18 
(5.9 mg, 0.01 mmol, 1.0 equiv) were dissolved in extra dry DMF (5 mL) and flushed with argon. After 
5 min flushing with Argon 1.0 mL (2.0 equiv) of a stock solution of CuBr (6.6 mg, 0.05 mmol) and 
Me6-TREN (18.0 mg, 0.05 mmol) in extra dry flushed DMF (2 mL) was added and the resulting mixture 
was placed at 40 °C overnight. The reaction was stopped after 18 hours through exposure to air and 
dilution with CH2Cl2 (10 mL). The solvents were evaporated and the crude mixture was purified by 
preparative TLC (CH2Cl2/MeOH 4:1 v/v) to obtain a light greenish solid. The product was dissolved in 
an EDTA solution (30 mL, 0.067 M) and subsequently extracted with CH2Cl2 (2  50 mL). The 
combined organic layers were dried with Na2SO4 and evaporation to yield again a light greenish solid. 
Yield: N.D. No analyses were performed. 
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Method B: 
 
To a cooled solution (0 °C) of conjugate 29 (44.0 mg, 0.015 mmol) and peptide 11 (12.0 mg, 
0.023 mmol, 1.5 equiv) dissolved in DMF (3 mL) was added DiPEA (11 µl, 0.06 mmol, 4.0 equiv). After 
stirring for 10 min at 0 °C, PyBOP (20 mg, 0.039 mmol, 2.6 equiv) was added and the rxm was stirred 
for an additional 30 min at 0 °C. The reaction mixture was warmed to rt and stirred for 18 hours. After 
evaporation of the solvent, the residue was purified by preparative TLC (CH2Cl2/MeOH 4:1 v/v). The 
spot at RF = 0.35 was extracted using BuOH/AcOH/ H2O (16:4:1 v/v) yielding compound 27 as a 
yellowish solid (32 mg, 65%). Characterisation was done by means of MALDI-ToF mass spectrometry. 
MALDI-ToF MS; calcd for 27 [M+H]+ 3282, found; 3285. 
 
 
Biological evaluation 
 
Determination of the selectivity of PS21-peptides 26 and 28 for thrombin over 2M-thrombin 
 
Sample preparation:  
PS21-Gly-Gly-Arg-AMC (26, 5.7 mg) was dissolved in 1 mL THF (2150 M) and subsequently diluted 
with THF to obtain a solution of 430 M (1 mL). 
Lyophilized PS21-Gly-Gly-Arg-AMC42 (26, 5.7 mg) was dissolved in a mixture of 1 mL THF and 1 mL 
milliQ water and subsequently diluted with milliQ water to obtain a solution of 430 M (1 mL). 
PS21-Gly-Gly-Arg-AMC (28, 1.4 mg) was dissolved in 1.2 mL THF to obtain a solution of 430 M 
(1.2 mL). 
 
Enzyme preparation:  
Human thrombin (hFIIa), 4.4 M stock solution, was diluted with BOA buffer to obtain a solution of 
880 nM (400 L). Lyophilized 2M-thrombin complex (2M-T) was reconstituted with 1 mL milliQ water 
to obtain a solution of 600 nM (1 mL). Both the hFIIa and the 2M-T solution were kept at 0 °C and 
warmed to 37 °C prior to use. 
 
Kinetic experiment: 
A set of 8 wells of an Immulon 2HB, round-bottom 96-well plate, was filled with 100 μL of the 
appropriate substrate (quadruple measurement). A set of four wells in a 96 wells plate was filled with 
20 μL hFIIa and the second set of four wells was filled with 20 μL 2M-T. The 96 wells plate was 
placed in an Ascent reader, Thermolab systems OY fluorometer equipped with a 390/460 filter set 
(excitation /emission) at 37 °C. In a typical experiment fluorescence was measured continuously 
during 40 min. The obtained data was organized in Microsoft Excel®. 
 
Determination of kinetic parameters (KM and kcat) for mPEG-peptides 1, 3 and 5, and for the peptide-
spacer-PMMA-PEG substrates 15, 16 and 17. 
 
The following solutions were prepared and stored at the indicated temperatures: 
 
Substrates: 
Polymer-peptide 1 (57 mg, 0.01 mmol) was dissolved in 1.0 mL HEPES buffer (20 mM, 140 mM NaCl, 
pH 7.35) to give a 10 mM stock solution. From this stock solution a series of dilutions was prepared 
(total volume of 500 μL) to give final substrate concentrations in the well of 100, 200, 400, 600, 800, 
1000, 1250, and 1500 M. The dilutions were kept at 37 °C. 
Polymer-peptide 3 (136 mg, 0.025 mmol) was dissolved in 1.2 mL milliQ water to give a 29.5 mM 
stock solution. From this stock solution a series of dilutions was prepared (total volume of 500 μL) to 
give final substrate concentrations in the well of 118, 236, 354, 472, 590, 708, 826, and 944 M. The 
dilutions were kept at 37 °C. 
Polymer-peptide 5 (27.9 mg, 0.02 mmol) was dissolved in 0.5 mL BSA60+ buffer (bovine serum 
albumin, Sigma, A-7030, 60 mg/mL containing NaCl (8.18 mg/mL)) to give a 10 mM stock solution. 
From this stock solution a series of dilutions was prepared (total volume of 500 μL) to give final 
substrate concentrations in the well of 50, 100, 200, 400, 600, 800 and 1000 M. The dilutions were 
kept at 37 °C. 
Polymer-peptide 15 (56.65 mg, 2.5 mol) was dissolved in 0.5 mL BSA60+ buffer to give a 5 mM stock 
solution. From this stock solution a series of dilutions was prepared (total volume of 500 μL) to give 
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final substrate concentrations in the well of 25, 50, 100, 200, 300, 400 and 500 M. The dilutions are 
kept at 37 °C. The same procedure was applied on polymer-peptide 16 (54.38 mg, 2.5 mol) and 
polymer-peptide 17 (57.94 mg, 2.5 mol).  
 
Fluo-solution:  
Z-Gly-Gly-Arg-AMC (61.5 mg, 0.1 mmol, Bachem, I-1140) was dissolved in 1.0 mL DMSO to give a 
100 mM stock solution. 7.5 μL of the 100 mM stock solution and 292.5 μL BSA60 buffer 
(NOT containing NaCl) were shortly vigorously mixed to give a Fluo-solution of 2.5 mM. The solution 
was kept at room temperature. 
 
h-Thrombin:  
A solution of 0.6 M activated human thrombin (denoted hFIIa) was prepared from a 4.4 M FIIa stock 
solution via dilution with BSA5 buffer (5 mg/mL). The FIIa solution was kept at 0 °C. Prior to use it was 
warmed to 37 °C. 
 
Calibrator:  
Lyophilized α2M-T complex (Thrombinoscope BV, The Netherlands) was reconstituted in 1 mL 
deionized water to give a final enzyme concentration of 600 nM. The calibrator solution was kept at 
0 °C. Prior to use it was warmed to 37 °C. 
 
Kinetic experiment:  
A set of four wells of an Immulon 2HB, round-bottom 96-well plate, was filled with 100 μL of each 
appropriate substrate concentration (total 4  8 wells, quadruple measurement). A set of four wells in a 
96 wells plate was filled with 80 μL BSA5 buffer followed by 20 μL of Fluo solution. The 96 wells plate 
was placed in a Ascent reader, Thermolab systems OY fluorometer equipped with a 390/460 filter set 
(excitation/emission) and allowed to warm to 37 °C (approximately 5 min). To all the wells containing 
substrate, 20 μL of 0.6 M hFIIa solution was added to initiate hydrolysis (200 nM end concentration in 
wells, 4  8 wells in total). To the wells containing the Fluo-solution, 20 μL of calibrator was added to 
initiate hydrolysis. In a typical experiment fluorescence was measured continuously during 40 minutes 
at 37 °C. The obtained data was organized in Microsoft Excel® and the kinetic parameters were 
obtained by fitting the data to the Michaelis-Menten equation. For the determination of KM and kcat the 
initial reaction velocity of the first 10 minutes was used. The amidolytic activity was calculated by 
comparing the arbitrary fluorescence values to those of an AMC-calibration curve. Results of different 
experiments were compared by correcting the amidolytic activity of each experiment with the 
amidolytic activity found for the calibrator which was measured in the same 96 wells plate. 
 
Determination of the selectivity of mPEG-peptides 1, 3 and 5 for thrombin over 2M-thrombin  
 
The following solutions were prepared and stored at the indicated temperatures: 
 
Sample preparation: 
mPEG-Gly-Gly-Arg-AMC (1, 57 mg, 0.01 mmol) was dissolved in 1 mL HEPES buffer (pH 7.35) to 
obtain a stock solution of 10 mM (1 mL) which was subsequently diluted with HEPES buffer (pH 7.35) 
to a 1.2 mM solution (1 mL). 
mPEG-Gly-Pro-Arg-AMC (3, 136 mg, 0.025) was dissolved in 1.2 mL milliQ water to obtain a stock 
solution of 29.5 mM (1.2 mL) which was subsequently diluted with HEPES buffer (pH 7.35) to a 
1.13 mM solution (1 mL).   
mPEG-Ala-Pro-Arg-AMC (5, 55.7 mg, 0.01 mmol) was dissolved in 1.0 mL BSA60+ to obtain a stock 
solution of 10 mM (1 mL) which was subsequently diluted to a 1.2 mM solution (1 mL). 
 
Enzyme preparation:  
Human thrombin: 4.5 M or 13.5 M stock solution was diluted with BSA5 buffer to obtain a solution of 
600 nM (400 L). Lyophilized 2M-thrombin complex (2M-T) was reconstituted with 1 mL milliQ water 
to obtain a solution of 600 nM (1 mL). Both the hFIIa and the 2M-T solution were kept at 0 °C and 
were warmed to 37 °C prior to use. 
 
Kinetic experiment:  
Identical to the experiment performed with PS-peptides (vide supra) 
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Determination of the selectivity of peptide-spacer-P(PEGMA) substrates 15, 16 and 17 for thrombin 
over 2M-thrombin  
 
The following solutions were prepared and stored at the indicated temperatures: 
 
Sample preparation: 
AMC-Arg-Gly-Gly-spacer-P(PEGMA) (15, 56.65 mg) was dissolved in 0.5 mL BSA60+ buffer to obtain 
a solution of 5 mM (0.5 mL) which was subsequently diluted to a 0.6 mM solution (1.5 mL).  
AMC-Arg-Pro-Gly-spacer-P(PEGMA) (16, 54.38 mg) was dissolved in 0.5 mL BSA60+ buffer to obtain 
a solution of 5 mM (0.5 mL) which was subsequently diluted to a 0.6 mM solution (1.5 mL).  
AMC-Arg-Pro-Ala-spacer-P(PEGMA) (17, 57.94 mg) was dissolved in 0.5 mL BSA60+ buffer to obtain 
a solution of 5 mM (0.5 mL) which was subsequently diluted to a 0.6 mM solution (1.5 mL).  
 
Enzyme preparation:  
Human thrombin: 13.5 M stock solution was diluted with BSA5 buffer to obtain a solution of 600 nM 
(2 mL). 2M-thrombin complex (2M-T): stock 1.56 M was used as such. Both the hFIIa and the 
2M-T solution were kept at 0 °C and were warmed to 37 °C prior to use. 
 
Kinetic experiment:  
Identical to the experiment performed with PS-peptides (vide supra) 
 
Fluorescence based measurement of thrombin activity (TGT) 
 
A detailed experimental description of calibrated automated thrombin generation measurements is 
found in references 41 and 43, as well as in Chapter 3. The development of fluorescence intensity 
from 7-amino-4-methyl-coumarin was typically measured in a 96-well plate fluorometer (Ascent 
reader, Thermolabsystems OY, Helsinki Finland) equipped with a 390/460 filter set 
(excitation/emission) and a dispenser. Immulon 2HB, round-bottom 96-well plates (Dynex) were used. 
Minimal four readings were done per minute and experiments were carried out in quadruplicate unless 
otherwise indicated. 
To each well, 80 μL of NPPP was added. Wells in which TG was measured received 20 μL of buffer, 
containing the trigger but no Ca2+. Wells in which constant thrombin-like activity was to be measured 
received 20 μL of the 2M-T solution at the required concentration as indicated. For NPPP, the trigger 
consisted of 30 pM of recombinant tissue factor (rTF) and 24 μM phosphatidylserine/ 
phosphatidylcholine / phosphatidylethanolamine vesicles in HEPES-buffered saline.  
The 96-well plate was placed in the fluorometer and allowed to warm to 37 °C (minimal 10 min). The 
dispenser of the fluorometer was flushed with warm 100 mM CaCl2 solution, emptied, and then flushed 
with warm 1.0 mM mPEG-peptide solution in BSA5 (FluCa). At the start of the experiment, the 
instrument dispensed 20 μL of FluCa into all wells to be measured, registered this as zero time, shook 
the samples for 10 sec. and started reading. Thrombin generation was typically monitored during 
40 min. after which the experiment was halted and the obtained data was exported to an appropriate 
software program for further processing. 
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Metal-Free Azide – Alkene  
Cycloaddition Reactions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
 
In our search for a new bioorthogonal ligation method we explored the use of C-, N-, O- and S-bridged 
tricyclic alkenes and C-, N-, O- and S-bridged bicyclic alkenes in the 1,3-dipolar cycloaddition reaction. 
The synthesis of a variety of C-, N-, O- and S-bridged tricyclo[5.2.1.02,6]dec-8-ene-3,5-diones and N- 
and O-bridged norbornadienes is described. Their reactivity in the 1,3-dipolar cycloaddition reaction 
was tested with benzyl azide at ambient temperatures and in absence of a transition metal catalyst. 
The bridged tricylic-alkenes requiring prolonged reaction times and formed stable tetracyclic triazoline 
compounds. Inversely, the bridged bicyclic-alkenes gave a fast reaction with benzyl azide generating 
stable triazoles via a tandem cycloaddition – retro-Diels–Alder reaction sequence.*   
 
 
Reference 
*   Published in modified form; Sander S. van Berkel, A. (Ton) J. Dirks, Marjoke F. Debets, Floris L. van Delft, Jeroen J. L. 
M. Cornelissen, Roeland J. M. Nolte and Floris P. J. T. Rutjes, ChemBioChem 2007, 8 (13), 1504-1508. 
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7.1 Introduction 
 
 
Ligation methods play an important role in various fields of molecular and biomolecular science. 
Especially processes compatible with biological conditions are considered of high value. Methods 
such as Michael addition onto maleimides,1 the Staudinger ligation,2 and the Diels-Alder reaction3 are 
currently employed in the selective modification of proteins and other biomolecules. In recent years 
the Cu(I)-catalyzed variant  of the Huisgen 1,3-dipolar cycloaddition,4,5,6 also referred to as “click 
reaction”, has been increasingly applied in various fields of chemistry as a versatile and mild ligation 
method.7 This method allows for the synthesis of complex materials including bioconjugates,8 
glycopeptides,9 functionalized polymers,10 virus particles,11 and therapeutics.12 In the previous chapter 
we demonstrated the use of the copper-catalyzed 1,3-dipolar cycloaddition reaction in the coupling of 
polystyrene and the thrombin substrate H-Gly-Gly-Arg-AMC constructing polymer-peptide biohybrids.13 
Applying the copper-catalyzed cycloaddition reaction on the arginine-containing peptide fragment 
resulted in suboptimal yields. This was partly due to purification problems of the conjugates as a result 
of the basic guanidine moiety of the arginine residue. Secondly, the strong coordinating effect of the 
copper-ions to peptide fragments, consisting of the amino acid sequence -Gly-Gly-Xaa (Xaa residue 
side chain contains a basic amine moiety) reduced the amount of active catalyst and therewith the 
efficacy of the reaction.14 Finally, copper-ions coordinated to the guanidine moiety of arginine might 
inhibit the binding of this residue in the active site of thrombin.  
In order to circumvent the use of copper ions, Bertozzi and coworkers15 devised a strain-promoted 
[3+2] cycloaddition reaction.* This work was based on strain release of a cyclooctyne derivative upon 
reaction with a 1,3-dipole (e.g. azide) to form 1,2,3-triazoles as was previously reported by Banert.16 
This fast, efficient and bioorthogonal ligation method possesses one serious drawback, being the 
synthesis of the elusive cyclooctynes.  
Inspired by the work of Bertozzi we set out to develop a potential reaction partner, a dipolarophile, for 
the 1,3-dipolar cycloaddition reaction with an 1,3-dipole, e.g. an azide based on the principle of strain 
release. A literature survey revealed the use of 4,10-dioxatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione 
(I, Figure 7.1) as reactant in the 1,3-dipolar cycloaddition reaction.  
 
 
 
Figure 7.1 Schematic representation of reported 1,3-dipolar cycloaddition reactions of various 
dipolarophiles (tricyclic systems I, II and III) with different 1,3-dipoles.  
 
The tricyclic compound I was synthesized via a straightforward Diels–Alder17 between furan and 
maleic anhydride, first described by Otto Diels and Kurt Alder.18  In addition, this system was reacted 
with 1,3-dipoles (i.e. azides19 and nitriloxide20) in a 1,3-dipolar cycloaddition reaction to produce the 
corresponding tetracyclic systems (Figure 7.1). More recently compounds with the general structures II 
and III (Figure 7.1), produced via a Diels–Alder reaction between a diene (e.g. furan or 
cyclopentadiene) and maleimide, gave smooth conversions to tetracyclic triazole compounds upon 
reaction with either azides,21 nitriloxides,22 or benzylidene-phenylhydrazine.23 This concept of strain 
and reactivity of various alkenes was also elegantly described by Shea et al.24 further supporting the 
idea of using constrained cyclic alkene systems for the 1,3-dipolar cycloaddition reaction. 
                                                 
* The terms 1,3-dipolar cycloaddition and [3+2] cycloaddition, for constructing 5-membered heterocyclic structures, can both be 
used since  both reactions refer to a cycloaddition of a 3-atom containing 1,3-dipole and 2-atom containing dipolarophile 
(reference 38a). 
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Our envisaged target molecule (Figure 7.2) should comply with three criteria; (i) it should be a 
synthetically readily accessible compound, equipped with a functional group either incorporated or 
attached via a spacer; (ii) the structure should possess a constrained (cyclic) conformation to react in 
1,3-dipolar cycloaddition reaction in the absence of transition metal catalyst (e.g. copper); (iii) the 
target molecule must react in a 1,3-dipolar cycloaddition reaction under mild reaction conditions (i.e. 
room temperature, ambient atmosphere and preferably in water). The first two criteria are met with C-, 
N-, O- and S-bridged tricyclo[5.2.1.02,6]dec-8-ene-3,5-diones, as depicted in Figure 7.2.  
 
 
 
Figure 7.2 Target molecule; C-, N-, O- and S-bridged tricyclo[5.2.1.02,6]dec-8-ene-3,5-diones. 
 
The bridged tricyclo[5.2.1.02,6]dec-8-ene-3,5-diones can be obtained via a Diels-Alder reaction of the 
appropriate diene and maleic anhydride or maleimide. The maleic anhydride moiety can easily be 
post-modified via ring-opening with suitable nucleophiles and the maleimide can be post-modified by 
alkylation. Finally, the constrained double bond can react in a 1,3-dipolar cycloaddition reaction with 
1,3-dipoles to form triazolines (vide supra). 
 
 
7.2 Synthesis of C-, N-, O- and S-bridged  
 tricyclo[5.2.1.02,6]dec-8-ene-3,5-diones 
 
 
7.2.1 4,10-Dioxa-tricyclo[5.2.1.02,6]dec-8-ene-3,5-dione and  
 10-oxa-4-aza-tricyclo[5.2.1.02,6]dec-8-ene-3,5-dione 
 
To obtain a diverse set of tricyclic systems, Diels-Alder reactions were performed using a variety of 
substituted furans and maleic anhydride or maleimide resulting in compounds 1-9 (Figure 7.3). 
 
Figure 7.3 Diels-Alder reaction of substituted furan and either maleic anhydride or maleimide for the 
formation of the O-bridged compounds 1-9. 
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The products were generally obtained as a mixture of exo and endo isomers, of which the ratio was 
mainly determined by the substituents on the furan ring. Compound 1 was synthesized according to a 
literature procedure25 resulting in only the exo isomer in a reasonable yield (65%). The reaction 
between the maleimide and an excess of furan gave compound 2 in a moderate yield as a single 
isomer. Besides compounds 1 and 2 several bridge-head-substituted 10-oxa-4-aza-tricyclic systems 
were synthesized (3 to 9) starting from different substituted furans and maleimide. The reaction 
between methyl 3-furanoate and maleimide turned out to be troublesome and did not result in the 
formation of 3. As a result of the relatively low HOMO energies of the furans bearing an electron-
withdrawing group on the 2 and/or 5 position reactions needed to be carried out under high pressure 
(1.5 GPa) at ambient temperature. Products 4 and 5 were produced in this way but compound 7 
required additional heating to 50 °C.  
 
The synthesis of 1-nitro-7-carboxylic acid-10-oxa-4-aza-tricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (6) 
remained unsuccessful even at high-pressure and elevated temperatures. Electron-donating furan 
derivatives (R1 = 2-OMe and 2-Me) underwent the Diels-Alder reaction again smoothly. Compounds 8 
and 9 were formed at ambient temperature and pressure (method A) and gave mixtures of both the 
endo and exo isomer in ratios of 1:5 and 1:6 for 8 and 9, respectively. The results of the Diels-Alder 
reactions are summarized in Table 7.1 
 
 Table 7.1 Reaction conditions applied for the preparation of compounds 1-9. 
Entry X R1 R2 R3 Method Exo a Endoa 
1 O H H H A 1 (65) - 
2 NH H H H B 2 (32) - 
3 NH H H CO2Me A 3 (0) - 
4 NH H CO2H H C 4 (7) - 
5 NH H CO2Et H C 5 (76) - 
6 NH NO2 CO2H H C 6 (0) - 
7 NH CN NO2 H Cb 7 (20) -c 
8 NH H OMe H A 8a (47) 8b (11) 
9 NH H Me H A 9a (61) 9b (11) 
 Method A: Et2O, r.t., 16 hours; Method B: H2O, reflux, 16 hours; Method C: EtOAc, ΔP, r.t., 6-7 days. a) Isolated yields (%); 
b) 50 °C instead of r.t.; c) Found on TLC, not isolated. 
 
 
7.2.2 4,10-Diaza-tricyclo[5.2.1.02,6]dec-8-ene-3,5-dione 
 
A second relevant class of compounds to be evaluated in the cycloaddition reaction are the 4,10-
diaza-tricyclo[5.2.1.02,6]dec-8-ene-3,5-diones. Besides maleimide functionalization, the second bridged 
nitrogen atom can be used to introduce additional functionalities. Finally, substituents on the 2-position 
of pyrrole allow modification of the 4,10-diaza-tricyclic systems on the bridgehead position. Therefore, 
we set out to explore a small series of diaza-tricyclic systems, depicted in Figure 7.4. The Diels-Alder 
reactions were performed with maleimide or N-substituted maleimide and several N-protected 
pyrroles. Not all of the desired N-protected pyrroles were commercially available so that initial 
synthesis was required.  
 
Scheme 7.1 Protection of pyrroles with Boc, Ts or Ns protecting groups. Reagents and conditions: i) 
pyrrole, NaOH, p-TsCl, CH2Cl2, 0 °C (20 min)  r.t. 16 h. ii) pyrrole, NaOH, o-NsCl, CH2Cl2, 0 °C (20 
min)  r.t. 16 h. iii) 2-methoxylcarbonylpyrrole, NaH, THF, 0 °C (30 min), Boc2O in THF,  r.t. 18 h. 
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In Scheme 7.1 the N-protection of pyrrole and 2-methoxy-carbonyl pyrrole with either a tosyl-, ortho-
nosyl- or Boc-protecting group is depicted, generating compounds 18, 19 and 20. Tosyl protection of 
pyrrole26 produced compound 18 in good yield (87%). Applying the same procedure led to ortho-nosyl 
pyrrole 19, albeit, in a lower yield. The procedure described by Reese et al.27 allowed facile protection 
of pyrroles with a Boc-protecting group and resulted in the synthesis of compound 20 in an excellent 
yield (99%). 
 
 
 
Figure 7.4 Diels-Alder reaction of protected and substituted pyrroles with maleimide for the formation 
of the N-bridged compounds 10-17. 
 
 
 
Figure 7.5 Crystal structures of 4,10-diaza-tricyclo[5.2.1.02,6]dec-8-ene-3,5-diones. A = 10, B = 11, 
C = 14, D = 13. 
              
A B 
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Initially, the Diels-Alder reaction between N-Boc pyrrole and maleimide was attempted at ambient 
reaction conditions, however, this failed to produce compound 10. Applying high pressure (1.5 GPa) to 
the reaction mixture resulted in formation of the desired compound (10). Since the Diels-Alder reaction 
is known to be strongly solvent dependent,28 different solvents e.g. acetonitrile, dichloromethane and 
ethyl acetate were screened. Ethyl acetate gave the most satisfying results as it provided the product 
as a single exo-isomer in a good yield (85%). Applying the same reaction conditions provided 
compounds 11 and 12 in 13% and 80%, respectively (Table 7.2). Despite the initial observation of 
both isomers by 1H-NMR spectroscopy, only the thermodynamically more stable exo-isomer was 
isolated. In case of compound 11, the endo isomer 11b also was obtained after chromatography, 
however, a rapid retro-Diels–Alder reaction of this isomer gave both starting materials. Much to our 
surprise both the nosyl- and tosyl-protected pyrroles gave exclusively endo isomers. The configuration 
of endo compounds 13b and 14b was confirmed by X-ray crystallography (Figure 7.5). 
 
 Table 7.2 Reaction conditions1 applied for the preparation of compounds 10-17. 
Entry PG X R1 Temp Time Exo a Endo a 
1 Boc N-H H 50 °C 3 d 10 (85) - 
2 Boc N-Me H r.t. 6 d 11 (13) - 
3 Boc N-Ph H r.t. 6 d 12 (80) Trace 
4 o-Ns N-H H 50 °C 6 d - 13b (63) 
5 p-Ts N-H H 50 °C 6 d - 14b (77) 
6 Boc N-H MeO2C 50 °C 3 d 15a (11) 15b (20) 
7b Boc N-H B(OH)2 50 °C 3 d 10 (49) - 
8 Boc O H various conditions 17 (0) - 
 1) Conditions: EtOAc, N-protected pyrrole, maleimide (1 equiv.), ΔP, r.t. or 50 °C. a) Isolated yields (%). b) CH2Cl2 instead of  
EtOAc.  
 
The aforementioned conditions for the construction of tricyclic systems were additionally applied in the 
synthesis of compounds 15 and 16 starting from substituted pyrroles (i.e. N-Boc-pyrrole-2-boronic acid 
and compound 20). In case of compound 15, both isomers were obtained in moderate yield. The 
synthesis of compound 16 (Figure 7.4, and Table 7.2, entry 7) was performed in dichloromethane due 
to the poor solubility of N-Boc-pyrrole-2-boronic acid in ethyl acetate. After three days at 1.5 GPa and 
50 °C a white precipitate was obtained. Remarkably, the desired product 16 was not formed, but 
instead, compound 10 was obtained in a 49% yield. Deboronation of aromatic boronic acids is a 
known process, which generally proceeds under strong acidic conditions and elevated temperatures.29 
A similar process is known to proceed for boronic esters under the influence of acetic acid at lower 
temperatures.30 In our experiment, however, neither strong acids nor boronic esters were used. 
Presumably, the boronic acid catalyzes its own deboronation at 50 °C and high pressure. 
Attempts to obtain structure 17 applying various conditions including high pressure and elevated 
temperatures appeared unsuccessful. Possibly the product is formed under pressure, but instantly 
decomposes at atmospheric pressure via a retro-Diels–Alder reaction. 
 
 
7.2.3 10-Thia-, 10-methylene-, and 10-isopropylidene-4-aza-
tricyclo[5.2.1.02,6]dec-8-ene-3,5-dione 
 
Finally, the synthesis of compounds 21-23 bearing either a sulfur- or carbon atom on the bridged 
position (Figure 7.6) was attempted. Synthesis of compounds with the general structure of 21 is 
notoriously difficult due to the aromatic character of thiophene.31 Kotsuki et al. 32 reported on a solvent 
free reaction of thiophene and maleimide applying high pressure and elevated temperatures to 
produce the endo and exo isomer of compound 21 in good yields. Exploring these reaction conditions 
in order to obtain compound 21 were in our hands unsuccessful.  
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Figure 7.6 Diels-Alder reaction of thiophene, cyclopentadiene and fulvene with maleimide for the 
formation of compounds 21-23.  
 
Eventually, isomers 21a and 21b were synthesized by applying high pressure (1.5 GPa) and elevated 
temperature (50 °C), using dichloromethane as a solvent and prolonged reaction times (up to 7 days). 
The products were obtained in low yields after column chromatography and were crystallized to 
determine their structure (Figure 7.7 A and B). 
 
 
Figure 7.7 Crystal structures of: A = 21b, B = 21a, C = 22 and D = 23. 
 
The synthesis of compound 22 required initial cracking of dicyclopentadiene33 before proceeding with 
the Diels-Alder reaction as described in literature.34 Stereochemical studies have pointed out that the 
Diels-Alder reaction between cyclopentadienes and maleimides is prevalently endo-diastereoselective 
though can be influenced by solvent, temperature and catalyst.35 Two routes were therefore pursued 
in order to obtain the exo-isomer (methods B and C). In method B a low temperature and a relatively 
polar solvent (EtOAc) was used resulting in the formation of merely the endo-product in high yield 
(88%). Microwave reaction conditions were employed for in-situ cracking of dicylcopentadiene to 
cyclopentadiene, which subsequently could undergo the Diels-Alder reaction with maleimide. This 
reaction was performed in a sealed tube at a temperature of 150 °C using an apolar solvent (toluene). 
Under these conditions the desired exo-product was unfortunately not obtained, but instead, a 
moderate amount of the endo-isomer was isolated as confirmed by X-ray crystallography, Figure 7.7C. 
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Changing to the fulvene derivative, the Diels-Alder reaction with maleimide, performed according to 
literature precedent in refluxing toluene,36 gave the desired exo-product as a single isomer in good 
yield (23, 70%). Again the conformation of the isomer could be confirmed by X-ray crystallography 
(see Figure 7.7 D). The results obtained for the C- and S-bridged tricyclo[5.2.1.02,6]dec-8-ene-3,5-
dione are summarized in Table 7.3  
 
 Table 7.3 Reaction conditions applied for the preparation of compound 21-23  
Entry X Z Method Exo a Endo a 
1 S N-H A 21a (3.3) 21b (6.6) 
2 CH2 N-H B 22a (0) 22b (88) 
3 CH2 N-H C 22a (0) 22b (35) 
4 C=C(Me)2 N-H D 23 (70) - 
 a)  Isolated yields (%).  Method A: CH2Cl2, ΔP, 50 °C, 7d.; method B: EtOAc, r.t. 42 h; method C: Toluene, W (300 W), 
150 °C, 20 min; method D: Toluene, 110 °C, 24 h. 
 
 
7.3 1,3-Dipolar cycloaddition reactions with C-, N-, O- and 
S-bridged tricyclo[5.2.1.02,6]dec-8-ene-3,5-diones 
 
 
The applicability of the bridged tricyclic systems in 1,3-dipolar cycloaddition reactions was initially 
tested by reacting 4,10-dioxa-tricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (1) with benzyl azide in CDCl3 at 
25 °C (Scheme 7.2). The conversion was monitored by 1H-NMR spectroscopy showing that 1 partially 
decomposed to furan and maleic anhydride and gave only 10% of the desired tetracyclic triazoline 24.   
 
 
 
Scheme 7.2 Cycloaddition reactions of 1 and 2 with benzyl azide. 
 
Repeating the experiment using the more stable compound 2, formation of tetracyclic triazoline 25 
(20%) was observed without decomposition. The optimal solvent for the 1,3-dipolar cycloaddition 
reaction was determined by screening six deuterated solvents i.e. CDCl3, DMSO-d6, CD3OD, D2O, 
acetone-d6, CD3CN and C6D6 in the cycloaddition reaction of 10 with benzyl azide (Scheme 7.3). 
 
 
 
Scheme 7.3 Cycloaddition reactions of 10 with benzyl azide in different deuterated solvents. 
 
The conversions in the different solvents were determined by 1H-NMR spectroscopy after 48 hours. 
Apart from D2O and C6D6 (solubility problems) the reactions proceeded smoothly, with MeOD giving 
the highest conversion (60%). The reaction mixtures were combined and compound 26 was isolated 
(yield not determined). Structure elucidation using both 1H- and 13C-NMR spectroscopy indicated that 
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both the exo,exo compound 26a and the endo,exo compound 26b were formed (Scheme 7.3). 
Selective crystallization of a mixture 26a and 26b via evaporation from n-heptane/EtOAc (1:1 v/v) 
gave 26a as a single isomer, which was confirmed by X-ray crystallography (see Figure 7.8 A). 
 
 
 
Figure 7.8 Crystal structures of tetracyclic compound 26a (A) and norbornadiene 33 (B). 
 
Two effects that can play an important role in the rate of the cycloaddition reaction between 
tricyclo[5.2.1.02,6]dec-8-ene-3,5-diones and benzyl azide are the ring strain and electronic effects 
induced by the bridge atom. According to the classification of 1,3-dipoles, postulated by Sustmann,37 
an azide is an ambiphilic type dipole. The cycloaddition reaction can be considered as an interaction 
of the highest occupied molecular orbital (HOMO) of the 1,3-dipole (the azide) with the lowest 
unoccupied molecular orbital (LUMO) of the dipolarophile (the olefin). The lone pair electrons of the 
bridged atoms (i.e. O, N and S) can interact with the LUMO of the olefin in the tricyclic systems making 
it less prone to undergo cycloaddition.38 The ring strain in the tricyclic systems is partially determined 
by the size of the bridging atom which contracts the cyclohexene ring. In both cases the bridging 
atoms play a key role. To determine the effect of the bridging atoms, cycloaddition reactions of 
compounds 2, 10, 21 and 23 (all exo-configured) with benzyl azide were performed (Scheme 7.4). 
Furthermore, transition state energies of the reaction intermediates were calculated,39 and the different 
angles in the bridged systems were determined from the obtained crystal structures (see Figure 7.9).   
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Scheme 7.4 Formation of triazoline compounds 25-28 by reacting the bridged tricyclo[5.2.1.02,6]-dec-
8-ene-3,5-diones (2, 10, 21 and 23) with benzyl azide. 
 
 
 
Figure 7.9 Representation of the transition state intermediate for determining ΔG‡ and the angles of 
the bridged cyclohexene ring. 
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The 1,3-dipolar cycloaddition reactions of 2, 10, 21 and 23 with benzyl azide were performed in 
deuterated methanol as this appeared to be the prefered solvent (vide supra). Conversions were 
determined by 1H-NMR spectroscopy at fixed time intervals according to a preset time schedule. 
Graph 7.1 shows the formation of products 25-28 in a time span of 14 hours. 
 
Graph 7.1 Conversion plot of compounds 2, 10, 21 and 23 into tetracyclic triazolines 25-28 monitored 
by 1H-NMR spectroscopy over a period of 14 hours. 
 
In addition,  the cycloaddition reaction between endo 10-thia-4-aza-tricyclo[5.2.1.02,6]dec-8-ene-3,5-
dione (21b) and benzyl azide was monitored in time (not shown). In comparison to the exo-isomer 
(21a) a slightly lower conversion was observed after 14 hours (12% vs. 18% conversion for 21b and 
21b, respectively). Monitoring the cycloaddition of benzyl azide to endo 10-methylene-4-aza-
tricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (22b), showed no conversion. Since only a small decrease in 
conversion was observed between the endo and exo isomer (see previous results for 21a and 21b) it 
is likely that the exo-isomer, if obtained, would not be as reactive as the exo-isomers of compounds 25 
and 26.  
 
Although linear conversion was observed, the rate constants for the cycloaddition reaction could not 
be determined as a result of the incubation time (up to 175 min for 27) prior to the start of the 
reactions. Therefore, conversions were determined after 14 hours (see Table 7.4).   
  
Table 7.4 Determined ΔG‡, angles A1-A3 and conversions.  
Entry X ΔG‡ (kcal/mol) A1 (°) A2 (°) A3 (°) Conversion (%) 
1 O1 14.05 95.9 102.3 106.2 28.6 
2 N(Boc) 13.83 97.6 99.2 107.3 19.0 
3 S 15.33 79.6 101.8 110.7 18.7 
4 C=C(Me)2 15.83 96.1 99.8 107.9 12.3 
1) Compound 2 was crystallized from heptane/EtOAc 1:1 (crystal structure not shown, see Table 7.8). 
 
Calculations showed that the highest transition state energy (ΔG‡) was observed for compound 23 
which was also reflected in the lowest conversion after 14 hours (12.3%). Although the sulfur 
containing compound 21 has the smallest A1 angle (79.6°) no increased reactivity toward the 
cycloaddition reaction was found. A slightly lower ΔG value was found for 21 in comparison to 23 
resulting in a somewhat higher yield (18.7%). Although having the lowest transition state energy 
(13.83 kcal/mol), the N-containing tricyclic system 10 did not have the highest conversion rate. One of 
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the explanations could be the smaller value for A2 (99.2°) resulting in a smaller distance between the 
lone-pair electrons of the nitrogen and the double bound. Secondly, the Boc-protecting group might 
hinder cycloaddition from the top-side. Compound 2 having the smallest A3 angle value (106.2°) gave 
the highest conversion (28.6%). Monitoring the reaction of 10 and benzyl azide for an additional 2 
days a conversion of 55% was found. After 7 days, 92% of the desired product 25 was observed. The 
results summarized in Table 7.4 indicate that the differences in ΔG and angles between the C-, N-, O- 
and S-bridged tricyclo[5.2.1.02,6]dec-8-ene-3,5-diones are minimal which is reflected in the observed 
conversions (12.3%-28.6%) for the cycloaddition reactions.  
 
 
7.4 Design and synthesis of oxa- and aza-norbornadienes 
 
 
Since the outcome of the 1,3-dipolar cycloaddition reactions of tricyclic compounds 2, 10, 21 and 23 
with benzyl azide was somewhat disappointing we shifted our focus to bicyclic norbornadienes. In 
addition to the facile accessibility of norbornadiene systems, the increased ring-strain makes them 
suitable for studying their reactivity in the 1,3-dipolar cycloaddition reaction. By using substituted furan 
and alkyne building blocks functionalization of the bridged structures in a later stage remains a 
possibility.  
 
 
Table 7.5 Reaction conditions for the formation of oxanorbornadienes 29-32. 
Entry R1 R2 R3 Conditions Yield (%) 
1 H CO2Me CO2Me Et2O, r.t., 7 d 29 (70) 
2 H CF3 CO2Me Neat, 40 °C, 4 d* 30 (71) 
3 H H CO2Et Et2O, r.t., 7 d 31 (0) 
4 CO2Me Et Et Et2O, r.t., 16 h 32 (0) 
* The reaction was performed under an N2 or Ar atmosphere under Schlenk conditions. 
 
The oxa-bridged bicyclic systems 29 and 30 were prepared via a Diels-Alder reaction of substituted 
propiolates with furan (Table 7.5, entries 1 and 2).40,41 The synthesis of compound 31 was attempted 
starting from furan and ethyl propiolate, but no product formation was observed. Reacting 3-hexyne 
and methyl furan-3-carboxylate at ambient temperature also did not result in the formation of the 
desired product 32. In addition to the above mentioned oxanorbornadiene systems two 
azanorbornadiene derivatives 33 and 34 were synthesized according to literature procedures 
(Scheme 7.5).42,43   
 
 
 
Scheme 7.5 Synthesis of azanorbornadienes 34 and 35 starting from Boc-pyrrole. DMAD = dimethyl 
acetylenedicarboxylate. 
 
N-(Boc)-1,4-epiazanaphthalene 33 and dimethyl azanorbornadienedicarboxylate 34 were obtained in 
moderate yields (35% and 40%, respectively). The synthesis of epiazanaphthalene was pursued since 
fast cycloaddition of diazomethane to the double bond was previously reported by Wittig and 
Pohmer.44   
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7.5 1,3-Dipolar cycloaddition reactions with oxa- and aza-
norbornadienes 
 
 
To investigate the reactivity of the norbornadiene systems oxanorbornadiene 29 was subjected to the 
1,3-dipolar cycloaddition reaction with benzyl azide under ambient conditions. The reaction was 
performed in deuterated methanol to monitor the conversion of 29 into the expected triazolines 35 
and/or 36 (Scheme 7.6) by 1H-NMR spectroscopy. 
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Scheme 7.6 1,3-Dipolar cycloaddition of oxanorbornadiene 29 with BnN3. 
 
Much to our surprise, the anticipated triazolines 35 and/or 36 were not obtained, but instead the 
substituted triazole 37 was formed (Scheme 7.7), suggesting a cycloaddition reaction on the 
substituted double bond followed by a fast retro-Diels–Alder reaction. This two step process 
(cycloaddition – retro-Diels–Alder) was also observed by Reinhoudt et al.45 who reacted both aza- and 
oxanorbornadienes with different 1,3-dipoles. 
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Scheme 7.7 Triazole formation upon reaction of 29 with BnN3. 
 
 
Monitoring the course of the reaction by 
1H-NMR spectroscopy gave a conversion plot 
of oxanorbornadiene 29 to triazole 37 of 68% 
as shown in Graph 7.2. 
 
The triazole formation of the oxanorbornadiene 
systems can be explained by cycloaddition of 
the azide to the most electron deficient double 
bond (path A, depicted in Scheme 7.8), initially 
resulting in formation of the triazoline 
intermediate Ia. Subsequent loss of furan in a 
fast retro-Diels–Alder reaction leads to 
formation of the stable 1,4,5-trisubstituted 
1,2,3-triazoles A1 and A2. 
Azide cycloaddition onto the unsubstituted 
double bond (path B, Scheme 7.8), via 
intermediate Ib, results in the mono-substituted 
1,2,3-triazole B and a 3,4-substituted furan 
derivative. Although both double bonds can 
react in the tandem 1,3-dipolar cycloaddition – 
retro-Diels–Alder reaction, we predominantly 
found the 1,4,5-substituted triazoles A1 and A2. 
An identical mechanism holds for the reaction 
of azanorbornadienes with an azide. 
 
Graph 7.2. Rate of triazole formation. 1H-NMR 
monitoring of oxanorbornadiene 29 with benzyl 
azide (ratio 1:0.93) in methanol-d4 [100 mM] at 
25 °C. 
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Scheme 7.8 Reaction pathways for the formation of triazole compounds A1, A2, and B via triazoline 
intermediates Ia and Ib. 
 
In search for site selectivity, the groups of De Micheli46 and Pavlovic47 exposed 2,3-dimethoxy-
carbonyl-7-oxanorbornadiene to a variety of 1,3-dipoles to find that the 1,3-dipolar cycloaddition on the 
electron deficient double bond is controlled by interaction of the HOMO of the 1,3-dipole with the 
LUMO of the dipolarophile (i.e. oxanorbornadiene). By lowering the LUMO of the electron deficient 
double bond the reactivity of the dipolarophile is increased making it more susceptible to 1,3-dipolar 
cycloaddition. Consequently, compound 30, bearing the electron-withdrawing trifluoromethyl group 
and an ester moiety, was subjected to 1,3-dipolar cycloaddition to benzyl azide (Scheme 7.9). Indeed, 
an increase of reactivity was observed for the trifluoromethyl-bearing oxanorbornadiene since 
approximately 80% of the two expected triazole regio-isomers A1 and A2 was formed in a ratio of 2:3 
in a similar timeframe as before. 
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Scheme 7.9 Formation of triazoles A1 (39) and A2 (40) via a cycloaddition–retro-Diels–Alder reaction. 
 
Azides give clear-cut ambiphilic regioselectivity in 1,3-dipolar cycloaddition reactions. Electron-
deficient alkenes react rapidly with azides forming cycloaddition adducts such as A1 and A2, the result 
of the union of the largest terminal coefficient of the azide HOMO and the alkene LUMO.38b Triazole A2 
is the expected predominant isomer as a result of the polarization of the LUMO double bond due to 
the difference in electronegativity of the ester- and CF3-group. NMR techniques such as gHSQC and 
NOESY were employed to elucidate the configuration of the two regio-isomers. Unfortunately, both 
techniques were inconclusive so that we set out to crystallize one of the isomers. To initiate 
crystallization a para-nitrophenol ester was introduced in a two step protocol as displayed in 
Scheme 7.10. After the cycloaddition reaction of 30 with benzyl azide the two isomers were separated 
yielding compounds 39 and 40 in 36% and 54% yield, respectively. Continuing with the major isomer 
A2 (40), saponification was performed resulting in 41 which was subsequently coupled to p-nitrophenol 
to produce compound 42 in reasonable yield (68%). Crystallization from n-heptane/EtOAc and 
subsequent X-ray crystallography confirmed the structure of isomer A2 (see Scheme 7.10). 
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Scheme 7.10 Synthesis of p-nitrophenol ester 42 and the corresponding crystal structure. 
 
The 1H-NMR spectra of the reaction between oxanorbornadiene 30 and benzyl azide at t = 1 min and 
t = 850 min are partially depicted in Figure 7.10. The spectra clearly indicate a decrease of starting 
material corresponding to the consumption of oxanorbornadiene shown by the bridgehead signals 
( = 5.72, 5.69 ppm) decreasing in time. At the same moment, new distinct signals appear, belonging 
to the CH2-triazole ( = 5.96, 5.87, 5.62 ppm) of the products. 
 
 
 
Figure 7.11 1H-NMR spectra of the reaction between 30 and benzyl azide at t = 1 and t = 850 min.  
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By comparing the integrals of the CH2-triazole signals with the integrals of the bridgehead signals, the 
total molar fraction of the products can be determined. Subsequently, the molar fraction of the 
products can be plotted as a function of the reaction time resulting in the conversion plot of the 
reaction (Graph 7.3 A). From the conversion plot (Graph 7.3 A) the second order rate plot can be 
deduced by fitting the data to equation 1.  
 
kt =
1
[B]0 - [A]0
x ln
[A]0 · ([B]0 - [P])
([A]0 - [P]) · [B]0
Equation 1
 
 
Herein, k = 2nd order rate constant (M-1·s-1), t = reaction time (s), [A]0 = the initial concentration of 
substrate A (M), [B]0 = the initial concentration of substrate B (M), and [P] = the concentration of the 
products (M). 
 
 
Graph 7.3 Reaction between oxanorbornadiene 30 with benzyl azide (1:0.99) in CD3OD at 25 °C A: 
Conversion plot B: Second order rate plot. 
 
The initial concentration of oxanorbornadiene 30 was determined to be 0.10 M. By using the integral 
values from the 1H-NMR spectrum at t = 0, the initial concentration of the azido compound was 
adapted to this 0.10 M. In this particular example, the initial concentration of benzyl azide was 
calculated to be 0.099 M. Using these initial concentrations and the data obtained from Graph 7.3 A 
(typically up to 60% conversion), the second order rate plot was constructed (Graph  7.3 B). Linear 
regression (using Origin 6.1 software) of this dataset resulted in the following equation: 
 
1
[B]0 - [A]0
x ln
[A]0 · ([B]0 - [P])
([A]0 - [P]) · [B]0
= (8.77 ± 0.09) x 104 · t - 0.31 ± 0.1
 
 
Resulting in a rate constant for oxanorbornadiene system 30 of k = (8.77 ± 0.09)  104 M-1·s-1.  
 
The amount of side product (1-benzyl-1,2,3-triazole) that was formed, could easily be determined by 
comparing the integral value of the CH2-triazole ( = 5.62 ppm) with the sum of all CH2-triazole 
products. According to this calculation, only 3% of the undesired product following cycloaddition-retro 
Diels–Alder pathway B was formed. 
 
In addition to oxanorbornadienes 29 and 30, azanorbornadiene 34 was reacted with benzyl azide (5 
equiv) and the conversion was monitored during 14 hours (Scheme 7.11). Oxanorbornadiene 29 
reacted slightly faster as compared to the azanorbornadiene 34, although both gave full conversion 
after 14 hours (Graph 7.4). Apart from triazole 37 formation of the 1-benzyl-1H-1,2,3-triazole 38 was 
observed, albeit only in minute quantities (2-5%).  
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Scheme 7.11 Cycloaddition – retro-Diels–Alder reaction with excess BnN3. 
 
 
Triazole formation was significantly faster for 
oxanorbornadiene 30 compared to both 
azanorbornadiene 34 and the oxa-
norbornadiene 29. Complete conversion of 
compound 30 was achieved after 
approximately 210 minutes (Graph 7.4) while 
90% conversion was reached after 450 and 
800 minutes for compounds 29 and 34, 
respectively. 
 
Recent reports by Ju et al. also show 
successful applications of copper-free 1,3-
dipolar cycloaddition using either elevated 
temperatures48 or electron-deficient 
alkynes.49 To compare the reactivity of Diels-
Alder products 29 and 30 with the 
corresponding alkynes, 1,3-dipolar cyclo-
addition reactions were performed under 
ambient conditions using benzyl azide 
(1 equiv) and monitored over time by 1H-
NMR spectroscopy (Graph 7.5). The 
oxanorbornadienes 29 and 30 and their 
respective alkynes provided identical 1,4,5-
substituted triazoles as the products. 
 
 
R1
R2
O
R1
R2
or
40 R1 = CF3, R
2 = CO2Et, R
3 = Bn
N
N
N
R3
R1
R2
N
N
N
R3
R2
R1+
R3-N3
DMAD or 29: R1 = R2 = CO2Me
ETFB or 30: R1 = CO2Et, R2 = CF3
38 R1 = R2 = CO2Me, R
3 = Bn
39 R1 = CF3, R2 = CO2Et, R3 = Bn  
 
Scheme 7.12 Triazole formation monitored by 1H-NMR spectroscopy (vide infra) of acetylenes DMAD 
and ETFB (ethyl trifluorobutynoate), and oxanorbornadienes 29 and 30 with benzyl azide (1:1 ratio) in 
methanol-d4 [100 mM] at 25 °C. 
Graph 7.4 Rate of triazole formation. 1H-NMR 
experiments of oxanorbornadienes 29  and 
30  and azanorbornadiene 34  with benzyl 
azide (1:5 ratio) in methanol-d4 [100 mM] at 25 °C. 
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Graph 7.5 Rate of triazole formation. 1H-NMR experiments of the alkynes DMAD  and ETFB   
and the oxanorbornadienes 29  and 30  with benzyl azide (1:1 ratio) in methanol-d4 [100 mM] 
at 25 °C. 
 
Interestingly, the reaction rates of oxanorbornadienes 29 and 30 were approximately 5-fold higher 
than those of the corresponding alkynes. Additionally, the trifluoromethyl substituent led to a rate 
increase (1.3-fold and 2.3-fold for the oxanorbornadiene system and alkyne, respectively) as 
compared to the ester substituent (see Tables 7.6 and 7.7).  
 
To explore the scope of this tandem 1,3-dipolar cycloaddition – retro-Diels–Alder reaction a diverse 
set of reaction conditions and reactants were tested and monitored with 1H-NMR spectroscopy.50 In 
addition to the ester-functionalized oxanorbornadiene 30, a water soluble derivative 43 and the amide-
functionalized oxanorbornadiene 44 were synthesized (Scheme 7.11).  
 
O
CF3
OEt
O
THF
1M NaOH
0 °C  r.t.
30 min
O
CF3
OH
O
30 43 (83%)
O
CF3
H
N
O
44 (56%)
EDC, DMAP
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16 h
OMe
O
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Scheme 7.13 Conversion of oxanorbornadiene 30 to derivatives 43 and 44. 
 
From the NMR spectral data, the conversions, the ratios of the two regio-isomers, and the rate 
constants of the reactions were determined (Table 7.6). As shown in Graph 7.5, the rate of 29 (entry 1, 
Table 7.6) is somewhat lower than that of 30 (entry 3). By repeating the reaction described in entry 3, 
identical results were obtained demonstrating the high reproducibility of this reaction. Lowering of the 
concentration, i.e. 50 mM instead of 100 mM, did not affect the rate of the reaction nor the overall 
conversion (entry 4). Performing the reaction at an elevated temperature (37 °C, entry 5, Table 7.6) 
led to a higher reaction rate without increasing the formation of the undesired byproduct B. Use of 
deuterated chloroform (entry 6) as a solvent  had a negative effect on the reaction rate, which is more 
generally observed for cycloadditions in more apolar solvents. The outcome of the reaction between 
the water soluble compound 43 and benzyl azide (entry 8) was comparable to the results found for 
compound 30 (entry 3), hence enabling us to change the solvent to D2O. Altering the solvent also 
required a change of azide.  
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Both 3-azidopropylamine and azidoacetic acid are adequate water soluble alternatives for benzyl 
azide. Reacting oxanorbornadiene 43 with unprotected azidopropylamine (entry 10) led to increased 
quantities of byproduct B, which might be explained by salt bridge formation between the amine and 
the carboxylic acid (Figure 7.11), facilitating 1,3-dipolar cycloaddition on the unsubstituted double 
bond. The increase of temperature (37 °C, entry 11) again led to a higher reaction rate resulting in a 
slight decline of byproduct B formation. 
 
 
 
Figure 7.11 Proposed intermediates determining the reaction outcome of the reaction between 
compound 43 and azidopropargylamine or azidoacetic acid. 
 
The reaction of 43 with unprotected azidoacetic acid in D2O resulted in the selective formation of a 
single regio-isomer (1,4-dicarboxylic acid triazole), possibly due to electronic repulsion between the 
carboxylic acid moieties of oxanorbornadiene 43 and azidoacetic acid. Switching the R2 substituent 
from an ester or a carboxylic acid to an amide (i.e. compound 44, entry 13) led to a significant 
decrease of both the reaction rate and the selectivity. This effect may be attributed to an altered 
polarization of the double bond by the amide bond. The amide bond changes the electron density of 
the adjacent double bond, which is supported by the fact that more of the favored A2 isomer was 
formed. Finally, performing the reaction with 44 and azidoacetic acid (excess) resulted in a low 
reaction rate, while 20% of undesired byproduct B was formed. A generally observed phenomenon 
was the decrease of the reaction half-time upon subjection to larger quantities of benzyl azide with 
slight alteration of the reaction rate (entries 2, 7, 9 and 14). 
 
The reaction rates obtained under these conditions are of the same order of magnitude as those 
reported for the Staudinger ligation,51 most of the strain-promoted cyclooctyne-based [3+2] 
cycloadditions15 and the Diels-Alder ligation.3 In addition, the rates are significantly lower than those of 
the recently developed fluorinated cyclooctyne cycloadditions by Bertozzi et al.52 and the 
dibenzocyclooctyne developed in the group of Boons.53 Since cycloaddition reactions generally do not 
occur with common amino acid residues, this tandem 1,3-dipolar cycloaddition – retro-Diels–Alder 
(tandem crDA) reaction is envisaged to be a potentially useful metal-free bioconjugation method (see 
Chapter 8). 
 
 
7.6 Conclusions 
 
 
A series of C-, N-, O- and S-bridged tricyclo[5.2.1.02,6]dec-8-ene-3,5-diones was synthesized in 
moderate to good yield by applying the Diels–Alder reaction. Depending on the nature of the diene 
(e.g. pyrrole or thiophene) high pressure (1.5 GPa) was required for the formation of the tricyclic 
systems. The majority of the reactions gave a separable mixture of endo and exo isomers of which the 
correct stereochemistry was determined by NMR spectroscopy in combination with X-ray 
crystallography. 
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The tricyclic systems 2, 10, 23 and 25 were subsequently subjected to the 1,3-dipolar cycloaddition 
reaction with benzyl azide and conversions to the tetracyclic triazolines were monitored by 1H-NMR 
spectroscopy during 14 hours. Product formation was the highest for the oxygen-bridged tricycle, 
followed by the nitrogen- and sulphur-containing tricycles and finally the carbon-bridged tricycle.  
For a better understanding of the reactivity of the different tricyclic systems, the angles in the tricyclic 
systems (obtained from the crystal structures) and their transition state energies in the 1,3-dipolar 
cycloaddition reaction with benzyl azide (calculated) were compared to the conversions determined by 
1H-NMR spectroscopy. Diminutive differences in ΔG‡ and angles between the C-, N-, O- and S-
bridged tricyclo[5.2.1.02,6]dec-8-ene-3,5-diones were found which corresponded to the observed small 
differences in conversions (12.3%-28.6%) for the cycloaddition reactions. 
Reacting substituted alkynes in the presence of a diene (e.g. furan or N-Boc-pyrrole) resulted in the 
formation of various norbornadiene systems in moderate to good yield. Subjecting the norbornadienes 
to the 1,3-dipolar cycloaddition reaction with benzyl azide did not lead to expected tetracyclic triazoline 
compounds, but instead substituted triazoles were obtained as a result of a fast retro-Diels–Alder 
reaction. Comparison of aza- and oxanorbornadienes 29, 30 and 34 showed an increased reactivity 
for the oxanorbornadiene systems over the azanorbornadiene, moreover, the trifluoromethyl-
containing oxanorbornadiene 30 displayed the highest reactivity for the 1,2,3-triazole formation. The 
easily accessible trifluoromethyl-substituted oxanorbornadiene derivatives efficiently react with various 
azides in an elegant tandem 1,3-dipolar cycloaddition – retro-Diels–Alder (tandem crDA) reaction to 
form stable 1,2,3-triazole-linked compounds. Additionally, they possess an increased reactivity 
towards azides compared to the corresponding electron deficient alkynes. These versatile compounds 
have a distinct potential for application in bioconjugation as reactions can be performed in aqueous 
media, at ambient temperature and in the absence of a transition metal catalyst such as copper. 
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7.8 Experimental section 
 
General experimental: 
 
See Chapter 2 section 7. 
 
 
Instrumentations 
 
High-pressure reactions were carried out in a high-pressure apparatus developed at the Radboud 
University Nijmegen. Microwave reactions were carried out in a CEM Discover microwave. 
 
 
Synthesis 
 
exo-4,10-Dioxatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (1) 
 
Prepared according to a literature procedure:25 
Maleic anhydride (4.90 g, 50 mmol) and furan (20 mL, 275 mmol) were dissolved in Et2O 
(20 mL). The mixture was warmed to 30 °C and stirred for 24 hours. The product partially 
precipitated and after evaporation of the solvent the remaining product was obtained. The 
product stirred for 10 min. in Et2O (15 mL), filtered off, and dried in vacuo to obtain the 
pure product as a white powder (5.48 g, 65%) RF = 0.5 (n-Heptane/EtOAc, 2:1). 1H-NMR 
(300 MHz,CDCl3) : 6.58 (s, 2H), 5.46 (s, 2H), 3.18 (s, 2H). 
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exo-4-Aza-10-oxatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (2)  
 
Prepared according to a literature procedure:25 
Quantities used: maleimide (1.18 g, 12.11 mmol), furan (3 mL, 36 mmol) and H2O 
(30 mL). The reaction mixture was stirred for 3 days at 90 °C. Upon cooling, the 
compound precipitated and was filtered off to afford the pure product as a white powder 
(640 mg, 32%) RF = 0.35 (n-heptane/EtOAc 1:1). 1H-NMR (300 MHz, CDCl3) : 8.06 
(br s, 1H), 6.52 (s, 2H), 5.31 (s, 2H), 2.89 (s, 2H). 
 
exo-1-Carboxylic acid-10-oxa-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (4) 
 
Furan-2-carboxylic acid (75 mg, 0.66 mmol) and maleimide (64 mg, 0.66 mmol) were 
dissolved in EtOAc (1 mL). The solution was placed in a 1.0 mL Teflon vial. The vial 
was sealed and placed in a high-pressure reactor for 7 days at 1.5 GPa at 25 °C. The 
obtained crude reaction mixture was purified by column chromatography 
(n-heptane/EtOAc, 1:3) to afford the product as a white solid (10 mg, 7%) RF = 0.3 
(n-heptane/EtOAc, 1/3). 1H-NMR (300 MHz, DMSO-d6) : 11.30 (br s, 1H), 6.69 (dd, J = 5.6, 1.8 Hz, 
1H), 6.56 (d, J = 5.6 Hz, 1H), 5.21 (s, 1H), 3.14 (d, J = 6.5 Hz, 1H), 3.02 (d, J = 6.5 Hz, 1H).  
 
exo-1-Ethoxylcarbonyl-10-oxa-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (5) 
 
2-Ethoxycarbonylfuran (100 mg, 0.66 mmol) and maleimide (64 mg, 0.66 mmol) were 
dissolved in EtOAc (1 mL). The solution was placed in a 1.0 mL Teflon vial. The vial 
was sealed and placed in high-pressure reactor for 7 days at 1.5 GPa at 25 °C. The 
obtained crude reaction mixture was purified by column chromatography 
(n-heptane/EtOAc, 1:2) to afford the product as a white solid (120 mg, 76%) RF = 0.35 
(n-heptane/EtOAc, 1:2). 1H-NMR (300 MHz, CDCl3) : 8.10 (br s, 1H), 6.61 (d, J = 
1.6 Hz, 2H), 5.39 (s, 1H), 4.41 (q, J = 7.1 Hz, 2H), 3.21 (d, J = 6.5 Hz, 1H), 3.01 (d, J = 6.5 Hz, 1H), 
1.36 (t, J = 7.2 Hz, 3H). 13C-NMR (75 MHZ, CDCl3) : 175.7, 174.1, 166.4, 136.7, 135.6, 88.3, 80.5, 
52.0, 50.8, 49.3. LRMS (ESI+) m/z calcd for C11H12NO5 [M+H]+ 238.1, found: 238.2. 
 
exo-1-Nitro-4-cyano-10-oxa-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (7) 
 
2-Nitro-4-cyano-furan (90 mg, 0.66 mmol) and maleimide (64 mg, 0.66 mmol) were 
dissolved in EtOAc (1 mL). The solution was placed in a 1.0 mL Teflon vial. The vial was 
sealed and placed in high-pressure reactor for 7 days at 1.5 GPa at 50 °C. The obtained 
crude reaction mixture was purified by column chromatography (n-heptane/EtOAc, 1:3) 
to afford the product as a white solid (50 mg, 20%) RF = 0.35 (n-heptane/EtOAc, 1:3). 
1H-NMR (300 MHz, CD3OD) : 7.12 (d, J = 5.6 Hz, 1H), 6.99 (d, J = 5.6 Hz, 1H), 6.72 
(s, 1H), 3.80 (d, J = 6.6 Hz, 1H), 3.65 (d, J = 6.6 Hz, 1H). 13C-NMR (75 MHz, CDCl3) :174.2, 173.4, 
139.6, 136.8, 136.1, 113.3, 78.1, 55.3, 52.8. HRMS (ESI-) m/z calcd for C9H4N5O3 [M-H]- 234.0151, 
found: 234.0161. 
 
endo,exo-1-Methoxy-10-oxa-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (8a and 8b) 
 
2-Methoxyfuran (98 mg, 1 mmol) and maleimide (97 mg, 1 mmol) were 
dissolved in Et2O (2 mL) and stirred for 16 hours. The solvent was 
evaporated and the crude mixture was purified by column 
chromatography (n-heptane/EtOAc, 1:3), resulting in the two isomers as 
white solids. Analytical data exo compound 8a: yield; 92 mg (47%) RF = 
0.6 (n-heptane/EtOAc, 1:3). 1H-NMR (300 MHz, CDCl3) : 7.73 (br s, 
1H), 6.66 (dd, J = 5.8, 2.0 Hz, 1H), 6.50 (d, J = 5.8 Hz, 1H), 5.15 (d, J = 2.0 Hz, 1H), 3.61 (s, 3H), 3.08 
(d, J = 6.5 Hz, 1H), 2.96 (d, J = 6.4 Hz, 1H). 13C-NMR (75 MHZ, CDCl3) : 175.8, 175.3, 136.8, 133.3, 
114.9, 74.0, 54.5, 50.4, 49.4. Analytical data endo compound 8b: yield; 22 mg (11%) RF = 0.4 
(n-heptane:EtOAc, 1/3). 1H-NMR (300 MHz, CDCl3) : 7.43 (br s, 1H), 6.60 (dd, J = 5.8, 2.0 Hz, 1H), 
6.55 (d, J = 5.8 Hz,1H), 5.16 (dd, J = 5.6, 1.9 Hz, 1H), 3.78 (dd, J = 7.9, 5.6 Hz, 1H), 3.61 (s, 3H), 3.41 
(d, J = 7.9 Hz, 1H). 13C-NMR (75 MHZ, CDCl3) : 177.2, 174.4, 139.2, 135.2, 114.6, 75.7, 54.9, 52.8, 
48.6. HRMS (ESI+) m/z calcd for C9H10O4N [M+H]+ 196.0610, found: 196.0597.  
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endo,exo-1-Methyl-10-oxa-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (9a and 9b) 
 
2-Methylfuran (82 mg, 1 mmol) and maleimide (97 mg, 1 mmol) were 
dissolved in Et2O (2 mL) and stirred for 7 days. The solvent was 
evaporated and the crude mixture was purified by column 
chromatography (n-heptane/ EtOAc, 1:2), resulting in the two isomers as 
white solids. Analytical data exo compound 9a: yield; 110 mg (61%) RF = 
0.4 (n-heptane/EtOAc, 1:2). 1H-NMR (300 MHz, CDCl3) : 7.73 (br s, 1H), 6.51 (d, J = 5.8, 2.0 Hz, 1H), 
6.31 (d, J = 5.7 Hz, 1H), 5.22 (d, J = 1.7 Hz, 1H), 3.01 (d, J = 6.4 Hz, 1H), 2.75 (d, J = 6.3 Hz, 1H), 
1.76 (s, 3H). 
Analytical data endo compound 9b: yield; 20 mg (11%) RF = 0.5 (n-heptane/EtOAc, 1:2). 1H-NMR 
(300 MHz, CDCl3) : 6.49 (dd, J = 5.7, 1.5 Hz, 1H), 6.32 (d, J = 5.8 Hz, 1H), 5.21 (d, J = 5.6 Hz, 1H), 
3.68 (dd, J = 7.6, 5.6 Hz, 1H), 3.15 (d, J = 7.7 Hz, 1H), 1.82 (s, 3H). Anal. calcd. for C9H9NO3; 
C 60.33% H 5.06% N 7.82%, measured C 59.63% H 5.24% N 7.09%(+ 0.21 EtOAc). 
 
para-Toluenesulfonyl-pyrrole (18) 
 
Prepared according to literature procedure:26  
Quantities used: pyrrole (1.9 g, 0.30 mol), NaOH (3.6 g, 0.12 mol), p-TsCl (7.0 g, 0.37 mol) and 
CH2Cl2 (25 mL). The product was obtained as a crystalline solid (5.9 g, 89%). 1H-NMR 
(300 MHz, CDCl3) : 7.76-7.71 (m, 2H), 7.30-7.27 (m, 2H), 7.16-7.14 (m, 2H), 6.29-6.27 
(m, 2H), 2.39 (s, 1H). LRMS (ESI+) m/z calcd for C11H12NO2S [M+H]+ 222.1, found: 222.0. 
 
ortho-Nitrobenzenesulfonyl-pyrrole (19) 
 
Prepared according to a literature procedure:26  
Quantities used: pyrrole (194 mg, 3.0 mmol), NaOH (360 mg, 12.0 mmol), o-NsCl (923 mg, 
3.7 mmol) and CH2Cl2 (3.5 mL). The product was obtained as a light green solid (151 mg, 
21%). 1H-NMR (300 MHz, CDCl3) : 7.78-7.75 (m, 2H), 7.73-7.62 (m, 2H), 7.25 (dd, J = 2.1, 
4.5 Hz, 2H), 6.40-6.38 (m, 2H). LRMS (ESI+) m/z calcd for C10H9N2O4S [M+H]+ 253.0, found: 252.9. 
 
N-Boc-2-methoxycarbonylpyrrole (20) 
 
To a cooled solution (0 °C) of 2-methoxycarbonylpyrrole (625 mg, 5 mmol) in dry THF 
(25 mL) was added 60% NaH on mineral oil (260 mg, 6.5 mmol) in small portions. The 
solution was stirred for 10 min. before a solution of (Boc)2O (1.4 g, 6.5 mmol) in dry 
THF (10 mL) was added to the reaction mixture. The mixture became turbid and 
additional THF (10 mL) was added. The reaction mixture was stirred for 18 hours at room temperature. 
The mixture was quenched by the addition of H2O (20 mL). The product was extracted with EtOAc (5  
30 mL). The organic layers was dried over Na2SO4 and evaporation of the solvents yielded the product 
as an orange liquid (1.15 g, 99%) RF = 0.36 (n-heptane/EtOAc, 5:1). 1H-NMR (300 MHz, CDCl3) : 
8.21 (br s, 1H), 6.91 (dd, J = 0.5, 5.5 Hz, 1H), 6.50 (dd, J = 2.1, 5.5 Hz, 1H), 5.15 (d, J = 2.1Hz, 1H), 
3.85 (s, 3H), 1.37 (s, 9H). LRMS (ESI+) m/z calcd for C11H16NO4 [M+H]+ 226.1, found: 225.7. 
 
exo-4,10-Diaza-10-N-(Boc)-tricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (10) 
 
N-Boc-pyrrole (1.67 ml, 10 mmol,) and maleimide (0.97 g, 10 mmol) were dissolved in 
EtOAc (4.5 mL). The solution was placed in a 7.5 mL Teflon vial. The vial was sealed 
and placed in a high-pressure reactor for 3 days at 1.5 GPa at 50 °C. The formed 
precipitate was filtered and washed with heptane (3  10 mL). The residue was dried 
to give the pure product as a white solid (2.43 g, 92%) RF = 0.18 (n-heptane/EtOAc 
1:1). 1H-NMR (300 MHz, CDCl3) : 7.95 (br s, 1H), 6.53 (s, 2H), 5.06 (s, 2H) , 2.80 (s, 2H), 1.39 
(s, 9H). 13C-NMR (75 MHz, DMSO-d6)  (ppm): 177.5 (2C), 154.6, 137.8, 136.6, 80.5, 62.8 (2C), 49.1, 
48.4, 27.8. HRMS (ESI+) m/z calcd for C13H16N2NaO4 [M+Na]+ 287.1008, found: 287.1013. 
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exo-10-N-(Boc)-4-methyl-4,10-diazatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (11)  
 
N-Boc-pyrrole (0.25 mL, 1.5 mmol) and N-methyl maleimide (169.7 mg, 1.5 mmol) 
were dissolved in EtOAc (0.5 mL) and placed in a 0.7 mL Teflon vial. The vial was 
sealed and placed in a high-pressure reactor at 1.5 GPa for 6 days. Column 
chromatography (n-Heptane/EtOAc, 1:2) resulted in the product as a white solid 
(46 mg, 13%) RF = 0.3 (n-heptane/EtOAc, 1:2). 1H-NMR (300 MHz, CDCl3) : 6.52 
(s, 2H), 5.02 (s, 2H), 2.98 (s, 3H), 2.77 (s, 2H), 1.37 (s, 9H). 13C-NMR (75 MHz, CDCl3) : 175.7 (2C), 
155.0, 138.1, 136.4, 81.3, 63.0 (2C), 47.9 (2C), 28.0, 25.0. HRMS (ESI+) m/z calcd for C14H18N2NaO4 
[M+Na]+ 301.1164, found: 301.1166. 
 
exo-10-N-(Boc)-4-phenyl-4,10-diazatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (12)  
 
N-Boc-pyrrole (0.25 mL, 1.5 mmol) and N-phenyl maleimide (262.8 mg, 
1.5 mmol) were dissolved in EtOAc (0.7 mL) and placed in a 0.7 mL Teflon vial. 
The vial was sealed and placed in a high-pressure reactor at 1.5 GPa for 
6 days. A white solid was formed being the pure exo-product (117.5 mg, 80%) 
trace amounts of endo-product. RF = 0.35 (n-heptane/EtOAc, 1:2). 1H NMR 
(300 MHz, CDCl3) : 7.34-7.49 (m, 3H), 7.24-7.28 (m, 2H), 6.57 (s, 2H), 5.14 (s, 2H), 2.91 (s, 2H), 
1.36 (s, 9H). 13C-NMR (75 MHz, CDCl3)  (ppm):174.8 (2C), 154.9, 137.4 (2C), 131.7, 129.1 (2C), 
128.7, 126.4 (2C), 81.4, 63.6 (2C), 47.7(2C), 28.0. HRMS (ESI+) m/z calcd for C19H20N2NaO4 [M+Na]+ 
363.1321, found: 363.1320. 
 
endo-4,10-Diaza-10-(ortho-nitrobenzenesulfonyl)tricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (13)  
 
N-Nosyl-pyrrole (19, 151.0 mg, 0.6 mmol) and maleimide (58.2 mg, 0.6 mmol) were 
dissolved in EtOAc (0.45 mL) and placed in a 0.5 mL Teflon vial. The vial was sealed 
and placed in a high-pressure reactor for 6 days at 1.5 GPa at 50 °C. The formed 
precipitate was filtered off and washed with heptane (3  3 mL). Residue was dried to 
give pure brownish solid (133 mg, 63%) RF = 0.2 (n-heptane/EtOAc, 1:1). 1H-NMR 
(DMSO-d6) : 11.12 (s, 1H), 8.07-7.79 (m, 4H), 6.16 (t, J = 1.3, 2H), 5.11-5.09 (m, 2H), 3.69 (dd, J = 
1.5, 3.4,  2H). 13C-NMR (75 MHz, CDCl3) : 174.5 (2C), 133.9, 132.9 (2C), 131.5 (2C), 131.2, 130.0, 
123.6, 63.3 (2C), 46.3 (2C). HRMS (ESI+) m/z calcd for C14H11N3NaO6S [M+Na]+ 372.0266, found: 
372.0254.   
 
endo-4,10-Diaza-10-(para-toluenesulfonyl)tricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (14) 
  
N-Tosyl-pyrrole (18, 1.67 mL, 10 mmol) and maleimide (0.97 g, 10 mmol) were 
dissolved in EtOAc (4.5 mL). The solution was placed in a 7.5 mL Teflon vial. The vial 
was sealed and placed in a high-pressure reactor for 6 days at 1.5 GPa at 50 °C. The 
formed precipitate was filtered off and washed with heptane (3  10 mL). The product 
was obtained as a white solid (368 mg, 77%) RF = 0.2 (n-heptane/EtOAc, 1:1). 
1H-NMR (DMSO-d6) : 11.02 (s, 1H), 7.61 (d, 2H, J = 8.1Hz), 7.36 (d, 2H, J = 8.1Hz), 5.96 (t, J = 
1.3 Hz, 2H), 4.98-4.96 (m, 2H), 3.62 (dd, J = 1.5, 3.4 Hz, 2H), 2.37 (s, 3H). 13C-NMR (75 MHz, CDCl3) 
: 174.9 (2C), 143.8, 134.8, 131.8 (2C), 129.3 (2C), 127.3 (2C), 62.5 (2C), 46.6 (2C), 21.0. HRMS 
(ESI+) m/z calcd for C15H14N2NaO4S [M+Na]+ 341.0572, found: 341.0566. 
 
endo,exo-10-N-(Boc)-1-ethoxycarbonyl-4,10-diazatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione 
(15a and 15b) 
N-Boc-pyrrole-2-ethyl ester (20, 338 mg, 1.5 mmol) and maleimide 
(146 mg, 1.5 mmol) were dissolved in EtOAc (0.5 mL). The solution 
was placed in a 1.0 mL Teflon vial. The vial was sealed and placed 
in a high-pressure reactor for 6 days at 1.5 GPa at 50 °C. The 
formed precipitate was filtered off and washed with heptane (3  10 
mL). The precipitate contained both isomers which were separated 
with gradient column chromatography (n-heptane  n-heptane/ 
EtOAc 1:2) to afford the two isomers as white solids. Analytical data exo compound 15a; yield: 55 mg 
(11%). 1H-NMR (300 MHz, CDCl3) : : 8.21 (br s, 1H), 6.91 (dd, J = 0.5, 5.5 Hz, 1H), 6.50 (dd, J = 
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2.1, 5.5 Hz, 1H), 5.15 (d, J = 2.1Hz, 1H), 3.85 (s, 3H), 2.93 (s, 2H), 1.37 (s, 9H). 13C-NMR (75 MHz, 
CDCl3) : 174.3, 172.2, 166.4, 156.1, 138.7, 136.1, 82.6, 75.6, 66.1, 52.8, 52.4, 49.0, 27.9. 
Analytical data endo compound 15b; yield 95 mg (20%). 1H-NMR (300 MHz, CDCl3) : 8.58 (br s, 1H), 
6.65 (d, J = 5.7Hz, 1H), 6.51 (dd, J = 2.2, 5.8 Hz, 1H), 5.12 (ddd, J = 0.7, 2.2, 5.1 Hz, 1H), 3.94 (d, J = 
7.5 Hz, 1H), 3.93 (s, 3H), 3.70 (dd, J = 5.1, 7.8 Hz, 1H), 1.39 (s, 9H). 13C-NMR (50 MHz, CD3OD) : 
168.5, 158.1, 139.4, 137.5, 83.4, 76.7, 67.5, 54.6, 52.7, 50.5, 28.2. HRMS (ESI+) m/z calcd for 
C15H19N2O6 [M+H]+ 323.1243, found: 323.1236. 
 
endo,exo-4-Aza-10-thiotricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (21a and 21b) 
 
Thiophene (0.84 mL, 10 mmol) and maleimide (0.97g, 10 mmol) were 
dissolved in dry CH2Cl2 (6 mL) and placed in a 7.5 mL Teflon vial. The vial 
was sealed and placed in a high-pressure reactor for 7 days at 1.5 GPa at 
50 °C. Column chromatography (n-heptane/EtOAc 2:1) resulted in the two 
pure stereo-isomers as white solids. Analytical data exo compound 21a; 
yield: 60 mg (3.3%). 1H-NMR (300 MHz, CD3OD) : 6.58 (dd, J = 1.9, 2.5 Hz, 2H), 4.39-4.37 (m, 2H), 
3.21 (s, 2H). 13C-NMR (75 MHz, CDCl3) : 175.9 (2C), 139.6 (2C), 53.0 (2C), 51.5 (2C).  
Analytical data endo compound 21b; yield: 120 mg (6.6%). 1H-NMR (300 MHz, CD3OD) : 6.48 (t, J = 
2.4, 2H), 4.45-4.42 (m, 2H), 3.91 (dd, J = 1.4, 2.7 Hz, 2H). 13C-NMR (75 MHz, CDCl3) : 175.6 (2C), 
136.1 (2C), 52.1(2C), 51.9 (2C). Anal. calcd. for C8H7NO2S; C 53.02% H 3.89% N 7.73%, measured 
C 52.06% H 4.02% N 7.22% 
 
endo-10-Methylene-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (22a)  
 
Prepared according to method B (literature procedure):34  
Quantities used: cyclopentadiene (407 μL, 5.0 mmol), maleimide (485 mg, 5.0 mmol) and 
EtOAc (15 mL). The product was obtained as a crystalline solid (248 mg, 88%) RF = 0.3 
(n-heptane/EtOAc, 1:1). Analytical data vide infra.  
Prepared according method C: 
A microwave dedicated sealed tube was filled with dicyclopentadiene (134 μL, 2.0 mmol), maleimide 
(194 mg, 2.0 mmol) and toluene (2 mL). The mixture was placed in a microwave (300 W) programmed 
at a temperature of 150 °C for 20 min. The toluene was evaporated and the crude reaction mixture 
was purified by column chromatography (n-heptane/EtOAc, 1:1) to obtain the product as a crystalline 
solid (114 mg, 35%) RF = 0.3 (n-heptane/EtOAc, 1:1). 1H-NMR (400 MHz, CDCl3) : 8.25 (br s, 1H, 
NH), 6.19 (s, 2H), 3.37 (s, 2H), 3.30 (q, J = 4.0 Hz, 2H), 1.73 (d, J = 8.0 Hz, 2H), 1.51 (d, J = 8.0 Hz, 
2H). 13C-NMR (75 MHz, CDCl3) : 178.1 (2C), 134.5 (2C), 52.2, 47.3 (2C), 44.9 (2C). HRMS (ESI+) 
m/z calcd for C9H10NO2 [M+H]+ 164.0633. 
 
exo-10-Isopropylidene-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (23)  
 
Prepared according to literature procedure:36 
Quantities used: fulvene (220 μL, 2 mmol), maleimide (194 mg, 2.0 mmol) and toluene 
(2 mL). The product was obtained as a crystalline solid (248 mg, 70%) RF = 0.5 
(n-heptane/EtOAc, 1:1). 1H-NMR (300 MHz, CDCl3) : 7.91 (s, 1H), 6.41 (t, J = 1.8 Hz, 
2H), 3.74 (t, J = 1.8 Hz, 2H), 2.77 (s, 2H), 1.57 (s, 6H). Anal. calcd. for C12H13NO2; 
C 70.92% H 6.45% N 6.89%, measured C 70.37% H 6.36% N 6.83% 
 
Dimethyl 7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate (29) 
 
Prepared according to literature procedure:41 
Furan (0.64 mL, 10 mmol) and dimethyl acetylenedicarboxylate (DMAD, 1.22 mL, 
10 mmol) were dissolved in Et2O (4 mL). The mixture was stirred for 7 days at room 
temperature. H2O (10 mL) was added and the layers were separated. The water layer 
was extracted with Et2O (15 mL). The combined ether layers were washed with brine 
(20 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. The obtained liquid was 
purified by column chromatography (EtOAc/n-Heptane, 1/1) resulting in the desired product as a light 
yellow liquid (1.48 g (70%) RF = 0.6 (EtOAc/n-Heptane 1/1). FT-IR max film: (cm-1) 2950, 1709, 1429, 
1269, 1203, 1100, 875. 1H-NMR (300 MHz, CDCl3) : 7.22 (s, 2H),  5.68 (s, 2H),  3.83 (s, 6H). 
13C-NMR (75 MHz, CDCl3) : 162.7, 152.5, 142.8, 84.6, 51.9. HRMS (ESI+) m/z calcd for C10H10NaO5 
[M+Na]+ 233.0426, found: 233.0426. 
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3-Trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxylic acid ethyl ester (30) 
 
Prepared according to literature procedure:40 
Ethyl 2-fluorobut-2-ynoate (1.00 g, 0.86 mL, 6.02 mmol) was placed in a Schlenk tube 
which was fitted with a stopper, evacuated 
and back-filled with argon. Furan (498 mg, 
468 L, 7.32 mmol) was added and the 
reaction mixture was heated to 40 °C. The reaction was 
stirred at 40 °C under an argon atmosphere for 4 days. 
The resulting mixture was washed out with Et2O and 
concentrated in vacuo. The crude mixture was purified by 
column chromatography (EtOAc/n-heptane, 1:4) resulting 
in compound 30 as a slightly yellow oil (1.00 g, 71%). RF = 
0.43 (EtOAc/n-heptane, 1:4). FT-IR max film: (cm-1) 2975, 
1733, 1288, 1147. 1H-NMR (400 MHz, CDCl3) : 7.30 (dd, 
J = 5.3, 1.9 Hz, 1H), 7.20 (dd, J = 5.3, 1.9 Hz, 1H), 5.70 
(m, 1H), 5.66 (t, J = 1.7 Hz, 1H), 4.29 (m, 2H), 1.30 (t, J = 
7.1 Hz, 3H). 13C-NMR (75 MHz, CDCl3) : 161.39, [151.14, 
151.08, 150.99, 150.48] (q), 143.4, 142.2, 137.4, [126.5, 
122.9, 119.4, 115.8] (q, CF3), 84.7, 83.5, 61.4, 13.4. 
HRMS (EI+) m/z calcd for C10H10F3O3 [M+H]+ 234.0506, 
found: 234.0504.  
 
N-(Boc)-1,4-epiazanaphthalene (33)  
 
Prepared according to a modified literature procedure:42  
Quantities used: antranilic acid (2.4 g, 17.8 mmol), N-Boc-pyrrole (2.8 g, 17.8 mmol), 
isoamylnitrite (2.9 mL, 21.4 mmol) and DME (36 mL). The product was obtained after 
gradient column chromatography (n-heptane  n-heptane /EtOAc, 9:1) as an orange 
solid (1.5 g, 35%) RF = 0.32 (n-Heptane/EtOAc, 9:1). 1H NMR (300 MHz, CDCl3) : 7,25 (s, 2H), 7.15-
6.88 (m, 4H), 5.48 (s, 2H), 1.37 (s, 9H). LRMS (ESI+) m/z calcd for C15H17NO6 [M+H] 244.2, found: 
144.2 (M+H-Boc). 
 
Dimethyl 7-N-(Boc)-bicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate (34)  
 
Prepared according to a literature procedure:43 
N-Boc-pyrrole (1.67 mL, 10 mmol) and dimethyl acetylenedicarboxylate (DMAD, 
1.23 mL, 10 mmol) were dissolved in EtOAc (4.5 mL). The solution was placed in a 
7.5 mL teflon vial. The vial was sealed and placed in a high-pressure reactor at 
1.5 GPa at 50 °C for 18 hours. The crude reaction mixture was purified by column 
chromatography (EtOAc/n-heptane, 1:5) and was obtained as a slightly yellow solid 
(1.2 g, 40%). RF = 0.5 (EtOAc/n-heptane, 1:5). 1H-NMR (300 MHz, CDCl3) : 7,13 (s, 2H), 5.46 (s, 2H), 
3.82 (s, 6H), 1.41 (s, 9H). 13C-NMR (75 MHz, CDCl3) : 163.1, 153.8, 152.2, 143.1, 142.4, 81.3, 69.0, 
52.2, 27.9. LCQ MS(ESI-) m/z calcd for C15H18NO6 [M-H]- 308.09, found: 308.12.  
 
3-Trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxylic acid (43) 
 
Oxanorbornadiene 30 (500 mg, 2.13 mmol) was dissolved in THF (30 mL) and cooled to 
0 °C. 1 M NaOH (4.85 mL) was added drop wise. The mixture was stirred for 30 min. at 
0 °C and 1-2 hours at room temperature. After complete conversion the volume of the 
mixture was reduced to 50% of the original volume and H2O (20 mL) and EtOAc 
(15 mL) were added. The layers were separated and the aqueous layer was acidified to 
pH 4-5 with 2 M HCl. The water layer was extracted with EtOAc (2  20 mL). The combined organic 
layers were dried over MgSO4 and evaporated to dryness. The solid was washed with CH2Cl2 (2  
10 mL) to removed traces of EtOAc and THF. Compound 43 was obtained as an off-white solid 
(363 mg, 83%) RF = 0.1 (EtOAc/n-heptane, 1:2). FT-IR max film: (cm-1) 3300, 2928, 1714, 1326, 1271, 
1164, 1122, 880, 842, 709. 1H-NMR (400 MHz, CDCl3) : 8.80-7.57 (br s, 1H), 7.30 (dd, J = 5.3, 
1.9 Hz, 1H), 7.22 (dd, J = 5.3, 1.9 Hz, 1H), 5.74 (s, 1H), 5.70 (d, J = 1.3 Hz, 1H). 13C-NMR (75 MHz, 
CDCl3) : 166.2, [155.1, 154.6, 154.1, 153.6] (q), [150.7, 150.6] (d), 143.9, 142.6, [126.7, 123.1, 119.5, 
115.9] (q), 85.0, 84.2. HRMS (EI+) m/z calcd for C8H6F3O3 [M+H]+ 206.0191, found 206.0199. 
Figure 7.12. 1H-NMR signal 4.29 (m, 
2H) of compound 30, coupling of CF3 
and CH2.
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3-Trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxyl-Gly-OMe (44) 
 
Oxanorbornadiene carboxylic acid 43 (20.6 mg, 0.1 mmol), H-Gly-OMe·HCl 
(13.8 mg, 0.11 mmol) and 4-(dimethylamino)-pyridine (DMAP, 24.2 mg, 
0.2 mmol) were dissolved in CH2Cl2 (2 mL) and cooled to 0 °C. 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC·HCl, 21 mg, 0.11 mmol) 
was added and the reaction mixture was stirred at 0 °C for 30 min. The mixture 
was allowed to warm to room temperature and was stirred for an additional 16 hours. The reaction 
was quenched with 2 M HCl (2 mL) and extracted with EtOAc (2  5 mL). The combined organic layers 
were washed with brine (5 mL), dried over Na2SO4 and concentrated in vacuo. The crude mixture was 
purified by preparative TLC (CH2Cl2/MeOH, 9:1) resulting in compound 44 as a slightly yellow solid 
(15.5 mg, 56%) RF = 0.55 (CH2Cl2/MeOH, 9:1). 1H-NMR (400 MHz, CDCl3) : 7.33 (dd, J = 5.3, 2.0 Hz, 
1H), 7.16 (dd, J = 5.3, 2.0 Hz, 1H), 6.41 (br s, 1H, NH), 5.68 (m, 2H), 4.15 (dq, J = 18.5, 18.5, 18.5, 
5.2 Hz, 2H) 3.80 (s, 3H). 13C-NMR (50 MHz, CDCl3) : 166.6, 154.9, 154.2, 150.7, 144.0, 142.7, 
[124.8, 118.6] CF3, 85.1, 84.3. HRMS (ESI+) m/z calcd for C11H10F3NaNO4 [M+Na]+ 300.0460, found 
300.0459. 
 
Cycloaddition reactions of C-, N-, O- and S-bridged tricyclo[5.2.1.02,6]dec-8-ene-3,5-diones with 
benzyl azide 
 
General experimental for the cycloaddition of dipolarophiles 2, 10, 21 and 23 with benzyl azide 
followed by 1H-NMR  
 
A solution of the appropriate dipolarophile (0.05 mmol) in CD3OD (0.5 mL) was added to a test tube 
containing benzyl azide (31.3 L, 0.25 mmol). The mixture was briefly stirred using a vortex and then 
added to an NMR tube. Directly after the addition, the tube was placed in a Varian Inova 400 NMR 
apparatus at 25 °C, and reaction was monitored following a preset measurement schedule. The 
conversions to triazolines 25-28 were determined by integration of the newly formed benzylic 
CH2-protons.  
 
 
2,6-exo-8,12-exo-9-Benzyl-4,13-dioxa-9,10,11-triaza-tetracyclo [5.5.1.02,6.08,12]tridec-10-ene-3,5-
dione (24) 
A solution of compound 1 (8.0 mg, 0.05 mmol) in CDCl3 (0.5 mL) was added to a 
test tube containing benzyl azide (31.3 L, 0.25 mmol). The mixture was briefly 
stirred using a vortex and then added to an NMR tube. Directly after the addition, 
the tube was placed in a Varion inova 400 NMR apparatus at 25 °C, and reaction 
was monitored following a preset measurement schedule. The conversion to 
triazoline 24, determined by 1H-NMR, was found to be 10% after 14 hours. 1H-NMR 
(400 MHz, CDCl3) : 7.37 (s, 2H), 7.36-7.31 (m, 5H), 6.95 (s, 2H), 6.38 (s, 2H), 5.26 
(d, J = 15.5 Hz, 1H), 5.04 (d, J = 15.4 Hz, 1H), 4.74 (s, 2H), 4.80 (d, J = 9.3 Hz, 1H), 3.54 (d, J = 
9.3 Hz, 1H), 3.21 (d, J = 7.6 Hz, 1H), 3.03 (d, J = 7.5 Hz, 1H). 
 
2,6-exo-8,12-exo-9-Benzyl-13-oxa-4,9,10,11-tetra-aza-tetracyclo [5.5.1.02,6.08,12]tridec-10-ene-3,5-
dione (25) 
Compound 10 (132 mg, 0.8 mmol) was dissolved in 8 ml of EtOAc and benzyl 
azide (0.5 mL, 0.8 mmol) was added. The reaction was stirred for 7 days after 
which the crude mixture was purified by column chromatography 
(n-heptane/EtOAc, 1:3) to obtain compound 25 as a white powder (220 mg, 92%) 
RF = 0.3 (n-heptane/EtOAc, 1:3). 1H-NMR (300 MHz, CDCl3) : 7.36-7.25 (m, 5H), 
5.30 (s, 1H, NH), 5.19 (s, 1H), 5.09 (d, J = 15.6 Hz, 1H), 4.82 (d, J = 9.4 Hz, 1H), 
4.71, (s, 1H), 4.70 (d, J = 15.6 Hz, 1H), 3.54 (d, J = 9.2 Hz, 1H), 3.01 (d, J = 
7.1 Hz, 1H), 2.86 (d, J = 6.8 Hz, 1H). 13C-NMR (75 Mhz, CDCl3) : 176.7, 176.5, 135.2, 128.0 (2C), 
127.15, 127.10 (2C), 84.5, 81.6, 80.7, 60.9, 51.3, 47.5, 46.9. HRMS (ESI+) m/z calcd for C15H15N4O3 
[M+H]+ 299.1144, found: 299.1131. 
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2,6-exo-8,12-exo-13-N-(Boc)-9-benzyl-4,9,10,11,13-pentaazatetracyclo [5.5.1.02,6.08,12]tridec-10-
ene-3,5-dione (26) 
Compound 21 (52.8 mg, 0.2 mmol) was dissolved in CD3OD (2 mL) and benzyl 
azide (0.125 mL, 1.0 mmol) was added. The reaction mixture was stirred for 
7 days at room temperature monitoring the conversion by NMR spectroscopy at 
regular intervals. At a conversion of 96.5% the crude mixture was purified by 
column chromatography (n-heptane/EtOAc, 1:2) to yield the product as a white 
solid (65 mg, 83%) RF = 0.27 (n-heptane/EtOAc, 1:2). After crystallization from 
n-heptane/EtOAc (1:1) the exo-isomer 26 was obtained. 1H-NMR (300 MHz, 
CDCl3 exo-isomer) : 1.37 (s, 9H), 2.17 (s, 2H), 2.93 (s, 2H), 3.85 (s, 3H), 5.15 
(dd, J = 0.3, 2.4 Hz, 1H), 6.49-6.51 (dd, J = 2.4, 5.4 Hz, 1H), 6.91 (dd, J = 0.3, 5.4 Hz, 1H), 7.97 (br s, 
1H); (endo-isomer): 1.39 (s, 9H), 3.68-3.72 (dd, J = 5.1, 7.8 Hz, 1H), 3.93 (s, 3H), 3.93-3.95 (d, J = 
7.8 Hz, 1H), 5.10-5.13 (ddd, J = 0.9, 2.1, 5.1 Hz, 1H), 6.50-6.53 (dd, J =2.1, 5.7 Hz, 1H), 6.40-6.66 
(d, J = 5.7 Hz, 1H), 8.58 (br s, 1H). 13C-NMR (75 Mhz, CDCl3 exo-isomer) : 175.5, 175.3, 135.3 (2C), 
128.9 (2C), 128.3, 128.2 (2C), 85.1, 82.0, 62.1, 60.9, 59.8, 51.8, 48.2, 47.1, 27.8 (3C); (endo-isomer): 
175.6, 175.2, 135.2, 135.1, 129.0 (2C), 128.3, 128.1(2C), 85.9, 81.7, 70.4, 61.7, 60.6, 52.2, 47.8, 47.7, 
27.9 (3C). HRMS (ESI+) m/z calcd for C20H24N5O4 [M+H]+ 398.1828, found: 398.1821. 
 
 
Cycloaddition reactions of aza- and oxanorbornadiene derivatives with benzyl azide 
 
Cycloaddition of oxanorbornadiene 29 with benzyl azide: 
 
Dimethyl 1-benzyl-1H-1,2,3-triazole-4,5-dicarboxylate (37) 
 
Compound 29 (210 mg, 1.0 mmol) and benzyl azide (666 mg, 5 mmol) were 
dissolved in 5 mL THF and stirred for 18 hours. The solvent was evaporated 
and the crude mixture was purified by column chromatography (EtOAc/ 
n-heptane, 3:1) resulting in compound 37 as a white powder (160 mg, 60%) 
RF = 0.3 (EtOAc/n-Heptane, 3:1). 1H-NMR (400 MHz, CD3OD) : 7.34 (m, 3H), 
7.27 (d, J = 7.5, 2.0 Hz, 2H), 5.81 (s, 2H), 3.91 (s, 3H), 3.87 (s, 3H). 13C-NMR (75 MHz, CDCl3) : 
159.9, 158.3, 139.7, 133.4, 129.3, 128.5, 128.4, 127.5, 53.5, 52.8, 52.2. LC-MS (ESI+) m/z calcd for 
C13H14N3O4 [M+H]+ 276.01, found: 276.10. 
 
Cycloaddition of azanorbornadiene 34 with benzyl azide: 
 
A solution of azanorbornadiene 34 (15.4 mg, 0.05 mmol) in CD3OD (0.5 mL) was added to a test tube 
containing benzyl azide (31.3 L, 0.25 mmol). The mixture was briefly stirred using a vortex and then 
added to an NMR tube. Directly after the addition, the tube was placed in a Varian inova 400 NMR 
apparatus at 25 °C, and reaction was monitored following a preset measurement schedule. The 
conversion to triazole 37, determined by 1H-NMR, was found to be 90% after 14 hours. 1H-NMR 
(400 MHz, CD3OD) : 7.34 (m, 3H), 7.25 (m, 2H), 5.76 (s, 2H), 3.88 (s, 3H), 3.83 (s, 3H). 
 
Cycloaddition of oxanorbornadiene 30 with benzyl azide: 
 
Ethyl 1-benzyl-5-(trifluoromethyl)-1H-1,2,3-triazole-4-carboxylate (40) and ethyl 1-benzyl-4-
(trifluoromethyl)-1H-1,2,3-triazole-5-carboxylate (39) 
 
Benzyl azide (39.9 mg, 0.3 mmol) was added to a 
solution of oxanorbornadiene 30 (70.2 mg, 0.3 mmol) in 
CD3OD (3 mL) and the reaction mixture was stirred at 
room temperature for 16 hours. The solvent was 
removed under reduced pressure and the crude mixture 
was purified by preparative TLC (EtOAc/n-heptane, 3:1) 
resulting in compounds 40 (53 mg, 60%) RF = 0.70 (EtOAc/n-heptane, 3:1). 1H-NMR (400 MHz, CDCl3) 
 (ppm): 7.35 (m, 3H), 7.22 (dd, J = 6.6, 2.8 Hz, 2H), 5.76 (s, 1H), 4.45 (q, J = 7.1 Hz, 2H), 1.41 (t, J = 
7.1 Hz, 3H) and 39 (24 mg, 27%) RF = 0.75 (EtOAc/n-heptane, 3:1). 1H-NMR (400 MHz, CDCl3) : 7.34 
(s, 5H), 5.94 (s, 2H), 4.39 (q, J = 7.2, 7.2 Hz, 2H), 1.35 (t, J = 7.2 Hz, 3H) as slightly yellow oils. NMR 
techniques such as gHSQC and NOESY were employed to elucidate the configuration of the regio-
isomers, unfortunately both techniques were inconclusive.  
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Cycloaddition reactions with substituted propiolates with benzyl azide 
 
Cycloaddition of ethyl-trifluorobut-2-ynoate with benzyl azide: 
 
A solution of ethyl-trifluorobut-2-ynoate (8.3 mg, 0.05 mmol) in CD3OD (0.5 mL) was added to a test 
tube containing benzyl azide (6.3 μl, 0.05 mmol). The mixture was briefly stirred using a vortex and 
then added to an NMR tube. Directly after the addition, the tube was placed in a Varian inova 
400 NMR apparatus at 25 °C, and reaction was monitored following a preset measurement schedule. 
The conversion to triazole 39 and 40, determined by 1H-NMR, was found to be 37% (overall) after 
14 hours. 1H-NMR data of compounds 39 and 40 vide supra 
 
Cycloaddition of dimethyl acetyledicarboxylate with benzyl azide:  
 
A solution of dimethyl acetyledicarboxylate (7.1 mg, 0.05 mmol) in CD3OD (0.5 mL) was added to a 
test tube containing benzyl azide (6.3 L, 0.05 mmol). The mixture was briefly stirred using a vortex 
and then added to an NMR tube. Directly after the addition, the tube was placed in a Varian inova 
400 NMR apparatus at 25 °C, and reaction was monitored following a preset measurement schedule. 
The conversion to triazole 37, determined by 1H-NMR, was found to be 20% (overall) after 14 hours. 
1H-NMR data of compound 37 vide supra 
 
1-Benzyl-5-(trifluoromethyl)-1H-1,2,3-triazole-4-carboxylic acid (41) 
 
2M NaOH (1.25 mL) was added to a solution of 40 (53 mg, 0.18 mmol) in THF 
(4 mL) and the mixture was stirred at room temperature for 16 hours. H2O (2 mL) 
and EtOAc (4 mL) were added and the layers were separated. The aqueous 
layer was acidified with 2 M HCl to a pH of 1-2 and extracted with CH2Cl2 (2  
10 mL). The organic layer was dried over MgSO4 and concentrated in vacuo resulting in an off-white 
semi-solid (43.7 mg, 91%) RF = 0.15 (CH2Cl2/MeOH, 9:1). 1H-NMR (400 MHz, CDCl3) : 7.40-7.35 
(m, 3H), 7.24 (dd, J = 6.6, 2.8 Hz, 1H), 5.78 (s, 2H), 4.08 (br s, 1H). 
 
4-Nitrophenyl 1-benzyl-5-(trifluoromethyl)-1H-1,2,3-triazole-5-carboxylate (42) 
 
Compound 41 (43.7 mg, 0.16 mmol), p-NO2-phenol (22.4 mg, 0.16 
mmol) and 4-(dimethylamino)-pyridine (DMAP, 38.0 mg, 0.32 mmol) 
were dissolved in CH2Cl2 (4 mL). The mixture is cooled to 0 °C and  
EDC·HCl (32.8 mg, 0.17 mmol) was added. The mixture was stirred 
15 min. at 0 °C and 16 hours at room temperature. After completion 
of the reaction 1 M HCl (2 mL) was added and the aqueous layer was extracted with CH2Cl2 (2  
4 mL). The combined organic layers were dried over MgSO4, concentrated in vacuo, and purified by 
preparative TLC (CH2Cl2/MeOH, 9/1) resulting in compound 42 as an off-white solid. After 
crystallization from n-heptane/EtOAc (1:1 v/v) colorless crystals were obtained (42.5 mg, 68%) RF = 
0.5 (CH2Cl2/MeOH, 9:1). 1H-NMR (400 MHz, CDCl3) : 8.32 (d, J = 9.0 Hz, 2H), 7.46 (d, J = 9.0 Hz, 
2H), 7.41-7.35 (m, 3H), 7.30-7.24 (m, 2H), 5.82 (s, 1H). 13C-NMR (75 MHz, CDCl3) : 156.3, 154.5, 
145.8, CF3 (q, 144.9, 133.2, 117.2, 105.4), 138.1, 132.9, 129.3, 129.2, 127.6 (2C), 125.4, 122.6 (2C), 
120.8, 55.3. Anal. calcd. for C17H11F3N4O4; C 52.05% H 2.83% N 14.28%, measured C 52.21% 
H 2.70% N 13.77% 
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Table 7.8 Crystal data and structure refinement for compounds 2, 10 and 11a 
Parameters 2 10 11 
Crystal colour translucent colorless translucent colorless translucent colorless 
Crystal shape very regular fragment regular fragment rather regular platelet 
Crystal size (mm) 0.28 x 0.18 x 0.13 0.23 x 0.17 x 0.11 0.25 x 0.24 x 0.06  
Empirical formula   C8H7NO3 C13H16N2O4 C14H18N2O4 
Formula weight 165.15 264.28 278.30 
Temperature (K) 208 (2) 208(2) 208(2) 
Crystal system, space group Monoclinic,  P 21/c Monoclinic,  P 21 Monoclinic,  P 21/c 
Unit cell dimensions 
 
154 
2.400 < θ < 27.510 
105 reflections 
2.990 < θ < 27.490 
94 reflections 
2.570 < θ < 25.000 
A (°) 90 90 90 
B (°) 104.514(5) 101.186(6) 101.665(8) 
C (°) 90 90 90 
α (Å) 8.7674(5) 6.4458(4) 11.0875(10) 
β (Å) 7.6519(5) 8.2063(3) 10.6868(7) 
γ (Å) 10.8197(6) 12.4142(10) 12.0311(9) 
Volume (Å3) 702.70(7) 644.19(7)  1396.12(19) 
Z, Calculated density (mg/m3) 4,  1.561 2,  1.362 4,  1.324 
Absorption coefficient (mm-1) 0.122 0.102  0.098 
F(000) 344 280 592 
θ range (°) 2.40 - 27.51 2.99 - 27.49 2.57 - 25.00 
Index ranges -11 < = h < = 11, 
-9 < = k < = 9, 
-14 < = l < = 14. 
-8 < = h < = 8, 
-10 < = k < = 10,  
-15 < = l < = 16. 
-13 < = h < = 13, 
-12 < = k < = 12, 
-14 < = l < = 14. 
Reflections collected 14201 11017  21813 
Reflection unique [R(int)] 1610 [0.0274] 2911 [0.0227] 2460 [0.0420] 
Reflections observed 1349 ([Io>2θ(Io)]) 2625 ([Io>2θ(Io)]) 1903 ([Io>2θ(Io)]) 
Completeness to 2θ 25.00    92.3% = 25.00    99.8% 25.00    94.2% 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1610 / 0 / 109 2911 / 1 / 175 2460 / 0 / 185 
Goodness-of-fit on F2 1.177 1.069 1.136 
SHELXL-97 weight 
parameters 
0.0422, 0.3323 0.0367, 0.1240 0.0357, 0.8025 
Final R1, ωR2 indices [I>2(I)] 0.0458, 0.1010 0.0367, 0.0771 0.0531, 0.0988 
R1, ωR2 indices (all data) 0.0585, 0.1070 0.0441, 0.0806 0.0757, 0.1067 
Diff. peak and hole (e.A-3) 0.264 and -0.234 0.155 and -0.219  0.183 and -0.204 
a Experimental: radiation / wavelength = MoKa (graphite mon.) / 0.71073 A, diffractometer / scan = Nonius KappaCCD with 
area detector f and w scan, absorption correction = SADABS multiscan correction, computing = SHELXL-97. 
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Table 7.9 Crystal data and structure refinement for compounds 13, 14 and 21aa 
Parameters 13 14 21a 
Crystal colour translucent colorless translucent colorless translucent colorless 
Crystal shape small regular fragment rough fragment rather regular platelet 
Crystal size (mm) 0.16 x 0.11 x 0.05 0.19 x 0.16 x 0.11 0.19 x 0.13 x 0.02  
Empirical formula   C14H11N3O6S C15H14N2O4S C8H7NO2S 
Formula weight 349.32 318.34 181.21 
Temperature (K) 208(2) 208(2) 208(2) 
Crystal system, space group Triclinic,  P -1 Monoclinic,  P 21/a Orthorhombic,  P c a  
Unit cell dimensions 
 
74 reflections 
2.040 < θ < 25.000 
88 reflections 
2.980 < θ < 25.000 
71 reflections 
2.920 < θ < 25.000 
A (°) 72.589(3) 90 90 
B (°) 71.593(3) 92.529(5) 90 
C (°) 78.276(3) 90 90 
α (Å) 7.0006(3) 10.8073(7) 7.8516(2) 
β (Å) 10.3715(4) 6.4581(3) 8.9344(4) 
γ (Å) 10.9017(5) 20.5380(13) 22.2966(10) 
Volume (Å3) 711.44(5) 1432.05(15) 1564.09(11) 
Z, Calculated density (mg/m3) 2,  1.631 4,  1.477 8,  1.539 
Absorption coefficient (mm-1) 0.268 0.246 0.365 
F(000) 360 664 752 
θ range (°) 2.04 - 25.00 2.98 - 25.00 2.92 - 25.00 
Index ranges -8 < = h < = 8, 
-12 < = k < = 12, 
-12 < = l < = 12. 
-12 < = h < = 12, 
-7 < = k < = 7, 
-24 < = l < = 24. 
-9 < = h < = 9, 
-10 < = k < = 10, 
-26 < = l < = 26. 
Reflections collected 16282 21387 15432 
Reflection unique [R(int)] 2508 [0.0534] 2502 [0.0507] 1376 [0.0717] 
Reflections observed 1860 ([Io>2θ(Io)]) 1981([Io>2θ(Io)]) 992 ([Io>2θ(Io)]) 
Completeness to 2θ 25.00    99.8% 25.00    90.7% 25.00    97.0% 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2508 / 0 / 217 2502 / 0 / 200  1376 / 0 / 109  
Goodness-of-fit on F2 1.078 1.128 1.115 
SHELXL-97 weight 
parameters 
0.0234, 0.7940 0.0348, 1.2804 0.0171, 3.5911 
Final R1, ωR2 indices [I>2(I)] 0.0492, 0.0833 0.0511, 0.0953 0.0605, 0.0932 
R1, ωR2 indices (all data) 0.0764, 0.0915  0.0730, 0.1034 0.0950, 0.1046 
Diff. peak and hole (e.A-3) 0.301 and -0.343 0.257 and -0.358 0.280 and -0.381 
a Experimental: radiation / wavelength = MoKa (graphite mon.) / 0.71073 A, diffractometer / scan = Nonius KappaCCD with 
area detector f and w scan, absorption correction = SADABS multiscan correction, computing = SHELXL-97. 
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Table 7.10 Crystal data and structure refinement for compounds 21b, 22b and 23a 
Parameters 21b 22b 23 
Crystal colour translucent colorless translucent colorless translucent colorless 
Crystal shape rough fragment thick platelet rather regular fragment 
Crystal size (mm) 0.19 x 0.11 x 0.11  0.23 x 0.23 x 0.08 0.30 x 0.21 x 0.16 
Empirical formula   C8H7NO2S C9H9NO2 C12H13NO2 
Formula weight 181.21 163.17 203.23 
Temperature (K) 208(2) 208(2) 208(2) 
Crystal system, space group Triclinic,  P -1 Monoclinic,  P 21/c Monoclinic,  P 21/a 
Unit cell dimensions 
 
105 reflections  
2.530 < θ < 27.500 
85 reflections  
3.410 < θ < 27.490 
111 reflections 
2.580 < θ < 27.490 
A (°) 104.052(3) 90 90 
B (°) 90.096(4) 110.735(3) 92.459(5) 
C (°) 102.918(4) 90 90 
α (Å) 6.8710(3) 11.0902(7) 8.1117(4) 
β (Å) 7.0846(2) 6.0586(2) 11.4076(7) 
γ (Å) 8.2987(3) 12.1945(4) 10.9597(7) 
Volume (Å3) 381.29(3) 766.29(6) 1013.22(10) 
Z, Calculated density (mg/m3) 2,  1.578 4,  1.414 4,  1.332 
Absorption coefficient (mm-1) 0.374 0.101 0.091 
F(000) 188 344 432 
θ range (°) 2.53 - 27.50 3.41 - 27.49 2.58 - 27.49 
Index ranges -8 < = h < = 8,  
-9 < = k < = 9, 
-10 < = l < = 10. 
-14 < = h < = 14, 
-7 < = k < = 7, 
-15 < = l < = 15. 
-10 < = h < = 10,  
-14 < = k < = 14, 
-14 < = l < = 14. 
Reflections collected 12973 14688 19793 
Reflection unique [R(int)] 1743 [0.0280] 1762 [0.0257] 2324 [0.0316] 
Reflections observed 1527 ([Io>2θ(Io)]) 1493 ([Io>2θ(Io)]) 1892 ([Io>2θ(Io)]) 
Completeness to 2θ 25.00    99.9% 25.00    90.5% 25.00    94.5% 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1743 / 0 / 109 1762 / 0 / 109 2324 / 0 / 138 
Goodness-of-fit on F2 1.209 1.090 1.118 
SHELXL-97 weight 
parameters 
0.0297, 0.5189 0.0477, 0.2956 0.0443, 0.5405 
Final R1, ωR2 indices [I>2(I)] 0.0452, 0.1070 0.0448, 0.1005 0.0516, 0.1089 
R1, ωR2 indices (all data) 0.0540, 0.1100 0.0559, 0.1063 0.0681, 0.1161 
Diff. peak and hole (e.A-3) 0.321 and -0.236 0.233 and -0.277 0.288 and -0.251 
a Experimental: radiation / wavelength = MoKa (graphite mon.) / 0.71073 A, diffractometer / scan = Nonius KappaCCD with 
area detector f and w scan, absorption correction = SADABS multiscan correction, computing = SHELXL-97. 
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Table 7.11 Crystal data and structure refinement for compounds 26, 33 and 42a 
Parameters 26 33 42 
Crystal colour translucent colourless translucent colourless translucent colorless 
Crystal shape regular thin needle rather regular rod  rough thin needle 
Crystal size (mm) 0.21 x 0.07 x 0.02  0.31 x 0.17 x 0.11 0.28 x 0.05 x 0.04 
Empirical formula   C20H23N5O4 C15H17NO2 C17H11F3N4O4 
Formula weight 397.43 243.30 392.30 
Temperature (K) 208(2) 208(2) 208(2) 
Crystal system, space group Triclinic,  P -1 Orthorhombic,  P 21  Orthorhombic,  P 21 c a 
Unit cell dimensions 
 
18 reflections 
2.090 < θ < 21.990 
261 reflections 
2.550 < θ < 27.500 
34 reflections 
2.350 < θ < 22.510 
A (°) 94.53(2) 90 90 
B (°) 91.78(3) 90 90 
C (°) 97.94(2) 90 90 
α (Å) 6.2653(18) 6.0214(2) 5.598(2) 
β (Å) 16.061(4) 8.4124(9) 17.141(6) 
γ (Å) 19.577(6) 25.731(2) 17.324(10) 
Volume (Å3) 1943.3(10) 1303.40(18) 1662.4(13) 
Z, Calculated density (mg/m3) 4,  1.358 4,  1.240 4,  1.567 
Absorption coefficient (mm-1) 0.097 0.082 0.136 
F(000) 840 520 800 
θ range (°) 2.09 - 21.99 2.55 - 27.50 2.35 - 22.51 
Index ranges -6 < = h < = 6,  
-16 < = k < = 16, 
 -20 < = l < = 20. 
-7 < = h < = 7, 
-10 < = k < = 10, 
-32 < = l < = 33. 
-6 < = h < = 5, 
-18 < = k < = 17, 
-18 < = l < = 18. 
Reflections collected 32103 14624 9759 
Reflection unique [R(int)] 4762 [0.2071]  2940 [0.0233] 2073 [0.1435] 
Reflections observed 2578 ([Io>2θ(Io)]) 2541 ([Io>2θ(Io)]) 1222 ([Io>2θ(Io)]) 
Completeness to 2θ = 21.99    99.9% = 25.00    99.6%  22.51    98.5% 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4762 / 0 / 529 2940 / 0 / 166 2073 / 1 / 253  
Goodness-of-fit on F2 1.106 1.153 1.141 
SHELXL-97 weight 
parameters 
0.0000, 4.1673 0.0376, 0.2025 0.0367, 2.1879 
Final R1, ωR2 indices [I>2(I)] 0.0960, 0.1069 0.0444, 0.0862 0.0751, 0.1377 
R1, ωR2 indices (all data) 0.1896, 0.1290 0.0561, 0.0908 0.1505, 0.1686 
Diff. peak and hole (e.A-3) 0.279 and -0.254 0.162 and -0.199 0.296 and -0.307 
a Experimental: radiation / wavelength = MoKa (graphite mon.) / 0.71073 A, diffractometer / scan = Nonius KappaCCD with 
area detector f and w scan, absorption correction = SADABS multiscan correction, computing = SHELXL-97. 
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Abstract 
 
Easily accessible trifluoromethyl-substituted oxanorbornadiene derivatives efficiently react with various 
azides in a tandem 1,3-dipolar cycloaddition – retro-Diels-Alder (tandem crDA) reaction to form stable 
1,2,3-triazole-linked compounds.* Reactions can be performed in aqueous media, at ambient 
temperature and in the absence of a transition metal catalyst such as copper. The tandem crDA 
reaction was found to be an effective method for the preparation of a PEGylated oligopeptide and 
initial experiments using HEWL as a model protein demonstrated that this is a promising method for 
the labeling and functionalization of proteins. Utilizing the tandem crDA reaction for the ligation of 
cyclic-RGD to oxanorbornadiene-DTPA resulted in the formation of triazole containing conjugates. 
Moreover, this allows for the use of unprotected ligands for radiolabeling, e.g. DTPA. Optimization of 
the tandem crDA reaction led to the selective formation of a c(RGDfX)-CF3-triazole-DTPA conjugate, 
which showed a good IC50 value, desirable biodistribution and favorable lypophilicity in preliminary 
biological studies.# 
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8.1 Introduction 
 
 
The development of selective and site-specific bioorthogonal conjugation methods is an important 
topic in chemical biology.1 A wide range of methods such as the Staudinger ligation,2 native chemical 
ligation,3 genetic incorporation,4 expressed protein ligation,5 and the Diels-Alder ligation6 are currently 
employed in the selective modification of proteins and other biomolecules. Currently, an increasingly 
applied ligation method is the Cu-catalyzed variant of the Huisgen 1,3-dipolar cycloaddition reaction,7 
the so called “click reaction” developed by Sharpless8 and Meldal.9 An azide and alkyne are reacted 
under mild conditions in the presence of a copper catalyst to produce a stable 1,2,3-triazole. The wide 
variety of available azides and alkynes generated a window of opportunities for the application of this 
versatile and mild ligation method in various fields of chemistry.10 The copper-catalyzed 1,3-dipolar 
cycloaddition reaction is frequently employed as a tool for bioconjugation11 for the construction of 
complex materials such as modified surfaces,12 bioconjugates,13 functionalized polymers,14 virus 
particles,15 and therapeutics.16 
However, due to the toxicity of the copper catalyst to both bacterial and mammalian cells applications 
regarding in vivo ligation are limited. In order to circumvent the use of copper ions, several copper-free 
methodologies have been developed, resulting in the formation of stable 1,2,3-triazoles (see 
Figure 8.1). Bertozzi and coworkers17 devised a strain-promoted [3+2] azide – alkyne cycloaddition 
reaction involving azides and a strained cyclooctyne derivative. More recently Boons et al.18 
introduced the dibenzo-cyclooctyne, a second generation cyclooctyne. Furthermore, reports by Ju et 
al. showed the successful applications of copper-free 1,3-dipolar cycloaddition using electron-deficient 
alkynes and biomaterial functionalized azides.19   
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Figure 8.1 Copper-free triazole formation methodologies.  
 
We recently reported on a copper-free tandem 1,3-dipolar cycloaddition–retro-Diels–Alder (tandem 
crDA) ligation (see Chapter 7), resulting in a stable 1,2,3-triazole linkage.20 Since copper-catalyzed 
cycloaddition reactions generally do not occur with common amino acid residues, this tandem 1,3-
dipolar cycloaddition – retro-Diels-Alder (tandem crDA) reaction is envisaged to be a potentially useful 
metal-free bioconjugation method to construct bio(macro)molecules containing various functional 
groups. To explore the viability of this ligation method we investigated the chemical modification of a 
model peptide and a protein under mild physiological conditions.  
 
 
8.2 The tandem crDA reaction for the functionalization of 
biomolecules 
 
 
8.2.1 Synthesis of functionalized oxanorbornadiene systems 
 
In order to investigate the applicability of the oxanorbornadiene system as a bioconjugation tool, 
initially experiments were conducted to construct functional oxanorbornadiene systems. 
Oxanorbornadiene 1 was smoothly converted into the carboxylic acid derivative 2 and subsequently 
functionalized with different groups such as an amino acid, a fluorophore, poly(ethylene glycol) and 
Applications of the tandem crDA Reaction 
 213
linker molecules, resulting in compounds 3, 4, 7 and 9, respectively (Scheme 8.1). In general, the 
formation of an ester bond was found to be less high yielding than the formation of an amide bond 
(e.g. yields of compounds 6 and 8, 27% and 64%, respectively). Subsequent deprotection of the Boc- 
or tBu group under acidic conditions proceeded without difficulties yielding compounds 7 and 9 in good 
yields (84% and 99%, respectively).  
 
 
 
Scheme 8.1 Synthesis of functionalized oxanorbornadiene systems. Reagents and conditions: i) THF, 
1M NaOH, 0 °C → r.t., 30 min (83%); ii) ) H-Gly-OMe (1 equiv), DMAP (2 equiv), CH2Cl2, 0 °C then 
EDC·HCl (1.1 equiv), 0 °C → r.t., 16 h (56%); iii) 3-aminopropanol (2 equiv), dansyl-chloride, 
2,4,6-collidine (2 equiv), CH2Cl2, Ar-atm 1.5 h (20%); iv) DMAP (2 equiv), CH2Cl2, 0 °C then EDC·HCl 
(1.1 equiv), 0 °C → r.t., 18 h (25%); v) mPEG45 (0.2 equiv), DMAP (0.5 equiv), CH2Cl2, 0 °C then 
EDC·HCl (1.3 equiv), 0 °C → r.t., 36 h (86%); vi) tert-butyl 12-hydroxy-4,7,10-trioxadodecanoate 
(1 equiv), DMAP (2 equiv), CH2Cl2, 0 °C then EDC·HCl (1.1 equiv), 0 °C → r.t., 18 h (27%); vii) 
CH2Cl2, 0 °C then TFA, rt, 16 h (84% for 7, 99% for 9); viii) Boc-1-amino-3,6-dioxa-8-octanediamine 
(1 equiv), DMAP (2 equiv), CH2Cl2, 0 °C then EDC·HCl (1.1 equiv), 0 °C → r.t., 18 h (64%). 
 
The coupling of poly(ethylene glycol) to compound 2 proceeded smoothly resulting in the formation of 
5 in high yield (86%). The formation of compound 5 was confirmed by MALDI-ToF experiments (see 
experimental section Figure 8.9). The introduction of a fluorophore (i.e. dansyl, compound 4), which 
can be used for the visualization of proteins, was accomplished via a two step procedure. First 
dansylchloride was functionalized with an aminopropanol spacer (20%) and secondly the coupling to 
oxanorbornadiene 2 was performed to produce compound 4 in a somewhat disappointing yield (25%). 
 
 
8.2.2 PEGylation 
 
A well-established approach to improve pharmacological properties of biomolecules is conjugation 
with poly(ethylene glycol) (PEG), also termed PEGylation.21 New synthetic strategies for the covalent 
attachment of PEG to (poly)peptides are therefore of great interest. We investigated the applicability of 
the tandem crDA reaction for this purpose. 
 
The suitability of 5 was initially examined by reacting it with 3-azido-7-hydroxycoumarin (10). Since 
3-azidocoumarin derivatives are hardly fluorescent, but become strongly fluorescent upon triazole 
formation,22 they are highly suited as reaction indicators. The increase of fluorescence observed after 
stirring the two components (i.e. 5 and 10) in CH2Cl2 at room temperature for 15 hours indicated that 
the coupling had taken place. By 1H NMR spectroscopy the degree of functionalization was 
determined to be approximately 88%.  
Chapter 8 
 
 214
 
 
Scheme 8.2 Tandem crDA reaction of oxanorbornadiene functionalized PEG 5 with 3-azido-7-
hydroxycoumarin 10 and RGD-containing oligopeptide 12. Reagents and conditions: i) 1.2 mM PEG 5 
(1 equiv), coumarin 10 (3.7 equiv), CH2Cl2, 15 h, 25 °C; b) 3.4 mM PEG 5 (1 equiv), oligopeptide 12 
(2.7 equiv), H2O, 36 h, 37 °C.  
 
The covalent attachment of the azido-coumarin to the PEG (i.e., compound 11) was confirmed by size 
exclusion chromatography (SEC) using both UV- and refractive index detection (RI). After the 
cycloaddition reaction, SEC analysis using UV detection at  = 340 nm (Figure 8.2 right) showed a 
clear signal at the elution time of PEG. As the oxanorbornadiene functionalized PEG shows almost no 
UV response, this confirms that the coumarin was covalently attached to the PEG. As expected, in the 
RI traces no significant differences could be observed before and after the cycloaddition reaction 
(Figure 8.2 left). 
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Figure 8.2 SEC (CHCl3) traces of PEG before (dashed) and after (solid) cycloaddition with 3-azido-7-
hydroxycoumarin, RI (left) and UV (340 nm, right). 
 
To further evaluate the concept of PEGylation via the tandem crDA reaction, the azide-functionalized 
hexapeptide GGRGDG 12 was used. This oligopeptide was selected since the RGD segment is 
recognized by various cell receptors within the integrin family.23 Hence, RGD conjugates can be used 
to stimulate cell adhesion and are of great interest for medical applications.24 The GGRGDG sequence 
was synthesized on a Wang resin using standard Fmoc protection chemistry, and while still on the 
resin, azidoacetic acid was coupled to the N-terminus of the peptide. After cleavage from the resin, the 
fully unprotected oligopeptide 12 was mixed with oxanorbornadiene-functionalized PEG 5 and stirred 
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in water for 36 h at 37 °C. This resulted in the formation of the desired PEGylated peptide 13 with an 
efficient conversion of 80% (determined by 1H NMR spectroscopy). MALDI-ToF analysis of the mixture 
showed a distinct shift towards higher molecular weight, with an expected mass difference 
corresponding to the molecular weight of the oligopeptide (Figure 8.3). These results clearly 
demonstrate that the tandem crDA reaction can be used as a method for PEGylation. 
 
 
 
Figure 8.3. MALDI-ToF spectra of oxanorbornadiene-functionalized PEG 5 before (lower part) and 
after coupling with 2-azidoactyl-GGRGDG-OH (12) (upper part). 
 
 
8.2.3 Protein functionalization 
 
A different, though equally important application of bioconjugation chemistry is the labeling of proteins 
with fluorophores. To demonstrate the applicability of our new ligation method in this field a model 
protein, hen egg white lysozyme (HEWL), was functionalized with an oxanorbornadiene moiety by 
coupling derivative 7 to the lysine residues (six in total) and N-terminus.25 The coupling was performed 
in the presence of a large excess of the coupling reagent (EDC) and reactant (7) in order to achieve 
complete functionalization of all the free amine. However, MALDI-ToF analysis of the purified protein 
showed a molecular mass distribution corresponding to the functionalization of 2 – 7 available free 
amines of the lysozyme and an average of four oxanorbornadiene moieties per HEWL.  
 
Subsequently, the functionalized HEWL 14 was mixed with 3-azido-7-hydroxycoumarin 10 and gently 
shaken for 36 h at 25 °C (Scheme 8.3). As a control experiment native HEWL was also incubated with 
3-azido-7-hydroxycoumarin under the same conditions. The mixtures were run on a SDS-PAGE gel 
and analyzed with both UV illumination and Coomassie blue staining. Upon exposure to UV light (with 
a wavelength of 366 nm) a distinct fluorescent band was observed for the reaction between 
functionalized HEWL 14 and coumarin 10, which was not the case for the control experiment 
(Figure 8.5). Subsequent staining with Coomassie Blue, as expected, showed a band for both 
experiments without any significant difference. These initial results show that the tandem crDA 
reaction is a sufficient method for the labeling of oxanorbornadiene functionalized HEWL 14, and 
indicates that this method is a promising new tool for protein modification.  
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Scheme 8.3 Preparation of oxanorbornadiene functionalized HEWL 14 and subsequent reaction with 
3-azido-7-hydroxycoumarin (10). Reagents and conditions: i) 5.7 mg mL-1 HEWL (1 equiv), 7 
(35 equiv), EDC·HCl (48 equiv), sodium acetate buffer 100 mM, pH 5.5 with 9% THF, 14 h, 25 °C; ii) 
1.5 mg mL-1 HEWL (1 equiv), 3-azido-7-hydroxycoumarin (10) (48 equiv), sodium acetate buffer 20 
mM, pH 5.5 with 9% THF, 36 h, 25 °C. 
 
 
 
Figure 8.5 SDS-PAGE (15% running gel) analysis of the HEWL-coumarin conjugate (15) (lane 2) and 
a control experiment using native HEWL (lane 1). The SDS-PAGE gel was first photographed under 
exposure to UV light ( = 366 nm) (A) and subsequently stained with Coomassie Blue (B). 
 
A preliminary exploration of the bio-orthogonality of this approach consisted of the incubation of 
compound 1 with a pool of all 20 naturally occurring amino acids (in excess) in a phosphate buffer at 
room temperature for 72 hours. For the basic amino acid residues (i.e. Lys, Arg, His) traces of addition 
products with 2b could be detected probably formed via conjugate addition to the electron-deficient 
double bond. Adducts of Cys could not be detected, but are likely to be formed as well. These initial 
experiments show that Michael addition processes to a minor extent may interfere with the reported 
ligation method.  
 
 
8.3 Application of the crDA ligation methodology in tumor targeting 
 
 
Functionalized cyclic RGD-containing peptides are of significant diagnostic and therapeutic interest 
due to versatile application in both tumor targeting26 and tumor imaging.27 The major underlying 
mechanism responsible for the interest in such peptides is based on the binding affinity of the Arg-Gly-
Asp (RGD) motif to integrin receptors i.e. alpha-beta heterodimeric cell-surface receptors which are 
overexpressed on developing capillary cells.28,29 The interaction of integrins with specific matrix 
ligands is fundamental to invasion and formation of tumor-induced angiogenesis30,31 and metastasis.32 
A variety of RGD mimetics have been prepared for binding to αvβ3 integrin of the endothelium and 
tumor cells, leading to disturbed cell migration33 and regression34 or apoptosis35 of tumor cells. While 
linear and flexible RGD-containing peptides bind to a number of integrin receptor subtypes, including 
αIIbβ3, αvβ3 and αvβ536, the constrained cyclic RGD-containing peptides selectively bind to the αvβ3 
subtype.37 As a result, cyclic RGD derivatives have become an important therapeutic target for the 
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diagnosis of various solid tumors. Several modifications have been introduced to cyclic RGD peptides 
to improve receptor binding affinity (e.g. polyvalent constructs)38 and pharmacokinetic modifiers (e.g. 
polymer conjugates39 and glycosylated derivatives40). Similarly, the ε-amino group of the lysine residue 
in cyclo(-RGDfK-) has frequently been used for modification with ligands for radiolabeling (18F, 125I, 
64Cu, 99mTc, 111In)41 or with other biologically relevant moieties.42  
However, conjugation strategies for chemoselective functionalization of cyclic RGD peptides with 
radiolabels or bioactive compounds are limited. Conjugation can be achieved with typical peptide 
coupling reagents, or with other methods such as thioester or thioether coupling, bromoacetyl 
derivatization or oxime ligation, but most of the typical conjugation procedures suffer from poor 
selectivity or low yield. The synthesis of triazole-linked cyclic RGD-conjugates via copper-catalyzed, 
azide–alkyne cycloaddition has also recently been described.38c,40c Nevertheless, there still exists a 
strong demand for a bioconjugation reaction with increased efficiency and chemoselectivity involving 
mutually reactive conjugation partners that are synthetically readily accessible.38c  
We have demonstrated that the copper-free tandem crDA ligation could be applied to ligate PEG and 
fluorescent labels with several bio(macro)molecules under physiological conditions, including a linear 
RGD peptide and a protein.20 After these successful experiments, it appeared to us that the absence 
of copper during conjugation may be particularly favorable for the introduction of ligands for 
radiolabeling such as DOTA or DTPA when metal-free conditions are crucial. For example, the 
tandem crDA paves the way for coupling DTPA constructs to azido-functionalized cyclic RGD peptides 
resulting in conjugates for application in tumor targeting and imaging. 
 
 
8.3.1 Synthesis of cRGD and oxanorbornadiene-DTPA 
 
The approach for the synthesis of oxanorbornadiene-spacer-DTPA 17 is depicted in Scheme 8.4. The 
previously prepared oxanorbornadiene 9 with the particular ethylene glycol spacer was chosen, both 
for distancing the bulky diethylenetriaminepentaacetic acid (DTPA) ligand from the reactive 
oxanorbornadiene, and to potentially improve the pharmacokinetic characteristics of the conjugate.43 
Secondly, the amide-linked conjugate 9 displayed enhanced stability over the esters under 
physiological conditions. The free amine 9 was coupled to tetra-O-tert-butyl protected DTPA to give 
compound 16 in a reasonable yield (64%). The desired oxanorbornadiene-DTPA conjugate (oxanor-
DTPA, 17) was obtained in a sluggish reaction (4 days) in quantitative yield after removal of the tert-
butyl groups with concentrated TFA in CH2Cl2. 
 
 
 
Scheme 8.4 i) tetra-O-tert-Bu-DTPA, EDC, DMAP, CH2Cl2 (81%); ii) TFA, CH2Cl2 (99%); iii) NH4OAc 
buffer (pH 5.5), InCl3. 
 
Next, our attention was focused on the synthesis of N-δ-azido-cyclo(-Arg-Gly-Asp-D-Phe-Orn-) 23 (or 
for short, c(RGDfX(N3)), Scheme 8.5). Haubner et al.44 demonstrated that substitution of the valine 
residue in the parent peptide c(-RGDfV-) for a lysine residue did not affect the activity or selectivity, 
enabling this position for any anchoring without interference with biological activity.45 Consequently, 
the valine residue was substituted for an azide-functionalized ornithine derivative. N-δ-azido-Fmoc-L-
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ornithine (19) was prepared by diazotransfer reaction on Fmoc-L-Orn-OH and N--Fmoc-D-
phenylalanine (20) was synthesized by Fmoc-protection of H-D-Phe-OH in an excellent yield (91%).  
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Scheme 8.5 i) TfN3, CuSO4, H2O (64%); ii) FmocCl, DiPEA, 1,4-dioxane (91%); iii) Fmoc-based 
SPPS; iv) TFA, TIPS, H2O (90:4.75:4.75) (29% over two steps); v) DPPA, NaHCO3, DMF (87%); vi) 
TFA, CH2Cl2 (93%). 
 
The linear pentapeptide was then synthesized using Fmoc-based solid-phase peptide synthesis 
(SPSS) on a trityl resin according to a modified literature procedure.46 Cleavage of the protected 
peptide from the resin gave H-Asp(OtBu)-D-Phe-Orn(N3)-Arg(PMC)-Gly-OH (21) in an overall yield of 
29%. Subsequent cyclization under the influence of diphenylphosphoryl azide (DPPA) followed by 
crystallization resulted in the desired N-δ-azido-cyclo(-Arg(PMC)-Gly-Asp(OtBu)-D-Phe-Orn-) (22) in 
an excellent yield (87%). In the final step, c(RGDfX(N3)) (23) was obtained by deprotection of PMC 
and tert-butyl protecting groups in concentrated trifluoroacetic acid (TFA). Characterization by 1H-NMR 
and LC-MS analysis showed that the desired product was obtained in a purity of more than 97%. 
 
The conjugation behavior of the cyclic RGD peptide with DTPA-functionalized oxanorbornadiene in the 
tandem crDA was studied by means of 1H-NMR spectroscopy, LC-MS analysis and HPLC with 
radiolabel detection. Monitoring the reaction by NMR spectroscopy was performed by dissolving 
oxanor-DTPA (17) in a mixture of D2O and CD3OD which was subsequently added to a slight excess 
of cyclic RGD peptide 23 (1.5 equiv), leading to a final concentration of 6.6 M. Under these 
conditions, 1,3-dipolar cycloaddition retro-Diels–Alder-reaction of 17 and 23 was expected to lead, via 
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furan elimination to triazole adduct 24 (Scheme 8.6). Compound 24, although depicted as a single 
compound in Scheme 8.6, was expected to be formed as a mixture of regioisomeric products A1 and 
A2 as a result of the lack of regioselectivity in the first step of the crDA process, i.e. the 1,3-dipolar 
cycloaddition (Scheme 8.7).  
 
 
 
Scheme 8.6 Conjugation experiment of c(RGDfX(N3)) 23 with oxanor-DTPA (17) and Me-oxanor-
DTPA (33) resulting in c(RGDfX)-CF3-triazole-DTPA conjugate 24 (major 1,4-isomer shown). 
 
 
 
Scheme 8.7 Reaction pathways for the formation of triazole compounds A1, A2, and B in the tandem 
crDA reaction. 
 
The conversion to conjugate 24 was monitored by 1H NMR spectroscopy (400 MHz) by integration of 
the furan protons with respect to the disappearing bridgehead protons of the oxanorbornadiene. First 
of all, the reaction was found to proceed rather slowly, requiring 4 days for complete disappearance of 
compound 17. After this time, LC-MS analysis (UV detection of the RGD motif) of the reaction mixture 
(Figure 8.6A) revealed two signals for the desired triazole-containing conjugate 24 as a mixture of two 
regioisomers (55.5%, A1 and A2 ratio 1:1.5), along with residual cyclic RGD peptide (initially 1.5 equiv 
found; 34.2%, Figure 8.6B). Surprisingly, a third product was also observed (10.1%) and based on 
mass spectral analysis the structure was assigned to a 1H-1,2,3-triazole product B (Scheme 8.7) 
resulting from undesired cycloaddition on the unsubstituted double bond of the oxanorbonadiene 
moiety, followed by CF3-substituted furan elimination by retro-Diels–Alder reaction. This increase of 
undesired byproduct formation was also previously observed for the oxanorbornadiene glycine ester 3 
(see Chapter 7). In addition to analysis by NMR spectroscopy and LC-MS, HPLC analysis with 
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radiolabel detection was performed to confirm complete substrate conversion. Monitoring the reaction 
by radiolabel detection required a radiolabeled DTPA-complex. Indium-111 was selected as a suitable 
radiolabel due to its long half-time (111In, t1/2 = 67.2 h) and its stability in the DTPA chelate. Thus, the 
oxanor-DTPA conjugate (17) was labeled with In-111 by addition of approximately 100 µCi 111InCl3 to 
a solution of 17 in a metal-free NH4OAc buffer (pH 5.5). The mixture was incubated for 1 hour at room 
temperature after which the 111In-oxanor-DTPA complex (18, Scheme 8.4) was formed, concluded by 
a radiochemical purity check using an HPLC fitted with an in-line NaI detector (Figure 8.6D). A total 
volume of 50 μL of the 111In-labeled oxanor-DTPA complex (approximately 10 µCi) was used to 
perform the tandem crDA reaction with N-δ-azido-cyclo(-Arg-Gly-Asp-D-Phe-Orn-) (23) under identical 
conditions as reported vide supra. 
 
 
 
Figure 8.6 LC-MS chromatograms; A = crude crDA reaction of 17 and 23 after 4 days: (▼) = isomer B 
(10.1%), (*) = isomer A1 (21.3%), (*) = isomer A2 (33.2%) and (●) = residual c(RGDfX(N3)) 23 (34.2%). 
B = c(RGDfX(N3)) 23. C = oxanor-DTPA derivative 17. Radiolabel traces; D = (♦) 111In-oxanor-DTPA 
complex (18). E = reaction mixture comprised of (~) = byproduct in starting material (♦) = 18, (▼) = 
111In-DTPA-labeled CF3-furan formed concomitantly with product B, (*) = isomer A1, (*) = isomer A2. 
 
Figure 8.6E clearly shows the conversion of 111In-oxanor-DTPA (18) into the two isomers of c(RGDfX)-
CF3-triazole-DTPA conjugate 24 (marked with *). Corresponding to LC-MS analysis, approximately 
14% of the undesired 111In-DTPA-labeled CF3-furan formed concomitantly with product B was also 
detected.  
 
 
8.3.2 Second generation oxanorbornadiene 
 
In order to suppress cycloaddition on the unsubstituted side of the amide-oxanorbornadiene system, 
optimization of the tandem crDA process was undertaken. To this end, four methyl-substituted 
oxanorbornadienes were synthesized (25-28, Scheme 8.8) and the reaction characteristics in the 
tandem crDA reaction were evaluated by 1H-NMR spectroscopy using benzyl azide in CD3OD at 25 °C 
as a model system (Table 8.1). 
 
Reaction of ethyl 4,4,4-trifluorobutynoate with 3-methylfuran resulted in the formation of two 
regioisomers (25a and 25b) in good yield (72%). Saponification of 25a,b was followed by coupling of 
the resulting acids 26a,b to glycine methyl ester, leading to compounds 27a,b which served as a 
model system for the amide-linked glycol spacer. Apart from these compounds, 1,4-dimethyl-
oxanorbornadiene derivative 28 was prepared in excellent yield (91%) starting from 2,5-dimethylfuran. 
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Scheme 8.8 i) Neat, 40 °C (25a/b 72%); ii) THF, 1 M NaOH, (26a/b 80%); iii) H-Gly-OMe, DMAP, 
EDC·HCl, CH2Cl2 (27a/b 74%); iv) 1,4-dioxane, reflux (91%). 
 
The oxanorbornadiene derivatives 1, 3 and 25-28 were subsequently reacted with benzyl azide in the 
tandem crDA reaction. Product formation upon reaction of the oxanorbornadienes with benzyl azide 
(R4-N3) can produce three triazole products as is illustrated in Scheme 8.7. The formation of the 
triazole isomers A1, A2 and B was monitored by 1H-NMR spectroscopy and the kinetic data for the 
formation of the desired isomers A1 and A2 was consequently calculated (depicted in Table 8.1). 
 
Table 8.1. Products and kinetic data of reactions between oxanorbornadiene derivatives 1, 3 and 25-28 and 
benzyl azide (at 25 ºC and 100 mM in CD3OD) obtained by monitoring the reactions with 1H-NMR 
spectroscopy (400 MHz). R1, R2 and R3 as depicted in Scheme 8.8 (R4 = Bn). 
Entry  R1 R2 R3 Equiv 
R4-N3 
A  
(%) 
A1:A2 B  
(%) 
t1/2  
(min) 
Rate × 104  
(M-1·s-1) 
1 1 H H OEt 0.99 97 1:1.5 3 205 8.7 ± 0.09 
2[a] 25 H Me OEt 1.20 nd nd nd nd nd 
3 26 H Me OH 1.04 >99 1:1.3 trace 360 4.2 ± 0.18 
4 28 Me H OEt 1.39 94 1:1.2 6 490 2.6 ± 0.10 
5 3 H H Gly-OMe 1.32 84 1:2.4 16 590 1.9 ± 0.03 
6 27 H Me Gly-OMe 1.08 97 1:2.1 3 >900 1.5 ± 0.01 
[a] not stable, partial oxaquadricyclane formation. nd = not determined. 
 
The cycloaddition reaction of the ester oxanorbornadiene derivative 1 with benzyl azide gave clean 
conversion to the desired isomers A1 and A2 (Table 8.1, entry 1).20 Subjecting the methyl-substituted 
oxanorbornadiene 25a/b to the tandem crDA reaction conditions (entry 2) resulted, apart from the 
expected cycloaddition product, in the partial formation of oxaquadricyclanes 29a/b (Scheme 8.9).47 
The unexpected oxaquadricyclane formation can be attributed to an intramolecular migration of the 
electron-rich methyl-substituted double bond to the accepting electron-deficient double bond.48  
 
Chapter 8 
 
 222
 
 
Scheme 8.9 Formation of oxa-quadricyclanes 29a/b from compound 25a/b upon subjection to tandem 
crDA reaction conditions. 
 
Much to our satisfaction, upon performing the crDA reaction with the less electron-withdrawing 
carboxylic acid derivative 26a/b (entry 3), neither quadricyclane nor undesired isomer B formation was 
observed. The reaction rate, however, slightly decreased compared to the ethyl ester 
oxanorbornadiene derivative 1. The oxanorbornadiene with methyl substituents on both bridgehead 
positions (i.e. compound 28) gave comparable amounts of isomer B with respect to compound 1 
(entries 4 and 1, respectively). However, the rate of the reaction dropped by a factor four, which 
suggested that substitution at the bridgehead position merely affected the rate of the tandem crDA 
reaction. Cycloaddition of benzyl azide and compound 3 (bearing the desired, more stable, amide 
bond at the 3-position of the oxanorbornadiene) considerably increased the amount of undesired 
isomer B compared to compound 1 (16% and 3%, respectively). Apart from that, the rate of the 
cycloaddition reactions diminished considerably as a five-fold decrease in reaction rate was observed. 
A similar decrease in reaction rate was found for the amide containing Me-oxanorbornadiene (27, 
entry 6), though in the same order of magnitude as the unsubstituted oxanorbornadiene glycine 
conjugate 3 (1.5 and 1.9, respectively). Gratifyingly, almost full suppression of isomer B formation was 
achieved with the glycine-substituted Me-oxanorbornadiene 27a/b. Taking everything into 
consideration, the monomethyl-substituted oxanorbornadiene was considered the most suitable 
reaction partner for conjugation to N-δ-azido-cyclo(-Arg-Gly-Asp-D-Phe-Orn-) 23 since the reaction 
rate in the tandem crDA reaction is not negatively influenced, whereas formation of the undesired 
isomer B is effectively suppressed. To this end, a mixture of methyl-substituted oxanorbornadiene-
DTPA complex (Me-oxanor-DTPA, 33a and 33b) was synthesized from compound 26a/b in a four-
step reaction sequence (Scheme 8.10). Radiolabeling of compound 33a/b gave the desired 111In-Me-
oxanor-DTPA complex (34a and 34b) in the final step. 
 
 
 
Scheme 8.10 i) 1-N-Boc-3,6-dioxa-octane-1,8-diamine, EDC, DMAP, CH2Cl2 (47% for 30a/b); ii) TFA, 
CH2Cl2 (99% for 31a/b); iii) tetra-O-tert-Bu-DTPA, EDC, DMAP, CH2Cl2 (44% for 32a/b); iv) TFA, 
CH2Cl2 (99%); v) NH4OAc buffer (pH 5.5), InCl3. 
 
The unlabeled Me-oxanor-DTPA complex 33a/b and N-δ-azido-cyclo(-Arg-Gly-Asp-D-Phe-Orn-) (17) 
were used in the tandem crDA reaction and monitored by 1H-NMR spectroscopy. Similar reaction 
conditions as mentioned before were applied to give nearly full conversion to conjugate 24 after five 
days at 37 °C.  
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After lyophilization of the reaction 
mixture, the sample was subjected to LC-
MS analysis (Figure 8.7). Much to our 
satisfaction, only three peaks were 
observed, comprising the two isomers of 
c(RGDfX)-CF3-triazole-DTPA conjugate 
24 (51.4%, A1 and A2 1:1.5, Scheme 8.6) 
along with residual cRGD peptide 
(48.2%, initially 1.5 equiv used) and no 
undesired 1-c(RGDfX)-1H-1,2,3-triazole 
(isomer B) could be detected. 
 
 
Figure 8.7 LC-MS chromatogram of the crude crDA reaction of 33 and 17 after 5 days (*) = isomer A1 
(22.4%), (*) = isomer A2 (29.0%) and (●) = c(RGDfX(N3)) (33, 48.2%). 
 
 
8.3.3 Biological evaluation of DTPA-triazole-cRGD conjugate 
 
Having obtained the c(RGDfX)-CF3-triazole-DTPA conjugate 24 (or for short DTPA-c(RGDfX)) as 
mixture of the two regioisomers we set out to determine its biological behavior both in vitro and in vivo 
by determining the binding affinity (IC50), lypophilicity (logP), and the biodistribution in nude BALB/c 
mice with SK-RC-52 tumors. To this end both the unlabeled DTPA-c(RGDfX) conjugate 24 and the 
labeled version, 111In-DTPA-c(RGDfX), were required. For the solid-phase binding experiment the 
divalent tracer compound 111In-DOTA-Glu-[c(Arg-Gly-Asp-D-Phe-Lys)]2 (or short 111In-DOTA-E-
[c(RGDfK)]2) was used to compete with conjugate 24 and DOTA-E-[c(RGDfK)]2. 
 
 
8.3.3.3 Solid-phase binding assay 
 
The affinities (IC50) of DTPA-c(RGDfX) and the conventional DOTA-E-[c(RGDfK)]2 for the human αvβ3 
integrin were determined in a solid phase binding assay experiment with 111In-DOTA-E-[c(RGDfK)]2 as 
a tracer. Binding of 111In-labeled DOTA-E-[c(RGDfK)]2 to the integrin was competed with DOTA-E-
[c(RGDfK)]2 and DTPA-c(RGDfX) in a concentration dependent manner. The results of these 
determinations are summarized in Graph 8.1. The IC50 values calculated from the graphs were 
125 nM for DOTA-E-[c(RGDfK)]2 and 191 nM for the DTPA-c(RGDfX) regioisomers. The R2 of the 
trend lines for DOTA-E-[c(RGDfK)]2 and DTPA-c(RGDfX) were 0.9968 and 0.9855, respectively.  
 
 
The affinity for the human αvβ3 integrin 
receptor of the DTPA-c(RGDfX) 
conjugate is comparable and is in the 
same order of magnitude as the IC50 
values found by Dijkgraaf et al. for 
monovalent peptide complexes DOTA-
E-[c(RGDfX)], DOTA-E-c(nRGDfK) and 
DOTA-peptidomimetic, 236 nM, 403 
nM and 219 nM, respectively.49 Since 
DTPA-c(RGDfX) is a monovalent 
peptide and DOTA-E-[c(RGDfK)2] a 
divalent peptide, which is expected to 
have a lower IC50, these results 
indicate that DTPA-c(RGDfX) has a 
relatively high affinity for αvβ3.  
 
 
 
 
Graph 8.1 Competition of specific binding of 111In-DOTA-E-[c(RGDfK)]2 to αvβ3 with DOTA-E-
[c(RGDfK)]2 (■) and DTPA-c(RGDfX) (24) (▲). 
Chapter 8 
 
 224
8.3.3.2 Octanol/water partition coefficient 
 
To determine the lipophilicity of the combined compounds 24a and 24b, the n-octanol-water partition 
coefficient was determined. The logP value for the combined DTPA-triazole-c(RGD)-conjugate 
regioisomers was determined in duplo: -2.45 ± 0.57 and -2.99 ± 0.25. Hence, the mean logP value 
was -2.72 ± 0.49, a number comparable to previously reported logP values for poly(ethylene glycol)39a 
or glucose40a-containing cyclic RGD derivatives. 
 
 
8.3.3.3 Biodistribution 
 
The in vivo behavior of the DTPA-c(RGDfX) conjugate 24 (mixture of regioisomers) was evaluated in 
nude BALB/c mice bearing subcutaneous (s.c.) SK-RC-52 tumors. These subcutaneously growing 
tumors express the αvβ3 integrin at a relatively high level. The biodistribution of the 111In-DTPA-
c(RGDfX) conjugate (obtained via crDA reaction of c(RGDfX(N3)) (23) with 33a/b) was determined by 
sacrificing five nude BALB/c mice with s.c. SK-RC-52 tumors, 2 hours post-injection (p.i.). The 
receptor-mediated localization of the 111In-labeled compounds was investigated by determining the 
biodistribution of the 111In-labeled compounds in the presence of an excess unlabeled compound. 
Therefore, the four remaining mice were injected with an excess of non-labeled DTPA-c(RGDfX) 
simultaneously with 111In-DTPA-c(RGDfX) and sacrificed 2 hour p.i., so as to monitor the non-
specificity uptake. Blood, muscle, tumor, lung, spleen, kidney, liver and intestine were obtained from 
both sets of mice and were subsequently tested on radioactivity. The obtained results of the 
biodistribution are summarized in Figure 8.8. 
 
 
Figure 8.8 Biodistribution of 111In-DTPA-c(RGDfX) conjugate in the absence and presence of an 
excess of unlabeled DTPA-c(RGDfX) in BALB/c mice with SK-RC-52 tumors 2 hours p.i. 
 
The 111In-labeled conjugate displayed rapid blood clearance; 0.17 ± 0.02 %ID/g in absence and 0.46 ± 
0.63 %ID/g in presence of an excess of DTPA-c(RGDfX). The latter value is rather high due to one 
mouse having an increased level of radioactivity in its blood (1.41 %ID/g) while uptake in its other 
tissue was average. High uptake was found in the tumor, kidney and intestine respectively 2.21 ± 1.28 
%ID/g, 1.88 ± 0.34 %ID/g and 1.53 ± 0.32 %ID/g, respectively. A medium uptake was found in the 
spleen and liver (0.88 ± 0.12 %ID/g and 0.97 ± 0.18 %ID/g) and low uptake in the muscle and lung 
(0.19 ± 0.06 %ID/g, 0.41 ± 0.06 %ID/g). The specific uptake of 111In labeled DPTA-c(RGDfX) by the 
tumor tissue was αvβ3-mediated since coinjection of an excess of unlabeled DPTA-c(RGDfX) showed 
a significant decrease of activity concentration in tumor tissue. Virtually no specific uptake was 
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observed in the muscle, lung and kidneys. The spleen, liver and intestine also showed specific uptake 
of 111In labeled DPTA-c(RGDfX) indicating that the uptake in these organs was also αvβ3-mediated. 
Dijkgraaf et al. demonstrated – although tested in another model – that this high uptake by other 
organs can be reduced by the introduction of longer PEG-tails (higher hydrophilicity) and the use of 
multivalent RGD peptides.50 The biodistribution studies were, as the in vitro assays, carried out with 
unpurified 111In-DTPA-c(RGDfX). The unconjugated c(RGDfX) present in the mixture could have 
competed with 111In-DTPA-c(RGDfX) for binding to the αvβ3 integrin. This competition perhaps resulted 
in a lower specific uptake in the tissues containing the αvβ3 receptor; tumor, spleen and intestine. 
 
 
8.4 Conclusions 
 
 
We have demonstrated that easily accessible trifluoromethyl-substituted oxanorbornadiene derivatives 
efficiently react with various azides in an elegant tandem 1,3-dipolar cycloaddition – retro-Diels-Alder 
(tandem crDA) reaction to form stable 1,2,3-triazole-linked compounds. These versatile compounds 
have a distinct potential for bioconjugation reactions as these reactions can be performed in aqueous 
media, at ambient temperature and in the absence of a transition metal catalyst such as copper. The 
tandem crDA reaction was found to be an effective method for the preparation of a PEGylated 
oligopeptide and initial experiments using HEWL as a model protein demonstrated that this reaction is 
a promising new bioconjugation method for the labeling and functionalization of proteins.  
Tandem cycloaddition–retro-Diels-Alder reaction of substituted oxanorbornadienes and functionalized 
azides is a powerful tool for constructing complex bioconjugates by formation of trifluoromethyl 
substituted triazole adduct. The 1,3-dipolar cycloaddition of DTPA-functionalized oxanorbornadiene 
and N-δ-azido-cyclo(-Arg-Gly-Asp-D-Phe-Orn-) resulted in the formation of the desired c(RGDfX)-CF3-
triazole-DTPA conjugate and a small amount of an undesired 1-c(RGDfX)-1H-1,2,3-triazole. 
Introduction of methyl substituents on the oxanorbornadiene suppressed cycloaddition on the 
unfunctionalized side of the oxanorbornadiene systems, thereby effectively eliminating the formation of 
undesired 1-c(RGDfX)-1H-1,2,3-triazole. Preliminary biological evaluation of the c(RGDfX)-CF3-
triazole-DTPA conjugate showed a good IC50 value (192 nM) and favorable lypophilicity (-2.72) that 
could result in positive pharmacokinetic behavior in vivo. Results from biodistribution studies using 
nude BALB/c mice bearing SK-RC-52 tumor cells showed highest uptake of 111In- labeled DTPA-
c(RGDfX) in the tumor tissue. Blocking experiments with excess DTPA-c(RGDfX) indicated that 
uptake in the tumor was αvβ3-mediated, which also applied for the uptake in the spleen, liver and 
intestine. The labeled compounds were cleared rapidly from the blood. The biodistribution studies 
were, as the in vitro assays, carried out with unpurified DTPA-c(RGDfX) conjugate. The presence of 
unconjugated c(RGDfX) could have competed with 111In-DTPA-c(RGDfX) for binding to the αvβ3 
integrin receptors. This competition perhaps resulted in a lower specific uptake in the tissues 
containing the αvβ3 receptor; tumor, spleen and intestine. In addition, the DTPA-c(RGDfX) is 
comprised of a mixture of two regioisomers which might differ in αvβ3 binding affinity as a result of 
dissimilar electronic and steric effects in close proximity of  the cyclic pentapeptide. As a result, the 
IC50 values might be lower using purified DTPA-c(RGDfX) conjugate. It is therefore recommended that 
these initial in vitro and in vivo assays are repeated with purified, single regioisomers of the DTPA-
c(RGDfX) conjugate.   
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8.6 Experimental section  
 
 
General experimental: 
 
See Chapter 2 section 7 
 
 
Instrumentation 
 
LC-MS analysis was performed on a Shimadzu LC-MS 2010A system, equipped with a Zorbax Extend 
C18 column, 3.5 um, 4.6 × 150 mm, Agilent Technologies, Palo Alto, CA, USA, eluting with a mobile 
phase gradient-profile: 0 - 5 minute 10% acetonitril / 90% water (0.1% TFA), 5 - 30 minute gradient to 
95% acetonitril / 5% water (0.1% TFA), 30 - 40 minute 95% acetonitrile / 5% water (0.1% TFA). 
Molecular weight distributions were measured with a Shimadzu SEC, equipped with a guard column 
and a PL gel 5 m mixed D column (Polymer Laboratories) with differential refractive index and UV ( 
= 254 nm and  = 330 nm) detection using either THF or CHCl3 as an eluent (1 mL/min at 35 C). In 
both cases PS standards were used for calibration. 
 
 
Methods and Materials 
 
111InCl3 was obtained from Tyco Mallinckrodt, Petten, The Netherlands. Hen egg white lysozyme 
(HELW) was obtained from Sigma. The water used in the biological procedures was deionized using a 
Labconco Water Pro PS purification system.  
 
 
Synthesis 
 
The synthesis of compounds 1, 2 and 3 is described in Chapter 7.  
 
3-(5-(Dimethylamino)naphthalene-1-sulfonamido)propyl-3-(trifluoromethyl)-7-oxa-
bicyclo[2.2.1]hepta-2,5-diene-2-carboxylate (4) 
 
To a flame dried 50 mL round bottom flask was added, dansyl 
chloride (283 mg, 1.05 mmol), anhydrous CH2Cl2 (20 mL) and 2,4,6-
collidine (280 μL, 2.11 mmol). Subsequently, 3-aminopropanol 
(160 μL, 2.11 mmol) was added and the mixture was allowed to stir 
under an Ar atmosphere for 1.5 hours. The reaction mixture was 
diluted with EtOAc (100 mL) and washed with an aqueous 10% 
(w/w) solution of citric acid (3  75 mL) and a saturated aqueous NaHCO3 solution (2  75 mL). After 
drying over Na2SO4, the mixture was concentrated in vacuo, yielding a greenish solid (65 mg, 20%) 
RF = 0.1 (EtOAc/n-heptane, 1/1). 1H-NMR (300 MHz, CDCl3) : 8.53 (dt, J = 1.0, 1.0, 8.6 Hz, 1H), 
8.31-8.20 (m, 1H), 8.23 (dd, J = 1.3, 7.3 Hz, 1H), 7.55-7.48 (m, 2H), 7.17 (dd, J = 0.7, 7.6 Hz, 1H), 
5.46 (t, J = 5.9 Hz, 1H), 3.64 (t, J = 5.7 Hz, 2H), 3.04 (q, J = 6.1 Hz, 2H), 2.88 (s, 6H), 1.68-1.50 
(m, 2H). A mixture of oxanorbornadiene carboxylic acid 1 (46.0 mg, 0.22 mmol), 5-(dimethylamino)-N-
(3-hydroxypropyl)naphthalene-1-sulfonamide (60.0 mg, 0.19 mmol) and 4-(dimethylamino)-pyridine 
(DMAP, 55.2 mg, 0.45 mmol) in anhydrous CH2Cl2 (4 mL) was cooled to 0 °C. 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC·HCl, 64.5, 0.34 mmol) was added and the 
mixture was stirred at 0 °C for 1 hour. The mixture was allowed to warm to room temperature and 
stirred for another 18 hours. The mixture was concentrated in vacuo before purification by preparative 
TLC (CH2Cl2/MeOH, 9/1). The product was obtained as a greenish solid (24 mg, 25%) RF = 0.8 
(CH2Cl2/MeOH, 9:1). 1H-NMR (300 MHz, CDCl3) : 8.57-8.49 (m, 1H), 8.32-8.21 (m, 1H), 7.57-7.48 
(m, 2H), 7.29-7.10 (m, 3H), 5.67-5.53 (m, 2H), 4.89 (t, J = 6.3 Hz, 1H), 4.16-4.01 (m, 2H), 2.98 (q, J = 
6.6 Hz, 2H), 2.89 (s, 6H), 1.80-1.56 (m, 2H). 
O
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-Methoxy--(trifluoromethyl-7-oxa-bicyclo[2.2.1.]hepta-2,5-diene-2-carbonyl)  
poly(ethylene glycol) (5) 
A mixture of oxanorbornadiene carboxylic acid 1 (80 mg, 0.39 mmol), 
-methoxy poly(ethylene glycol) (mPEG, 152 mg, 0.076 mmol) and 
DMAP (22 mg, 0.18 mmol) in anhydrous CH2Cl2 (4 mL) was cooled to 
0 °C. EDC·HCl (94.5 mg, 0.49 mmol) was added and the mixture was 
stirred for 1.5 hours at 0 °C. The mixture was allowed to warm to room 
temperature and stirred for another 36 hours. After dilution with CH2Cl2 
(50 mL) the reaction mixture was washed with a saturated aqueous NaHCO3 solution (2  50 mL) and 
a saturated aqueous NH4Cl solution (2  50 mL). Subsequently, the organic phase was dried over 
Na2SO4 and concentrated in vacuo, affording a yellowish solid (142 mg, 86%). 1H-NMR (400 MHz, 
CDCl3) : 7.27 (dd, J = 1.9, 5.3 Hz, 1H), 7.17 (dd, J = 1.9, 5.3 Hz, 1H, oxanorbornadiene), 5.72 
(m, 1H, oxanorbornadiene), 5.63 (t, J = 1.7, 1H, oxanorbornadiene), 4.34 (m, 2H, O-CH2-CH2-CO2), 
3.62 (br s, 180H, O-(CH2CH2) -O), 3.35 (s, 3H, CH3-O). ESI-ToF (ESI+) analysis (Figure 8.9) shows a 
clear shift of the molecular weight distribution towards higher molecular weight. The [M+Na] peaks for 
n = 38 were assigned for both compounds; ESI-ToF (ESI+) [M+Na] hydroxyl functionalized mPEG m/z 
= 1727.94 (calc. m/z = 1728.02), [M+Na] oxanorbornadiene functionalized mPEG (5) m/z = 1915.86 
(calc. m/z = 1916.03). By subtracting the two peaks, the expected difference of m/z = 187.92 (calc. 
m/z = 188.01) is found. Note: No fresh calibration sample was acquired while measuring the samples. 
 
 
Figure 8.9 ESI-ToF spectra of hydroxyl-functionalized mPEG and oxanorbornadiene-functionalized 
mPEG. Note: The extra distributions on the lower molecular weight side (only slightly visible) belong to 
the double charged species. 
Chapter 8 
 
 228
3,6,9-Trioxadodecan-12-oic acid, 1-[[3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-
carboxyl] oxy]-1,1-dimethylethyl ester (6) 
A mixture of 1 (103 mg, 0.50 mmol), tert-butyl-12-
hydroxy-4,7,10-trioxadodecanoate (139 mg, 0.50 mmol) 
and DMAP (121 mg, 1.00 mmol) in CH2Cl2 (6 mL) was 
cooled to 0 °C before adding EDC·HCl (105 mg, 
0.55 mmol). The mixture was stirred for 5 min at 0 °C 
and 18 hours at room temperature. The reaction mixture was acidified with HCl (2M) to a pH of 1-2 
and extracted with CH2Cl2 (2  10 mL). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The crude mixture was purified by preparative TLC (CH2Cl2/MeOH, 9:1) 
resulting in compound 6 as a slightly yellow oil (65 mg (27%)). RF = 0.81 (CH2Cl2/MeOH, 9:1). FT-IR 
max film (cm-1): 2971, 2868, 1731, 1666, 1359, 1338, 1273, 1117, 878. 1H-NMR (400 MHz, CDCl3) : 
7.19 (dd, J = 5.3, 1.9 Hz, 1H), 7.29 (dd, J = 5.3, 1.9 Hz, 1H), 5.71 (dd, J = 2.9, 1.6 Hz, 1H), 5.66 (t, J = 
1.7 Hz, 1H), 4.36 (ddt, J = 11.9, 7.1, 4.9 Hz, 2H), 3.73 (t, J = 4.9 Hz, 2H), 3.70 (t, J = 6.6 Hz, 2H), 3.64 
(s, 6H), 3.60 (m, 2H), 2.49 (t, J = 6.6 Hz, 2H), 1.44 (s, 9H). 13C-NMR (75 MHz, CDCl3) : 170.8, 161.6 
(q), 151.8, 151.3 (q), 143.9 (q), 142.6, [126.9, 123.3, 119.7, 116.2] (q of CF3), 85.1, 83.9 (q) 80.4, 
70.60, 70.55, 70.50, 70.3, 68.6, 66.8, 64.7, 36.2, 28.0. HRMS (ESI+) m/z calc. for C21H29F3NaO8 
[M+Na]+ 489.1712, found: 489.1719. 
 
3,6,9-Trioxadodecan-12-oic acid, 1-[[3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-
carboxyl]oxy]-12-carboxylic acid (7) 
A solution of compound 6 (65 mg, 0.13 mmol) in CH2Cl2 
(2 mL) was cooled to 0 °C before trifluoroacetic acid (TFA, 
55 L) was added drop wise. The mixture was stirred for 
30 min at 0 °C and 16 hours at room temperature. The 
solvent was removed and the residue was dissolved in 
H2O (5 mL) and dioxane (3 mL) and subsequently freeze-
dried. The product was purified by preparative TLC (CH2Cl2/MeOH, 9:1), resulting in compound 7 as a 
colorless oil (44.6 mg (84%)). RF = 0.25 (CH2Cl2/MeOH, 9:1). FT-IR max film: (cm-1) 3434, 2928, 2846, 
1731, 1455, 1260, 1104, 793. 1H-NMR (400 MHz, CDCl3) : 7.60 (br s, 1H), 7.30 (dd, J = 5.3, 1.9 Hz, 
1H), 7.20 (dd, J = 5.3, 1.9 Hz, 1H), 5.72 (m, 1H), 5.66 (t, J = 1.7 Hz, 1H), 4.44-4.31 (m, 2H), 3.79-3.72 
(m, 4H), 3.65 (s, 4H), 3.64 (s, 4H), 2.63 (t, J = 6.3 Hz, 2H). 13C-NMR (50 MHz, CDCl3) : 176.2, 161.7, 
151.3, 144.0, 142.7, [124.3, 119.1] (CF3), 109.7, 85.2, 84.1, 70.6, 70.4, 68.7, 66.4, 64.8, 34.9. HRMS 
(ESI-) m/z calc. for C17H20F3O8 [M-H]- 409.1110, found: 409.1103. 
 
N-{Boc}-N’-{3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxyl}-3,6-dioxaoctane-
1,8-diamine (8) 
To a solution of oxanorbornadiene 2 (34.7 mg, 0.17 mmol) 
and 1-N-Boc-3,6-dioxa-8-octane-1,8-diamine (41.8 mg, 
0.17 mmol) in CH2Cl2 (1.5 mL) was added 
4-(dimethylamino)-pyridine (DMAP, 41.1 mg, 0.34 mmol). 
The mixture was cooled to 0 °C and EDC·HCl (21 mg, 
0.11 mmol) was added slowly. The mixture was stirred for 
30 min at 0 °C and 16 hours at room temperature. The reaction mixture was acidified with HCl (2 M) to 
a pH of 1-2 and extracted with CH2Cl2 (2  5 mL). The combined organic layers were dried over 
MgSO4, concentrated in vacuo, and purified by preparative TLC (CH2Cl2/MeOH, 9:1) resulting in 
compound 3 as a slightly yellow oil (47.8 mg, 64%). RF = 0.50 (CH2Cl2/MeOH, 9:1). 1H-NMR 
(400 MHz, CD3OD) : 7.30 (dd, J = 5.3, 1.9 Hz, 1H), 7.21 (dd, J = 5.3, 1.9 Hz, 1H), 5.65 (t, J = 1.6, 1.6 
Hz, 1H), 5.55 (m, 1H), 3.59 (s, 4H) 3.56 (dd, J = 10.5, 5.0 Hz, 2H), 3.49 (t, J = 5.7 Hz, 2H), 3.45 
(dd, J = 11.3, 5.5 Hz, 2H), 3.20 (t, J = 5.7 Hz, 2H), 1.41 (s, 9H). 13C-NMR (50 MHz, CD3OD) : 165.2, 
158.5, 144.7, 143.6, [126.6, 121.2] CF3, 87.1, 84.4, 80.1, 71.3, 70.3, 41.2, 40.4, 28.8. LRMS (ESI+) 
m/z calc. for C19H28F3N2O6 [M+H]+ 437.1, found: 437.1. 
 
N,N’-{3-Trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxyl}-3,6-dioxaoctane-1,8-
diamine·TFA (9) 
To a cooled solution (0 °C) of 8 (47.8 mg, 0.11 mmol) in dry CH2Cl2 
(2 mL) was added drop wise TFA, 0.5 mL, 2.85 mmol). The reaction 
was stirred at 0 °C for 1 hour after which the reaction was complete. 
The solvent was evaporated and the crude mixture was dissolved in 
H2O (5 mL) and dioxane (5 mL) and lyophilized to afford compound 
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9 as a light yellow solid (49.0 mg, 99%). RF = 0.09 (CH2Cl2/MeOH, 9:1). 1H-NMR (400 MHz, CD3OD) : 
7.30 (ddd, J = 5.3, 1.9 Hz, 0.7 Hz, 1H), 7.22 (ddd, J = 5.3, 1.9, 0.7 Hz, 1H), 5.66 (s, 1H), 5.55 (s, 1H), 
3.76 (t, J = 4.9, 2H) 3.64, (s, 4H), 3.57 (t, J = 5.9 Hz, 2H), 3.38-3.55 (m, 4H), 3.09 (t, J = 5.7 Hz, 2H). 
13C-NMR (50 MHz, CD3OD) : 165.3, 156.2, 144.6, 143.7, 127.8, [126.5, 121.2] CF3, 87.1, 84.5, 71.3, 
70.3, 67.9, 40.7, 40.3. HRMS (ESI+) m/z calc. for C14H20F3 N2O4 [M+H]+ 337.1375, found: 337.1376. 
 
3-Azido-7-hydroxycoumarin (10) 
 
This compound was prepared according to a literature procedure:22 
1H-NMR (DMSO, 400 MHz): δ = 10.53 (s, 1H), 7.60 (s, 1H), 7.48 (d, J = 8.5 Hz, 
1H), 6.81 (dd, J = 8.5, 2.3 Hz, 1 H), 6.76 (d, J = 2.3 Hz, 1H). FT-IR max film (cm-1): 
3291, 2115, 1679, 1616, 1303. 
 
-Methoxy--(3-(5-(trifluoromethyl)-1H-1,2,3-triazol-4-carbonyl)-7-hydroxy-coumarin) 
poly(ethylene glycol) (11) 
 
A mixture of oxanorbornadiene-functionalized PEG 5 (7.7 mg, 
3.5  10-3 mmol) and 3-azido-7-hydroxy coumarin (10) (2.6 mg, 
0.013 mmol) in CH2Cl2 (3 mL) was stirred for 15 hours at room 
temperature. The presence of fluorescence (when irradiated by 
UV light of  = 366 nm) indicated that the reaction took place. 
The mixture was concentrated in vacuo and characterized without further purification. From 1H-NMR 
analysis the level of functionalization was determined to be 88%. 1H-NMR (400 MHz, CDCl3,) : 8.12 
(s, 1H), 7.52 (d, J = 8.5 Hz, 1H), 7.00 (d, J = 1.9 Hz, 1H), 6.96 (dd, J = 2.2, 8.4 Hz, 1H), 4.46-4.40 
(m, 2H, O-CH2-CH2-CO2), 3.63 (br s, 180H, O-(CH2CH2) -O), 3.37 (s, 3H, CH3-O). 
 
Azidoacetyl-Gly-Gly-Arg-Gly-Asp-Gly-OH (12) 
 
Azide-functionalized N3-Ac-GGRGDG-OH (12) 
was synthesized by standard solid-phase 
methods using a Wang resin.51 A suspension of 
Wang resin (30 g) in DMF (300 mL) was cooled 
in an ice bath, after which Fmoc-Gly-OH (13.5 g, 
45 mmol), 1-hydroxybenzotriazole hydrate 
(HOBt, 9.2 g, 60 mmol) and N,N’-diisopropyl 
carbodiimide (DIPCDI, 4.3 g, 34 mmol) were 
added. This mixture was shaken for 6 hours. The functionalized resin was filtered and washed 
repeatedly with CH2Cl2, DMF, and isopropyl alcohol. Unfunctionalized groups on the resin were 
capped by adding benzoyl chloride (10.2 mL) and pyridine (8.4 mL) to a suspension of the resin in 
CH2Cl2 (300 mL) at 0 °C. The mixture was shaken for 30 min, filtered and washed repeatedly with 
CH2Cl2, DMF, and isopropyl alcohol. Then the Fmoc-Gly functionalized Wang resin (1 g, loading; 
0.67 mmol/g) was swollen in DMF (20 mL) and filtered three times. Subsequently, the mixture was 
shaken in a 20% (v/v) solution of piperidine in DMF (20 mL) for 30 min to remove the Fmoc protecting 
group. A positive Kaiser test indicated the completeness of this reaction. After filtering and washing 
with DMF (3  20 mL), the next amino acid was coupled by adding a mixture of Fmoc-Asp(OtBu)-OH 
(500 mg, 1.22 mmol), HOBt (405 mg, 3.00 mmol) and DIPCDI (340 mg, 2.70 mmol) in DMF (20 mL). 
The mixture was shaken for 45 min, after which it was filtered and washed with DMF (3  20 mL). A 
negative Kaiser test indicated the completeness of the reaction. The deprotection-coupling sequence 
was repeated with the following amino acids: Fmoc-Gly-OH (210 mg, 0.71 mmol), Fmoc-Arg(PMC)-
OH (700 mg, 1.77 mmol), and Fmoc-Gly-OH (210 mg, 0.71 mmol) twice. After deprotection of the 
terminal Fmoc group, 2-azidoacetic acid52 (158 mg, 1.56 mmol) was coupled to the peptide by shaking 
the mixture with HOBt (405 mg, 3.00 mmol) and DIPCDI (340 mg, 2.70 mmol) in DMF (20 mL) for 
45 min. The mixture was washed repeatedly with DMF and MeOH. Subsequently, the resin was stirred 
in a mixture of TFA/TiPS/H2O (95:2.5:2.5, 3.5 mL) to cleave the peptide from the resin. The peptide 
was precipitated in Et2O and stirred in TFA/H2O (95:5, 3 mL) for 4 hours to achieve a complete 
deprotection of the amino acid residues. Upon precipitation in Et2O and drying in vacuo the peptide 
was obtained as an off-white solid (350 mg, 87%) 1H-NMR (400 MHz, D2O) : 4.93-4.71 (m, 1H), 4.35 
(dd, J = 5.7, 8.7 Hz, 1H), 4.11 (s, 2H), 4.07-3.89 (m, 8H), 3.21 (t, J = 6.7 Hz, 2H), 2.99-2.75 (m, 2H), 
1.97-1.85 (m, 1H), 1.85-1.73 (m, 1H), 1.73-1.56 (m, 2H). FT-IR max film (cm-1): 3285, 3092, 2928, 
2114, 1651, 1540, 1186. ESI-ToF (ESI-) m/z calc.for C20H31N12O10 599.229 [M-H]-, found: 599.233.  
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-Methoxy--(3-(5-(trifluoromethyl)-1H-1,2,3-triazol-4-carbonyl)-acetyl-Gly-Gly-Arg-Gly-Asp-OH) 
poly(ethylene glycol) (13) 
 
 
A mixture of oxanorbornadiene-functionalized PEG 5 (14.7 mg, 6.7 10-3 mmol) and 2-azidoactyl-Gly-
Gly-Arg-Gly-Asp-Gly-OH (12) (10.7 mg, 0.018 mmol) in H2O (2 mL) was stirred for 36 hours at 37 °C. 
The mixture was concentrated in vacuo and characterized without further purification. By comparing 
the 1H-NMR integral of an oxanorbornadiene bridgehead signal ( = 5.83) with the -CH2-triazole 
signals ( = 5.68 – 5.62) of the product, the conversion was determined to be 80%. MALDI-ToF 
analysis (using indoleacrylic acid (IAA) as a matrix) of the mixture clearly showed a shift of the 
molecular weight distribution towards higher mass (Figure 8.3). The mass of the end groups can be 
derived from a molecular weight distribution by plotting the molecular mass against N. Consequently, 
the intercept (N = 0) affords the mass of the end groups. N, in case of the obtained PEG-Gly-Gly-Arg-
Gly-Asp-Gly-OH was defined as 34 for the peak assigned with m/z = 2293.696. Using this peak as a 
reference also N for the other peaks was determined and a plot of mass versus N was constructed. 
Linear regression (using Origin 6.1 software) of this dataset resulted in the following equation:  
 
Mass = 44.08  N + 794.67  
 
Herein, 44.08 corresponded with the mass of one repeating unit of PEG (calc 44.03) and the intercept 
of 794.67 corresponded to the -methoxy (calc 31.02) and -Gly-Gly-Arg-Gly-Asp-Gly-OH 
(calc. 721.23) end groups, plus an additional proton, sodium and water. 
 
Typical procedure for the functionalization of Hen Egg White Lysozyme (HEWL) (14): 
 
Hen Egg White Lysozyme (5.7 mg, 4.010-4 mmol) 
was dissolved in 1 mL of sodium acetate buffer 
(100 mM, pH 5.5). After the addition of an azide- or 
oxanorbornadiene-functionalized carboxylic acid 
(1410-3 mmol, as a solution in 100 μL THF), 
EDC·HCl (3.8 mg, 1910-3 mmol) was added as a solution in sodium acetate buffer (100 mM, pH 5.5, 
200 μL). The reaction mixture was shaken at room temperature for 14 hours. Subsequently, the 
protein was separated from low molecular weight compounds by a sephadex G50 column using a 
sodium acetate solution (20 mM, pH 5.5) as the eluent. 
 
Preparation of conjugate (15): 
 
The oxanorbornadiene-functionalized HEWL 14 
(typically, 300 μL of a 1.5 mg/mL solution, 
3.3 10-5 mmol) was mixed with 3-azido-7-
hydroxycoumarin (10) (1.6 10-3 mmol) and 
shaken for 36 hours. As a control experiment, 
non-functionalized HEWL was also incubated with 3-azido-7-hydroxycoumarin (10) under the same 
conditions. After 36 hours the crude mixtures were analyzed by SDS-PAGE (15%), and for the 
reaction a clear fluorescent band was observed at the position of HEWL. As expected the control 
experiment showed no fluorescent band (see Figure 8.5). Since 3-azidocoumarin derivatives are 
known to become strongly fluorescent upon undergoing a cycloaddition the observed fluorescent band 
furthermore proved that the coumarin was covalently attached to the HEWL. Upon staining with 
coomassie blue, as expected, no mass differences were observed between the reaction mixture and 
the control experiment (see Figure 8.5). 
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N-(2-O-tert-Butyl-DTPA-acetamide),N’-(3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-
carboxyl)-3,6-dioxaoctane-1,8-diamine (16) 
 
Compound 9 (49 mg, 0.11 mmol) was dissolved in dry 
CH2Cl2 (2 mL) and DMAP (26.6 mg, 0.22 mmol) and 
diethylenetriamine-N,N,N",N"-tetra-tert-butyl acetate-N'-
acetic acid ((DTPA-tert-butyl ester) 67.8 mg, 0.11 mmol) 
were added. The mixture was cooled to 0 °C followed by 
addition of EDC·HCl (23.1 mg, 0.12 mmol). After 1 hour 
stirring at 0 °C the mixture was allowed to warm to room 
temperature and was stirred for an additional 4 hours. 
The reaction mixture was quenched with 1 M HCl (2 mL) and the water layer was extracted with 
CH2Cl2 (2  2 mL). The combined organic layers were dried over Na2SO4 and subsequently 
evaporated. The crude product was purified by preparative TLC (MeOH/CH2Cl2 1:9) to obtain pure 
product as a colorless oil (38 mg, 81%). 1H-NMR (400 MHz, CDCl3) : 8.23 (br s, NH 1H), 7.32 
(dd, J = 5.3, 2.1 Hz, 1H), 7.13 (dd, J = 5.3, 2.1 Hz, 1H) 6.81 (br s, NH 1H), 5.62 (dd, J = 1.4, 0.5 Hz, 
2H), 3.62-3.50 (m, 8H), 3.49-3.42 (m, 4H), 3.39 (s, 8H), 3.12 (s, 2H), 2.77 (t, J = 6.6 Hz, 4H), 2.61 
(t, J = 6.5 Hz, 4H), 1.43 (s, 36H). 13C-NMR (50 MHz, CDCl3) :172.2, 170.5 (4C), 162.2, 143.7, 141.9, 
86.0, 83.5, 81.0 (4C), 70.5, 70.0, 69.7, 69.4, 58.5, 55.8 (4C), 53.7, 53.4, 52.1 (2C), 39.4, 38.6, 28.1. 
LRMS (ESI+) m/z calc. for C44H74F3N5O13 [M+H]+ 936.52, found: 936.40. 
 
N-(2-DTPA-acetamide),N’-(3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxyl)-3,6-
dioxaoctane-1,8-diamine (17) 
To a solution of 16 (49 mg, 0.11 mmol) in DCM (2 mL), 
TFA (200 µL, 1.14 mmol) was added. This mixture was 
stirred for 5 days (until MS analysis did not show any 
starting material). The product was obtained after 
lyophilization with H2O/dioxane as a white solid (28 mg, 
99%). 1H-NMR (400 MHz, CD3OD) : 7.32 (dd, J = 5.3, 
1.9 Hz, 1H), 7.23 (dd, J = 5.3, 1.9 Hz, 1H), 5.67 (s, 1H), 
5.58 (s, 1H), 4.24 (br s, NH, 1H), 3.66 (s, 2H) 3.62-3.57 
(m, 16H) ppm 3.50-3.37 (m, 8H), 3.20 (br s, 4H). 13C-NMR (50 MHz, CD3OD) : 174.31, 174.28, 
174.15,174.14, 167.2, 164.9, 155.9, 144.3, 143.4, 127.6 (q, CF3), 86.9, 84.2, 71.1, 71.0, 70.04, 70.00, 
67.9, 55.8 (4C), 53.8 (2C), 50.9, 50.8, 40.2, 40.1. LRMS (ESI_) m/z calc. for C28H39F3N5O13 [M-H]- 
710.25, found: 710.30. 
 
Fmoc-Orn(N3)-OH (19) 
 
Modified literature procedure:53 To a solution of sodium azide (1.00 g, 15.4 mmol) in 
water (3 mL) were added CH2Cl2 (3 mL) and triflic anhydride (1.3 mL, 7.73 mmol) at 
0 °C, while the mixture was vigorously stirred. After stirring for 2 h at 0 °C the 
phases were separated and the aqueous phase was extracted with CH2Cl2 (5 mL). 
The combined organic phases were washed with saturated aqueous NaHCO3 
solution (5 mL). The resulting triflic azide solution was added drop wise to a solution 
of Fmoc-Orn-OH·HCl (1.00 g, 2.57 mmol), CuSO4 (16 mg, 64 μmol) and NaHCO3 
(436 mg, 5.19 mmol) in water (9 mL) followed by the addition of methanol until the mixture became a 
suspension. The mixture was stirred for 4 h at room temperature. The organic solvents were removed 
in vacuo and the resulting suspension was acidified with 1 M aqueous HCl to pH 3 after which the 
precipitate was isolated by filtration and washed with water. The residue was dissolved in ether, dried 
over Na2SO4 and concentrated in vacuo. Purification was performed by flash chromatography 
(CH2Cl2/MeOH/AcOH = 98:2:0.3 → 98:5:0.5) and the product was coevaporated with toluene (4 times) 
yielding a white solid (621 mg, 64%).1H-NMR (CD3OD, 200 MHz) : 7.83 (m, 2H), 7.72 (m, 2H), 7.24 
(m, 4H), 4.41 (d, J = 6.3 Hz, 2H), 4.29 (m, 1H), 4.19 (m, 1H), 4.29 (m, 1H), 4.19 (m, 1H), 3.39 (m, 1H), 
1.90 (m, 2H), 1.75 (m, 2H). LRMS (ESI-) m/z calc. for C20H19O4N4 [M-H]- 379.1, found: 378.9. FT-IR 
max film (cm-1): 2109, 1718, 1630, 1238. 
 
Fmoc-D-Phe-OH (20) 
 
According to literature procedure:54 H-D-Phe-OH (530 mg, 1.37 mmol) yielded 1.13 g (91%) Fmoc-D-
Phe-OH as a white solid after purification by crystallization from EtOAc. 
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H-Asp(OtBu)-D-Phe-Orn(N3)-Arg(PMC)-Gly-OH (21) 
 
Compound 21 was synthesized via standard solid-phase 
peptide synthesis (SPPS) using a modified literature 
procedure:46 To a suspension of trityl chloride resin 
(300 mg of 1.5 mmol/g loaded resin) in dry CH2Cl2 
(2.5 mL) was added a solution of Fmoc-Gly-OH (0.174 g, 
0.58 mmol) and DiPEA (235 μL, 1.35 mmol) in dry CH2Cl2 
(2.5 mL) and the mixture was shaken at room 
temperature for 2.5 h. MeOH (470 μL) and DiPEA (94 μL) 
were added and the mixture was shaken for another 
15 min. The resin was washed with NMP (3  2.5 mL), 
CH2Cl2 (5  2.5 mL) and MeOH (3  2.5 mL) and dried in vacuo. The Fmoc-protected resin was 
suspended in a solution of 20% piperidine in NMP (2  20 mL) and shaken for 5 and 15 min. The resin 
was washed with NMP (6  20 mL). A positive Kaiser test indicated completion of the peptide coupling 
reaction. After filtering and washing with DMF (3  20 mL), the next amino acid was coupled by adding 
a mixture of Fmoc-Arg(PMC)-OH (960 mg, 1.45 mmol, 2.5 equiv),TBTU (465 mg, 1.45 mmol, 
2.5 equiv), HOBt (196 mg, 1.45 mmol, 2.5 equiv) and DiPEA (0.67 mL, 4.1 mmol, 7 equiv) dissolved in 
NMP (100 mL) to the resin. The reaction mixture was shaken at room temperature for 90 min and 
washed with NMP (6  20 mL). A negative Kaiser test indicated completion of the peptide coupling 
reaction. The deprotection-coupling sequence was repeated with the following amino acids: Fmoc-
Orn(N3)-OH (551 mg, 1.45 mmol, 2.5 equiv), Fmoc-D-Phe-OH (561 mg, 1.45 mmol, 2.5 equiv) and 
Fmoc-Asp(OtBu)-OH (596 mg, 1.45 mmol, 2.5 equiv). For the coupling of Fmoc-D-Phe-OH 2,4,6-
collidine (1.9 mL, 14.5 mmol, 25 equiv) was used instead of DiPEA. The resin was washed with DCM 
(4  20 mL) and treated with a solution of TFA, H2O, and triisopropylsilane (TIPS) (90:4.75:4.75; 
20 mL) for 3  10 min. After removal of the resin by filtration, the filtrates were combined and stirred for 
another 2.5 h. The collected filtrates were evaporated, coevaporated with toluene and lyophilized with 
tert-BuOH/H2O/dioxane yielding a white foam (126 mg, 29%). 1H-NMR (400 MHz, CD3OD) : 7.33-
7.23 (m, 5H), 4.59 (t, J = 8.0 Hz, 1H), 4.39 (dd, J = 9.5, 4.4 Hz, 1H), 4.19 (t, J = 6.5 Hz, 1H), 4.00 
(dd, J = 10.5, 3.9 Hz, 1H), 3.85 + 3.62 (AB-system J = 17.0 Hz, 2H), 3.20-3.14 (m, 4H), 3.02 (d, J = 
8.0 Hz, 2H), 2.83-2.77 (m, 2H), 2.67 (t, J = 6.7 Hz, 2H), 2.56 (s, 3H), 2.55 (s, 3H), 2.10 (s, 3H), 1.95-
1.80 (m, 4H), 1.80-1.73 (m, 1H), 1.69-1.60 (m, 1H), 1.58-1.49 (m, 2H), 1.47 (s, 9H), 1.31 (s, 6H), 1.22-
1.08 (m, 2H). LC-MS (EI+) purity +97%, m/z calc. for C44H66N11O11S [M+H]+ 955.5, found: 956.6. 
 
Cyclo-(-Arg(PMC-Gly-Asp(OtBu)-D-Phe-Orn(N3)-) (22) 
 
To a solution of the linear peptide 21 (100 mg, 0.10 mmol) in dry 
DMF (21 mL) were added diphenylphosphoryl azide (68 μL, 
0.31 mmol) and NaHCO3 (43.9 mg, 0.52 mmol) and the mixture 
was stirred for 44 h at room temperature. The mixture was 
filtered, diluted with EtOAc (100 mL) and washed with saturated 
aqueous NH4Cl-solution (2  100 mL) and brine (2  100 mL). 
The organic phase was dried over Na2SO4 and concentrated. 
The material was stirred with Et2O for 10 minutes and the white 
precipitate was collected by filtration, washed with Et2O (3 times) 
and dried, yielding a white solid (85 mg, 87%).1H-NMR 
(400 MHz, CDCl3/CD3OD/D2O) : 7.28-7.18 (m, 5H), 4.70 (dd, 
J = 8.2 Hz, 1H), 4.55 (d, J = 8.0 Hz, 1H), 4.21 (br s, 1H), 4.21 + 
3.34 (AB-system, J = 14.9 Hz, 2H), 3.94 (dd, J = 10.4 Hz, 1H), 
3.14-3.11 (m, 4H), 2.96 (d, J = 8.0 Hz, 2H), 2.74 (dd, J = 16.1, 
8.2 Hz, 1H), 2.63 (t, J = 6.9 Hz, 2H), 2.52 (s, 3H), 2.51 (dd, J = 
16.1, 8.2 Hz, 1H) 2.50 (s, 3H), 2.06 (s, 3H), 1.85-1.77 (m, 3H), 
1.76-1.67 (m, 1H), 1.64-1.55 (m, 1H), 1.52-1.41 (m, 3H), 1.39 (s, 9H), 1.28 (s, 6H) 1.21-1.12 (m, 2H). 
LC-MS (EI+) purity +97%, m/z calc. for C44H64N11O10S [M+H]+ 937.5, found: 938.7. 
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Cyclo-(-Arg-Gly-Asp-D-Phe-Orn(N3)-)·TFA (23) 
 
The cyclic peptide 22 (84 mg, 90 μmol) was dissolved in a mixture of 
TFA/H2O 95:5 (5 mL) and the mixture was stirred for 3 h. The 
solvent was removed and the residue was co-evaporated with 
toluene. The material was dissolved in H2O (15 mL), extracted with 
EtOAc (2  10 mL) and the aqueous phase was evaporated to 
dryness. The product was lyophilized with H2O/dioxane, yielding a 
white solid (61 mg, 93%). 1H-NMR (400 MHz, D2O) : 7.42-7.21 
(m, 5H), 4.64 (dd, J = 10.0, 6.0 Hz, 1H), 4.37 (dd, J = 9.1, 5.6 Hz, 
1H), 4.21 + 3.52 (AB-system, J = 15.0 Hz, 2H), 3.92 (dd, J = 10.4, 
4.8 Hz, 1H), 3.25-3.15 (m, 4H), 3.09 (dd, J = 13.1, 6.2 Hz, 1H), 3.00-
2.90 (m, 2H), 2.75 (dd, J = 16.8, 6.5 Hz, 1H), 1.92-1.62 (m., 3H), 
1.59-1.47 (m, 3H), 1.26-1.16 (m, 2H). 13C-NMR (50 MHz, D2O 
(dioxane residue used as reference) : 174.9, 174.8, 173.7, 173.3, 
172.0, 171.9, 157.3, 136.6, 129.8 (2C), 129.5 (2C), 127.9, 67.19 
(dioxane), 55.8, 55.6, 53.1, 50.7, 50.2, 44.1, 41.1, 37.5, 34.9, 28.1, 
27.9, 25.2, 25.1. HRMS (ESI+) m/z calc. for C26H38N11O7 [M+H]+ 616.2956, found: 616.2907. FT-IR 
max film (cm-1): 3274, 2098, 1640, 1126.  
 
1,4-Dimethyl-3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxylic acid ethyl ester (28) 
 
To a solution of ethyl 4,4,4-trifluoro-2-butynoate (436 mg, 2.62 mmol) in dioxane 
(0.5 mL), 2,5-dimethylfuran (279 μL, 2.62 mmol) was added. The mixture was heated 
to 103 °C under a nitrogen atmosphere and stirred overnight. The reaction mixture was 
cooled and diluted with CH2Cl2 after which all the solvents were evaporated. The crude 
product was purified by column chromatography (MeOH/CH2Cl2 1:9) to obtain the pure 
product as a white solid (238 mg, 91%). 1H-NMR (300 MHz, CDCl3) : 7.01 (d, J = 5.1 Hz, 1H), 6.91 
(d, J = 5.1 Hz, 1H), 4.30 (m, 2H), 1.81 (s, 3H), 1.74 (s, 3H), 1.31 (t, J = 7.1 Hz, 2H). 13C-NMR 
(75 MHz, CDCl3) : 163.7, 154.6, 149.0 (q, J = 35 Hz), 147.5, 146.7, 121.9 (q, CF3, J = 270 Hz), 92.6, 
91.4, 61.6, 15.1, 14.8, 13.9. Both HRMS and LRMS techniques were employed to acquire the mass of 
the described compound. Unfortunately, none of the techniques used gave a comprehensible mass 
spectrum. 
 
5-Methyl-3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxylic acid ethyl ester 
(25a) and 6-methyl-3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxylic acid ethyl 
ester (25b) 
A mixture of ethyl 4,4,4-trifluorobutynoate (0.61 g, 3.65 mmol) and 3-methylfuran 
(0.30 g, 3.65 mmol) was stirred under an Ar-atmosphere for 4 days. The crude was 
purified by column chromatography (EtOAc/n-heptane 1:5), resulting in a mixture of 
two regio-isomers (ratio 1:1.4 for 25b and 25a, respectively) as a slightly yellow oil 
(0.65 g, 72%). 1H-NMR (300 MHz, CDCl3) peaks assigned to compound 25a : 6.65 
(m, 1H), 5.38 (s, 1H), 5.30 (d, J = 1.5 Hz, 1H), 4.28 (m, 2H), 1.99 (d, J = 2.0 Hz, 3H), 
1.31 (t, J = 6.9 Hz, 3H). Peaks assigned to compound 25b : 6.58 (m, 1H), 5.61 (s, 1H), 5.56 (d, J = 
1.5 Hz, 1H), 4.27 (m, 2H), 2.05 (d, J = 2.0 Hz, 3H), 1.32 (t, J = 6.9 Hz, 3H).13C-NMR (75 MHz, CDCl3) 
: 162.1, 162.3, 156.2, 154.8, 152.0 (q), 151.2 (q), 150.8, 150.3, 133.7,134.5, 122.2 (q, CF3), 121.5 
(q, CF3), 88.6, 87.4 (d), 85.9, 84.8, 61.7 (2C), 14.3, 14.2, 14.0 (2C). FT-IR max film (cm-1): 2989, 1735, 
1718, 1671, 1342, 1303, 1286, 1212, 1156, 1126, 880. LRMS (ESI+) m/z calc. for C11H12F3O3 [M+H]+ 
249.1, found: 249.0.  
 
5-Methyl-3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxylic acid (26a) and 
6-methyl-3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxylic acid (26b) 
 
A mixture of 25a and 25b (0.30 g, 1.22 mmol) was dissolved in THF (16 mL) and 
cooled to 0 °C. 1 M NaOH (aq) (1.22 mL) was added drop wise and the mixture was 
stirred overnight at room temperature. TLC analysis showed still some starting 
material after reacting overnight and another 1.22 mL aqueous NaOH (1 M) was 
added. After 30 minutes the reaction was completed and the volume of THF was 
reduced to 50% of the original volume by evaporation using a nitrogen flow. The mixture was diluted 
with aqueous HCl (5 mL, 1 M) and extracted with EtOAc (2  75 mL). The organic layer was dried over 
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Na2SO4 and evaporated under reduced pressure to obtain a yellow solid (0.26 g, 95%). A mixture of 
two regioisomers was obtained in a ratio of 1:1.4 for 26b and 26a, respectively. 1H-NMR (300 MHz, 
CDCl3) peaks assigned to compound 26a : 6.67 (t, J = 2.0 Hz, 1H), 5.56 (s, 1H), 5.34 (d, J = 1.5 Hz, 
1H), 2.01 (d, J = 2.0, 3H). Peaks assigned to compound 26b : 6.59 (t, J = 2.0 Hz, 1H), 5.60 (s, 1H), 
5.42 (d, J = 1.5 Hz, 1H), 2.05 (d, J = 2.0 Hz, 3H). 13C-NMR (75 MHz, CDCl3) : 166.7, 166.4, 150.9 (q), 
149.9 (q), 134.4, 133.2, 121.2 (q, CF3), 121.0 (q, CF3), 88.3, 87.5, 84.9, 84.8, 14.1, 14.0. HRMS (ESI-) 
m/z calc. for C9H6F3O3 [M-H]- 219.0269, found: 219.0253. 
 
5-Methyl-3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxyl glycine methyl ester 
(27a) and 6-methyl-3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxyl glycine 
methyl ester (27b) 
Oxanorbornadiene carboxylic acids 26a and 26b (87.5 mg, 0.39 mmol), 
glycine methyl ester·HCl (158 mg, 1.26 mmol) and DMAP (183 mg, 
1.50 mmol) were dissolved in CH2Cl2 (16 mL) and cooled to 0 °C. EDC·HCl 
(80 mg, 0.42 mmol) was added and the reaction mixture was stirred at 0 °C 
for 30 min. The mixture was allowed to warm to room temperature and was 
stirred for an additional 16 hours. The reaction was quenched with a 10% aqueous solution of citric 
acid (20 mL) and extracted with EtOAc (2  20 mL). The combined organic layers were washed with 
brine (20 mL), dried over Na2SO4 and concentrated in vacuo. The crude mixture was purified by 
preparative TLC (CH2Cl2/MeOH, 9:1) resulting in a mixture of compounds 27a and 27b (ratio of 1.4:1) 
as a colorless oil (85 mg, 74 %). 1H-NMR (300 MHz, CDCl3) peaks assigned to compound 27a : 6.69 
(m, 1H), 5.56 (br s, 1H), 5.31 (d, J = 1.5 Hz, 1H), 4.13 (m, 2H), 3.78 (s, 3H), 1.98 (d, J = 1.5 Hz, 3H). 
Peaks assigned to compound 27b : 6.56 (m, 1H), 5.56 (m, 1H), 5.37 (br s, 1H), 4.13 (m, 2H), 3.78 
(s, 3H), 2.09 (d, J = 1.5 Hz, 3H). 13C-NMR (75 Mhz, CDCl3) : 169.4, 162.2, 153.9, 134.3, 133.2, 89.4, 
87.1, 86.7, 84.3, 52.6, 41.4, 14.0. HRMS (ESI+) m/z calc. for C12H12O4NF3Na [M+Na]+ 314.0616, 
found: 314.0597. 
 
N-(Boc)-N’-(5-methyl-3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxyl)-3,6-
dioxa-octane-1,8-diamine (30a) and N-(Boc)-N’-(6-methyl-3-trifluoromethyl-7-oxa-bicyclo 
[2.2.1]hepta-2,5-diene-2-carboxyl)-3,6-dioxaoctane-1,8-diamine (30b) 
 
To a solution of a mixture of compounds 26a and 26b 
(49 mg, 0.21 mmol) and 1-N-Boc-3,6-dioxa-8-octane-1,8-
diamine (50.9 mg, 0.21 mmol) in dry CH2Cl2 (1.5 mL) was 
added DMAP (50.6 mg, 0.41 mmol). The mixture was 
cooled to 0 °C and EDC·HCl (44.1 mg, 0.23 mmol) was 
added slowly. The mixture was stirred for 30 min at 0 °C and 16 hours at room temperature. The 
reaction mixture was acidified with HCl (2 M) to a pH of 1-2 and extracted with CH2Cl2 (2  5 mL). The 
combined organic layers were dried over MgSO4, concentrated in vacuo, and purified by preparative 
TLC (CH2Cl2/MeOH, 9:1) resulting in compounds 30a and 30b as a slightly yellow oil (44.4 mg, 47%) 
A mixture of two regioisomers was obtained in a ratio of 1:1.4 for 30b and 30a, respectively. 
1H-NMR (300 MHz, CDCl3) peaks assigned to compound 30a : 6.70 (d, J = 6.7 Hz, 1H), 6.44 (br s, 
NH, 1H), 5.54 (s, 1H), 5.28 (s, 1H), 4.96 (br s, NH 1H), 3.60-3.52 (m, 10H), 3.30 (q, J = 5.2 Hz, 2H), 
1.97 (d, J = 1.6 Hz, 3H), 1.44 (s, 9H). Peaks assigned to compound 30b : 6.55 (d, J = 6.6 Hz, 1H), 
6.44 (br s, NH, 1H), 5.54 (s, 1H), 5.34 (s, 1H), 4.96 (br s, NH, 1H), 3.30 (q, J = 5.2 Hz, 2H), 3.60-3.52 
(m, 10H), 3.30 (q, J = 5.2 Hz, 2H), 2.10 (d, J = 1.9 Hz, 3H), 1.44 (s, 9H). 13C-NMR (75 MHz, CDCl3) : 
162.4, 155.9, 154.5, 153.8, 134.8, 133.1, 122.8 (q, CF3), 89.4, 86.7, 84.1, 70.4, 70.2, 70.1, 69.4, 40.3, 
39.4, 28.4, 14.0. HRMS (ESI+) m/z calc. for C20H30F3N2O6 [M+H]+ 451.2056, found: 451.2078. 
 
N,N’-(5-methyl-3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxyl)-3,6-dioxaoctane-1,8-
diamine (31a) and N,N’-(6-methyl-3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxyl)-
3,6-dioxaoctane-1,8-diamine (31b) 
To a cooled solution (0 °C) of a mixture of 30a and 30b (42 mg, 
0.093 mmol) in dry CH2Cl2 (2 mL) was added drop wise TFA 
(0.5 mL, 2.85 mmol). The reaction was stirred at 0 °C for 1 hour 
after which the reaction was complete. The solvent was 
evaporated and the crude mixture was dissolved in H2O (5 mL) 
and dioxane (5 mL) and lyophilized to afford compound 31a and 31b as a light yellow solid (43.1 mg, 
99%). A mixture of two regioisomers was obtained in a ratio of 1:1.4 for 31b and 31a, respectively. 
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1H-NMR (400 MHz, CDCl3) peaks assigned to compound 31a : 7.84 (br s, NH3 3H), 7.92 (br s, NH, 
1H), 6.66 (s, 1H), 5.52 (s, 1H), 5.27 (s, 1H), 3.70-3.46 (m, 10H), 3.15 (m, 2H), 1.96 (s. 3H). Peaks 
assigned to compound 31b : 7.84 (br s, NH3, 3H), 7.92 (br s, NH, 1H), 6.55 (s, 1H), 5.52 (s, 1H), 5.31 
(s, 1H), 3.70-3.46 (m, 10H), 3.15 (s, 2H), 2.06 (s, 3H). 13C-NMR (50 MHz, CDCl3) : 159.1, 154.0, 
151.1, 134.8, 133.1, 105.0, 103.0, 101.0, 100.0, 86.8, 86.5, 40.3, 14.0. HRMS (ESI+) m/z calc. for 
C15H22F3N2O4 [M+H]+ 351.1532, found: 351.1541.  
 
N-(2-O-tert-Butyl-DTPA-acetamide),N’-(5-methyl-3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-
diene-2-carboxyl)-3,6-dioxaoctane-1,8-diamine·TFA (32a) and N-(2-O-tert-butyl-DTPA-acetamide),N’-
(6-methyl-3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxyl)-3,6-dioxaoctane-1,8-
diamine·TFA (32b) 
Compounds 31a and 31b (39 mg, 0.084 mmol) were 
dissolved in dry CH2Cl2 (2 mL) and DMAP (20.4 mg, 
0.17 mmol) and diethylenetriamine-N,N,N",N"-tetra-
tert-butyl acetate-N'-acetic acid (DTPA-tert-butyl 
ester) 53 mg, 0.084 mmol) were added. The mixture 
was cooled to 0 °C followed by addition of EDC·HCl 
(17.5 mg, 0.09 mmol). After 1 hour stirring at 0 °C the 
mixture was allowed to warm to room temperature 
and was stirred for an additional 4 hours. The reaction mixture was quenched with 1 M HCl (2 mL) and 
the water layer was extracted with CH2Cl2 (2  2 mL). The combined organic layers were dried over 
Na2SO4 and subsequently evaporated. The crude product was purified by preparative TLC 
(CH2Cl2/MeOH, 9:1) to obtain pure product as a light brown oil (35 mg, 44%). A mixture of two 
regioisomers was obtained in a ratio of 1:1.4 for 32b and 32a, respectively. 
1H-NMR (400 MHz, CDCl3) peaks assigned to compound 32a : 8.22 (br s, NH, 1H), 6.75 (br s, NH, 
1H), 6.69 (t, J = 1.9 Hz, 1H), 5.53 (s, 1H), 5.27 (s, 1H), 3.60-3.39 (m, 18H), 3.11 (s, 2H), 2.77 (t, J = 
6.5 Hz, 2H), 2.61 (t, J = 6.5 Hz, 2H), 1.96 (d, J = 1.3 Hz, 3H), 1.43 (s, 36H). Peaks assigned to 
compound 32b : 8.22 (br s, NH, 1H), 6.75 (br s, NH, 1H), 6.54 (t, J = 1.9 Hz, 1H), 5.51 (s, 1H), 5.33 
(s, 1H), 3.60-3.39 (m, 18H), 3.11 (s, 2H), 2.77 (t, J = 6.5 Hz, 2H), 2.61 (t, J = 6.5 Hz, 2H), 2.09 (d, J = 
1.7 Hz, 3H), 1.43 (s, 36H). 13C-NMR (75 MHz, CDCl3) : 172.2, 170.5, 162.5, 155.2 (q), 153.7, 142.5, 
134.4, 122.8 (q, CF3), 89.3, 86.7, 84.0, 81.0, 70.5, 70.0, 69.8, 69.4, 58.6, 55.8, 53.8, 52.1, 39.4, 38.6, 
28.1, 14.0. HRMS (ESI+) m/z calc. for C45H75F3N5O13 [M+H]+ 950.5313, found: 950.5361. 
 
N-(2-DTPA-acetamide),N’-(5-methyl-3-trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-
carboxyl)-3,6-dioxaoctane-1,8-diamine (33a) and N-(2-DTPA-acetamide),N’-(6-methyl-3-
trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxyl)-3,6-dioxaoctane-1,8-diamine (33b) 
 
To a solution of compounds 32a and 32b (25 mg, 
0.026 mmol) in 2 mL of CH2Cl2, 200 µL TFA was 
added. This mixture was stirred for 6 days (until MS 
analysis did not show starting material). The product 
was obtained as a white solid in quantitative yield 
(+99%) after lyophilization with H2O/dioxane. A mixture 
of two regioisomers was obtained in a ratio of 1:1.4 for 
33b and 33a, respectively. 1H-NMR (400 MHz, 
CD3OD) peaks assigned to compound 33a : 6.96 (t, J = 1.7 Hz, 1H), 5.50 (s, 1H), 5.36 (s, 1H), 4.31 
(br s, 2H), 3.66-3.58 (m, 18H), 3.49-3.42 (m, 2H), 3.30-3.15 (m, 8H), 1.99 (d, J = 1.5 Hz, 3H). Peaks 
assigned to compound 33b : 6.63 (m, 1H), 5.56 (s, 1H), 5.30 (s, 1H), 4.31 (br s, 2H), 3.66-3.58 
(m, 18H), 3.48-3.42 (m, 2H,), 3.28-3.14 (m, 8H), 2.07 (d, J = 1.7 Hz, 3H). 13C-NMR (75 MHz, CD3OD) 
: 174.6 (4C), 167.2, 165.6, 155.8, 135.4, 90.5, 87.7, 84.1, 71.4, 71.3, 70.3, 68.2, 55.9, 55.6, 54.3, 
50.9, 40.5, 40.4, 14.0. HRMS (ESI+) m/z calc. for C29H43F3N5O13 [M+H]+ 726.2809, found: 726.2837. 
 
 
Radiolabeling experiments  
 
The DTPA-linked oxanorbornadiene systems 17 and 33a/b were labeled with 111In by dissolving 
oxanor-DTPA 17 or Me-oxanor-DTPA 33a/b (5 μg, 7.0 nmol) in 5 μL H2O. Subsequently, metal-free 
NH4OAc buffer (90 μL, 0.25 M, pH 5.5) and 5 µL (~100 µCi) 111InCl3 were added to each of the 
reaction mixtures. The mixtures were allowed to incubate for 1 hour at room temperature after which 
the radiochemical purity was checked by high-performance liquid-chromatography (HPLC) 
O
N
N
COOH
COOH
N
HOOC
HOOC
O
CF3
H
N
O
O
H
N
2
Me 5
6
O
N
N
COOtBu
COOtBu
N
tBuOOC
tBuOOC
O
CF3
H
N
O
O
H
N
2
Me 5
6
Chapter 8 
 
 236
(HP1100 series, LC system, Agilent Technologies, Palo Alto, CA, USA) using a RP-C18 column 
(5 μm, 4.6 mm  250 mm, Alltech, Deerfield, IL, USA) eluted with a gradient mobile phase (0-100% B 
over 20 min, solvent A = 0.1% TFA in water, solvent B = 0.1% TFA in acetonitrile) at 1 mL/min. The 
radioactivity of the eluates was monitored with an in-line NaI radiodetector (Raytest GmbH, 
Straubenhardt, Germany). 
 
 
Conjugation studies 
 
General procedure for reactions between oxanorbornadiene derivatives and benzyl azide compounds 
monitored by 1H-NMR spectroscopy. 
 
A solution of an oxanorbornadiene derivative (0.05 mmol) in a deuterated solvent (0.5 mL) was added 
to a test tube containing benzyl azide (various equivalents). The mixture was briefly mixed with a 
vortex and then added to an NMR tube. Directly after the addition, the tube was placed in a Varian 
Inova 400 MHz NMR apparatus at 25 °C and the reaction was monitored following a preset 
measurement schedule. 
 
General procedure for the synthesis of c(RGDfX)-CF3-triazole-DTPA conjugate 24 via cycloaddition 
reaction between oxanorbornadiene derivatives and N-δ-azido-cyclo(-Arg-Gly-Asp-D-Phe-Orn-) (23) 
monitored by 1H-NMR spectroscopy. 
 
A solution of oxanor-DTPA (17) or Me-oxanor-DTPA (33a/b) (2.82 and 2.88 mg, respectively, 
3.97 µmol) in CD3OD/D2O (0.5 mL/0.1 mL) was added to a test tube containing cyclic RGD peptide 
(23) (4.3 mg, 5.96 µmol). The mixture was briefly mixed using a vortex and added to an NMR tube. 
The tube was then directly placed in a 400 MHz NMR apparatus at 37 °C and the reaction was 
monitored following a preset measurement schedule. After completion of the reaction the resulting 
mixtures were lyophilized and analyzed by HRMS and electrospray LC-MS analysis performed on a 
Shimadzu LC-MS 2010A system. HRMS (ESI+) m/z calc. for C50H74F3N16O19 [M+H]+ 1257.5112, 
found: 1257.5235. 
 
General procedure for cycloaddition reactions between 111In-labeled oxanorbornadiene derivatives and 
N-δ-azido-cyclo(-Arg-Gly-Asp-D-Phe-Orn-) (23) monitored by HPLC with an in-line NaI radiodetector. 
 
All tandem crDA reactions were performed at 37 °C in a total volume of 50 μL with 0.5 μg (0.70  10-3 
μmol) 111In-labeled DTPA complex (10 µCi) unless described otherwise. An incubator was used to 
warm the reactions to 37 °C during 4 days. The conversion was checked by HPLC using a RP-C18 
column eluted with a gradient mobile phase (0-100% B over 20 min, solvent A = 0.1% TFA in water, 
solvent B = 0.1% TFA in acetonitrile) at 1 mL/min. The radioactivity of the eluates was monitored using 
an in-line NaI radiodetector. 
 
 
In vitro assays 
 
Octanol-water partition coefficient 
 
For the lipophilicity determination, approximately 70.000 cpm 111In-DTPA-cRGD was diluted to a 
volume of 3 mL with phosphate-buffered saline (PBS) and an equal volume of n-octanol was added to 
obtain a binary phase system. After mixing the two layers vigorously for 10 seconds and gently for 
another 2 min, the two layers were separated by centrifugation (500 G, 5 min). Three 250 μL samples 
were taken from each layer and their activity was measured in a 3II well type NaI gamma counter 
(Wallac 1480-Wizard 3). The logP value was determined in two independent experiments. 
 
Solid-phase αvβ3 binding assay 
 
Affinity of the DTPA-triazole-cRGD conjugate 24 and the conventional DOTA-E-[cRGDfK)]2 for the αvβ3 integrin was determined by a solid-phase competitive binding assay using 111In-DOTA-E-
[cRGDfK)]2 as a tracer. Labeling was performed following the procedure described by Boerman et al.55 
111InCl3 (90 μCi/μg) was added to 5 μg DOTA-E-[cRGDfK)]2 dissolved in 100 μL metal free HEPES 
buffer (1M, pH 6.0). The mixture was heated to 100 ˚C during 15 min after which the chemical purity 
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was determined with HPLC. Microtiter 96-well vinyl assay plates (Corning B.V., Schiphol-Rijk, The 
Netherlands) were coated with a solution of purified human integrin αvβ3 (150 ng/mL) in Triton X-100 
Formulation (Chemical International, Temecula, CA, USA) in coating buffer (25 mM Tris·HCl (pH 7.4), 
150 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2 and 1 mM MnCl2) for 18 hours at 4 °C (100 μL/well). After 
washing the plate twice with binding buffer (coating buffer supplemented with 0.1% BSA (bovine 
serum albumin)), all wells were blocked with 200 μL blocking buffer (coating buffer supplemented with 
1% BSA) during 3.5 hours at room temperature. The wells were washed twice with binding buffer and 
subsequently incubated with 100 μL binding buffer containing 200.000 cpm of 111In-DOTA-E-
[cRGDfK)]2 and appropriate dilutions of non-labeled DOTA-E-[cRGDfK)]2 or DTPA-cRGD conjugate 
dissolved in 20 μL binding buffer for 1 hour at 37 °C. The competitive displacement study of the 
dilutions was performed in triplicate. Finally, the plate was washed three times, the wells were cut and 
the radioactivity in each well was counted using a γ-counter (Wallac 1480-Wizard® 3, Perkin-Elmer, 
Boston, MA, USA). The IC50 values of both the DOTA-E-[cRGDfK)]2 and DTPA-triazole-cRGD 
conjugate were determined by non-linear regression (GraphPad Pris 4.0 Software Package, San 
Diego, CA, USA).  
 
 
In vivo assays 
 
Cell culture 
 
The αvβ3 expressing cell line SK-RC-52 was derived from a mediastinal metastasis of a primary Gural 
SK-RC-52. The SK-RC-52 cells were cultured in RPMI 1640 medium (Gibco Life Technologies, 
Gaithersburg, MD, USA) supplemented with 10% (v/v) fetal calf serum (FCS),  2 mmol/L glutamine 
(Glu), 100 U/mL penicillin and 100 μg/mL streptomycin (penstrep). Cells were cultured at 37 °C under 
a humidified atmosphere with 5% CO2. The cells were washed in saline, trypsinized for 15 min at 
37 °C, washed and suspended in RPMI 1640 medium (1  107 cells/mL). 
 
Nude mouse tumor model 
 
On day 0, nine male nude BALB/c mice (6-8 weeks old) were injected subcutaneously (s.c.) in the 
right flank with 0.2 mL SK-RC-52 cell suspension of 1  107 cells/mL RPMI 1640. Radiolabeled DTPA-
c(RGDfX) was administered approximately two weeks after tumor cell inoculation when the s.c. tumors 
were 5-8 mm in diameter. 
 
Biodistribution 
 
On day 18, when the tumors reached a diameter of 5-8 mm, the mice were randomly divided into two 
groups of five and four mice. For biodistribution studies, each mouse of the first group received 10 μCi 
111In-labeled DTPA-c(RGDfX) via a tail vein (i.v.). The other four mice were injected i.v. with a solution 
of 10 μCi 111In-labeled DTPA-c(RGDfX) supplemented with 10 μg dimeric RGD peptide to investigate 
the receptor-mediated localization of the 111In labeled peptide. All mice were killed by CO2/O2 
asphyxiation 2 hours post-injection (p.i.). Blood, muscle, tumor, lung, spleen, kidney, liver and intestine 
were collected, weighed and counted in a γ-counter (Wallac 1480-Wizard® 3, Perkin-Elmer, Boston, 
MA, USA). The percentage injected dose per gram (%ID/g) was calculated for each tissue. The animal 
experiments were approved by the local animal welfare committee and performed according to 
national regulations. 
 
 
Statistical analysis 
 
The mean values for the solid phase binding assay and the lipophilicity studies are given ± standard 
deviation (S.D.). Statistical analysis was performed using a Welch’s corrected unpaired t test or one-
way analysis of variance using GraphPad InStat software (version 4.00, GraphPad Software). The 
level of significance was set at p<0.05. 
 
Chapter 8 
 
 238
8.7 References 
 
 
1  P. F. van Swieten, M. A. Leeuwenburgh, B. M. Kessler, H. S. Overkleeft, Org. Biomol. Chem. 2005, 3, 20-27. 
2  a) E. Saxon, J. I. Armstrong, C. R. Bertozzi, Org. Lett. 2000, 2, 2141-2143; b) A. Watzke, M. Köhn, M. 
Gutierrez-Rodriguez, R. Wacker, H. Schröder, R. Breinbauer, J. Kuhlmann, K. Alexandrov, C. M. Niemeyer, 
R. S. Goody, H. Waldmann, Angew. Chem. Int. Ed. 2006, 45, 1408-1412; c) M.-L. Tsao, F. Tian, P. G. 
Schultz, ChemBioChem 2005, 6, 2147-2149; d) F. L. Lin, H. M. Hoyt, H. van Halbeek, R. G. Bergman, C. R. 
Bertozzi, J. Am. Chem. Soc. 2005, 127, 2686-2695. 
3  P. E. Dawson, S. B. H. Kent, Ann. Rev. Biochem. 2000, 69, 923-960. 
4  A. Deiters, T. A. Cropp, M. Mukherji, J. W. Chin, J. C. Anderson, P. G. Schultz, J. Am. Chem. Soc. 2003, 
125, 11782-11783. 
5  a) D. Schwarzer, P. A. Cole, Curr. Opin. Chem. Biol. 2005, 9, 561-569; b) N. Budisa, ChemBioChem 2004, 5, 
1176-1179. 
6  a) A. Dantes de Araújo, J. M. Palomo, J. Cramer, M. Köhn, H. Schröder, R. Wacker, C. Niemeyer, K. 
Alexandrov, H. Waldmann, Angew. Chem. Int. Ed. 2006, 45, 296-301; b) A. Dantes de Araújo, J. M. Palomo, 
J. Cramer, O. Seitz, K. Alexandrov, H. Waldmann, Chem. Eur. J. 2006, 12, 6095-6109. 
7  R. Huisgen, G. Szeimies, L. Mobius, Chem. Ber. 1967, 100, 2494-2507. 
8  V. V. Rostovtsev, L. G. Green, V. V. Fokin, K. B. Sharpless, Angew. Chem. Int. Ed. 2002, 41, 2596-2599. 
9  C. W. Tornøe, C. Christensen, M. Meldal, J. Org. Chem. 2002, 67, 3057-3064. 
10  a) For reviews, see; V. D. Bock, H. Hiemstra, J. H. van Maarseveen, Eur. J. Org. Chem. 2006, 51-68; b) J. E. 
Moses, A. D. Moorhouse, Chem. Soc. Rev. 2007, 36, 1249-1262; c) R. J. Pieters, D. T. S. Rijkers, R. M. J. 
Liskamp, QSAR Comb. Sci. 2007, 26, 1181-1190; d) A. J. Dirks, J. J. L. M. Cornelissen, F. L. van Delft, 
J. C. M. van Hest, R. J. M. Nolte, A. E. Rowan, F. P. J. T. Rutjes, QSAR Comb. Sci. 2007, 26, 1200-1210; e) 
Y. L. Angell, K. Burgess, Chem. Soc. Rev. 2007, 36, 1674-1689. 
11  Q. Wang, T. R. Chan, R. Hilgraf, V. V. Fokin, K. B. Sharpless, M. G. Finn, J. Am. Chem. Soc. 2003, 125,  
3192-3193. 
12  a) R. A. Decreau, J. P.  Collman, Y. Yang, Y. Yan,  N. K. Devaraj, J. Org. Chem. 2007, 72, 2794-2802; b) S. 
Cavalli, A. R. Tipton, M. Overhand, A. Kros, Chem. Commun. 2006, 3193-3195; c) X.-L. Sun, C. L. Stabler, 
C. H. Cazalis, E. L. Chaikof, Bioconjugate Chem. 2006, 17, 52-57. 
13  a) B. S. Lee, J. K. Lee, W.-J. Kim, Y. H. Jung, S. J. Sim, J. Lee, I. S. Choi, Biomacromolecules 2007, 8, 744-
749; b) J.-F. Lutz, H.G. Börner, K. Weichenhan, Austr. J. Chem. 2007, 60, 410-413; c) A. J. Dirks, S. S. van 
Berkel, N. S. Hatzakis, J. A. Opsteen, F. L. van Delft, J. J. L. M. Cornelissen, A. E. Rowan, J. C. M. van Hest, 
F. P. J. T. Rutjes, R. J. M. Nolte, Chem. Commun. 2005, 4172-4174. 
14  a) J.-F. Lutz, H.G. Börner, Prog. Polym. Sci. 2008, 33, 1-39; b) J.-F. Lutz, H.G. Börner, K. Weichenhan, 
Macromolecules 2006, 39, 6376-6383; c) W. H. Binder, R. Sachsenhofer, Macromol. Rapid Commun. 2007, 
28, 15-54. 
15  a) M. A. Bruckman, G. Kaur, L. A. Lee, F. Xie, J. Sepulveda, R. Breitenkamp, X. Zhang, M. Joralemon, T. P. 
Russell, T. Emrick, Q. Wang, ChemBioChem 2008, 9, 519-523; b) W.-H. Zhan, H. N. Barnhill, K. Sivakumar, 
H. Tian, Q. Wang, Tetrahedron Lett. 2005, 46, 1691-1695; c) S. Sen Gupta, J. Kuzelka, P. Singh, W. G. 
Lewis, M. Manchester, M. G. Finn, Bioconjugate Chem. 2005, 16, 1572-1579; d) S. Sen Gupta, K. S. Raja, E. 
Kaltgrad, E. Strable, M. G. Finn, Chem. Commun. 2005, 4315-4317. 
16  a) H. C. Kolb, K. B. Sharpless, Drug Discovery Today 2003, 8, 1128-1137; b) R. Manetsch, A. Krasinski, Z. 
Radic, J. Raushel, P. Taylor, K. B. Sharpless, H. C. Kolb, J. Am. Chem. Soc. 2004, 126, 12809-12818; c) G. 
G. Kochendoerfer, Curr. Opin. Chem. Biol. 2005, 9, 555-560. 
17  a) N. J. Agard, J. A. Prescher, C. R. Bertozzi, J. Am. Chem. Soc. 2004, 126, 15046-15047; b) N. J. Agard, J. 
A. Prescher, C. R. Bertozzi, J. Am. Chem. Soc. 2005, 127, 11196; c) N. J. Agard, J. M. Baskin, J. A. 
Prescher, A. Lo, C. R. Bertozzi, ACS Chem. Biol. 2006, 1, 644-648. 
18  X. Ning, J. Guo, M. A. Wolfert, G. J. Boons, Angew. Chem. Int. Ed. 2008, 120, 2285-2287. 
19  a) T. S. Seo, Z. Li, H. Ruparel, J. Ju, J. Org. Chem. 2003, 68, 609-612; b) Z. Li, T. S. Seo, J. Ju, Tetrahedron 
Lett. 2004, 45, 3143-3146. 
20  S. S. van Berkel, A. J. Dirks, M. F. Debets, F. L. van Delft, J. J. L. M. Cornelissen, R. J. M. Nolte, F. P. J. T. 
Rutjes, ChemBioChem 2007, 8, 1504-1508. 
21  a) J. M. Harris, R. B. Chess, Nature Rev. Drug Discovery 2003, 2, 214-221; b) F. M. Veronese, J. M. Harris, 
Adv. Drug Delivery Rev. 2002, 54, 453-456; c) P. Caliceti, F. M. Veronese, Adv. Drug Delivery Rev. 2003, 55, 
1261-1277. 
22  K. Sivakumar, F. Xie, B. M. Cash, S. Long, H. N. Barnhill, Q. Wang, Org. Lett. 2004, 6, 4603-4606. 
23  a) E. Ruoslahti, M. D. Pierschbacher, Science 1987, 238, 491-497; b) E. Ruoslahti, Annu. Rev. Cell Dev. 
Biol. 1996, 12, 697-715. 
24  a) U. Hersel, C. Dahmen, H. Kessler, Biomaterials 2003, 24, 4385-4415; b) J. Auernheimer, C. Dahmen, U. 
Hersel, A. Bausch, H. Kessler, J. Am. Chem. Soc. 2005, 127, 16107-16110; c) Y. Mei, K. L. Beers, H. C. M. 
Byrd, D. L. Vanderhart, N. R. Washburn, J. Am. Chem. Soc. 2004, 126, 3472-3476. 
25  Determined by PDB-file 4lyz from the RCSB protein data bank. 
Applications of the tandem crDA Reaction 
 239
 
26  R. J. Kok, A. J. Schraa, E. J. Bos, H. E. Moorlag, S. A. Asgeirsdottir, M. Everts, D. K. F. Meijer, G. Molema, 
Bioconjugate Chem. 2002, 13, 128-135. 
27  R. Haubner, H. J. Wester, W. A. Weber, C. Mang, S. I. Ziegler, S. L. Goodman, R. Senekowitsch-Schmidtke, 
H. Kessler, M. Schwaiger, Cancer Res. 2001, 61, 1781-1785. 
28  E. F. Plow, T. A. Haas, L. Zhang, J. Loftus, J. W. Smith, J. Chem. Biol. 2000, 275, 21785-21788. 
29  M. A. Arnaout, S. L. Goodman, J.-P. Xiong Curr. Opin. Cell Biol. 2002, 14, 641-651. 
30  B. P. Eliceiri, D. A. Cheresh, J. Clin. Invest. 1999, 103, 1227-1230. 
31  a) R. O. Hynes, Cell 1987, 48, 549-554; b) R. O. Hynes, Nature Medicine 2002, 8, 918-921. 
32  P. Clezardin, Cell. Mol. Life Sci. 1998, 54, 541-548. 
33  a) G. Maheshwari, G. Brown, D. A. Lauffenburger, A. Wells, L.G. Griffith, J. Cell Sci. 2000, 113, 1677-1686; 
b) P. C. Brooks, A. M. Montgomery, M. Rosenfeld, R. A. Reisfeld, T. Hu, G. Klier, D. A. Cheresh, Cell 1994, 
79, 1157-1164. 
34  a) I. C. Kang, Y. D. Lee, D. S. Kim, Cancer Res. 1999, 59, 3754-3760; b) C. D. Buckley, D. Pilling, N. V. 
Henriquez, G. Parsonage, K. Threlfall, D. Scheel-Toellner, D. L. Simmons, A. N. Akbar, J. M. Lord, M. 
Salmon, Nature 1999, 397, 534-539. 
35  D. Ravi, K. Ramadas, B. S. Mathew, K. R. Panikkar, M. K. Nair, M. R. Pillai, Oral Oncol. 2001, 37, 164-171. 
36  M. Pfaff, K. Tangemann, B. Müller, M. Gurrath, G. Müller, H. Kessler, R. Timpl, J. Engel, J. Biol. Chem. 1994, 
269, 20233-20238. 
37  a) M. Aumailley, M. Gurrath, G. Müller, J. Calvete, R. Timpl, H. Kessler, FEBS Lett. 1991, 291, 50-54; b) R. 
Haubner, D. Finsinger, H. Kessler, Angew. Chem. Int. Ed. 1997, 36, 1374-1389. 
38  a) M. Janssen, W. J. Oyen, L. F. Massuger, C. Frielink, I. Dijkgraaf, D. S. Edwards, M. Radjopadhye, F. H. 
Corstens, O. C. Boerman, Cancer Biother. Radiopharm. 2002, 17, 641-646; b) Y. Wu, X. Zhang, Z. Xiong, Z. 
Cheng, D. R. Fisher, S. Liu, S. S. Gambhir, X. Chen. J. Nucl. Med. 2005, 46, 1707-1717; c) I. Dijkgraaf, A. Y. 
Rijnders, A. Soede, A. C. Dechesne, G. Wilma van Esse, A. J. Brouwer, F. H. M. Corstens, O. Boerman, D. 
T. S. Rijkers, R. M. J. Liskamp, Org. Biomol. Chem. 2007, 5, 935-944. 
39  a) X. Chen, R. Park, A. H. Shahinian, J. R. Bading, P. S. Conti, Nucl. Med. Biol. 2004, 31, 11-19; b) A. Mitra, 
T. Coleman, M. Borgman, A. Nan, H. Ghandehari, B. R. Line, J. Control. Release 2006, 114, 175-183 
40  a) R. Haubner, H. J. Wester, F. Burkhart, R. Senekowitsch-Schmidtke, W. Weber, S. L. Goodman, H. 
Kessler,  M. Schwaiger, J. Nucl. Med. 2001, 42, 326-336; b) R. Haubner, B. Kuhnast, C. Mang, W. A. Weber, 
H. Kessler, H. J. Wester, M. Schwaiger, Bioconjugate Chem. 2004, 15, 61-69; c) B. H. M. Kuijpers, S. 
Groothuys, A. C. Soede, P. Laverman, O. C. Boerman, F. L. van Delft, F. P. J. T. Rutjes, Bioconjugate Chem. 
2007, 18, 1847-1854. 
41  Selected literature; a) Z.-F. Su, G. Liu, S. Gupta, Z. Zhu, M. Rusckowski, D. J. Hnatowich, Bioconjugate 
Chem. 2002, 13, 561-570; b) R. Haubner, H. J. Wester, U. Reuning, R. Senekowitsch-Schmidtke, B. 
Diefenbach, H. Kessler, G. Stocklin, M. Schwaiger, J. Nucl. Med. 1999, 40, 1061-1071; c) X. Chen, R. Park, 
M. Tohme, A. H. Shahinian, J. R. Bading, P. S. Conti, Bioconjugate Chem. 2004, 15, 41-49. 
42  Selected literature; a) S. I. Shen, P. R. Kotamraj, S. Bhattacharya, X. Li, B. R. Jasti, J. Drug Target. 2007, 15, 
51-58; b) K. Temming, D. L. Meyer, R. Zabinski, E. C. F. Dijkers, K. Poelstra, G. Molema and R. J. Kok, 
Bioconjugate Chem. 2006, 17, 1385-1394; c) X. Chen, C. Plasencia, Y. Hou, N. Neamati, J. Med. Chem. 
2005, 48, 1098-1106. 
43  Z. Wu, Z.-B. Li, W. Cai, L, He, F. T. Chin, X. Chen, Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 1823-1831. 
44  R. Haubner, R. Gratias, B. Diefenbach, S. L. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1996, 
118, 7461-7472. 
45  a) T. Weide, A. Modlinger, H. Kessler. Topics in current Chemistry 2007, 272, 1-50; b) A. Meyer, J. 
Auernheimer, A. Modlinger, H. Kessler Curr. Pharmaceut. Design 2006, 12, 2723-2747. 
46  G. Thumshirn, U. Hersel, S. L. Goodman, H. Kessler, Chem. Eur. J. 2003, 9, 2717-2725. 
47  Storage of compound 25a/b at -20 °C in the dark for 2 months also resulted in quadricyclane formation. 
48  K. Hirao, A. Yamashito, J. Fluor. Chem. 1987, 36, 293-305. 
49  I. Dijkgraaf, J. A. W. Kruijtzer, C. Frielink, A. C. Soede, H. W. Hilbers, W. J. G. Oyen, F. H. M. Corstens, R. 
M. J. Liskamp, O. C. Boerman, Nucl. Med. Biol. 2006, 33, 953-961. 
50  I. Dijkgraaf, S. Liu, J. A. W. Kruijtzer, A. C. Soede, W. J. G. Oyen, R. M. J. Liskamp, F. H. M. Corstens, O. C. 
Boerman, Nucl. Med. Biol. 2007, 34, 29-35. 
51  a) E. Atherton, R. C. Sheppard, Solid-Phase Peptide Synthesis, IRL Press: Oxford England, 1989; b) G. B. 
Fields, R. L. Noble, Int. J. Pept. Protein Res. 1990, 35, 161-214. 
52  Synthesis of azidoacetic acid: 2-bromoacetic acid (2.00 g, 14.4 mmol) was dissolved in water (15 mL) and 
cooled using an ice-bath. After the addition of NaN3 (4.00 g, 61.5 mmol) the mixture was allowed to warm to 
room temperature during a period of 16 hours. The reaction mixture was acidified to pH 1 by the addition of 
concentrated HCl, and subsequently extracted with EtOAc (3  75 mL). The combined organic phases were 
dried over Na2SO4 and concentrated in vacuo. After co-evaporation with CH2Cl2 (4  50 mL) the product was 
obtained as a slightly yellow liquid (1.36 g, 93%). 1H-NMR (400 MHz, CDCl3) : 8.25 (s, 1H), 3.98 (s, 2H). 
13C-NMR (CDCl3, 75 MHz) δ (ppm): 174.4, 50.1. FT-IR max film (cm-1): 3451, 2110, 1724, 1215. 
53  S. Liu, E. Cheung, M. C. Ziegler, M. Rajopadhye, D. S. Davis, Bioconjugate Chem. 2001, 12, 559-568. 
Chapter 8 
 
 240
 
54  F. Djedaïni-Pilard, N. Azaroual-Bellanger, M. Gosnat, D. Vernet, B. Perly, J. Chem. Soc., Perkin Trans. 1 
1995, 723-730. 
55  I. Dijkgraaf, J. A. W. Kruijtzer, C. Frielink, F. H. M. Corstens, W. J. G. Oyen, R. M. J. Liskamp, O. C. 
Boerman, Int. J. Cancer 2007, 120, 605-610. 
 
Epilogue 
 241
Epilogue 
 
 
The ultimate objective in thrombin generation assessment is to measure directly under physiological 
conditions in the “isolated organ” blood. Although such measurements have been reported1 they have 
to be interpreted with caution.2 As a result of fluorescence quenching of 7-amino-4-methylcoumarin 
(AMC) by hemoglobin and oxy-hemoglobin, such measurements are highly unreliable. The most 
obvious approach to circumvent this problem is the replacement of the coumarin fluorophore by a red-
fluorescent probe. Lakowicz et al.3 demonstrated that the use of the Rhodamine-800 fluorophore in 
whole blood samples gave sufficient fluorescent signal. The concept of applying Rhodamine-based 
fluorogenic substrates for monitoring peptidase activity was elegantly shown by Cummings.4 In 
addition, an article by Moody et al.5 described the synthesis of a phenoxazine red fluorescent probe 
and the coupling, via a spacer, to an amino acid.  
 
Ever since the start of this PhD-project, I have been intrigued (or maybe even obsessed) by the 
synthesis of a red-fluorescent-based thrombin specific substrate. Two critical issues needed to be 
addressed prior to the synthesis of these red-fluorescent substrates. Firstly, mono-amine-
functionalized red-fluorescent probes had to be made available. An amine functional probe is required 
since thrombin specifically hydrolyzes the C-terminus of the arginine residue and mono-functionalized 
probes are preferred for an accurate measurement. Fluorophores that fulfill these criteria, however, 
are extremely limited. The second issue to be addressed is the low nucleofilicity of the aromatic amine 
group (see Chapter 2). Since most of the red fluorescent probes possess a highly conjugated aromatic 
system the nucleofilic behavior of the amine-group is largely diminished.     
 
Together with a committed student we pursued the synthesis of these red-fluorescent thrombin 
substrates. Besides the coupling of some commercially available red fluorescent probes (e.g. 
Methylene violet and Cresyl violet) to Boc-Arg-OH, the synthesis of mono-amine-functionalized 
fluorophores was investigated. Both the synthesis of Rhodamines6 and phenoxazines5 was explored, 
generally resulting in tedious purifications and low yields. Much to our surprise, we found that reacting 
2-nitroso-5-diethylaminophenol and 5-amino-1-naphtol in DMF at elevated temperatures did not result 
in the expected mono-amino-functionalized Nile red derivative 1, but quantitative conversion to amino-
phenoxazine 2 was observed instead (Scheme 1).  
 
 
 
Scheme 1 Reaction of 2-nitroso-5-diethylaminophenol and 5-amino-1-naphtol. 
 
Since this unexpected product was obtained in quantitative yield, we were intrigued by the mechanism 
of its formation. A report by Möhlau7, who synthesized a similar compound, suggested that O2 was 
involved in the formation. However, performing the reaction under an N2-atmosphere also resulted in 
the formation of compound 2. A more satisfying mechanism was proposed by Klunder,8 who 
suggested that the tautomeric structure of DMF could participate in the reaction, both as nucleophile 
and electrophile. A proposed mechanism is depicted in Scheme 2. In brief; the formation of 
intermediates I – IV are straightforward addition-elimination reactions. The reduction of nitroso-
phenoxazine IV can be explained by the addition of the tautomeric 1,3-dipole structure of DMF (acting 
as a nucleophile). An intramolecular proton-shift generates dihydro-phenoxazine VII and ‘dimethyl 
isocyanate’, which immediately decomposes in the presence of water to dimethyl amine and carbon 
dioxide. Repeating the reaction sequence, with the tautomer of DMF now being an electrophile, results 
in the formation of dihydro-phenoxazine X. Finally, an 1,3-proton-shift results in the formation of 
compound 2. This is only a proposed mechanism, in-depth investigations are required to confirm of 
revise the postulated mechanism.  
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Scheme 2 Proposed mechanism for the formation of mono-amino-functionalized phenoxazine 2.  
 
Having explored various peptide coupling reagents and conditions for the construction of an amide 
bond between a fluorophore and Boc-Arg-OH we ultimately applied the POCl3 – pyridine methodology. 
This method proved to be successful for the coupling of electron poor anilines such as p-nitroanilines 
and coumarins to arginine (see Chapter 2). Gratifyingly, this method was found to be successful in the 
coupling of MV3Rax (a member of the Methylene violet family) to arginine producing the desired 
compound 3 (Figure 1). Due to a troublesome purification only a moderate yield (40%) was achieved. 
In the next step the Boc-protecting group was quantitatively removed under acid conditions generating 
H-Arg-MV3Rax (4). Applying standard peptide coupling conditions, the peptide chain was elongated 
with two glycine units producing Boc-protected Gly-Gly-Arg-MV3Rax 5 in a reasonable yield (64%). 
Last step in this synthesis was the deprotection of the Boc-group producing the desired red 
fluorescent thrombin substrate H-Gly-Gly-Arg-MV3Rax (6) as a di-HCl salt in nearly quantitatively 
yield. The absorption and emission spectra of MV3Rax and Boc-Arg-MV3Rax showed a small Stokes 
shift for both compounds (Figure 1, right frames). In addition, the wavelength shift between the 
coupled and uncoupled product was minute (21 nm) which requires a high-quality filter-set for the 
determination of the free MV3Rax. This substrate is currently tested for the application in thrombin 
generation assessment in whole blood. The outcome is expected to be a great improvement to the 
current thrombin generation assay, making it significantly superior to present-day clotting assays. 
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Figure 1. Synthesis of H-Gly-Gly-Arg-MV3Rax·2HCl. Reagents and conditions: i) POCl3, pyridine, -15 
°C (1 h), r.t. 2 h; ii) CH2Cl2, TFA, cat. HCl, r.t. 18 h; iii) DMF, Boc-Gly-Gly-OH, EDC·HCl, DMAP, 0 °C 
(30 min), r.t. 2 h; iv) 2 M HCl in EtOAc, cat. TFA, r.t. 8 h.  
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Summary 
 
 
Thrombosis lies at the basis of diseases such as cerebral- and coronary infarction and 
pulmonary embolism and thus can be considered the major cause of death in the western world. 
Thrombosis generally arises as a result of clot formation caused by a complex series of events 
involving a variety of enzymes, with a crucial role for the enzyme thrombin. Over-expression of 
thrombin can result in thrombosis while under-expression might lead to haemophilia. Therefore, it is 
clear that accurate monitoring of thrombin activity can be of vital importance to determine proper 
treatment regimen of a particular patient. Assessment of thrombin concentration in a blood sample can 
be used to estimate the coagulation ability. A tool for monitoring the generation and disappearance of 
thrombin, and thus the concentration in time, is the so-called thrombin generation test. The basic 
method (developed in 1953), has been modified, automated and optimized throughout the years and 
in current form (i.e. calibrated automated thrombography (CAT)) has found broad application in the 
field of haemostasis and thrombosis. In CAT, basically a chromogenic or fluorogenic thrombin specific 
peptide substrate is added to a clotting plasma sample. Upon hydrolysis of the substrate by thrombin, 
the chromophore or fluorophore is released from the substrate and can be measure 
spectrophotometrically. Monitoring the increase of the induced signal in time, and subsequent 
mathematical processing of this signal, results in a so-called thrombin generation curve which 
provides various essential parameters. 
 
The substrate currently in use in the thrombin generation test is the N-terminal protected fluorogenic 
tripeptide Z-Gly-Gly-Arg-AMC. This substrate, however, suffers low solubility in physiological media 
and provides moderate kinetic parameters. The disadvantages associated with this compound were a 
stimulus for the development of water-soluble analogues possessing improved kinetic parameters. To 
this end, a series of peptides containing the 7-amino-4-methylcoumarin (AMC) fluorophore were 
synthesized.  
 
 
 
Figure 1. Key intermediate H-Arg-AMC used for the synthesis of various thrombin substrates.  
 
Based on the common structural feature H-Arg-AMC a variety of fluorogenic thrombin substrates such 
as Ala-Gly-Arg-AMC, SQ68 mimic Et-malonyl-Gly-Arg-AMC, triazole-containing Gly-Gly-Arg-AMC and 
N-terminus substituted Gly-Gly-Arg-AMC (Figure 1) were constructed. 
 
A series of 23 peptidyl-AMC substrates were subjected to biological evaluation in order to 
determine binding constants (KM) and rate of hydrolysis (kcat) of both thrombin and factor Xa (another 
serine protease present in blood plasma). Next, the substrates displaying the desired kinetic 
parameters (kcat  1 s-1, KM  200 M and applicable at S  200 M) were employed in the thrombin 
generation test to generate thrombin generation curves. Evaluation of the acquired thrombograms 
showed that several substrates, including N-functionalized Gly-Gly-Arg-AMC and SQ68 derivative 
Et-malonyl-Gly-Arg-AMC could be potentially successful candidates for replacement of the substrate 
currently in use. In addition to kinetic parameter determination and thrombin generation assessment, a 
new tool for rapid screening of useful thrombin substrates, the so-called diagnostic plot, was evaluated 
for several fluorogenic substrates. 
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Figure 2. Methods for substrate suitability screening. Left: kinetic experiments. Middle: diagnostic plot. 
Right: thrombin generation cure (TGC) or thrombogram. 
 
This method is not only suitable for the determination of the applicable concentration range of a 
substrate (and thus the substrate suitability) but also allows the expedient transformation of data 
obtained by thrombin generation.  
 
The synthesis of a series of thrombin substrates can be achieved within several months. 
Subsequent biological evaluation of these compounds then provides the information required for 
further optimization. Since this is a labour intensive process with iteration cycles of several months, a 
route towards for solid-phase substrate synthesis was developed (Figure 3).  
 
 
 
Figure 3. Solid-phase methodology for the Arg-AMC containing thrombin substrates. 
 
The envisioned strategy was based on the coupling of a fully protected AMC-precursor to a solid 
support followed by the selective deprotection of the amine function and subsequent peptide 
synthesis. After introduction of a peptide chain, the desired substrate could be obtained by 
deprotection of the phenol followed by light isomerization of the double bond resulting in spontaneous 
ring-closure (i.e. AMC formation) and thus liberation of the thrombin substrate.  
The envisioned methodology required the synthesis of an orthogonally protected 3-aminophenyl-but-2-
enoic acid, an AMC-precursor that could be produced in a five-step reaction sequence in an overall 
yield of 29%. Subsequent coupling to a Wang-Br resin, N-deprotection, and coupling of Fmoc-Ala-OH 
were successfully applied. Unfortunately, the on-resin O-deprotection proved to be unsuccessful under 
various conditions. 
 
Biological evaluation of the peptidyl-AMC substrates showed the unsuitability of the substrate 
Gly-Pro-Arg-AMC for thrombin generation measurements as a result of the extremely high rate of 
hydrolysis. We reasoned that constraining the substrate in a cyclic conformation might result in 
reduced binding in the active site a result of steric hindrance, thus leading to a lower turnover.  
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Figure 4. Synthesis of cyclo(-GPR-AMC-[triazole]-spacer-) via the copper-catalyzed Huisgen 
cycloaddition and the subsequent hydrolysis by thrombin. 
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Macrocyclization was performed by an intramolecular copper-catalyzed 1,3-dipolar cycloaddition 
reaction. Because such a reaction required the presence of an azide- and a alkyne functionality, a 
route was developed toward 7-amino-4-azidomethylene-coumarin (AAMC) which was then coupled to 
arginine. The alkyne-containing fragment was obtained via the sequential coupling of hexynoic acid 
and proline to glyine. Condensation of the two synthons gave the azide-alkyne-functionalized 
precursor for the intramolecular copper-catalyzed 1,3-dipolar cyclization reaction The cyclic product, 
although obtained in low yield, was subsequently subjected to hydrolysis by thrombin to determine the 
kinetic parameters (Figure 4). Initial results indicate an increased binding constant (KM) and a similar 
rate of hydrolysis (kcat). 
 
Alpha-2-macroglobulin (2M) is a plasma glycoprotein involved in the encapsulation of thrombin. 
The steric bulk surrounding thrombin prevents the conversion of fibrinogen (the natural substrate) to 
fibrin. Small tripeptide substrates, however, such as Gly-Gly-Arg-AMC, are still able to reach the active 
site of thrombin and are consequently hydrolyzed. In order to suppress the undesired hydrolysis by the 
2M-thrombin complex we focused on the preparation of polymer-peptide constructs. Introduction of 
steric bulk to the peptide fragment was expected to eliminate undesired hydrolysis by the 2M-T 
complex while retaining hydrolysis by the available free thrombin (see Figure 5).  
 
 
 
Figure 5. Schematic representation of the hydrolysis of peptide and polymer-peptide substrates by 
either thrombin or the 2M-thrombin complex. 
 
Various polymerization reactions and conjugation methods were applied for the preparation of different 
types of polymer-peptides constructs, which included: MeO-PEG-peptide-AMC, poly(PEGMA)-
peptide-AMC and PS-peptide-AMC. The latter polymer-peptide was found to form a vesicular structure 
upon injection in water from a sample in dissolved THF. Unfortunately, these aggregates did not show 
any activity upon subjection to thrombin. The linear substrate MeO-PEG-Gly-Gly-Arg-AMC turned out 
to be a promising substrate showing suitable kinetic parameters, a good thrombogram, and high water 
solubility.    
  
As a result of the strong coordination of copper ions to the guanidine moiety of arginine residue, 
purification of the PS-peptide conjugates prepared via the copper-catalyzed 1,3-dipolar cycloaddition 
was generally found to be troublesome resulting in variable yields. This stimulated us to search for a 
new copper-free ligation method suitable for (bio)conjugation. 
 
 
 
Figure 6. The 1,3-dipolar cycloaddition reaction of benzyl azide with either a 10-oxa-4-aza-tricyclic 
system or an oxanorbornadiene system resulted in different reaction products.  
 
We focused on strain-promoted [3+2] cycloaddition reactions, i.e. reaction between azides and 
strained alkenes. It was envisaged that the strained alkene should comply with three criteria; (1) 
synthetically readily available; (2) it should have a pre- or post-modification site; (3) fast reaction under 
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ambient conditions in a [3+2] cycloaddition. Initially we started off with tricyclic systems having a 
heteroatom as bridge atom, simply constructed via a Diels–Alder reaction between furan, pyrrole or 
thiophene and maleimide. The tricyclic systems were subsequently tested for propensity to undergo 
[3+2] cycloaddition with benzyl azide (Figure 6, oxo-bridged tricycle shown), resulting in the formation 
of tetracyclic triazoline compounds in moderate to reasonable yield. The alternative oxanorbornadiene 
system, produced via a Diels–Alder reaction between furan and an electron-deficient alkyne, gave an 
unexpected reaction outcome upon reaction with benzyl azide. Instead of triazoline formation, 
formation of two triazole products was observed as a result of cycloaddition to the electron-poor 
double bond followed by a fast retro-Diels–Alder reaction (Figure 6). The reaction sequence, tandem 
cycloaddition retro-Diels–Alder (tandem crDA), gave high conversions in a variety of solvents, 
including aqueous solutions, and at ambient conditions.    
 
Since the tandem crDA reaction between oxanorbornadiene and azides proved to be a powerful 
copper-free ligation method for small molecules, we explored the use of this reaction as 
bioconjugation tool. The metal-free tandem crDA reaction was successfully applied in the PEGylation 
of linear RGD-containing peptides and the fluorescent labeling of polymers and proteins (Figure 7). 
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Figure 7. Applications of the tandem crDA reaction using functionalized oxanorbornadiene systems. 
 
Finally, the possibility of utilizing the tandem crDA reaction in tumor targeting was explored. To this 
end, cyclic azide-containing RGD peptide and 111In-labeled DTPA-oxanorbornadiene were synthesized 
and reacted in metal-free buffer to produce the 111In-labeled cRGD-CF3-spacer-DTPA conjugate. The 
conjugates (labeled and unlabeled) were subsequently used to determine the lipophilicity, the affinity 
for the αvβ3 receptor (solid-phase binding experiment), and the in vivo behavior in nude BALB/c mice 
bearing subcutaneous SK-RC-52 tumors (biodistribution experiments). The conjugate showed suitable 
lipophilicity (logP = 2.72), a good IC50 value (191 nM), and a high specific uptake in tumor tissue. 
These results demonstrate that the tandem crDA reaction is a promising tool for the bioconjugation of 
complex molecules and may be applied in various research areas.  
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Samenvatting 
 
 
Trombose ligt aan de grondslag van ziektes als hersenbloeding, hartinfarct en longembolie en 
kan dus worden beschouwd als de grootste doodsoorzaak in de Westerse wereld.  In de meeste 
gevallen ontstaat trombose als gevolg van de vorming van een bloedprop. Het ontstaan van een 
bloedprop is terug te leiden naar een serie complexe enzymatische reacties waarbij trombine een 
cruciale rol speelt. Over expressie van trombine kan leiden tot trombose, te lage expressie 
daarentegen kan leiden tot hemofilie. Het accurate vaststellen van de trombine concentratie is dus van 
groot belang voor het samenstellen van de juiste medicatie voor patiënten met een bloedstollings-
afwijking. Het juist bepalen van de concentratie trombine in bloed kan dus worden gebruikt om de 
mate van stolling te bepalen. Een methode om de aanmaak en afbraak van trombine te meten, en dus 
de concentratie in tijd, is de zogenaamde trombine generatie test. Deze methode (ontwikkeld in 1953) 
is door de jaren heen aangepast, geautomatiseerd en geoptimaliseerd en kent in de huidige vorm 
(genaamd  gekalibreerde, geautomatiseerde trombografie (CAT)) vele toepassingen op het gebied 
van hemostase en trombose. Het principe van CAT is gebaseerd op het toevoegen van een 
chromogeen of fluorogeen trombine specifiek peptide substraat aan een stollend plasma. Als gevolg 
van de hydrolyse van dit substraat door trombine, komt er een chromogeen of fluorescent molecuul 
vrij wat vervolgens spectrofotometrisch kan worden gemeten. De toename van het ontstane signaal 
kan in de tijd worden gevolgd en door middel van een aantal mathematische handelingen worden 
omgezet in een zogenaamde trombine generatie curve. Van deze curve kunnen enkele essentiële 
parameters worden afgeleid.  
 
Het substraat dat momenteel wordt gebruikt in de trombine generatie test is een N-terminus 
beschermd fluorogeen tripeptide Z-Gly-Gly-Arg-AMC. Dit substraat is echter slecht oplosbaar in 
fysiologische media en heeft matige kinetische eigenschappen. Deze nadelen waren de stimulans om 
wateroplosbare analoga met verbeterde kinetische eigenschappen te ontwikkelen. Daartoe werd een 
serie peptiden gesynthetiseerd met de fluorescente groep 7-amino-methyl-coumarine (AMC) hieraan 
gekoppeld (Figuur 1).  
 
  
Figuur 1.  Cruciaal intermediair H-Arg-AMC werd gebruikt voor de synthese van verschillende 
trombine substraten.  
 
Een uiteenlopende reeks van fluorogene trombine substraten met als gemeenschappelijke structurele 
eigenschap H-Arg-AMC werd gesynthetiseerd. Hierbij valt te denken aan de volgende substraten: 
Ala-Gly-Arg-AMC, SQ68 variant Et-malonyl-Gly-Arg-AMC, triazool bevattend Gly-Gly-Arg-AMC en 
N-terminus gesubstitueerde Gly-Gly-Arg-AMC varianten.  
 
Een serie van 23 peptide-AMC substraten werd vervolgens onderworpen aan een biologische 
evaluatie om de bindingsconstante (KM) en de hydrolyse snelheid (kcat) voor zowel trombine als 
factor Xa (een andere serine protease aanwezig in bloed plasma). De substraten met de gewenste 
kinetische parameters (kcat  1 s-1, KM  200 M en toepasbaar bij S  200 M) werden vervolgens 
toegepast in de trombine generatie test om trombine generatie curven te genereren. Evaluatie van de 
verkregen trombogrammen gaf aan dat verschillende substraten, waaronder N-gefunctionaliseerd Gly-
Gly-Arg-AMC en SQ68 derivaat Et-malonyl-Gly-Arg-AMC, goede kandidaten zouden kunnen zijn om 
het huidige substraat te vervangen.  
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Naast de bepaling van de kinetische parameters en het meten van de trombine generatie werd een 
nieuwe methode, de zogenaamde diagnostische plot, geëvalueerd om de toepasbaarheid van 
verschillende fluorogene substraten te bepalen. 
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Figuur 2. Methoden om de toepasbaarheid van substraten te testen. Links: kinetiek experiment. 
Midden: diagnostische plot. Rechts: trombine generatie curve of trombogram. 
 
Deze methode is niet alleen geschikt voor het bepalen van het bruikbare concentratiegebied van een 
substraat maar kan tevens worden toegepast om verkregen data van een trombine generatie meting 
eenvoudig te transformeren naar een trombogram. 
 
De synthese van een serie trombine specifieke substraten kan worden uitgevoerd binnen enkele 
maanden. De daarop volgende biologische evaluatie levert de nodige informatie op voor verdere 
optimalisatie. Omdat dit een arbeidsintensief proces is, met iteratie cyclus van enkele maanden, werd 
er een synthese route ontworpen om substraten te synthetiseren op vaste drager materiaal (Figuur 3). 
 
 
 
Figuur 3. Vaste drager methodologie voor de synthese van Arg-AMC bevattende trombine substraten. 
 
De strategie was gebaseerd op de koppeling van een volledig beschermde AMC-precursor aan de 
vaste drager gevolgd door de selectieve ontscherming van de amine-functie en vervolgens peptide 
synthese. Na het introduceren van de peptide keten aan de vaste drager, kan het gewenste substraat 
worden verkregen door de ontscherming van de alcohol-functie. Door licht isomerisatie van de 
dubbele binding kan spontane ringsluiting plaatsvinden (vorming van AMC), met als gevolg de 
afsplitsing van het trombine substraat van de vaste drager. Deze methodologie vereiste de synthese 
van volledig orthogonaal beschermd 3-aminofenol-but-2-enoyl zuur, een AMC-precursor welke in een 
vijf-staps synthese werd geproduceerd met een totale opbrengst van 29%. Vervolgens werd de 
koppeling aan een Wang-bromide hars, N-ontscherming en de koppeling van Fmoc-Ala-OH succesvol 
uitgevoerd. De ontscherming van de alcohol-functie op de vaste drager, gebruikmakend van 
verschillende reactie condities, bleek helaas niet tot het gewenste product te leiden. 
 
Biologische evaluatie van de peptide-AMC substraten wees uit dat het substraat Gly-Pro-Arg-
AMC ongeschikt was voor toepassing in de trombine generatie test als gevolg van een te hoge 
hydrolyse snelheid. Het vastleggen van dit substraat in een cyclische conformatie zou mogelijk 
kunnen leiden tot een verlaging van de bindingsaffiniteit voor trombine als gevolg van sterische hinder 
resulterend in een lagere hydrolyse snelheid. Macrocyclisatie werd uitgevoerd met behulp van een 
intramoleculaire koper gekatalyseerde 1,3-dipolaire cycloadditie reactie. Deze reactie vereist de 
aanwezigheid van zowel een azide- als een acetyleen functionaliteit. Als eerste werd er een route 
ontwikkeld voor de synthese van 7-amino-4-azidomethylenecoumarine (AAMC) welke vervolgens 
gekoppeld werd aan arginine. Vervolgens werd het acetyleen fragment verkregen via de sequentiële 
koppeling van hexynzuur en proline aan glycine. Uiteindelijk resulteerde de condensatie van de twee 
fragmenten in de azide- en acetyleen gefunctionaliseerde precursor voor de intramoleculaire koper 
gekatalyseerde 1,3-dipolaire cycloadditie reactie (Figuur 4). 
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Figuur 4. Synthese van cyclo(-GPR-AMC-[triazool]-spacer-) via een koper gekatalyseerde Huisgen 
cycloadditie reactie. De tweede stap is de hydrolyse van dit substraat door trombine. 
 
Het cyclisch product, verkregen in een lage opbrengst, werd vervolgens onderworpen aan de 
hydrolyse door trombine waarna de kinetische parameters konden worden bepaald. Resultaten lieten 
een verhoogde bindingsconstante (KM) zien en een gelijke hydrolyse snelheid (kcat). 
 
Alfa-2-macroglobuline (2-M) is een plasma glycoproteïne verantwoordelijk voor het omsluiten 
van trombine. Hierdoor wordt de hydrolyse van fibrinogeen (het natuurlijk substraat van trombine) 
verhinderd. Echter, kleine tripeptide substraten zoals Gly-Gly-Arg-AMC kunnen alsnog de ‘active-site’ 
van trombine bereiken en dus worden omgezet. Om deze ongewenste hydrolyse door het 2-M-
trombine complex te onderdrukken richtte wij ons op de synthese van polymeer-peptide constructen. 
Door het introduceren van sterische hinder aan het peptide fragment wordt de ongewenste hydrolyse 
door 2-M-T onderdrukt. De hydrolyse van het polymeer-peptide substraat door vrij trombine wordt 
echter niet beïnvloed door deze sterische hinder (zie Figuur 5). 
 
 
Figuur 5. Schematische weergave van de hydrolyse van peptide- en polymeer-peptide substraten 
door trombine of 2-M-trombine complex. 
 
Verschillende polymerisatie reacties en conjugatie methoden werden toegepast om verschillende 
typen polymeer-peptide constructen te maken, waaronder: MeO-PEG-peptide-AMC, poly(PEGMA)-
peptide-AMC en PS-peptide-AMC. Het laatst genoemde polymeer-peptide bleek vesiculaire structuren 
te vormen na injectie in water vanuit een THF oplossing. Deze aggregaten vertoonde helaas geen 
activiteit op trombine. Het lineaire substraat MeO-PEG-Gly-Gly-Arg-AMC bleek een veel belovend 
substraat met gunstige kinetische parameters, een goed trombogram en hoge wateroplosbaarheid.  
 
Als gevolg van de sterke affiniteit van koper ionen voor de guanidine groep van het arginine 
residu werd de zuivering van de PS-peptide conjugaten, gesynthetiseerd via de koper gekatalyseerde 
1,3-dipolaire cycloadditie reactie, bemoeilijkt met als gevolg variabele opbrengsten. Dit stimuleerde 
ons om te zoeken naar een nieuwe, koper-vrije koppelingsmethode geschikt voor (bio)conjugatie. 
Hierbij werd gefocust op door spanning gestimuleerde [3+2] cycloadditie reacties, dat wil zeggen 
reacties tussen azides en gespannen alkenen. Deze gespannen alkenen moeten voldoen aan de 
volgende drie criteria; (1) synthetisch makkelijk toegankelijk; (2) moeten een pre- of post-modificatie 
plaats bezitten; (3) moeten onder omgevingstemperatuur en druk een snelle [3+2] cycloadditie reactie 
geven. Initieel werd er gekeken naar tricyclische systemen met een heteroatoom als brugatoom welke 
eenvoudig te synthetiseren waren via een Diels–Alder reactie tussen furaan, pyrrol of thiofeen en 
maleimide. Vervolgens werden deze tricyclische systemen getest op hun reactiviteit in de [3+2] 
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cycloadditie reactie met benzyl azide (Figuur 6, oxa-gebrugd verbinding weergegeven). Dit resulteerde 
in de vorming van tetracyclische triazoline verbinding in matige tot redelijke opbrengsten. 
 
 
 
Figuur 6. 1,3-Dipolaire cycloadditie reactie tussen benzyl azide en een 10-oxa-4-aza-tricyclisch 
systeem of een oxanorbornadieen systeem, resulteert in verschillende reactieproducten. 
 
Het alternatief, een oxanorbornadieen, verkregen uit een Diels–Alder reactie tussen furaan en een 
elektronen deficiënt acetyleen, gaf een onverwachte uitkomst na reactie met benzyl azide. In plaats 
van de vorming van triazoline werd de vorming van twee triazool producten waargenomen. Dit bleek 
het gevolg van een cycloadditie aan de elektronen deficiënte dubbele binding gevolgd door een retro-
Diels–Alder reactie (Figuur 6). Deze reactie, tandem cycloadditie retro-Diels–Alder (tandem crDA), 
gave hoge opbrengsten in verschillende oplosmiddelen, waaronder waterige oplossingen, en onder 
milde reactieomstandigheden.      
 
De tandem crDA reactie tussen een oxanorbornadieen en azides heeft bewezen een zeer 
efficiënte, koper-vrije conjugatie methode te zijn voor kleine moleculen. In vervolg onderzoek werd 
gekeken naar de toepasbaarheid van deze methode op het gebied van bioconjugatie. De metaal-vrije 
tandem crDA reactie werd succesvol toegepast in het koppelen van PEG polymeren aan lineaire RGD 
bevattende peptiden en het fluorescent labelen van polymeren en eiwitten (Figuur 7).    
 
 
Figuur 7. Toepassingen van de tandem crDA reactie gebruikmakend van gefunctionaliseerde 
oxanorbornadieen systemen. 
 
Tenslotte werd de mogelijkheid bekeken om de tandem crDA reactie toe te passen in kanker 
onderzoek. Hiervoor werden zowel cyclisch azide gefunctionaliseerd RGD peptide als 111In gelabeld 
DTPA-oxanorbornadieen gesynthetiseerd en samengevoegd in een metaal-vrije buffer. Dit resulteerde 
in een 111In gelabeld cRGD-CF3-spacer-triazool-DTPA conjugaat. De conjugaten (zowel gelabeld als 
ongelabeld) werden vervolgens gebruikt voor het bestuderen van de lipofiliciteit, de bindingsaffiniteit 
voor de v3 receptor (vaste drager bindingsexperiment), en het in vivo gedrag in naakte BALB/c 
muizen met subcutaan SK-RC-52 tumoren (biodistributie experiment). De conjugaten vertoonden 
gunstige lipofiliciteit (logP = –2.72), een goede IC50 waarde (191 nM) en een hoge specifieke opname 
in tumor weefsel. Deze resultaten bevestigen dat de tandem crDA reactie een veel belovende 
bioconjugatie methode is voor de synthese van complexe moleculen en kan mogelijk worden 
toegepast in verschillende onderzoeksgebieden.  
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